
<html lang="en"     class="pb-page"  data-request-id="40fcc0e3-829d-4aa0-a4e9-cfd82b0300b2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-21;article:article:10.1021/acs.jmedchem.0c00237"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Adenosine A2A Receptor Antagonists for Cancer Immunotherapy" /></meta><meta name="dc.Creator" content="Fazhi  Yu" /></meta><meta name="dc.Creator" content="Chenyu  Zhu" /></meta><meta name="dc.Creator" content="Qiong  Xie" /></meta><meta name="dc.Creator" content="Yonghui  Wang" /></meta><meta name="dc.Description" content="Currently, the most promising therapeutic modality for cancer treatment is the blockade of immune checkpoint pathways, which has revolutionized cancer therapy in the past 15 years. Strategies targe..." /></meta><meta name="Description" content="Currently, the most promising therapeutic modality for cancer treatment is the blockade of immune checkpoint pathways, which has revolutionized cancer therapy in the past 15 years. Strategies targe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 15, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00237" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00237" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00237" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00237" /></link>
        
    
    

<title>Adenosine A2A Receptor Antagonists for Cancer Immunotherapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00237" /></meta><meta property="og:title" content="Adenosine A2A Receptor Antagonists for Cancer Immunotherapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0011.jpeg" /></meta><meta property="og:description" content="Currently, the most promising therapeutic modality for cancer treatment is the blockade of immune checkpoint pathways, which has revolutionized cancer therapy in the past 15 years. Strategies targeting and modulating adenosine A2A receptor (A2AR), an emerging alternative immune checkpoint, have shown the potential to produce significant therapeutic effects. In this review, we describe the immunosuppressive activities of A2AR and A2BR in the tumor microenvironment (TME), followed by a summary and discussion of the structure–activity relationship (SAR) of the A2AR (and dual A2AR/A2BR) antagonists that have been experimentally confirmed to exert oncoimmunological effects. This review also provides an update on the compounds under clinical evaluation and insights into the ligand binding modes of the receptor." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00237"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00237">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00237&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00237&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00237&amp;href=/doi/10.1021/acs.jmedchem.0c00237" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 12196-12212</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00173" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00262" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Adenosine A<sub>2A</sub> Receptor Antagonists for Cancer Immunotherapy</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Fazhi Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fazhi Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fazhi++Yu">Fazhi Yu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chenyu Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chenyu Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chenyu++Zhu">Chenyu Zhu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qiong Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiong Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiong++Xie">Qiong Xie</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yonghui Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yonghui Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#265f4948414e534f5147484166405342474808434253084548"><span class="__cf_email__" data-cfemail="c9b0a6a7aea1bca0bea8a7ae89afbcada8a7e7acadbce7aaa7">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yonghui++Wang">Yonghui Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0262-2431" title="Orcid link">http://orcid.org/0000-0002-0262-2431</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00237&amp;href=/doi/10.1021%2Facs.jmedchem.0c00237" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 12196–12212</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 15, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 February 2020</li><li><span class="item_label"><b>Published</b> online</span>15 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00237" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00237</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D12196%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DFazhi%2BYu%252C%2BChenyu%2BZhu%252C%2BQiong%2BXie%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D21%26contentID%3Dacs.jmedchem.0c00237%26title%3DAdenosine%2BA2A%2BReceptor%2BAntagonists%2Bfor%2BCancer%2BImmunotherapy%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D12212%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00237"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2151</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00237" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Adenosine A2A Receptor Antagonists for Cancer Immunotherapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Fazhi&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Chenyu&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Qiong&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Yonghui&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;12196-12212&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00237&quot;},&quot;abstract&quot;:&quot;Currently, the most promising therapeutic modality for cancer treatment is the blockade of immune checkpoint pathways, which has revolutionized cancer therapy in the past 15 years. Strategies targeting and modulating adenosine A2A receptor (A2AR), an emerging alternative immune checkpoint, have shown the potential to produce significant therapeutic effects. In this review, we describe the immunosuppressive activities of A2AR and A2BR in the tumor microenvironment (TME), followed by a summary and discussion of the structure–activity relationship (SAR) of the A2AR (and dual A2AR/A2BR) antagonists that have been experimentally confirmed to exert oncoimmunological effects. This review also provides an update on the compounds under clinical evaluation and insights into the ligand binding modes of the receptor.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00237&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00237" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00237&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00237" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00237&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00237" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00237&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00237&amp;href=/doi/10.1021/acs.jmedchem.0c00237" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00237" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00237" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00237%26sid%3Dliteratum%253Aachs%26pmid%3D32667814%26genre%3Darticle%26aulast%3DYu%26date%3D2020%26atitle%3DAdenosine%2BA2A%2BReceptor%2BAntagonists%2Bfor%2BCancer%2BImmunotherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D21%26spage%3D12196%26epage%3D12212%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291308" title="Nucleic acids">Nucleic acids</a>,</li><li><a href="/action/doSearch?ConceptID=291081" title="Immunotherapy">Immunotherapy</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/jmcmar.2020.63.issue-21/20201112/jmcmar.2020.63.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Currently, the most promising therapeutic modality for cancer treatment is the blockade of immune checkpoint pathways, which has revolutionized cancer therapy in the past 15 years. Strategies targeting and modulating adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R), an emerging alternative immune checkpoint, have shown the potential to produce significant therapeutic effects. In this review, we describe the immunosuppressive activities of A<sub>2A</sub>R and A<sub>2B</sub>R in the tumor microenvironment (TME), followed by a summary and discussion of the structure–activity relationship (SAR) of the A<sub>2A</sub>R (and dual A<sub>2A</sub>R/A<sub>2B</sub>R) antagonists that have been experimentally confirmed to exert oncoimmunological effects. This review also provides an update on the compounds under clinical evaluation and insights into the ligand binding modes of the receptor.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Following radiotherapy/chemotherapy and targeted drug therapy, cancer immunotherapy has now become the third revolutionary strategy to combat neoplastic diseases.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> These treatments, which target the maladaptive appropriation of the immune system in the human body instead of the cancer itself, represent a substantial change in the approach to the treatment of many cancers. Along with academia, industries are embracing this approach and extensively investing in cancer immunotherapy treatments.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Several types of cancer immunotherapy exist. Some treatments help the immune system to directly inhibit cancer, including checkpoint inhibitors, adoptive cell transfer, and treatment vaccines. Treatments that enhance the immune response to fight cancer include cytokines and bacillus Calmette–Guérin. Among them, the development of immune checkpoint inhibitors has been a hot research area in recent years (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The past few years have witnessed the clinical success of the application of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) blockade to treat a variety of tumors. Noticeably, most of the reported checkpoint inhibitors are monoclonal antibodies (mAbs), and thus the administration schedule is time-consuming and costly. More importantly, some immune-associated adverse events related to mAb- and cell-based bioremediation are frequently reported and still lack effective solutions. Compared to biological agents, small molecules have their own advantages, such as a higher oral bioavailability, better permeability of the tumor microenvironment (TME), and a lower risk of causing harmful immunogenicity.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The bioavailability of small molecules is more easily controlled, thus avoiding some of the immune-related adverse events. The lower production and management costs will also result in better patient accessibility. Therefore, small molecules for use as immune checkpoint inhibitors are urgently needed.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Immune checkpoint signaling pathways in the TME and relevant intervention strategies for cancer immunotherapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In fact, numerous small molecules have been reported to modulate immunosuppression or activate innate and/or adaptive immune signaling pathways in the treatment of cancer (when biological agents usually do not work). BMS-986189 (an antagonist of programmed cell death 1 ligand 1 (PD-L1), phase 1),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> ADU-S100 (an agonist of stimulator of interferon genes receptor (STING), phase 2),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> CA-170 (a dual antagonist of V-domain Ig suppressor of T cell activation (VISTA) and PD-L1, phase 1),<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> CA-327 (a dual antagonist of T-cell immunoglobulin and mucin domain-3 (TIM-3) and PD-L1, IND filed),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and epacadostat (an inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1), phase 1/2/3)<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> are all promising small molecules being investigated in clinical trials for cancer immunotherapy. Considering the challenges in developing small-molecule antagonists of PD-1/PD-L1 and TIM-3 and the frustrating clinical outcomes of IDO inhibitors, scientists are striving to discover new immune checkpoint molecules in small molecule drug discovery and development. Adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) signaling emerges as a novel immune checkpoint pathway. Historically, the A<sub>2A</sub>R has long been a target for neurological diseases. The molecular structures and SAR of A<sub>2A</sub>R antagonists have been thoroughly and chronologically reviewed by Baraldi et al. in 2008,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> de Lera Ruiz et al. in 2013,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and Jazayeri et al. in 2017.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Recently, the biological rationale for A<sub>2A</sub>R antagonism in oncology has been extensively reviewed by Sitkovsky et al. in 2016,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Congreve et al. in 2018,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and Gessi et al. in 2019.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, the detailed molecular structure has rarely been disclosed. Current progress in the research and development of small molecule drugs targeting A<sub>2A</sub>R is considerably striking, with seven small molecule entities under clinical evaluation for cancer (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Here, we describe the pharmacological activities of A<sub>2A</sub>R and/or A<sub>2B</sub>R in immunosuppression and provide an overview of the reported A<sub>2A</sub>R (and dual A<sub>2A</sub>R/A<sub>2B</sub>R) antagonists specifically used in cancer immunotherapy. This review also provides an update on the compounds under clinical evaluation and insights into the ligand binding modes of the receptor.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. A<sub>2A</sub>R Antagonists in Clinical Trials for Cancer Immunotherapy<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug name</th><th class="colsep0 rowsep0" align="center">indications</th><th class="colsep0 rowsep0" align="center">sponsor</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">intervention/treatment</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD4635</td><td class="colsep0 rowsep0" align="left">Advanced solid malignancies</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Single agent</td><td class="colsep0 rowsep0" align="left">NCT03980821</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PC<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>/mCPRC<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">+ Durvalumab/oleclumab</td><td class="colsep0 rowsep0" align="left">NCT04089553</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Advanced solid malignancies/NSCLC<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a>/mCPRC/CRC<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Single agent alone and in combination with durvalumab/abiraterone acetate/enzalutamide/oleclumab/docetaxel</td><td class="colsep0 rowsep0" align="left">NCT02740985</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">MedImmune</td><td class="colsep0 rowsep0" align="left">1/2</td><td class="colsep0 rowsep0" align="left">+ oleclumab</td><td class="colsep0 rowsep0" align="left">NCT03381274</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Taminadenant (PBF-509/NIR178)</td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">Palobiofarma</td><td class="colsep0 rowsep0" align="left">1/2</td><td class="colsep0 rowsep0" align="left">Single agent alone and in combination with PDR001</td><td class="colsep0 rowsep0" align="left">NCT02403193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC/TNBC<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a>/PDAC<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a>/MSS<a class="ref internalNav" href="#t1fn8" aria-label="h">h</a>/OC<a class="ref internalNav" href="#t1fn9" aria-label="i">i</a>/RCC<a class="ref internalNav" href="#t1fn10" aria-label="j">j</a>/mCPRC</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">+ NZV930/PDR001</td><td class="colsep0 rowsep0" align="left">NCT03549000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC/RCC/pancreatic cancer/urothelial cancer/head and neck cancer/DLBCL<a class="ref internalNav" href="#t1fn11" aria-label="k">k</a>/MSS/TNBC/melanoma</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">+ PDR001</td><td class="colsep0 rowsep0" align="left">NCT03207867</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">+ KAZ954</td><td class="colsep0 rowsep0" align="left">NCT04237649</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">+ PDR001/LAG525</td><td class="colsep0 rowsep0" align="left">NCT03742349</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PBF-999</td><td class="colsep0 rowsep0" align="left">Cancer</td><td class="colsep0 rowsep0" align="left">Palobiofarma</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Single agent</td><td class="colsep0 rowsep0" align="left">NCT03786484</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EOS100850</td><td class="colsep0 rowsep0" align="left">Solid tumor</td><td class="colsep0 rowsep0" align="left">iTeos</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Single agent</td><td class="colsep0 rowsep0" align="left">NCT03873883</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ciforadenant (CPI-444)</td><td class="colsep0 rowsep0" align="left">NSCLC/RCC/CRC/TNBC/cervical cancer/OC/PC/endometrial cancer/sarcoma/squamous cell carcinoma of the head and neck/bladder cancer/mCPRC/non-Hodgkin lymphoma</td><td class="colsep0 rowsep0" align="left">Corvus</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">+ CPI-006</td><td class="colsep0 rowsep0" align="left">NCT03454451</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">RCC/mCPRC</td><td class="colsep0 rowsep0" align="left">Corvus</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Single agent alone and in combination with atezolizumab</td><td class="colsep0 rowsep0" align="left">NCT02655822</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Multiple myeloma</td><td class="colsep0 rowsep0" align="left">Corvus</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Single agent alone and in combination with daratumumab</td><td class="colsep0 rowsep0" align="left">NCT04280328</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">Roche</td><td class="colsep0 rowsep0" align="left">1/2</td><td class="colsep0 rowsep0" align="left">+ Atezolizumab</td><td class="colsep0 rowsep0" align="left">NCT03337698</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AB928</td><td class="colsep0 rowsep0" align="left">NSCLC/nonsquamous NSCLC/squamous NSCLC/lung cancer</td><td class="colsep0 rowsep0" align="left">Arcus</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">+ AB122/AB154</td><td class="colsep0 rowsep0" align="left">NCT04262856</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC/squamous cell carcinoma of the head and neck/breast cancer/CRC/melanoma/bladder cancer/OC/endometrial cancer/Merkel cell carcinoma/gastresophageal cancer/RCC/castration-resistant prostate cancer</td><td class="colsep0 rowsep0" align="left">Arcus</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">+ AB122</td><td class="colsep0 rowsep0" align="left">NCT03629756</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Gastresophageal cancer/CRC</td><td class="colsep0 rowsep0" align="left">Arcus</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">+ mFOLFOX</td><td class="colsep0 rowsep0" align="left">NCT03720678</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">TNBC/OC</td><td class="colsep0 rowsep0" align="left">Arcus</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">+ IPI-549/Pegylated liposomal doxorubicin/nanoparticle albumin-bound paclitaxel</td><td class="colsep0 rowsep0" align="left">NCT03719326</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC metastatic/NSCLC/nonsquamous NSCLC/sensitizing EGFR gene mutation</td><td class="colsep0 rowsep0" align="left">Arcus</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">+ AB122/carboplatin/pemetrexed/pembrolizumab</td><td class="colsep0 rowsep0" align="left">NCT03846310</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CRC</td><td class="colsep0 rowsep0" align="left">Roche</td><td class="colsep0 rowsep0" align="left">1/2</td><td class="colsep0 rowsep0" align="left">+ Atezolizumab/regorafenib</td><td class="colsep0 rowsep0" align="left">NCT03555149</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Pancreatic adenocarcinoma</td><td class="colsep0 rowsep0" align="left">Roche</td><td class="colsep0 rowsep0" align="left">1/2</td><td class="colsep0 rowsep0" align="left">+ Atezolizumab/gemcitabine/Nab-paclitaxel</td><td class="colsep0 rowsep0" align="left">NCT03193190</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CS3005</td><td class="colsep0 rowsep0" align="left">Advanced solid tumor</td><td class="colsep0 rowsep0" align="left">CStone</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Single agent</td><td class="colsep0 rowsep0" align="left">NCT04233060</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Preladenant (MK-3814)</td><td class="colsep0 rowsep0" align="left">Neoplasm</td><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">Terminated</td><td class="colsep0 rowsep0" align="left">Single agent alone and in combination with pembrolizumab</td><td class="colsep0 rowsep0" align="left">NCT03099161</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Information from ClinicalTrials.gov updated on April 29, 2020.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Prostate cancer.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Metastatic castration-resistant prostate cancer.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Non-small-cell lung cancer.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Colorectal carcinoma.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Triple negative breast cancer.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Pancreatic ductal adenocarcinoma.</p></div><div class="footnote" id="t1fn8"><sup><sup>h</sup></sup><p class="last">Colorectal cancer microsatellite stable.</p></div><div class="footnote" id="t1fn9"><sup><sup>i</sup></sup><p class="last">Ovarian cancer.</p></div><div class="footnote" id="t1fn10"><sup><sup>j</sup></sup><p class="last">Renal cell carcinoma.</p></div><div class="footnote" id="t1fn11"><sup><sup>k</sup></sup><p class="last">Diffuse large B cell lymphoma. “+” indicates “in combination with”.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  Targeting A<sub>2A</sub>R for Cancer Immunotherapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56550" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56550" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The naturally occurring purine nucleoside adenosine was first discovered in 1929 to influence a wide range of physiological functions.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Adenosine exerts its effects by modulating four subtypes of specific G-protein-coupled receptors (GPCRs): A<sub>1</sub>R, A<sub>2A</sub>R, A<sub>2B</sub>R, and A<sub>3</sub>R.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> Upon activation, A<sub>2A</sub>R and A<sub>2B</sub>R promote adenylyl cyclase (AC) activation and subsequent cyclic AMP (cAMP) production by recruiting the G<sub>s</sub> protein, while A<sub>1</sub>R and A<sub>3</sub>R exert the opposite functions by recruiting the G<sub>i</sub> protein.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> A<sub>2A</sub>Rs are expressed at high levels in the striatum of the brain and in immune cells and display high affinity for adenosine. A<sub>2B</sub>Rs are also widely expressed but mostly at low levels and are less sensitive to adenosine.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A<sub>2A</sub>R has long been a drug target, particularly for Parkinson’s disease.<a onclick="showRef(event, 'ref13 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref13 ref24 ref25">(13,24,25)</a> More importantly, the therapeutic potential of A<sub>2A</sub>R blockade using small molecules has been validated by the successful launch of istradefylline in both Japan and America as an adjunct treatment for Parkinson’s disease. Recently, A<sub>2A</sub>R has been reported to be a promising target for cancer immunotherapy.<a onclick="showRef(event, 'ref15 ref16 ref17 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref26 ref27 ref28">(15−17,26−28)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  Mechanism of A<sub>2A</sub>R Signaling in Immunosuppression</h3><div class="NLM_p last">The human immune system is activated to fight against pathogens while inducing an array of mechanisms to protect against an excess inflammatory response or autoimmunity.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Unfortunately, these bypasses are sometimes hijacked by tumors, thus leading to immune evasion. These bypasses include inhibitory receptors such as PD-1, CTLA-4, TIM-3, and A<sub>2A</sub>R, together with their related signaling networks, and are known as “immune checkpoint pathways”.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> Physiologically, the extracellular level of adenosine is very low.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Pathologically, an elevated level of extracellular adenosine (∼10 μM vs <1 μM in normal tissues)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> is specifically present in the TME and is available for tumor cells,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> cancer-related fibroblasts,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and some immune cells, such as regulatory T cells (Tregs),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> myeloid-derived suppressor cells (MDSCs),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> endothelial cells,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and T helper cell 17 (Th17).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Upon binding to the A<sub>2A</sub>R or A<sub>2B</sub>R, adenosine triggers increased cAMP-protein kinase A signaling concomitant with immune regulation. Activation of A<sub>2A</sub>R mediates the primary immunosuppression in the TME. Several studies from different research groups found that elevated intracellular cAMP in T cells upon A<sub>2A</sub>R activation resulted in T cell anergy, reduced levels of interleukin-2 (IL-2), tumor necrosis factor (TNFα), and interferon-γ (IFN-γ) and compromised CD8+ T cell infiltration.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> The natural killer (NK) cell cytotoxicity was inhibited by this pathway as well.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> A<sub>2A</sub>R activation on Tregs promotes their proliferation, increases PD-1 and CTLA-4 expression, and enhances immunosuppression.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Macrophages have recently been shown to contribute to the suppression of antitumor immunity upon A<sub>2A</sub>R activation.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Meanwhile, Wang et al. found that the adhesion and subsequent transmigration of antitumor T cells was disabled when endothelial A<sub>2A</sub>R was activated.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Although displaying low affinity for adenosine, A<sub>2B</sub>R was recently shown to exert immunosuppressive effects on the adenosine-rich TME. By activating A<sub>2B</sub>R, adenosine alters the differentiation of cells of the mononuclear-phagocyte system. This event results in angiogenesis, tumor metastasis, and the suppression of lymphocyte-mediated antitumor immunity.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> According to studies by Novitskiy et al., the capacity of dendritic cells (DCs) to prime and amplify T helper cell 1 (Th1) immune responses is inhibited upon A<sub>2B</sub>R stimulation.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Activation of A<sub>2B</sub>R might also drive the differentiation of naïve T cells into the Treg phenotype.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  A<sub>2A</sub>R Blockade in Cancer</h3><div class="NLM_p last">As outlined above, A<sub>2A</sub>R is overexpressed and exerts profound immunosuppressive effects on the TME. Logically, strategies targeting A<sub>2A</sub>R have the potential to restore the anticancer functions of multiple immune cell subsets. Sitkovsky et al. conducted seminal studies and showed that the CL8-1 melanoma cell line and the RMA T cell lymphoma line were completely rejected in A<sub>2A</sub>R null mice, depending on CD8+ T cell activity.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> In both a sarcoma model and a poorly immunogenic LL-LCMV tumor model, an increase in CD8+ T cell-mediated tumor regression was observed following pharmacological A<sub>2A</sub>R blockade.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> In both the 4T1.2 mouse model of breast carcinoma and the B16F10 mouse model of melanoma, the incidence of metastasis was also reduced after the administration of A<sub>2A</sub>R antagonists.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Studies examining the combination of A<sub>2A</sub>R inhibition with the blockade of PD-1,<a onclick="showRef(event, 'ref41 ref43 ref53'); return false;" href="javascript:void(0);" class="ref ref41 ref43 ref53">(41,43,53)</a> CTLA-4,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> chimeric antigen receptor T-cell immunotherapy (CAR-T),<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and doxorubicin (a kind of chemotherapy)<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> all reported synergetic antitumor effects. Similarly, pharmacological blockade of A<sub>2B</sub>R exerted significant antitumor effects, such as attenuated prostate cancer cell proliferation,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> slowed growth of bladder and breast tumors,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> reduced tumor growth and immune suppression mediated by MDSCs,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and the inhibition of vascular endothelial growth factor (VEGF) production and angiogenesis.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Notably, excessive blockade of A<sub>2A</sub>R signaling occasionally stimulates tumor growth in some models.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> As shown in the study by Cekic et al., global A<sub>2A</sub>R deletion reduces the number of naïve T cells.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Some other researchers also showed that global A<sub>2A</sub>R deletion acutely activates T cells but compromises long-term antitumor effects on ectopic melanoma and bladder tumors.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> This result may be attributed to the reduced numbers of CD8+ T cells and effector-memory differentiation. Despite the complex and even paradoxical role that A<sub>2A</sub>R may play in the immunopathogenesis, the discovery and translation of A<sub>2A</sub>R antagonists from the bench to bedside in the treatment of cancer have flourished in recent years, with several selective A<sub>2A</sub>R antagonists or dual A<sub>2A</sub>/A<sub>2B</sub>R antagonists entering clinical trials.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">3.  Small-Molecule A<sub>2A</sub>R Antagonists for Cancer Immunotherapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Adenosine receptors modulate a wide range of physiological pathological events.<a onclick="showRef(event, 'ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75">(63−75)</a> Treatment through A<sub>2A</sub>R antagonism has attracted a substantial capital investment, and numerous research papers and patents on small-molecule A<sub>2A</sub>R antagonists have been published and well-reviewed.<a onclick="showRef(event, 'ref12 ref13 ref14 ref28 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref28 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84">(12−14,28,76−84)</a> Historically, A<sub>2A</sub>R antagonists were mainly developed and tested in patients with neurological conditions.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Considering the well-established clinical benefits of checkpoint (PD-1/PD-L1/CTLA-4) inhibitors and the promising preclinical results of A<sub>2A</sub>R blockade, some of those A<sub>2A</sub>R antagonists previously designed for neurological conditions have now been redirected toward cancers.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.1.  Oncoimmunological Effects and Binding Modes of Previously Reported A<sub>2A</sub>R Antagonists</h3><div class="NLM_p">The A<sub>2A</sub>R antagonists described in this section were historically studied for neurological conditions, and their SAR and clinical status were also detailed in these studies.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Here, we have focused on their application as tool molecules in antitumor immunological models. The ligand binding mode will be described here as well.</div><div class="NLM_p">Caffeine (<b>1</b>, hA<sub>2A</sub><i>K</i><sub>i</sub> = 23 400 nM, hA<sub>2B</sub><i>K</i><sub>i</sub> = 20 500 nM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), a naturally occurring nonselective adenosine receptor antagonist, was first used by Sitkovsky and colleagues to determine the antitumor effects on the CL8-1 melanoma model and the CMS4 lung-metastasis model.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> On the basis of the scaffold of xanthine, istradefylline (<b>2</b>, KW6002, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was developed by Kyowa Kirin Co., Ltd. for Parkinson’s disease. Istradefylline was reported to undergo dimerization via [2 + 2] cycloaddition.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> However, the photochemical instability is not relevant to its use as a drug. It possesses a high binding affinity for A<sub>2A</sub>R and shows excellent selectivity over other ARs with a trans-styryl substituent at the 8-position (hA<sub>2A</sub><i>K</i><sub>i</sub> = 36 nM, hA<sub>2B</sub><i>K</i><sub>i</sub> = 1800 nM, hA<sub>1</sub><i>K</i><sub>i</sub> = 2830 nM, and hA<sub>3</sub><i>K</i><sub>i</sub> > 3000 nM). Istradefylline also shows potential in treating oncological diseases.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> Repurposing of this launched drug may provide unique translational opportunities, including a higher possibility of a successful transition to market and a lower cost for clinical availability than new drugs.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Previously reported A<sub>2A</sub>R antagonists that were subsequently analyzed in antitumor immunological models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Due to the poor water solubility of xanthine derivatives and the potential instability caused by the inclusion of the 8-styryl substituent, numerous medicinal chemistry efforts have been devoted to identifying non-xanthine A<sub>2A</sub>R antagonists. Compounds with the pyrazolo-triazolo-pyrimidine core represent the first potent and selective non-xanthine antagonists of A<sub>2A</sub>R.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a> SCH58261 (<b>3</b>, hA<sub>2A</sub><i>K</i><sub>i</sub> = 1.1 nM, highly selective over hA<sub>2B</sub><i>K</i><sub>i</sub> = 1110 nM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was subsequently discovered by Ongini et al. from Schering-Plough in 1993.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Notably, the N<sup>7</sup> derivatives were more selective for A<sub>2A</sub>R than the corresponding N<sup>8</sup> derivatives. In addition to its good pharmacokinetic properties in the Parkinson’s disease model, SCH58261 exerted significant antitumor effects on many cancer models. SCH58261 increased cytokine (IFN-γ, TNF-α, IL-10, IL-2, and IL-4) production in engineered CAR-T cells and/or patient-derived CAR-T cells.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Combined with the anti-PD-1 mAb, SCH58261 also increased IFN-γ production by CD8+ T lymphocytes in the presence of NECA (a selective A<sub>2A</sub>R agonist).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Furthermore, SCH58261 was effective at reducing the metastasis of tumors expressing CD73 endogenously (4T1.2 breast tumors) and ectopically (B16F10 melanoma) through the activation of NK cells.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> When combined with adoptive T cells, anti-PD-1 mAb, and doxorubicin, SCH58261 also significantly suppressed tumor growth in ID8-OVA-bearing mice,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> AT-3ova<sup>dim</sup> CD73+ tumor-bearing mice or MC38ova<sup>dim</sup> CD73+ tumor-bearing mice,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and 4T1.2 tumor-bearing mice,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> respectively. An irreversible A<sub>2A</sub>R antagonist, FSPTP (<b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), was designed based on SCH58261 and incorporated a fluorosulfonyl moiety to study the receptor reserve.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Notably, experiments using FSPTP showed increased growth rates for ectopic melanoma and bladder tumors, possibly due to the impaired CD8+ T cell differentiation and accumulation.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Thus, irreversible blockade of A<sub>2A</sub>R signaling resulted in a T cell survival defect in specific tumors.</div><div class="NLM_p">Since these triheterocyclic compounds still display poor solubility and are difficult to synthesize, the Zeneca Group plc (also known as AZN now) developed a bicyclic triazolo-triazine compound ZM241385 (<b>5</b>, hA<sub>2A</sub><i>K</i><sub>i</sub> = 0.8 nM vs hA<sub>1</sub><i>K</i><sub>i</sub> = 255 nM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) in 1995, which was also a potent hA<sub>2B</sub>R antagonist (hA<sub>2B</sub><i>K</i><sub>i</sub> = 50 nM).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Like SCH58261, ZM241385 was widely used as a pharmacological tool in various tumor models. ZM241385 alone significantly inhibited tumor growth in a lung metastasis model<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and induced a remarkable delay in tumor growth in melanoma-bearing mice when combined with anti-CTLA-4 mAb.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p">Previously, a series of compounds derived from benzoxazole, thiazolopyridine, and benzothiophene cores were shown to be potent A<sub>2A</sub>R antagonists.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The 4-morpholino-6-methoxybenzothiazoles containing a variety of urea and amide side chains appeared to be the most interesting and selective A<sub>2A</sub>R antagonists. Among these analogues, tozadenant (<b>6</b>, also known as SYN115, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which was identified by Roche in 2005, entered phase 3 clinical trials for Parkinson’s disease. It exhibited potent and selective A<sub>2A</sub>R binding affinity (hA<sub>2A</sub><i>K</i><sub>i</sub> = 5 nM, hA<sub>2B</sub><i>K</i><sub>i</sub> = 700 nM, hA<sub>1</sub><i>K</i><sub>i</sub> = 1350 nM).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a>Although the trial terminated due to unexpected safety issues,<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> tozadenant in combination with anti-PD-1 mAb was confirmed by Beavis et al. to inhibit the growth of AT-3ova<sup>dim</sup> CD73+ breast carcinoma.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p">The discovery of historic A<sub>2A</sub>R antagonists relied mainly on empirical or ligand-based design. Since the first structure of A<sub>2A</sub>R bound to the antagonist ZM241385 was resolved in 2008,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> a series of elegant studies conducted by Heptares Therapeutics and other companies or institutes made human A<sub>2A</sub>R one of the best structurally characterized GPCRs.<a onclick="showRef(event, 'ref98 ref99 ref100 ref101 ref102 ref103 ref104 ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref98 ref99 ref100 ref101 ref102 ref103 ref104 ref105 ref106">(98−106)</a> These structural data have helped scientists to understand historic ligand binding modes and discover novel A<sub>2A</sub>R antagonists. The crystal structures of A<sub>2A</sub>R bound to ZM241385<a onclick="showRef(event, 'ref97 ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref97 ref104 ref105">(97,104,105)</a> or caffeine<a onclick="showRef(event, 'ref103 ref106'); return false;" href="javascript:void(0);" class="ref ref103 ref106">(103,106)</a> confirmed a common orthosteric binding site (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A–C): (1) the core moieties established van der Waals interactions with M270<sup>7.35</sup> and I274<sup>7.39</sup> and a π–π stacking interaction with the aromatic ring of F168<sup>ECL2</sup>; (2) N253<sup>6.55</sup> formed hydrogen bonds (H bonds) with either the naked amino group at the 7 position of ZM241385 or O<sup>11</sup>/O<sup>13</sup> from the xanthine heterocycle of caffeine; (3) the neighboring residue E169<sup>ECL2</sup> also contributed to a hydrogen bond interaction with the ligand. Similarly, the compound tozadenant, which was derived from a completely different core plane, occupied the orthosteric pocket by forming H bonds with N253<sup>6.55</sup> and a π–π interaction with F168<sup>ECL2</sup> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). This result suggested the importance of the oxygen atom at the 4 position, N<sup>3</sup>, and nitrogen atom at the 2 position in ligand binding. The 4-hydroxy-4-methylpiperidine moiety located upright on the benzothiazole ring hydrogen-bonded to T256<sup>6.58</sup> suggested a favorable polar interaction in this area (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structures of ZM241385, caffeine, and tozadenant. The receptor is colored gray. Residues and side chains that interact with the ligand are shown as sticks and colored by element (carbon, gray; nitrogen, blue; oxygen, red; sulfur, yellow). Polar contacts are presented as dashed lines, and water molecules are shown as red spheres. The ligands are shown as sticks, and PDB codes are shown in the figure: (A) ZM241385, the salt bridge is intact; (B) ZM241385, the salt bridge is broken; (C) caffeine, the two distinct binding orientations in the structure are overlaid; (D) tozadenant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the orthosteric binding site, other subbinding sites also exist. As mentioned above, caffeine showed micromolar range affinities for both A<sub>2A</sub>R and A<sub>2B</sub>R. Antagonists larger than caffeine might exploit subsidiary binding sites to increase their binding affinity. Taking ZM241385 as an example, the phenylethylamine group explored the extracellular surface of the receptor. In one conformation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A),<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> the salt bridge (which functioned as a cap closing the top of the orthosteric binding pocket and was known to affect ligand binding kinetics<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a>) between E169<sup>ECL2</sup> and H264<sup>ECL3</sup> was intact. The phenol ring established van der Waals interactions with H264<sup>ECL3</sup>, L267<sup>7.32</sup>, and M270<sup>7.35</sup> and extended toward the solvent-exposed surface. In another conformation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B),<a onclick="showRef(event, 'ref97 ref107'); return false;" href="javascript:void(0);" class="ref ref97 ref107">(97,107)</a> the salt bridge was broken. The phenol ring hydrogen-bonded to A63<sup>2.61</sup> and formed van der Waals interactions with S67<sup>2.65</sup>, Y271<sup>7.36</sup>, and I274<sup>7.39</sup>. All these interactions contributed to the good binding affinity and selectivity of ZM241385. Noticeably, the subsidiary binding pocket formed by S67<sup>2.65</sup>, Y271<sup>7.36</sup>, I274<sup>7.39</sup>, Y9<sup>1.35</sup>, and other residues was later identified by Sun et al. as a potential allosteric site.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div><div class="NLM_p last">The chemical diversity of compounds cocrystallized with A<sub>2A</sub>R has provided novel insights into the binding modes and facilitated the derivatization and optimization of existing ligands. This structure-based drug design (SBDD) strategy is exemplified by the development of recently reported A<sub>2A</sub>R antagonists.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.2.  Recently Reported A<sub>2A</sub>R Antagonists for Cancer Immunotherapy</h3><div class="NLM_p">Due to the focused industrial investment in cancer therapy with A<sub>2A</sub>R antagonists and the rapid development of X-ray crystallography in adenosine receptors, the discovery of novel A<sub>2A</sub>R antagonists specific for cancer immunotherapy has substantially increased in recent years. Here, we describe the most relevant compounds as treatments for cancer organized by pharmaceutical companies.</div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.2.1.  AdoRx</h4><div class="NLM_p">AdoRx Therapeutics is pursuing the identification of “fit for purpose” adenosine receptor antagonists to treat cancer, with two programs including antagonists of A<sub>2A</sub>R and dual blockade of A<sub>2A</sub>R/A<sub>2B</sub>R in preclinical development. The company has recently patented a series of pyrimidine derivatives. Compounds with the general formula <b>A</b> were defined as A<sub>2A</sub>R antagonists for the treatment of cancer (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> For R<sup>1</sup> and X<sup>2</sup>-R<sup>2</sup>, furan and arylmethanamine groups appeared to be preferred, with compound <b>7</b> being a representative molecule (hA<sub>2A</sub><i>K</i><sub>i</sub> = 3.3 nM, hA<sub>2B</sub><i>K</i><sub>i</sub> = 440 nM, hA<sub>1</sub><i>K</i><sub>i</sub> = 1721 nM, and hA<sub>3</sub><i>K</i><sub>i</sub> = 908 nM, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Substitutions were introduced at the X<sup>1</sup> position to further improve the potency for the A<sub>2A</sub> subtype, leading to the discovery of compound <b>8</b> (hA<sub>2A</sub><i>K</i><sub>i</sub> = 0.11 nM, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Importantly, in the CD3/CD28-stimulated IL-2 release NECA reversal assay, the IC<sub>50</sub> value of compound <b>8</b> was 9 nM, which is much lower than the value of compound <b>7</b> (IC<sub>50</sub> = 77 nM). Unfortunately, compound <b>8</b> showed poor selectivity over A<sub>1</sub>R (<i>K</i><sub>i</sub> = 1.7 nM) and A<sub>3</sub>R (<i>K</i><sub>i</sub> = 11 nM). Modification of the side chain at the X<sup>1</sup> position provided the selective A<sub>2A</sub>R antagonist <b>9</b> (hA<sub>2A</sub><i>K</i><sub>i</sub> = 1.3 nM vs hA<sub>1</sub><i>K</i><sub>i</sub> = 260 nM, hA<sub>3</sub><i>K</i><sub>i</sub> = 62 nM, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). However, when comparing the A<sub>2A</sub>R binding affinity, compound <b>9</b> was 12-fold less potent than compound <b>8</b>. Interestingly, compound <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) showed incredibly high potency for A<sub>2A</sub>R/A<sub>2B</sub>R, with <i>K</i><sub>i</sub> values of 0.078 nM and 5.4 nM. It was also selective over A<sub>1</sub> and A<sub>3</sub> receptors (230- and 2487-fold, respectively). Additionally, compound <b>10</b> was the most potent compound in the pCREB (phosphorylated cAMP-response element binding protein) assay (IC<sub>50</sub> = 17 nM). Notably, compounds <b>7</b>–<b>10</b> displayed moderate potency in the lipopolysaccharide (LPS)-stimulated TNFα release NECA reversal assay (IC<sub>50</sub> > 200 nM).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Selected A<sub>2A</sub>R antagonists from AdoRx Therapeutics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">3.2.2.  Arcus</h4><div class="NLM_p">Arcus Biosciences’ lead program targeting the adenosine pathway has created innovative cancer immunotherapies using its small molecule discovery and development capabilities. In July 2018, Arcus published the first patent on azolopyrimidine (<b>B</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) for the treatment of cancer-related disorders.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> For the exocyclic amino group, double substitutions significantly reduced the potency for A<sub>2A</sub>R. A single substitution was tolerable, and the naked amino group appeared to be optimal. A slight reduction in potency was observed when R<sup>4</sup> was a methyl group rather than a hydrogen atom. Small substitutions, such as a methyl or hydroxymethyl group, were tolerable at R<sup>3</sup>. One of the representative compounds, <b>11</b>, is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, with <i>K</i><sub>B</sub> (similar to IC<sub>50</sub>) < 100 nM reported in a human A<sub>2A</sub>R CHO-TREx cAMP functional assay. Importantly, a phase 1/2 compound AB928 (<b>12</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) was also included in this patent. Compared with compound <b>11</b>, AB928 contains methylbenzonitrile instead of the furan (potential toxicophore) fragment at the Ar<sup>2</sup> position. Possibly due to its dual antagonism of A<sub>2A</sub>R/A<sub>2B</sub>R (<i>K</i><sub>B</sub> = 1.5 nM and 2.0 nM, respectively), AB928 outperformed its competitors in preclinical testing.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> AB928 (100 mg/kg, po, b.i.d.) alone<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> or in combination with either anti-PD-1 (5 mg/kg)<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> or doxorubicin (6 mg/kg)<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> exerted significant antitumor effects on either B16-F10 melanoma or AT3-OVA tumor models. In a phase 1 dose-escalation study, the mean <i>T</i><sub>max</sub> values of AB928 (75 mg, 150 mg, and 200 mg) were approximately 2 h according to SAD (a single ascending dose) cohorts and 1.5 h according to MAD (a multiple ascending dose) cohorts. The mean <i>C</i><sub>max</sub> was approximately 1172 ng/mL, and <i>t</i><sub>1/2</sub> was approximately 20 h.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> At the ASCO meeting in 2019,<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Arcus further disclosed that AB928 in combination with chemotherapy or AB122 (a human anti-PD-1 mAb) showed favorable safety and pharmacokinetics/pharmacodynamics (PK/PD) profiles, induced CD8+ T cell infiltration into the tumor, and resulted in tumor response/disease stabilization in subjects with advanced tumors. Seven phase 1/2 trials on AB928 are recruiting subjects to evaluate its safety, tolerability, and combination therapy in patients (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Arcus has further committed to developing dual A<sub>2A</sub>R/A<sub>2B</sub>R antagonists. In November 2018, Arcus concomitantly published two patents on quinazoline-pyridine (<b>C</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>)<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> and quinazoline-pyrazole (<b>D</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>)<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> and their uses in cancer treatment as dual A<sub>2A</sub>R/A<sub>2B</sub>R antagonists. These derivatives may be designed through a ring-merging strategy compared to structure <b>B</b>. Pyridine and pyrazole were optimal moieties at the Ar<sup>1</sup> position, with both compound <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) and compound <b>15</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) showing potent dual A<sub>2A</sub>R/A<sub>2B</sub>R inhibition (<i>K</i><sub>B</sub> < 100 nM). Compound <b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), a pyridine-<i>N</i>-oxide analogue of compound <b>13</b>, might be a metabolite under physiological conditions. Notably, both the <i>S</i> and <i>R</i> enantiomers of compound <b>14</b> maintained a high potency for A<sub>2A</sub>R/A<sub>2B</sub>R (<i>K</i><sub>B</sub> < 100 nM). Interestingly, compound <b>16</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), similar to compound <b>15</b>, also displayed low <i>K</i><sub>B</sub> values for A<sub>2A</sub>R/A<sub>2B</sub>R, which suggested good substituent tolerance at the N<sup>1</sup> position.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Selected A<sub>2A</sub>R antagonists from Arcus Biosciences.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">3.2.3.  Bristol-Myers Squibb/Corvus/Vernalis</h4><div class="NLM_p">Vipadenant (<b>17</b>, also known as V2006, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) was first developed by Vernalis researchers as a treatment for Parkinson’s disease.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> In addition to the high selectivity over A<sub>3</sub>R, compound <b>17</b> showed potent binding affinity for A<sub>2A</sub>R (<i>K</i><sub>i</sub> = 1.3 nM), A<sub>2B</sub>R (<i>K</i><sub>i</sub> = 62.4 nM), and A<sub>1</sub>R (<i>K</i><sub>i</sub> = 68 nM). Notably, compound <b>17</b> showed some toxicity that was not discovered in preclinical studies, and it was discontinued in 2010 in a phase 2 clinical trial for Parkinson’s disease.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Currently, compound <b>17</b> is authorized to Bristol-Myers Squibb for preclinical cancer immunology research. In 2018, the cocrystal structure of compound <b>17</b> and A<sub>2A</sub>R was resolved by Marshall et al., which provided significant insights into the binding mode of small molecules bearing the [1,2,3]triazolo[5,4-<i>d</i>]pyrimidine core.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> The basal region of the orthosteric binding site was delimited by W246<sup>6.48</sup>, which was engaged in van der Waals contacts to the furan ring of compound <b>17</b>. Similarly, compound <b>17</b> was identified by H bonds and π–π interactions similar to those of ZM241385 at the orthosteric site. The 2-methylaniline moiety distinctly protruded outward at TM1 and hydrogen-bonded to Y9<sup>1.35</sup>, whose position and rotamers significantly modulated the potential allosteric pocket to accommodate various moieties (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Ciforadenant (<b>18</b>, known as CPI-444, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) also originated from in-house research by Vernalis. It appeared to be a “longer” version of compound <b>17</b>. Since the potential allosteric pocket was conformationally malleable, the pyridine moiety might also protrude into this subsidiary site, and the tetrahydrofuran, a polar functional group that improves water solubility, would extend toward another subpocket. Compound <b>18</b> displayed good binding affinity for A<sub>2A</sub>R (<i>K</i><sub>i</sub> = 3.4 nM) and selectivity against A<sub>1</sub>R (<i>K</i><sub>i</sub> = 192 nM), A<sub>2B</sub>R (<i>K</i><sub>i</sub> = 3975 nM), and A<sub>3</sub>R (<i>K</i><sub>i</sub> = 2498 nM).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> In addition to the potent inhibition of cAMP in HEK-293 cells (IC<sub>50</sub> = 17 nM) and primary human T cells (IC<sub>50</sub> = 70 nM), compound <b>18</b> suppresses pCREB and restores pERK (phosphorylated extracellular regulated protein kinases) levels in human immune cells. Remarkably, while both MC38 and CT26 models are characterized by high levels of extracellular adenosine, only the former was inhibited by compound <b>18</b> (10 mg/kg).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Considering its antitumor effect alone or in combination with other immune checkpoint inhibitors and the completed phase 1 study on pharmacokinetics in healthy subjects (NCT03237988), compound <b>18</b> is now being analyzed in a phase 1/1b trial on the safety and tolerability in advanced cancers (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) sponsored by Corvus Pharmaceuticals.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A, C) Selected A<sub>2A</sub>R antagonists from Vernalis, Evotec/Exscientia, and Hanmi. (B) Cocrystal structure of vipadenant bound to A<sub>2A</sub>R. The ligand is shown as sticks, and the PDB code is shown in the figure. The receptor is shown as a cartoon and colored gray, whereas residues and side chains that interact with the ligand are shown as sticks and colored by element. Polar contacts are presented as dashed lines and water molecules are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">3.2.4.  Evotec/Exscientia</h4><div class="NLM_p last">At the AACR Annual Meeting in 2018,<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Evotec and Exscientia presented a poster describing A<sub>2A</sub>R/CD73 small-molecule inhibitors for cancer immunotherapy. A novel nonbrain-penetrating (ratio of AUC<sup>brain/plasma</sup> = 0.013) A<sub>2A</sub>R antagonist EVOEX21546 (<b>19</b>, structure not disclosed, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C) was reported.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> In the human A<sub>2A</sub>R SPR screening assay, the <i>K</i><sub>D</sub> value was 6 nM. It also reduced cAMP production by NECA-stimulated HEK cells expressing human A<sub>2A</sub>R (EC<sub>50</sub> = 526 nM) and showed potency in restoring IL-2 production in primary human CD3+ T lymphocytes <i>in vitro</i>. DMPK (drug metabolism and pharmacokinetics) data showed that EVOEX21546 has a favorable profile (hERG alert IC<sub>50</sub> > 30 μM, non-off-target at 10 μM, <i>t</i><sub>1/2</sub> = 2.5 h, and AUC<sub>(0–inf)</sub> = 56476 ng·h/mL in tumor). Further evaluations using <i>in vivo</i> models are ongoing.</div></div><div id="sec3_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">3.2.5.  Hanmi</h4><div class="NLM_p last">Benefiting from the high-resolution crystal structure of A<sub>2A</sub>R bound to ZM241385 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EIY">4EIY</a>),<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> researchers from Hanmi Pharmaceutical developed a series of novel A<sub>2A</sub>R antagonists (named after HM) using computer-aided drug design (CADD). In addition to the good docking performance, the selected HM compounds (structure not disclosed, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C) showed good A<sub>2A</sub>R binding affinity, with IC<sub>50</sub> values ranging from 2.0 to 6.5 nM. Compared to CPI-444, compound HM87086 (<b>20</b>, IC<sub>50</sub> = 3.7 nM, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C) exhibited a higher potency of cAMP inhibition in HEK293-A<sub>2A</sub>R cells in the presence of both low and high adenosine concentrations. HM87086 and HM87119 (<b>21</b>, IC<sub>50</sub> = 3.0 nM, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C) also inhibited CREB phosphorylation and abrogated A<sub>2A</sub>R-mediated inhibition of cytotoxicity in CD8+ T cells from human whole blood. In the CT-26-bearing syngeneic mouse model, HM87086 (50 mg/kg, po, b.i.d.) significantly inhibited tumor growth in combination with anti-PD-L1 (10 mg/kg, iv, q3d). Accordingly, Hanmi Pharmaceutical may have selected a candidate and started a GLP (good laboratory practice) toxicity study in the second half of 2019.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div></div><div id="sec3_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">3.2.6.  iTeos</h4><div class="NLM_p">In preliminary studies, a research group from iTeos Therapeutics found that some of the A<sub>2A</sub>R antagonists designed for Parkinson’s disease dramatically lost potency in the high adenosine environment within tumors. Usually, a 30-fold dose was required to restore full target inhibition within tumors for cancer treatment.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> EOS100850 (<b>22</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) was specifically designed for immuno-oncology. It exhibited strong cAMP inhibition that was unaffected by adenosine levels, and its PD activity extended well beyond its PK. This “insurmountable/noncompetitive” profile was potentially attributed to its prolonged residence time.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In addition to the good selectivity for A<sub>2A</sub>R (270-/1200-/40000-fold over A<sub>1</sub>R/A<sub>2B</sub>R/A<sub>3</sub>R, respectively) and nonbrain penetration (avoiding possible CNS-related adverse effects at high doses), compound <b>22</b> showed A<sub>2A</sub>R IC<sub>50</sub> values for cAMP and pCREB inhibition of 1.83 nM (human T cells) and 11.2 nM (CD8 T cells) in a tumor-like environment, respectively. All these characteristics enabled EOS100850 to outperform its competitors. Moreover, EOS100850 in combination with anti-CTLA-4 mAb increased the number of CD8+ T cells and activated macrophages that infiltrated the TME. It inhibited tumor growth with a higher complete response rate than a single anti-CTLA-4 agent and induced immunological memory in the EMT-6 mouse model.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> EOS100850 was proposed to be a best-in-class A<sub>2A</sub>R antagonist designed for immuno-oncology, and it has now been advanced into a phase 1 clinical trial (NCT03873883). Although the structure of EOS100850 was not disclosed, iTeos published a patent on 2-oxothiazole derivatives (<b>E</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) as A<sub>2A</sub>R inhibitors for use in the treatment of cancers in October 2018.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Some of the compounds (containing an amide rather than a carboxyl side chain at the R<sup>2</sup> position) remained potent on HEK-cAMP inhibition at high concentrations of adenosine, while most of them showed subnanomolar potency at low concentrations of NECA. Compound <b>23</b> (IC<sub>50</sub> = 0.5/2 nM in the presence of 3/5 nM of NECA and 49 nM in the presence of 5 μM adenosine, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) dose-dependently restored IL-2 production in CGS-21680-treated human T cells. It also inhibited A<sub>2A</sub>R-mediated CREB phosphorylation with an IC<sub>50</sub> of 20 nM. Replacement of the amino/amide group with a sulfinyl group led to the discovery of compound <b>24</b> (racemate, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), which showed potency at rescuing the secretion of IFNγ, TNFα, IL-8, and IL-10 in whole blood. Both the (+) and (−) enantiomers potently inhibited cAMP production. Compound <b>25</b> (IC<sub>50</sub> = 0.6/2 nM in the presence of 3/5 nM of NECA and 25 nM in the presence of 5 μM adenosine, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) further exhibited complete inhibition of CD4-CREB after 30 min at the dose of 0.1 mg/kg (po) and 70% inhibition after 12 h at the dose of 1 mg/kg (po). Notably, all the reported examples contained a furan group at the R<sup>1</sup> position.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Selected A<sub>2A</sub>R antagonists from iTeos Therapeutics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">3.2.7.  Merck</h4><div class="NLM_p">The SAR of the pyrazolo[4,3-<i>e</i>]-1,2,4-triazolo[1,5-<i>c</i>]pyrimidine scaffold has been extensively studied previously, leading to the discovery of preladenant (<b>26</b>, also named MK-3814, hA<sub>2A</sub><i>K</i><sub>i</sub> = 1.1 nM, approximately 1000-fold over other ARs, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Although the phase 3 clinical trials for Parkinson’s disease have been terminated because of the failure to show efficacy compared with the placebo, preladenant had been advanced to a phase 1 study for advanced solid tumors (NCT03099161). Unfortunately, this trial was also terminated in June 2019 as the data did not support the study end point. Merck & Co. remained committed to immuno-oncology, with three patents on A<sub>2A</sub>R antagonists used for neoplasms published in 2019.<a onclick="showRef(event, 'ref130 ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref130 ref131 ref132">(130−132)</a> Similar to the benzothiazole compound tozadenant (<b>6</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), thiazolo[4,5-<i>c</i>]pyridine derivatives <b>27</b>–<b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) were disclosed, in which a nitrogen atom was introduced to improve the PK properties. Compared to tozadenant (<i>t</i><sub>1/2</sub> = 0.172 h, <i>C</i><sub>max</sub> = 449 ng/mL at 1 mg/kg, iv), compound <b>27</b> (hA<sub>2A</sub> cAMP IC<sub>50</sub> < 10 nM, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) showed a similar mouse PK profile (<i>t</i><sub>1/2</sub> = 0.184 h, <i>C</i><sub>max</sub> = 337 ng/mL at 1 mg/kg, iv). Replacement of the urea side chain with an aryl amide led to the discovery of compound <b>28</b> (hA<sub>2A</sub> cAMP IC<sub>50</sub> < 10 nM, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), which displayed a better PK profile (<i>t</i><sub>1/2</sub> = 0.817 h, <i>C</i><sub>max</sub> = 1390 ng/mL at 1 mg/kg, iv). Interestingly, the <i>t</i><sub>1/2</sub> value of compound <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was again reduced to 0.331 h, which indicated the importance of the nitrogen atom.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> In another patent, Merck disclosed a series of benzimidazole derivatives as A<sub>2A</sub>R antagonists.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> These compounds are bioisosteres of tozadenant, in which the sulfur atom replaced with a nitrogen atom. The half-lives of these compounds were longer than tozadenant, which was clarified in the examples of compound <b>30</b> (<i>t</i><sub>1/2</sub> = 0.839 h, <i>C</i><sub>max</sub> = 2650 ng/mL at 1 mg/kg, iv, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and its analogues. Likewise, an aryl amide replacement further prolonged the half-life (compound <b>31</b>, <i>t</i><sub>1/2</sub> = 1.72 h, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). However, the <i>C</i><sub>max</sub> value was reduced to 733 ng/mL at 1 mg/kg after an intravenous injection. Modification of the side chain produced compound <b>32</b> (<i>t</i><sub>1/2</sub> = 1.15 h, <i>C</i><sub>max</sub> = 2100 ng/mL, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), which also exhibited high affinity for A<sub>2A</sub>R (hA<sub>2A</sub> cAMP IC<sub>50</sub> < 10 nM) and approximately 1000-fold selectivity over the other three subtypes. When the morpholine was replaced with a (hetero)aryl moiety, a significant improvement in the PK profile of compound <b>33</b> (<i>t</i><sub>1/2</sub> = 0.867 h, <i>C</i><sub>max</sub> = 1320 ng/mL, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and compound <b>34</b> (<i>t</i><sub>1/2</sub> = 1.11 h, <i>C</i><sub>max</sub> = 1440 ng/mL, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was not observed. Unfortunately, although these compounds were potent inhibitors of A<sub>2A</sub>R (hA<sub>2A</sub> cAMP IC<sub>50</sub> < 10 nM), they displayed a limited ability to restore the cytokine secretion that was suppressed by adenosine, with IC<sub>50</sub> values of more than 100–1000 nM. Only compound <b>35</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) showed potency in restoring IL-2 (IC<sub>50</sub> = 40 nM) and IFN-γ (IC<sub>50</sub> = 40 nM) secretion. Through scaffold hopping, a series of quinoxalines were derived from benzothiazoles while maintaining the key groups unchanged.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Both compounds <b>36</b> (hA<sub>2A</sub> cAMP IC<sub>50</sub> < 100 nM, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and <b>37</b> (hA<sub>2A</sub> cAMP IC<sub>50</sub> < 100 nM, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) have <i>t</i><sub>1/2</sub> values of more than 2 h. When the aryl group was replaced with tetrahydropyran in compound <b>38</b> (<i>t</i><sub>1/2</sub> = 0.92 h, <i>C</i><sub>max</sub> = 908 ng/mL, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) as an example, the half-life was reduced significantly. Even compound <b>39</b> (<i>t</i><sub>1/2</sub> = 0.338 h, <i>C</i><sub>max</sub> = 1220 ng/mL, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), in which the urea side chain replaced with an aryl amide, displayed a poor PK profile.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Selected A<sub>2A</sub>R antagonists from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">3.2.8.  Novartis/Palobiofarma</h4><div class="NLM_p">2,6-Bis(heteroaryl)-4-aminopyrimidines were first disclosed by Almirall Prodesfarma SA as A<sub>2A</sub>R antagonists.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> However, researchers from Palobiofarma SL surprisingly found that the potency of the compounds was considerably increased by introducing an electron-withdrawing substitute at position 5 of the pyrimidine ring.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Taminadenant (<b>40</b>, also known as PBF-509/NIR178, hA<sub>2A</sub><i>K</i><sub>i</sub> = 12 nM, 25-fold more potent than the unsubstituted compound, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) was one of the representative compounds. Derivatives of compound <b>40</b> with a chloro/cyano substitution at position 5 or pyrrolidyl/ethylthiol/trifluoroethoxyl substitution at position 6 also maintained the binding affinity. However, except for PBF-509, none of these compounds have been reported to be used in cancer immunotherapy.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> PBF-509 showed high selectivity over other adenosine receptors (2500 nM for A<sub>1</sub>R, 1000 nM for A<sub>2B</sub>R, and 5000 nM for A<sub>3</sub>R). In the cAMP inhibition assay, the IC<sub>50</sub> value was 25 nM. Additionally, PBF-509 did not show any relevant activity in the presence of a panel of other receptors and enzymes. Furthermore, PBF-509 significantly reduced the tumor burden of mice with B16-CD73+ (15 mg kg<sup>–1</sup> day<sup>–1</sup>, po) or MCA205 (30 mg kg<sup>–1</sup> day<sup>–1</sup>, po) tumors. In a more clinically relevant model, PBF-509 combined with anti-PD-L1 restored immune responsiveness in tumor-infiltrating lymphocytes from freshly resected tumors of non-small-cell lung cancer. PBF-509 has now been advanced to a phase 1/2 study by Novartis and Palobiofarma for patients with advanced malignancies (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Novartis AG then disclosed compound <b>41</b> (hA<sub>2A</sub><i>K</i><sub>i</sub> = 50 nM, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), an active metabolite of PBF-509, which exerted antitumor effects alone or in combination with one or more immunotherapeutic agents.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Possibly because the pyrazole at the C2 position was liable to oxidization, a nitrogen was introduced at this position. Additionally, as mentioned above, the pyrazole at the C6 position was disposable, and thus a propargylamine group was used. PBF-999 (<b>42</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) with a simple biaryl structure was subsequently discovered. It is a novel phosphodiesterase-10A (PDE-10A)/A<sub>2A</sub>R dual antagonist. An increase in intracellular cyclic guanosine monophosphate (cGMP) levels is known to inhibit tumor proliferation and induce apoptosis. However, cGMP levels are low in cancer cells due to the overexpression of PDE-10A. PBF-999 binds to and inhibits the activity of PDE-10A, thereby preventing the degradation of cGMP. Antagonism of both A<sub>2A</sub>R and PDE-10A might therefore exert synergistic antitumor effects. PBF-999 was reported to be safe and well tolerated in the dose escalation (ranging from 20 mg to 120 mg) arm of a phase 1 clinical trial. The corresponding dose expansion study is in progress (NCT03786484).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Selected A<sub>2A</sub>R antagonists from Novartis/Palobiofarma.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">3.2.9.  Selvita</h4><div class="NLM_p">The Selvita research group has also discovered a novel series of potent dual A<sub>2A</sub>/A<sub>2B</sub> adenosine receptor antagonists.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> SEL330-584 (<b>43</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A) displayed very high potency for A<sub>2A</sub>R/A<sub>2B</sub>R in the presence of 0.1 μM adenosine (EC<sub>50</sub> = 0.26/3.6 nM) and high potency in the presence of 100 μM adenosine (EC<sub>50</sub> = 92/634 nM). SEL330-639 (<b>44</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A) also displayed very high potency for A<sub>2A</sub>R/A<sub>2B</sub>R in the presence of 0.1 μM of adenosine (EC<sub>50</sub> = 0.25/6.4 nM) and high potency in the presence of 100 μM of adenosine (EC<sub>50</sub> = 4.2/1618 nM). However, CPI-444 and AZD4635 (a clinical compound to be discussed later) almost completely lost their activities in high adenosine environment, with EC<sub>50</sub> > 10 000 nM.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Notably, both compounds <b>43</b> and <b>44</b> exclusively restored the function of monocyte-derived dendritic cells (moDC cells, driven by A<sub>2B</sub>R) compared to A<sub>2A</sub>R antagonists such as CPI-444. Further results from <i>in vivo</i> testing were disclosed for compound <b>44</b>.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> It was somewhat more potent than AB928 in inhibiting CREB phosphorylation in C57BL/6 mice even 12 h after administration (50 mg/kg for compound <b>44</b> and 100 mg/kg for AB928). Additionally, compound <b>44</b> showed an excellent PK profile (<i>t</i><sub>1/2</sub> = 3.6 h, <i>C</i><sub>max</sub> = 23 000 ng/mL, AUC = 6500 ng·h/mL at 3 mg/kg, po, in mice) and antitumor effects on B16-F10/CT26 tumor models. In January 2019, Selvita published a patent on imidazo[1,2-<i>a</i>]pyrazin-8-amines, as exemplified by compound <b>45</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A), as A<sub>2A</sub>R antagonists (rA<sub>2A</sub><i>K</i><sub>b</sub> < 10 μM).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Unfortunately, no additional data were reported.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A, B) Selected A<sub>2A</sub>R antagonists from Selvita and Sosei Heptares/AstraZeneca. (C) The clinical candidate AZD4635 was discovered using SBDD. The ligands are shown as sticks, and PDB codes are shown in the figure: 3UZA-<b>47</b> and 6GT3-<b>48</b>. The receptor is shown as a cartoon and colored gray, whereas residues and side chains that interact with the ligand are shown as sticks and colored by element. Polar contacts are presented as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">3.2.10.  Sosei Heptares/AstraZeneca</h4><div class="NLM_p last">Benefiting from its unique stabilized receptor (StaR) technology, researchers at Heptares Therapeutics (now named Sosei Heptares after acquisition) identified several novel A<sub>2A</sub>R antagonists lacking a furan ring through a virtual screen.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> By use of ligand docking and biophysical mapping (BPM), the 1,3,5-triazine (<b>46</b>, hA<sub>2A</sub> p<i>K</i><sub>i</sub> = 8.99, 59-fold selective over hA<sub>1</sub>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B) formed hydrogen bonds with N253<sup>6.55</sup>. Another key interaction with H278<sup>7.43</sup> suggested that this compound was located deeper in the pocket.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Considering the proposed binding mode, Congreve et al. hypothesized that the 1,2,4-triazine isomer (<b>47</b>, hA<sub>2A</sub> p<i>K</i><sub>i</sub> = 8.11, hA<sub>1</sub> p<i>K</i><sub>i</sub> = 7.07, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B) might bind to A<sub>2A</sub>R in a more reasonable manner to allow direct access to the ribose pocket. Further X-ray crystallography studies (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UZA">3UZA</a>)<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> confirmed that the amino-triazine core hydrogen bonded to N253<sup>6.55</sup> as both a donor and acceptor. The residue F168<sup>ECL2</sup> formed a perpendicular π–π stacking interaction on one side of the core, while the residue M270<sup>7.35</sup> established a hydrophobic interaction on the other side. Further studies of the SAR showed that only small groups would be tolerated in the phenyl moiety at the C5 position. The models also suggested the potential of the compound to form a hydrogen bond between the aryl moiety at the C6 position and the ribose binding pocket. Therefore, the pyridyl nitrogen was a privileged functional group. These works led to the discovery of novel A<sub>2A</sub>R antagonist <b>48</b> (later known as AZD4635/HTL1071, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B)<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> with the application of the SBDD strategy (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C). Recently, the cocrystal structure of AZD4635 bound to A<sub>2A</sub>R (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GT3">6GT3</a>) was resolved, and the structural data definitely confirm the SBDD strategy.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> AZD4635 bound to human A<sub>2A</sub>R with a <i>K</i><sub>i</sub> of 1.7 nM and showed excellent selectivity over the other two adenosine receptors (160 nM for A<sub>1</sub>R and >10 000 nM for A<sub>3</sub>R). The <i>K</i><sub>i</sub> value for A<sub>2B</sub>R was 64 nM, suggesting that it is a potent dual A<sub>2A</sub>R/A<sub>2B</sub>R antagonist. AZD4635 also displayed high potency in the cAMP inhibition assay (hA<sub>2A</sub> IC<sub>50</sub> = 0.79/142.9 nM, rA<sub>2A</sub> IC<sub>50</sub> = 9.7/96.7 nM in the presence of 0.1 μM/10 μM adenosine, respectively). In addition to restoring the functions of T cells and CD103+ dendritic cells,<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> AZD4635 (50 mg/kg, po, b.i.d.) significantly suppressed tumor growth in combination with anti-PD-L1.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> This compound has now been out licensed to AstraZeneca for immuno-oncological clinical trials in patients with advanced solid malignancies (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In a phase 1a trial, the free plasma concentration of AZD4635 (75 and 100 mg, qd) was much greater than the <i>in vivo</i> IC<sub>50</sub> (10 nM) over the dosing interval, with no dose-limiting toxicities noted. Considering the excellent PK profile (<i>t</i><sub>1/2</sub> = 13 h, AUC = 4365 ng·h/mL on day 1 and AUC = 5709 ng·h/mL on day 15, both at a dose of 100 mg, qd), AZD4635 was recommended for dosing at 100 mg once a day in a phase 2 trial.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">4.  Conclusions and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28142" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28142" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Immunotherapy targeting CTLA-4 and PD-1/PD-L1 benefits patients with neoplastic disease, as more than 10 checkpoint antibodies have been approved worldwide. The success of checkpoint inhibitors has increased the potential of A<sub>2A</sub>R as a clinically significant target. Several A<sub>2A</sub>R antagonists have been advanced to clinical trials for the treatment of various types of cancers. The failure of preladenant in a phase 1 trial, however, suggested that A<sub>2A</sub>R antagonists originally developed for neurological conditions may not be sufficiently efficacious for cancer treatment.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Studies from iTeos and Selvita research groups have revealed that some of the A<sub>2A</sub>R antagonists designed for Parkinson’s disease dramatically lost potency in a high adenosine environment.<a onclick="showRef(event, 'ref125 ref137'); return false;" href="javascript:void(0);" class="ref ref125 ref137">(125,137)</a> Generally, much higher extracellular adenosine levels are present in the TME than in the conditions of Parkinson’s disease. A reasonable speculation is that more or stronger A<sub>2A</sub>R antagonists are needed to overcome the elevated adenosine levels. However, if we simply increase the doses of these antagonists to regain antitumor effects, CNS side effects would likely occur.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Therefore, novel A<sub>2A</sub>R antagonists with increased efficacy (particularly in the TME) and appropriate brain penetration must be developed to herald a bright future for cancer immunotherapy. On the other hand, blockade of A<sub>2B</sub>R was recently reported to exert antitumor effects. Since A<sub>2B</sub>R has a low affinity for adenosine, antagonism of A<sub>2B</sub>R might still be efficient in the adenosine-rich TME, while antagonism of A<sub>2A</sub>R is quite demanding because of its high affinity for adenosine. Therefore, dual antagonism of A<sub>2A</sub>R/A<sub>2B</sub>R may result in some unique biological activities, which also deserves some attention.</div><div class="NLM_p">However, researchers must carefully examine the safety of A<sub>2A</sub>R antagonism. The excessive blockade of A<sub>2A</sub>R, such as global A<sub>2A</sub>R deletion and irreversible A<sub>2A</sub>R antagonism (by FSPTP), has been conditionally shown to be detrimental. Blockade of A<sub>2A</sub>R appeared to be beneficial under the conditions of chronically elevated adenosine levels. Therefore, a pharmacological intervention blocking A<sub>2A</sub>R varies with the stages and/or types of cancers and requires a suitable dosing program.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Additionally, A<sub>2A</sub>R in immune cells exerts a protective effect on excess inflammation. The activation of antitumor immune cells by A<sub>2A</sub>R antagonism might cause paroxysmal immunity (or the pathological cytokine “storm”) in patients with cancer.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">With the advances in membrane protein engineering and crystallography, structure-based drug design will revolutionize our ability to design novel drugs.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The development of AZD4635 is a very good example of how success in achieving structural insights has directly translated to the discovery of a drug candidate. However, the development of ligands with better selectivity remains a challenge. Thus, continuing efforts to determine the structures of all four adenosine receptors are essential for the discovery and development of novel potent A<sub>2A</sub>R antagonists or dual A<sub>2A</sub>R/A<sub>2B</sub>R antagonists. Additionally, the structural data have suggested the existence of another allosteric pocket. Compounds specifically designed to bind to this site have the potential to modulate the properties of orthosteric ligands, which is a promising pharmacological strategy to overcome some of the issues mentioned above.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00237" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61005" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61005" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yonghui Wang</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry,
School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0262-2431" title="Orcid link">http://orcid.org/0000-0002-0262-2431</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c4bdabaaa3acb1adb3a5aaa384a2b1a0a5aaeaa1a0b1eaa7aa"><span class="__cf_email__" data-cfemail="9ce5f3f2fbf4e9f5ebfdf2fbdcfae9f8fdf2b2f9f8e9b2fff2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fazhi Yu</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry,
School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chenyu Zhu</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry,
School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiong Xie</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry,
School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>F.Y. and C.Z. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Fazhi Yu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=BIO-d7e3236-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Fazhi Yu</b> obtained his B.S. degree in traditional Chinese medicine from Chongqing Medical University and then received his M.S. degree in pharmacy from Fudan University in 2017. He is currently studying for a Ph.D. degree in medicinal chemistry at Fudan University. His research focuses on anticancer drug discovery targeting adenosine receptors, smoothened receptor, and epidermal growth factor receptor.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Chenyu Zhu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=BIO-d7e3241-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chenyu Zhu</b> obtained his B.S. degree in pharmaceutical engineering from East China University of Science and Technology in 2019. Since then, he has been pursuing a Master’s degree in medicinal chemistry at Fudan University under the direction of Professor Yonghui Wang and Associate Professor Qiong Xie. His research interests mainly include the discovery and development of novel small-molecule regulators targeting adenosine A<sub>2A</sub> receptor.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Qiong Xie</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=BIO-d7e3249-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Qiong Xie</b> received her B.S. and Ph.D. degrees from Fudan University in 2002 and 2007. She joined the School of Pharmacy at Fudan University as an Assistant Professor in 2007 and became an Associate Professor in 2017. Between 2010 and 2011, she performed postdoctoral research as a visiting scholar at the University of Arizona. Her research interests focus on small-molecule drug discovery for autoimmune diseases, cancer immunotherapy, neurodegenerative diseases, and neuropathic pain. She has published more than 40 publications in peer-reviewed journals and has over 20 patents and patent filings. She was also one of the recipients of 2017 “Shanghai Science and Technology Progress Award” (First Prize).</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Yonghui Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=BIO-d7e3254-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yonghui Wang</b> obtained his Ph.D. in organic chemistry from Virginia Tech in 1997 and received his postdoctoral training in physical and synthetic organic chemistry at Harvard University from 1997 to 2001. He then worked in GlaxoSmithKline R&D as a principal scientist, investigator, and associate director for more than 12 years. In 2014, he became a Professor in the School of Pharmacy at Fudan University, China. His current research focuses on small-molecule drug discovery for autoimmune diseases and cancer immunotherapy. He has published more than 60 scientific papers and is a co-inventor of 32 PCT international patents.</p></figure></div><div class="ack" id="ACK-d7e3267-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Tony Wang and Caitlin Wang for proofreading the manuscript. We also thank the ACS authoring services for language editing. This review was supported by grants from National Science Foundation of China (Grants 81874287 and 81973163), Shanghai Bio-pharmaceutical Science and Technology Supporting Plan (Grants 17431902100 and 19431900100), and the National Science and Technology Major Project Key New Drug Creation and Manufacturing Program, China (Grant 2018ZX09711002-003-014).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">NECA</td><td class="NLM_def"><p class="first last">(2<i>S</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-aminopurin-9-yl)-<i>N</i>-ethyl-3,4-dihydroxyoxolane-2-carboxamide</p></td></tr><tr><td class="NLM_term">CGS-21680</td><td class="NLM_def"><p class="first last">3-[4-[2-[[6-amino-9-[(2<i>R</i>,3<i>R</i>,4<i>S</i>,5<i>S</i>)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">ASCO</td><td class="NLM_def"><p class="first last">American Society of Clinical Oncology</p></td></tr><tr><td class="NLM_term">AACR</td><td class="NLM_def"><p class="first last">American Association for Cancer Research</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 146 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarhini, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panelli, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarour, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H. J.</span></span> <span> </span><span class="NLM_article-title">Next generation of immunotherapy for melanoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3445</span>– <span class="NLM_lpage">3455</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.14.6423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1200%2FJCO.2007.14.6423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=18612161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvVWitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3445-3455&author=J.+M.+Kirkwoodauthor=A.+A.+Tarhiniauthor=M.+C.+Panelliauthor=S.+J.+Moschosauthor=H.+M.+Zarourauthor=L.+H.+Butterfieldauthor=H.+J.+Gogas&title=Next+generation+of+immunotherapy+for+melanoma&doi=10.1200%2FJCO.2007.14.6423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Next generation of immunotherapy for melanoma</span></div><div class="casAuthors">Kirkwood, John M.; Tarhini, Ahmad A.; Panelli, Monica C.; Moschos, Stergios J.; Zarour, Hassane M.; Butterfield, Lisa H.; Gogas, Helen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3445-3455</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose Immunotherapy has a long history with striking but limited success in patients with melanoma.  To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States.  Design Tumor evasion of host immune responses, and strategies for overcoming tumor-induced immunosuppression are reviewed.  Several novel immunotherapies currently in worldwide phase III clin. testing for melanoma are discussed.  Results The limitations of immunotherapy for melanoma stem from tumor-induced mechanisms of immune evasion that render the host tolerant of tumor antigens.  For example, melanoma inhibits the maturation of antigen-presenting cells, preventing full T-cell activation and downregulating the effector antitumor immune response.  New immunotherapies targeting crit. regulatory elements of the immune system may overcome tolerance and promote a more effective antitumor immune response.  These include monoclonal antibodies that block the cytotoxic T lymphocyte-assocd. antigen 4 (CTLA4) and toll-like receptor 9 (TLR9) agonists.  Blockade of CTLA4 prevents inhibitory signals that downregulate T-cell activation.  TLR9 agonists stimulate dendritic cell maturation and ultimately induce a more effective immune response.  These approaches have been shown to stimulate acute immune activation with concomitant appearance of transient adverse events mediated by the immune system.  The pattern and duration of immune responses assocd. with these new modalities differ from those assocd. with cytokines and cytotoxic agents.  In addn., vaccines are being developed that may ultimately target melanoma either alone or in combination with these immunomodulatory therapies.  Conclusion The successes of cytokine and interferon therapy of melanoma, coupled with an array of new approaches, are generating new enthusiasm for the immunotherapy of melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyeng-cXpDZLVg90H21EOLACvtfcHk0lg6G5uyOnKvvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvVWitrY%253D&md5=bc7e4b7b8d72758e8ca3762b3079880c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.6423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.6423%26sid%3Dliteratum%253Aachs%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DTarhini%26aufirst%3DA.%2BA.%26aulast%3DPanelli%26aufirst%3DM.%2BC.%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DZarour%26aufirst%3DH.%2BM.%26aulast%3DButterfield%26aufirst%3DL.%2BH.%26aulast%3DGogas%26aufirst%3DH.%2BJ.%26atitle%3DNext%2520generation%2520of%2520immunotherapy%2520for%2520melanoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3445%26epage%3D3455%26doi%3D10.1200%2FJCO.2007.14.6423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalabi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard-Lucey, V. M.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of the clinical immuno-oncology landscape</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1093%2Fannonc%2Fmdx755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29228097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzgt1ejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=84-91&author=J.+Tangauthor=A.+Shalabiauthor=V.+M.+Hubbard-Lucey&title=Comprehensive+analysis+of+the+clinical+immuno-oncology+landscape&doi=10.1093%2Fannonc%2Fmdx755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of the clinical immuno-oncology landscape</span></div><div class="casAuthors">Tang J; Shalabi A; Hubbard-Lucey V M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Advances from immuno-oncology (IO) are changing the standard of care of many types of cancer, and the paradigm of cancer treatments and drug development is being rewritten on a regular basis.  Moreover, an unprecedented number of new investigational agents and companies are entering the field of IO.  As such, it has become challenging for oncology physicians conducting clinical trials, industry veterans developing IO drugs, and even regulators reviewing novel IO agents to keep track of the rapidly evolving landscape.  To help the key stake holders in the field understand the latest IO landscape, we sought to present an unbiased, neutral, scientifically curated, and timely updated analysis of all the current IO agents in clinical development and the clinical trials testing these agents.  We based our analyses on information collected from numerous trusted and publicly available sources.  We have developed two databases.  One database tracks 2004 IO agents (940 in clinical stage and 1064 in preclinical stage) against 303 targets, from 864 companies; the other tracks 3042 active clinical trials of these agents with a target enrollment of 577 076 patients.  This report provides key analyses of these data.  Furthermore, we will discuss a number of important and actionable trends in the current IO landscape: a large number of companies developing agents against the same IO targets; a rapid increase in the number of anti-PD-1/L1 combination studies, many of which are testing the same combinations and following inefficient patterns; and a significant increase in the number of small, investigator-initiated studies.  For each of the findings, we speculate the causes and discuss a few initiatives that aim to address some of these challenges.  Finally, by making these landscape analyses available, we aspire to inform the cancer community as they seek to strive for efficiencies and innovation while avoiding duplication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDxZXleW3oBeQ4Pl9hzjQhfW6udTcc2eZnNE5RJkuUEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzgt1ejug%253D%253D&md5=b8f7bb2b63892317cfdb0fe26f2860c9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx755%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DShalabi%26aufirst%3DA.%26aulast%3DHubbard-Lucey%26aufirst%3DV.%2BM.%26atitle%3DComprehensive%2520analysis%2520of%2520the%2520clinical%2520immuno-oncology%2520landscape%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3D84%26epage%3D91%26doi%3D10.1093%2Fannonc%2Fmdx755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marin-Acevedo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dholaria, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soyano, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chumsri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span> <span> </span><span class="NLM_article-title">Next generation of immune checkpoint therapy in cancer: new developments and challenges</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">39</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0582-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1186%2Fs13045-018-0582-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29544515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=39&author=J.+A.+Marin-Acevedoauthor=B.+Dholariaauthor=A.+E.+Soyanoauthor=K.+L.+Knutsonauthor=S.+Chumsriauthor=Y.+Lou&title=Next+generation+of+immune+checkpoint+therapy+in+cancer%3A+new+developments+and+challenges&doi=10.1186%2Fs13045-018-0582-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Next generation of immune checkpoint therapy in cancer: new developments and challenges</span></div><div class="casAuthors">Marin-Acevedo, Julian A.; Dholaria, Bhagirathbhai; Soyano, Aixa E.; Knutson, Keith L.; Chumsri, Saranya; Lou, Yanyan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39/1-39/20</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response.  In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response.  Immune checkpoint therapies act by blocking or stimulating these pathways and enhance the body's immunol. activity against tumors.  Cytotoxic T lymphocyte-assocd. mol.-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death ligand-1(PD-L1) are the most widely studied and recognized inhibitory checkpoint pathways.  Drugs blocking these pathways are currently utilized for a wide variety of malignancies and have demonstrated durable clin. activities in a subset of cancer patients.  This approach is rapidly extending beyond CTLA-4 and PD-1/PD-L1.  New inhibitory pathways are under investigation, and drugs blocking LAG-3, TIM-3, TIGIT, VISTA, or B7/H3 are being investigated.  Furthermore, agonists of stimulatory checkpoint pathways such as OX40, ICOS, GITR, 4-1BB, CD40, or mols. targeting tumor microenvironment components like IDO or TLR are under investigation.  In this article, we have provided a comprehensive review of immune checkpoint pathways involved in cancer immunotherapy, and discuss their mechanisms and the therapeutic interventions currently under investigation in phase I/II clin. trials.  We also reviewed the limitations, toxicities, and challenges and outline the possible future research directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXlwLaO-CI8bVg90H21EOLACvtfcHk0ljRAdAglzq3hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqur0%253D&md5=129ab4c9c697f1205e079af49a154ea0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0582-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0582-8%26sid%3Dliteratum%253Aachs%26aulast%3DMarin-Acevedo%26aufirst%3DJ.%2BA.%26aulast%3DDholaria%26aufirst%3DB.%26aulast%3DSoyano%26aufirst%3DA.%2BE.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DChumsri%26aufirst%3DS.%26aulast%3DLou%26aufirst%3DY.%26atitle%3DNext%2520generation%2520of%2520immune%2520checkpoint%2520therapy%2520in%2520cancer%253A%2520new%2520developments%2520and%2520challenges%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D39%26doi%3D10.1186%2Fs13045-018-0582-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targets in immuno-oncology</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.chembiol.2017.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28938090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1148-1160&author=D.+Dhanakauthor=J.+P.+Edwardsauthor=A.+Nguyenauthor=P.+J.+Tummino&title=Small-molecule+targets+in+immuno-oncology&doi=10.1016%2Fj.chembiol.2017.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Targets in Immuno-Oncology</span></div><div class="casAuthors">Dhanak, Dashyant; Edwards, James P.; Nguyen, Ancho; Tummino, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1148-1160</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in understanding the role and mol. mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clin. practice in the treatment of cancer.  Presently, multiple biol. drugs targeting the immune checkpoint proteins PD(L)1 or CTLA4 have been approved and/or are in advanced stages of clin. development for many cancers.  In addn., combination therapy with these agents and other immunomodulators is being intensively explored with the aim of improving primary response rates or prolonging overall survival.  The effectiveness of cancer immunotherapy with biologics is spurring research in alternate approaches including small-mol.-mediated targeting of intracellular pathways modulating the innate and adaptive immune response.  This focus of this review is on some of the key intracellular pathways where the development of a small-mol. therapeutic is attractive, tractable, and potentially synergistic with extracellular biol.-mediated immune checkpoint blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSIXjWBbl9wbVg90H21EOLACvtfcHk0ljRAdAglzq3hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurnL&md5=7f0f2368bec10000a87a3234bb82c035</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26atitle%3DSmall-molecule%2520targets%2520in%2520immuno-oncology%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D1148%26epage%3D1160%26doi%3D10.1016%2Fj.chembiol.2017.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule immuno-oncology therapy: advances, challenges and new directions</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190308131805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.2174%2F1568026619666190308131805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30854972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGhtL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=180-185&author=S.+Chenauthor=Z.+Songauthor=A.+Zhang&title=Small-molecule+immuno-oncology+therapy%3A+advances%2C+challenges+and+new+directions&doi=10.2174%2F1568026619666190308131805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions</span></div><div class="casAuthors">Chen, Shulun; Song, Zilan; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">180-185</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Oncol. immunotherapy has gained significant advances in recent years and benefits cancer patients with superior efficacy and superior clin. responses.  Currently over ten immune checkpoint antibodies targeting CTLA-4 and PD-1/PD-L1 have received regulatory approval worldwide and over thousands are under active clin. trials.  However, compared to the rapid advance of Monoclonal Antibody (mAb), studies on immunotherapeutic small mols. have far lagged behind.  Small mol. immunotherapy not only can target immunosuppressive mechanisms similar to mAbs, but also can stimulate intracellular pathways downstream of checkpoint proteins in innate or adaptive immune cells that mAbs are unable to access.  Therefore, small mol. immunotherapy can provide an alternative treatment modality either alone or complementary to or synergistic with extracellular checkpoint mAbs to address low clin. response and drug resistance.  Fortunately, remarkable progress has achieved recently in the pursuit of small mol. immunotherapy.  This review intends to provide a timely highlight on those clin. investigated small mols. targeting PD-1/PD-L1, IDO1, and STING.  The most advanced IDO1 inhibitor epacadostat have been aggressively progressed into multiple clin. testings.  Small mol. PD-1/PD-L1 inhibitors and STING activators are still in a premature state and their decisive application needs to wait for the ongoing clin. outcomes.  Since no small mol. immunotherapy has been approved yet, the future research should continue to focus on discovery of novel small mols. with distinct chemo-types and higher potency, identification of biomarkers to precisely stratify patients, as well as validation of many other immune-therapeutic targets, such as LAG3, KIRs, TIM-3, VISTA, B7-H3, and TIGIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIg_rDysKA6LVg90H21EOLACvtfcHk0liRqWR1Cap4qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGhtL7E&md5=944b0fc0de82574b1a24f3e910eaccf4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190308131805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190308131805%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSmall-molecule%2520immuno-oncology%2520therapy%253A%2520advances%252C%2520challenges%2520and%2520new%2520directions%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D180%26epage%3D185%26doi%3D10.2174%2F1568026619666190308131805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinska-Szostak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlicki, Ł.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarganes-Tzitzikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Bioactive macrocyclic inhibitors of the Pd-1/Pd-L1 immune checkpoint</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">13732</span>– <span class="NLM_lpage">13735</span>, <span class="refDoi"> DOI: 10.1002/anie.201707707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1002%2Fanie.201707707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOit7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=13732-13735&author=K.+Magiera-Mularzauthor=L.+Skalniakauthor=K.+M.+Zakauthor=B.+Musielakauthor=E.+Rudzinska-Szostakauthor=%C5%81.+Berlickiauthor=J.+Kocikauthor=P.+Grudnikauthor=D.+Salaauthor=T.+Zarganes-Tzitzikasauthor=S.+Shaabaniauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Bioactive+macrocyclic+inhibitors+of+the+Pd-1%2FPd-L1+immune+checkpoint&doi=10.1002%2Fanie.201707707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint</span></div><div class="casAuthors">Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Zak, Krzysztof M.; Musielak, Bogdan; Rudzinska-Szostak, Ewa; Berlicki, Lukasz; Kocik, Justyna; Grudnik, Przemyslaw; Sala, Dominik; Zarganes-Tzitzikas, Tryfon; Shaabani, Shabnam; Doemling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">13732-13735</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Blockade of the immunoinhibitory PD-1/PD-L1 pathway using monoclonal antibodies has shown impressive results with durable clin. antitumor responses.  Anti-PD-1 and anti-PD-L1 antibodies have now been approved for the treatment of a no. of tumor types, whereas the development of small mols. targeting immune checkpoints lags far behind.  We characterized two classes of macrocyclic-peptide inhibitors directed at the PD-1/PD-L1 pathway.  We show that these macrocyclic compds. act by directly binding to PD-L1 and that they are capable of antagonizing PD-L1 signaling and, similarly to antibodies, can restore the function of T-cells.  We also provide the crystal structures of two of these small-mol. inhibitors bound to PD-L1.  The structures provide a rationale for the checkpoint inhibition by these small mols., and a description of their small mol./PD-L1 interfaces provides a blueprint for the design of small-mol. inhibitors of the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxuarSIlQEobVg90H21EOLACvtfcHk0liRqWR1Cap4qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOit7%252FO&md5=b1634408007340ca0990d2607c96c1a9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fanie.201707707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201707707%26sid%3Dliteratum%253Aachs%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DRudzinska-Szostak%26aufirst%3DE.%26aulast%3DBerlicki%26aufirst%3D%25C5%2581.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DZarganes-Tzitzikas%26aufirst%3DT.%26aulast%3DShaabani%26aufirst%3DS.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DBioactive%2520macrocyclic%2520inhibitors%2520of%2520the%2520Pd-1%252FPd-L1%2520immune%2520checkpoint%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D13732%26epage%3D13735%26doi%3D10.1002%2Fanie.201707707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huck, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kötzner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbahns, K.</span></span> <span> </span><span class="NLM_article-title">Small molecules drive big improvements in immuno-oncology therapies</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4412</span>– <span class="NLM_lpage">4428</span>, <span class="refDoi"> DOI: 10.1002/anie.201707816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1002%2Fanie.201707816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlWqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=4412-4428&author=B.+R.+Huckauthor=L.+K%C3%B6tznerauthor=K.+Urbahns&title=Small+molecules+drive+big+improvements+in+immuno-oncology+therapies&doi=10.1002%2Fanie.201707816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Drive Big Improvements in Immuno-Oncology Therapies</span></div><div class="casAuthors">Huck, Bayard R.; Koetzner, Lisa; Urbahns, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4412-4428</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Immunooncol. therapies have the potential to revolutionize the armamentarium of available cancer treatments.  To further improve clin. response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment.  This Review highlights the significance of small mols. in this approach, which holds promise to provide increased benefit to cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobJKXxvd05sLVg90H21EOLACvtfcHk0liRqWR1Cap4qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlWqsbo%253D&md5=bef3a381977686b5bdb432a76364b066</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fanie.201707816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201707816%26sid%3Dliteratum%253Aachs%26aulast%3DHuck%26aufirst%3DB.%2BR.%26aulast%3DK%25C3%25B6tzner%26aufirst%3DL.%26aulast%3DUrbahns%26aufirst%3DK.%26atitle%3DSmall%2520molecules%2520drive%2520big%2520improvements%2520in%2520immuno-oncology%2520therapies%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D4412%26epage%3D4428%26doi%3D10.1002%2Fanie.201707816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huizinga, H. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span> <span> </span><span class="NLM_article-title">A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015–2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1512706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1080%2F13543776.2018.1512706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30107136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OltrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=665-678&author=S.+Shaabaniauthor=H.+P.+S.+Huizingaauthor=R.+Buteraauthor=A.+Kouchiauthor=K.+Guzikauthor=K.+Magiera-Mularzauthor=T.+A.+Holakauthor=A.+D%C3%B6mling&title=A+patent+review+on+PD-1%2FPD-L1+antagonists%3A+small+molecules%2C+peptides%2C+and+macrocycles+%282015%E2%80%932018%29&doi=10.1080%2F13543776.2018.1512706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)</span></div><div class="casAuthors">Shaabani, Shabnam; Huizinga, Harmen P. S.; Butera, Roberto; Kouchi, Ariana; Guzik, Katarzyna; Magiera-Mularz, Katarzyna; Holak, Tad A.; Doemling, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">665-678</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The protein-protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clin. practice.  However, only a small percentage of cancer patients benefit from PD1/PD-L1 directed mAbs.  Moreover, some patients experience immune related side effects upon treatment with these mAbs.  Recently, several at.-resoln. structures of human PD1/PD-L1, and small mols., peptides and mAbs with PD-L1 and PD1 open the field for structure based drug design.  Small mols. and peptides targeting PD1/PD-L1 promise to enhance tumor activity while showing less immune related side effects.  We reviewed the small mols. classes and peptides targeting PD1/PD-L1.  Currently approved PD1/PD-L1 directed therapeutics show room for improvement.  Three classes of non mAb small mol. classes have been discovered so far: (cyclic) peptides as direct competitive PD1/PD-L1 antagonists; small mols. disrupting PD1/PD-L1 and inducing a PD-L1 dimerization; and a small mol. class of unknown mode-of-action.  An example of the later group CA-170 is currently investigated in a Phase 1 trial in patients with advanced solid tumors and lymphomas.  Potential advantages of small mols. over mAbs include high distribution and better tumor penetration, improved PK/PD, less side effects and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ3xRey_KylLVg90H21EOLACvtfcHk0ljfOSrK00fl-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OltrbF&md5=a07b11ef81736c8f2c3258229ae3177d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1512706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1512706%26sid%3Dliteratum%253Aachs%26aulast%3DShaabani%26aufirst%3DS.%26aulast%3DHuizinga%26aufirst%3DH.%2BP.%2BS.%26aulast%3DButera%26aufirst%3DR.%26aulast%3DKouchi%26aufirst%3DA.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26atitle%3DA%2520patent%2520review%2520on%2520PD-1%252FPD-L1%2520antagonists%253A%2520small%2520molecules%252C%2520peptides%252C%2520and%2520macrocycles%2520%25282015%25E2%2580%25932018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D665%26epage%3D678%26doi%3D10.1080%2F13543776.2018.1512706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span>ClinicalTrials.gov
home page. <a href="https://clinicaltrials.gov/ct2/show/NCT02812875?term=NCT02812875&amp;draw=2&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02812875?term=NCT02812875&draw=2&rank=1</a> (accessed Jun 17, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov%0Ahome+page.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02812875%3Fterm%3DNCT02812875%26draw%3D2%26rank%3D1+%28accessed+Jun+17%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00990</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1715-1730&author=T.+Wangauthor=X.+Wuauthor=C.+Guoauthor=K.+Zhangauthor=J.+Xuauthor=Z.+Liauthor=S.+Jiang&title=Development+of+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+signaling+pathway&doi=10.1021%2Facs.jmedchem.8b00990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway</span></div><div class="casAuthors">Wang, Tianyu; Wu, Xiaoxing; Guo, Changying; Zhang, Kuojun; Xu, Jinyi; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1715-1730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The clin. success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy.  Currently, most drugs targeting this pathway are monoclonal antibodies.  Small-mol. inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include prodn. difficulties and their long half-life.  Recently, progress has been reported on anti-PD-1/PD-L1 small-mol. inhibitors.  In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-mol. inhibitors.  The structures and the preclin. and clin. studies of several peptide-based small-mol. candidate compds. in clin. trials are discussed.  We also illustrate the design strategies underlying reported nonpeptidic small-mol. inhibitors and provide insight into possible future exploration.  Development of small-mol. drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonItidshja8LVg90H21EOLACvtfcHk0ljfOSrK00fl-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL&md5=2fc7ee8e9bb8d37c7569913a4529d753</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00990%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520signaling%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1715%26epage%3D1730%26doi%3D10.1021%2Facs.jmedchem.8b00990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakharia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1007/s00281-018-0702-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs00281-018-0702-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30203227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=41-48&author=A.+J.+Mullerauthor=M.+G.+Manfrediauthor=Y.+Zakhariaauthor=G.+C.+Prendergast&title=Inhibiting+IDO+pathways+to+treat+cancer%3A+lessons+from+the+ECHO-301+trial+and+beyond&doi=10.1007%2Fs00281-018-0702-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond</span></div><div class="casAuthors">Muller, Alexander J.; Manfredi, Mark G.; Zakharia, Yousef; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  With immunotherapy enjoying a rapid resurgence based on the achievement of durable remissions in some patients with agents that derepress immune function, commonly referred to as "checkpoint inhibitors," enormous attention developed around the IDO1 enzyme as a metabolic mediator of immune escape in cancer.  In particular, outcomes of multiple phase 1/2 trials encouraged the idea that small mol. inhibitors of IDO1 may improve patient responses to anti-PD1 immune checkpoint therapy.  However, recent results from ECHO-301, the first large phase 3 trial to evaluate an IDO1-selective enzyme inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in advanced melanoma, showed no indication that epacadostat provided an increased benefit.  Here it discuss several caveats assocd. with this failed trial.  First is the uncertainty as to whether the target was adequately inhibited.  In particular, there remains a lack of direct evidence regarding the degree of IDO1 inhibition within the tumor, and previous trial data suggest that sufficient drug exposure may not have been achieved at the dose tested in ECHO-301.  Second, while there is a mechanistic rationale for the combination tested, the preclin. data were not particularly compelling.  More efficacious combinations have been demonstrated with DNA damaging modalities which may therefore be a more attractive alternative.  Third, as a highly selective IDO1 inhibitor, epacadostat was advanced aggressively despite preclin. genetic evidence of tumors bypassing IDO1 blockade.  Indeed, a well-grounded literature starting in 2011 points to targeting strategies that account for both IDO and tryptophan 2,3-dioxygenase as more appealing directions to pursue, including dual inhibitors and inhibitors of nodal downstream effector pathways such as aryl hydrocarbon receptor blockade.  Overall, the clin. readout from a single trial with significant limitations is by no means a definitive test for the field.  While biomarker information yet to be gleaned from ECHO-301 may yet reveal useful information regarding IDO1 pathway drugs, better rationalized compds. and better rationalized trial designs will be important in the future to accurately gage medical impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-55ynvYhvLVg90H21EOLACvtfcHk0ljVDoOfW06Uug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI&md5=b672f039dcfd843d6c849167846e13a5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00281-018-0702-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-018-0702-0%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DManfredi%26aufirst%3DM.%2BG.%26aulast%3DZakharia%26aufirst%3DY.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibiting%2520IDO%2520pathways%2520to%2520treat%2520cancer%253A%2520lessons%2520from%2520the%2520ECHO-301%2520trial%2520and%2520beyond%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2019%26volume%3D41%26spage%3D41%26epage%3D48%26doi%3D10.1007%2Fs00281-018-0702-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1021/cr0682195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0682195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=238-263&author=P.+G.+Baraldiauthor=M.+A.+Tabriziauthor=S.+Gessiauthor=P.+A.+Borea&title=Adenosine+receptor+antagonists%3A+translating+medicinal+chemistry+and+pharmacology+into+clinical+utility&doi=10.1021%2Fcr0682195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Tabrizi, Mojgan Aghazadeh; Gessi, Stefania; Borea, Pier Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-263</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the chem. and pharmacol. of adenosine A1, A2A, A2B and A3 receptor antagonists and their therapeutic potential in clin. developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXhQGKqAVLbVg90H21EOLACvtfcHk0ljVDoOfW06Uug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1OisQ%253D%253D&md5=1ae9e978507a1bbe7ab7aea0bdb33bb8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fcr0682195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0682195%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DGessi%26aufirst%3DS.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DAdenosine%2520receptor%2520antagonists%253A%2520translating%2520medicinal%2520chemistry%2520and%2520pharmacology%2520into%2520clinical%2520utility%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D238%26epage%3D263%26doi%3D10.1021%2Fcr0682195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Lera Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor as a drug discovery target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3623</span>– <span class="NLM_lpage">3650</span>, <span class="refDoi"> DOI: 10.1021/jm4011669</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011669" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3623-3650&author=M.+de%0ALera+Ruizauthor=Y.+H.+Limauthor=J.+Zheng&title=Adenosine+A2A+receptor+as+a+drug+discovery+target&doi=10.1021%2Fjm4011669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor as a Drug Discovery Target</span></div><div class="casAuthors">de Lera Ruiz, Manuel; Lim, Yeon-Hee; Zheng, Junying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3623-3650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The adenosine A2A receptor is a G-protein-coupled receptor (GPCR) that has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications.  Herein the authors describe adenosine A2A receptor distribution, signaling pathways, pharmacol., and mol. structure, followed by a summary and SAR discussion of the most relevant series of adenosine A2A agonists and antagonists.  This review also provides an update of the A2A ligands that are undergoing or have undergone clin. studies, including the two currently marketed agonists adenosine and regadenoson.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUPGC7zBCkbVg90H21EOLACvtfcHk0ljVDoOfW06Uug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7bJ&md5=846641d1ac3ad16b6335af6b4df15f08</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm4011669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011669%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%2BRuiz%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DY.%2BH.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520receptor%2520as%2520a%2520drug%2520discovery%2520target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3623%26epage%3D3650%26doi%3D10.1021%2Fjm4011669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Structurally enabled discovery of adenosine A2A receptor antagonists</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.6b00119</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00119" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWkur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=21-37&author=A.+Jazayeriauthor=S.+P.+Andrewsauthor=F.+H.+Marshall&title=Structurally+enabled+discovery+of+adenosine+A2A+receptor+antagonists&doi=10.1021%2Facs.chemrev.6b00119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists</span></div><div class="casAuthors">Jazayeri, Ali; Andrews, Stephen P.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-37</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past decade there has been a revolution in the field of G protein-coupled receptor (GPCR) structural biol.  Many years of innovative research from different areas have come together to fuel this significant change in the fortunes of this field, which for many years was characterized by the paucity of high-resoln. structures.  The detn. to succeed has been in part due to the recognized importance of these proteins as drug targets, and although the pharmaceutical industry has been focusing on these receptors, it can be justifiably argued and demonstrated that many of the approved and com. successful GPCR drugs can be significantly improved to increase efficacy and/or reduce undesired side effects.  In addn., many validated targets in this class remain to be drugged.  It is widely recognized that application of structure-based drug design approaches can help medicinal chemists a long way toward discovering better drugs.  The achievement of structural biologists in providing high-resoln. insight is beginning to transform drug discovery efforts, and there are a no. of GPCR drugs that have been discovered by use of structural information that are in clin. development.  This review aims to highlight the key developments that have brought success to GPCR structure resoln. efforts and exemplify the practical application of structural information for the discovery of adenosine A2A receptor antagonists that have potential to treat multiple conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMOXpKZXAHwrVg90H21EOLACvtfcHk0lhVMJ8xmtOHyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWkur3L&md5=5e0a332b9f43eae4854f1681a79ff184</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00119%26sid%3Dliteratum%253Aachs%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructurally%2520enabled%2520discovery%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D21%26epage%3D37%26doi%3D10.1021%2Facs.chemrev.6b00119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatfield, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.coph.2016.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=27429212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFegurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=90-96&author=S.+M.+Hatfieldauthor=M.+Sitkovsky&title=A2A+adenosine+receptor+antagonists+to+weaken+the+hypoxia-HIF-1%CE%B1+driven+immunosuppression+and+improve+immunotherapies+of+cancer&doi=10.1016%2Fj.coph.2016.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer</span></div><div class="casAuthors">Hatfield, Stephen M.; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90-96</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Hypoxic and adenosine rich tumor microenvironments represent an important barrier that must be overcome to enable T and NK cells to reject tumors.  The A2A adenosine receptor (A2AR) on activated immune cells was identified as a crit. and non-redundant mediator of physiol. immunosuppression.  Observations showing that tumor-protecting A2AR also suppress and redirect the anti-tumor immune response pointed to the importance of inhibiting this pathway to improve cancer immunotherapy.  We advocated (i) blocking immunosuppressive adenosine-A2AR-cAMP-mediated intracellular signaling by A2AR antagonists and (ii) weakening hypoxia-HIF-1α-mediated accumulation of extracellular adenosine by oxygenation agents that also inhibits CD39/CD73 adenosine-generating enzymes.  In view of commencing clin. trials of synthetic A2AR antagonists in combination with cancer immunotherapies, we discuss their promise and exclusion criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHOKqtoNK0LbVg90H21EOLACvtfcHk0lhVMJ8xmtOHyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFegurzJ&md5=2a5f9a1d5184083a06e736cb768f2599</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DHatfield%26aufirst%3DS.%2BM.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DA2A%2520adenosine%2520receptor%2520antagonists%2520to%2520weaken%2520the%2520hypoxia-HIF-1%25CE%25B1%2520driven%2520immunosuppression%2520and%2520improve%2520immunotherapies%2520of%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D29%26spage%3D90%26epage%3D96%26doi%3D10.1016%2Fj.coph.2016.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span> <span> </span><span class="NLM_article-title">Targeting adenosine A2A receptor antagonism for treatment of cancer</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1534825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1080%2F17460441.2018.1534825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30336706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSlsr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=997-1003&author=M.+Congreveauthor=G.+A.+Brownauthor=A.+Borodovskyauthor=M.+L.+Lamb&title=Targeting+adenosine+A2A+receptor+antagonism+for+treatment+of+cancer&doi=10.1080%2F17460441.2018.1534825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting adenosine A2A receptor antagonism for treatment of cancer</span></div><div class="casAuthors">Congreve, Miles; Brown, Giles A.; Borodovsky, Alexandra; Lamb, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">997-1003</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A Receptor (A2AR) antagonists are an emerging class of agents that treat cancers, both as a monotherapy and in combination with other therapeutic agents.  Several studies support the accumulation of extracellular adenosine in the tumor microenvironment as a crit. mechanism in immune evasion implicating A2AR antagonists for use in immuno-oncol.  In this perspective article, the authors briefly outline the history of the A2AR antagonist field for central nervous system indications and give their perspective on the status of agents progressing today in oncol.  A brief description of the biol. rationale in oncol. is given.  A particular focus of this article is progress in A2AR structure detn. and its impact on Structure-Based Drug Design.  Thus understanding of the A2AR antagonist mechanism of action has changed and is now being clin. validated by several key companies in the oncol. field.  This area is likely to rapidly develop over the next 1-2 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsUKYxjhu-TbVg90H21EOLACvtfcHk0lh4auoz6oIMzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSlsr7J&md5=d45041fe45a473e6750fd2195be826de</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1534825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1534825%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DG.%2BA.%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26atitle%3DTargeting%2520adenosine%2520A2A%2520receptor%2520antagonism%2520for%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D997%26epage%3D1003%26doi%3D10.1080%2F17460441.2018.1534825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merighi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincenzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessi, S.</span></span> <span> </span><span class="NLM_article-title">Targeting A3 and A2A adenosine receptors in the fight against cancer</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1080/14728222.2019.1630380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1080%2F14728222.2019.1630380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31189400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=669-678&author=S.+Merighiauthor=E.+Battistelloauthor=L.+Giacomelliauthor=K.+Varaniauthor=F.+Vincenziauthor=P.+A.+Boreaauthor=S.+Gessi&title=Targeting+A3+and+A2A+adenosine+receptors+in+the+fight+against+cancer&doi=10.1080%2F14728222.2019.1630380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting A3 and A2A adenosine receptors in the fight against cancer</span></div><div class="casAuthors">Merighi, Stefania; Battistello, Enrica; Giacomelli, Luca; Varani, Katia; Vincenzi, Fabrizio; Borea, Pier Andrea; Gessi, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">669-678</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  There is a vicious cycle of tumor hypoxia, high adenosine levels, immune suppression and cancer growth that involves the use of adenosine receptor ligands in tumors.  After several years of research, the candidates emerging as promising new anticancer drugs are A3 adenosine receptor agonists and A2A receptor antagonists.  The authors give an updated overview of the field related to A3 receptor agonists and A2A receptor antagonists in cancer and propose their perspectives on the status of these compds. in oncol.  The rationale for the modulation of adenosine receptors in cancer is addressed, starting from the first in vitro evidence of their efficacy up to the animal and clin. studies.  A3 and A2A receptors are attractive targets in oncol. therapy due to their involvement in cancer progression and immune-resistance.  Of relevance, the A3 subtype is also a tumor marker to be used in a personalized drug treatment program while the A2A receptor, playing a non-redundant role in immunomodulation, may be blocked in combination with checkpoint inhibitors to improve their efficacy.  The future will reveal how successful this approach is in the fight against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLmD7ZrrPY47Vg90H21EOLACvtfcHk0lh4auoz6oIMzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKjsbfL&md5=05f51bbcd65ad3d79770f188db174e03</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F14728222.2019.1630380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2019.1630380%26sid%3Dliteratum%253Aachs%26aulast%3DMerighi%26aufirst%3DS.%26aulast%3DBattistello%26aufirst%3DE.%26aulast%3DGiacomelli%26aufirst%3DL.%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DVincenzi%26aufirst%3DF.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DGessi%26aufirst%3DS.%26atitle%3DTargeting%2520A3%2520and%2520A2A%2520adenosine%2520receptors%2520in%2520the%2520fight%2520against%2520cancer%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2019%26volume%3D23%26spage%3D669%26epage%3D678%26doi%3D10.1080%2F14728222.2019.1630380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drury, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szent-Györgyi, A.</span></span> <span> </span><span class="NLM_article-title">The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1929</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.1929.sp002608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1113%2Fjphysiol.1929.sp002608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16994064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaA3cXis1aitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1929&pages=213-237&author=A.+N.+Druryauthor=A.+Szent-Gy%C3%B6rgyi&title=The+physiological+activity+of+adenine+compounds+with+especial+reference+to+their+action+upon+the+mammalian+heart&doi=10.1113%2Fjphysiol.1929.sp002608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart</span></div><div class="casAuthors">Drury, A. N.; Szent-Gyorgyi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">1929</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">213-37</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">A substance, which gave oil hydrolysis adenine, a pentose and H3PO4, was isolated from heart muscle.  It appeared to be adenylic acid having a physiol. action identical with adenylic acid and with adenosine prepd. from yeast nucleic acid.  The physiol. effects are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruSBD-A05bQbVg90H21EOLACvtfcHk0lh4auoz6oIMzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA3cXis1aitQ%253D%253D&md5=c30c03073b42a0825ed6db7c9e756cc3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.1929.sp002608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.1929.sp002608%26sid%3Dliteratum%253Aachs%26aulast%3DDrury%26aufirst%3DA.%2BN.%26aulast%3DSzent-Gy%25C3%25B6rgyi%26aufirst%3DA.%26atitle%3DThe%2520physiological%2520activity%2520of%2520adenine%2520compounds%2520with%2520especial%2520reference%2520to%2520their%2520action%2520upon%2520the%2520mammalian%2520heart%26jtitle%3DJ.%2520Physiol.%26date%3D1929%26volume%3D68%26spage%3D213%26epage%3D237%26doi%3D10.1113%2Fjphysiol.1929.sp002608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bodin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span> <span> </span><span class="NLM_article-title">Increased release of ATP from endothelial cells during acute inflammation</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1007/s000110050341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs000110050341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9754870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK1cXls1CntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1998&pages=351-354&author=P.+Bodinauthor=G.+Burnstock&title=Increased+release+of+ATP+from+endothelial+cells+during+acute+inflammation&doi=10.1007%2Fs000110050341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Increased release of ATP from endothelial cells during acute inflammation</span></div><div class="casAuthors">Bodin, P.; Burnstock, G.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">351-354</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">The effects of lipopolysaccharide (LPS), a potent inflammatory mediator, on the shear stress stimulated release of ATP were investigated on endothelial cells.  Human umbilical vein endothelial cells (HUVEC) in primary cultures were subjected to shear stress using a cone and plate app.  ATP released by the cells was measured by luminometry, using a luciferin-luciferase assay.  Under shear stress alone (25 dyn/cm2), ATP accumulates into the culture medium and reaches a max. after 3-5 min of stimulation (121.7 pmol/mL).  The shear stress-stimulated release of ATP was increased after a 4 h pre-incubation of endothelial cells with 50 μg/mL (314.4 pmol/mL) and 10 μg/mL lipopolysaccharide (207.7 pmol/mL).  Dexamethasone inhibited the effects of lipopolysaccharide.  These results show that non-damaged endothelial cells release ATP under exptl. inflammatory conditions and support an early role of extracellular ATP in the inflammatory process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdMdGxEFsl2LVg90H21EOLACvtfcHk0lhkXAGwBfDqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1CntLg%253D&md5=5de42506ac8a2e05dc0206424f4a5d2f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs000110050341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs000110050341%26sid%3Dliteratum%253Aachs%26aulast%3DBodin%26aufirst%3DP.%26aulast%3DBurnstock%26aufirst%3DG.%26atitle%3DIncreased%2520release%2520of%2520ATP%2520from%2520endothelial%2520cells%2520during%2520acute%2520inflammation%26jtitle%3DInflammation%2520Res.%26date%3D1998%26volume%3D47%26spage%3D351%26epage%3D354%26doi%3D10.1007%2Fs000110050341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AP, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1211%2F0022357011775631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=11734617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=527-552&author=B.+B.+Fredholmauthor=I.+J.+APauthor=K.+A.+Jacobsonauthor=K.+N.+Klotzauthor=J.+Linden&title=International+Union+of+Pharmacology.+XXV.+Nomenclature+and+classification+of+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors</span></div><div class="casAuthors">Fredholm, Bertil B.; IJzerman, Adriaan P.; Jacobson, Kenneth A.; Klotz, Karl-Norbert; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">527-552</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Four adenosine receptors have been cloned and characterized from several mammalian species.  The receptors are named adenosine A1, A2A, A2B, and A3.  The A2A and A2B receptors preferably interact with members of the Gs family of G proteins and the A1 and A3 receptors with Gi/o proteins.  However, other G protein interactions have also been described.  Adenosine is the preferred endogenous agonist at all these receptors, but inosine can also activate the A3 receptor.  The levels of adenosine seen under basal conditions are sufficient to cause some activation of all the receptors, at least where they are abundantly expressed.  Adenosine levels during, e.g., ischemia can activate all receptors even when expressed in low abundance.  Accordingly, expts. with receptor antagonists and mice with targeted disruption of adenosine A1, A2A, and A3 expression reveal roles for these receptors under physiol. and particularly pathophysiol. conditions.  There are pharmacol. tools that can be used to classify A1, A2A, and A3 receptors but few drugs that interact selectively with A2B receptors.  Testable models of the interaction of these drugs with their receptors have been generated by site-directed mutagenesis and homol.-based modeling.  Both agonists and antagonists are being developed as potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOCrJphTwDrVg90H21EOLACvtfcHk0lhkXAGwBfDqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D&md5=060ea8a3d7b07fdc4b2c8acc3b4d4745</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1211%2F0022357011775631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357011775631%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DAP%26aufirst%3DI.%2BJ.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXV.%2520Nomenclature%2520and%2520classification%2520of%2520adenosine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D527%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghisu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Tacca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span> <span> </span><span class="NLM_article-title">Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2008.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.pharmthera.2008.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=18848843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWrs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2008&pages=233-253&author=L.+Antonioliauthor=M.+Fornaiauthor=R.+Colucciauthor=N.+Ghisuauthor=M.+Tuccoriauthor=M.+Del+Taccaauthor=C.+Blandizzi&title=Regulation+of+enteric+functions+by+adenosine%3A+pathophysiological+and+pharmacological+implications&doi=10.1016%2Fj.pharmthera.2008.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications</span></div><div class="casAuthors">Antonioli, Luca; Fornai, Matteo; Colucci, Rocchina; Ghisu, Narcisa; Tuccori, Marco; Del Tacca, Mario; Blandizzi, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-253</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The wide distribution of ATP and adenosine receptors as well as enzymes for purine metab. in different gut regions suggests a complex role for these mediators in the regulation of gastrointestinal functions.  Studies in rodents have shown a significant involvement of adenosine in the control of intestinal secretion, motility and sensation, via activation of A1, A2A, A2B or A3 purinergic receptors, as well as the participation of ATP in the regulation of enteric functions, through the recruitment of P2X and P2Y receptors.  Increasing interest is being focused on the involvement of ATP and adenosine in the pathophysiol. of intestinal disorders, with particular regard for inflammatory bowel diseases (IBDs), intestinal ischemia, post-operative ileus and related dysfunctions, such as gut dysmotility, diarrhea and abdominal discomfort/pain.  Current knowledge suggests that adenosine contributes to the modulation of enteric immune and inflammatory responses, leading to anti-inflammatory actions.  There is evidence supporting a role of adenosine in the alterations of enteric motor and secretory activity assocd. with bowel inflammation.  In particular, several studies have highlighted the importance of adenosine in diarrhea, since this nucleoside participates actively in the cross-talk between immune and epithelial cells in the presence of diarrhoeogenic stimuli.  In addn., adenosine exerts complex regulatory actions on pain transmission at peripheral and spinal sites.  The present review illustrates current information on the role played by adenosine in the regulation of enteric functions, under normal or pathol. conditions, and discusses pharmacol. interventions on adenosine pathways as novel therapeutic options for the management of gut disorders and related abdominal symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHBJtp93EULVg90H21EOLACvtfcHk0lhkXAGwBfDqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWrs7fF&md5=f150ca845905466fd9b23d74224407f5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DFornai%26aufirst%3DM.%26aulast%3DColucci%26aufirst%3DR.%26aulast%3DGhisu%26aufirst%3DN.%26aulast%3DTuccori%26aufirst%3DM.%26aulast%3DDel%2BTacca%26aufirst%3DM.%26aulast%3DBlandizzi%26aufirst%3DC.%26atitle%3DRegulation%2520of%2520enteric%2520functions%2520by%2520adenosine%253A%2520pathophysiological%2520and%2520pharmacological%2520implications%26jtitle%3DPharmacol.%2520Ther.%26date%3D2008%26volume%3D120%26spage%3D233%26epage%3D253%26doi%3D10.1016%2Fj.pharmthera.2008.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kull, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, W.</span></span> <span> </span><span class="NLM_article-title">Structure and function of adenosine receptors and their genes</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1007/s002100000313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs002100000313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=11111830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFCru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2000&pages=364-374&author=B.+B.+Fredholmauthor=G.+Arslanauthor=L.+Halldnerauthor=B.+Kullauthor=G.+Schulteauthor=W.+Wasserman&title=Structure+and+function+of+adenosine+receptors+and+their+genes&doi=10.1007%2Fs002100000313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of adenosine receptors and their genes</span></div><div class="casAuthors">Fredholm, Bertil B.; Arslan, Giulia; Halldner, Linda; Kull, Bjorn; Schulte, Gunnar; Wasserman, Wyeth</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">364-374</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with 130 refs.  Four adenosine receptors have been cloned from many mammalian and some non-mammalian species.  In each case the translated part of the receptor is encoded by two sep. exons.  Two sep. promoters regulate the A1 receptor expression, and a similar situation may pertain also for the other receptors.  The receptors are expressed in a cell and tissue specific manner, even though A1 and A2B receptors are found in many different cell types.  Emerging data indicate that the receptor protein is targeted to specific parts of the cell.  A1 and A3 receptors activate the Gi family of G proteins, whereas A2A and A2B receptors activate the Gs family.  However, other G proteins can also be activated even though the physiol. significance of this is unknown.  Following the activation of G proteins several cellular effector pathways can be affected.  Signaling via adenosine receptors is also known to interact in functionally important ways with signaling initiated via other receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqi7IPIpeDOLVg90H21EOLACvtfcHk0liVkaGImvRaFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFCru7g%253D&md5=26a3b7f257b3748da01ab4ef33a81953</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs002100000313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002100000313%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DArslan%26aufirst%3DG.%26aulast%3DHalldner%26aufirst%3DL.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DSchulte%26aufirst%3DG.%26aulast%3DWasserman%26aufirst%3DW.%26atitle%3DStructure%2520and%2520function%2520of%2520adenosine%2520receptors%2520and%2520their%2520genes%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2000%26volume%3D362%26spage%3D364%26epage%3D374%26doi%3D10.1007%2Fs002100000313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ralevic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span> <span> </span><span class="NLM_article-title">Receptors for purines and pyrimidines</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">492</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9755289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK1cXmvFamur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1998&pages=413-492&author=V.+Ralevicauthor=G.+Burnstock&title=Receptors+for+purines+and+pyrimidines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Receptors for purines and pyrimidines</span></div><div class="casAuthors">Ralevic, Vera; Burnstock, Geoffrey</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-492</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review, with >1000 refs.  Extracellular purines (adenosine, ADP, and ATP) and pyrimidines (UDP and UTP) are important signaling mols. that mediate diverse biol. effects via cell-surface receptors termed purine receptors.  In this review particular emphasis is placed on the discrepancy between the pharmacol. properties and native and recombinant receptors for these agents.  There are two main families of purine receptors, adenosine or P1 receptors, and P2 receptors, recognizing primary ATP, ADP, UTP, and UDP.  Adenosine/P1 receptors have been further subdivided, according to convergent mol., biochem., and pharmacol. evidence into four subtypes, A1, A2A, A2B and A3, all of which couple to G proteins.  Based on differences in mol. structure and signal transduction mechanisms, P2 receptors divide naturally into two families of ligand-gated ion channels and G protein-coupled receptors termed P2X and P2Y receptors, resp.; to date seven mammalian P2X receptors (P2X1-7) and five mammalian P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11) have been cloned, characterized and accepted as valid members of the P2 receptor family.  As correlates between cloned and endogenous receptors are established, the structural subdivision will replace an earlier system of subclassification identifying endogenous P2X, P2Y, P2U, P2T, and P2Z receptors principally according to their pharmacol. profiles.  A prominent issue addressed in this review is the apparent mismatch of pharmacol. data in biol. tissue relating to the P2 receptor subtypes classified on the basis of mol. structure.  While it is logically satisfying to base receptor subclassification on amino acid sequencing where differences of 30-40% are generally regarded as justification for subtyping, it would seem that differences in sequence of less than 50% (even single point mutations) can result in substantial differences in pharmacol. profile.  Thus, receptor heterogeneity among species, together with receptor coexpression and the possible expression of new receptor subtypes that have not yet been cloned, complicates interpretation of pharmacol. responses in some tissues.  Thus, it will become apparent in the present review that , at least with the use of currently available, largely unselective agonists and antagonists, some response profiles do not fit those expected for the known P2 receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY-5Zb4ISCA7Vg90H21EOLACvtfcHk0liVkaGImvRaFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvFamur0%253D&md5=9163ccc1e49f176eff77388a15690b1d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRalevic%26aufirst%3DV.%26aulast%3DBurnstock%26aufirst%3DG.%26atitle%3DReceptors%2520for%2520purines%2520and%2520pyrimidines%26jtitle%3DPharmacol.%2520Rev.%26date%3D1998%26volume%3D50%26spage%3D413%26epage%3D492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. G.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors as therapeutic targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrd1983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnrd1983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16518376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=247-264&author=K.+A.+Jacobsonauthor=Z.+G.+Gao&title=Adenosine+receptors+as+therapeutic+targets&doi=10.1038%2Fnrd1983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as therapeutic targets</span></div><div class="casAuthors">Jacobson, Kenneth A.; Gao, Zhan-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-264</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world.  There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischemic diseases, sleep disorders, immune and inflammatory disorders and cancer.  After more than three decades of medicinal chem. research, a considerable no. of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clin. evaluated, although none has yet received regulatory approval.  However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoG29EyQFoSbVg90H21EOLACvtfcHk0liVkaGImvRaFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr4%253D&md5=85ad553154bd61f24a6bb594f960f9bc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd1983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1983%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26atitle%3DAdenosine%2520receptors%2520as%2520therapeutic%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D247%26epage%3D264%26doi%3D10.1038%2Fnrd1983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltzschig, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors as drug targets--what are the challenges?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1038/nrd3955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnrd3955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23535933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Glsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=265-286&author=J.+F.+Chenauthor=H.+K.+Eltzschigauthor=B.+B.+Fredholm&title=Adenosine+receptors+as+drug+targets%2D%2Dwhat+are+the+challenges%3F&doi=10.1038%2Fnrd3955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as drug targets - what are the challenges?</span></div><div class="casAuthors">Chen, Jiang-Fan; Eltzschig, Holger K.; Fredholm, Bertil B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">265-286</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine signalling has long been a target for drug development, with adenosine itself or its derivs. being used clin. since the 1940s.  In addn., methylxanthines such as caffeine have profound biol. effects as antagonists at adenosine receptors.  Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors.  There is strong evidence that adenosine has a functional role in many diseases, and several pharmacol. compds. specifically targeting individual adenosine receptors - either directly or indirectly - have now entered the clinic.  However, only one adenosine receptor-specific agent - the adenosine A2A receptor agonist regadenoson (Lexiscan; Astellas Pharma) - has so far gained approval from the US Food and Drug Administration (FDA).  Here, we focus on the biol. of adenosine signalling to identify hurdles in the development of addnl. pharmacol. compds. targeting adenosine receptors and discuss strategies to overcome these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqhEzWXi1WS7Vg90H21EOLACvtfcHk0lgxvCBRE_iPsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Glsrs%253D&md5=898fee7a68273ebfbd5a1d3dca307dc5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3955%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DEltzschig%26aufirst%3DH.%2BK.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DAdenosine%2520receptors%2520as%2520drug%2520targets--what%2520are%2520the%2520challenges%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D265%26epage%3D286%26doi%3D10.1038%2Fnrd3955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Immunosuppressive activities of adenosine in cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.coph.2016.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=27209048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslagtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=7-16&author=B.+Allardauthor=P.+A.+Beavisauthor=P.+K.+Darcyauthor=J.+Stagg&title=Immunosuppressive+activities+of+adenosine+in+cancer&doi=10.1016%2Fj.coph.2016.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Immunosuppressive activities of adenosine in cancer</span></div><div class="casAuthors">Allard, Bertrand; Beavis, Paul A.; Darcy, Phillip K.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7-16</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Multiple immunosuppressive mechanisms impede anti-tumor immunity.  Among them, the accumulation of extracellular adenosine is a potent and widespread strategy exploited by tumors to escape immunosurveillance through the activation of purinergic receptors.  In the immune system, engagement of A2a and A2b adenosine receptors is a crit. regulatory mechanism that protects tissues against excessive immune reactions.  In tumors, this pathway is hijacked and hinders anti-tumor immunity, promoting cancer progression.  Different groups have highlighted the therapeutic potential of blocking CD73-dependent adenosine-mediated immunosuppression to reinstate anti-tumor immunity.  Phase clin. trials evaluating anti-CD73 antibodies and A2a receptor antagonists in cancer patients are currently ongoing.  We here review the recent literature on the immunosuppressive effects of extracellular adenosine and discuss the development of adenosine inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYRzXPb0hO57Vg90H21EOLACvtfcHk0lgxvCBRE_iPsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslagtrk%253D&md5=70aeee8a8e49cae26f539a446900bbee</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DImmunosuppressive%2520activities%2520of%2520adenosine%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D29%26spage%3D7%26epage%3D16%26doi%3D10.1016%2Fj.coph.2016.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emens, L. A.</span></span> <span> </span><span class="NLM_article-title">Targeting adenosine for cancer immunotherapy</span>. <i>J. Immunotherapy Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s40425-018-0360-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1186%2Fs40425-018-0360-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29914571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosFamtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=57&author=R.+D.+Leoneauthor=L.+A.+Emens&title=Targeting+adenosine+for+cancer+immunotherapy&doi=10.1186%2Fs40425-018-0360-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting adenosine for cancer immunotherapy</span></div><div class="casAuthors">Leone Robert D; Emens Leisha A; Emens Leisha A</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer therapy.  To extend the impact of immunotherapy to more patients and a broader range of cancers, targeting additional mechanisms of tumor immune evasion will be critical.  Adenosine signaling has emerged as a key metabolic pathway that regulates tumor immunity.  Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment.  Hypoxia, high cell turnover, and expression of CD39 and CD73 are important factors in adenosine production.  Adenosine signaling through the A2a receptor expressed on immune cells potently dampens immune responses in inflamed tissues.  In this article, we will describe the role of adenosine signaling in regulating tumor immunity, highlighting potential therapeutic targets in the pathway.  We will also review preclinical data for each target and provide an update of current clinical activity within the field.  Together, current data suggest that rational combination immunotherapy strategies that incorporate inhibitors of the hypoxia-CD39-CD73-A2aR pathway have great promise for further improving clinical outcomes in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-_cHN3uno-2Zyxfu64m4ffW6udTcc2eYb72PzVWXRjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosFamtw%253D%253D&md5=589bd113854d2c7b520182c688a2b348</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2Fs40425-018-0360-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-018-0360-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DR.%2BD.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26atitle%3DTargeting%2520adenosine%2520for%2520cancer%2520immunotherapy%26jtitle%3DJ.%2520Immunotherapy%2520Cancer%26date%3D2018%26volume%3D6%26spage%3D57%26doi%3D10.1186%2Fs40425-018-0360-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diniz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptor ligands on cancer therapy: a review of patent literature</span>. <i>Recent Pat. Anti-Cancer Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.2174/1574892812666171108115959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.2174%2F1574892812666171108115959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29119938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1antro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=40-69&author=J.+B.+Sousaauthor=P.+Frescoauthor=C.+Dinizauthor=J.+Goncalves&title=Adenosine+receptor+ligands+on+cancer+therapy%3A+a+review+of+patent+literature&doi=10.2174%2F1574892812666171108115959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature</span></div><div class="casAuthors">Sousa, Joana B.; Fresco, Paula; Diniz, Carmen; Goncalves, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on Anti-Cancer Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-69</span>CODEN:
                <span class="NLM_cas:coden">RPADDY</span>;
        ISSN:<span class="NLM_cas:issn">1574-8928</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine is a purine, with an adenine group and a ribose sugar, formed endogenously by ATP catabolism both intracellularly and extracellularly.  Among the medicinal features of adenosine and its receptors (A1, A2A, A2B and A3), anticancer activity has been an intense field of research.  The present review focuses on the patent literature from 2002 onwards (2002-May 2017).  Patents were searched and downloaded from the open access patent data bases and are available online.  A significant no. of patents (65) have been published on adenosine receptor ligands claiming anticancer activity, or presenting new methods of prepn. or treatment thereof, from 2002-2017 (May).  From these, 35 were published highlighting the promising attributes of compds./ methods to fight cancer.  Most of the compds. act as adenosine A3 receptor agonists, while others act as antagonists for the other adenosine receptor subtypes.  The signaling events triggered by activation of adenosine A3 receptor or by blockade of adenosine A1, A2A and A2B receptors can reverse an environment from being pro-cancer to an anti-cancer in the body.  The promising anticancer effects mediated by adenosine receptor ligands put them in the forefront as new drug candidates.  The present compilation can be worthy to medicinal chemists, pharmacologists, biochemists and other researchers focusing on the putative anticancer activity of adenosine receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVYkWyOZz0NLVg90H21EOLACvtfcHk0lj8BYefWnLVTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1antro%253D&md5=f1b4db6d480cb190418dddf35e74b396</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F1574892812666171108115959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1574892812666171108115959%26sid%3Dliteratum%253Aachs%26aulast%3DSousa%26aufirst%3DJ.%2BB.%26aulast%3DFresco%26aufirst%3DP.%26aulast%3DDiniz%26aufirst%3DC.%26aulast%3DGoncalves%26aufirst%3DJ.%26atitle%3DAdenosine%2520receptor%2520ligands%2520on%2520cancer%2520therapy%253A%2520a%2520review%2520of%2520patent%2520literature%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D40%26epage%3D69%26doi%3D10.2174%2F1574892812666171108115959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">The blockade of immune checkpoints in cancer immunotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrc3239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnrc3239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22437870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVegtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=252-264&author=D.+M.+Pardoll&title=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&doi=10.1038%2Fnrc3239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The blockade of immune checkpoints in cancer immunotherapy</span></div><div class="casAuthors">Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">252-264</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Among the most promising approaches to activating therapeutic antitumor immunity is the blockade of immune checkpoints.  Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiol. immune responses in peripheral tissues in order to minimize collateral tissue damage.  It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens.  Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors.  Cytotoxic T-lymphocyte-assocd. antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval.  Preliminary clin. findings with blockers of addnl. immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumor immunity with the potential to produce durable clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosDPsOq8t6CrVg90H21EOLACvtfcHk0litQawtzJRW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVegtrw%253D&md5=d278a058ffb1ccd3f678c1ae3ac0e55e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnrc3239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3239%26sid%3Dliteratum%253Aachs%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DThe%2520blockade%2520of%2520immune%2520checkpoints%2520in%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D252%26epage%3D264%26doi%3D10.1038%2Fnrc3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belikoff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukashev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span> <span> </span><span class="NLM_article-title">Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-14-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F2326-6066.CIR-14-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24990240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWgtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=598-605&author=M.+V.+Sitkovskyauthor=S.+Hatfieldauthor=R.+Abbottauthor=B.+Belikoffauthor=D.+Lukashevauthor=A.+Ohta&title=Hostile%2C+hypoxia-A2-adenosinergic+tumor+biology+as+the+next+barrier+to+overcome+for+tumor+immunologists&doi=10.1158%2F2326-6066.CIR-14-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists</span></div><div class="casAuthors">Sitkovsky, Michail V.; Hatfield, Stephen; Abbott, Robert; Belikoff, Bryan; Lukashev, Dmitriy; Ohta, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">598-605</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as crit. and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity.  However, this immunosuppressive mechanism can be highjacked by bacteria and tumors to provide misguided protection for pathogens and cancerous tissues.  Inhibitors of the hypoxia-A2-adenosinergic pathway represent a conceptually novel type of immunol. coadjuvants that could be combined with cancer vaccines, adoptive cell transfer, and/or blockade of neg. immunol. regulators to further prolong patient survival and to minimize treatment-related side effects.  In support of this approach are preclin. studies and findings that some human cancers are resistant to chemotherapies and immunotherapies due to the tumor-generated extracellular adenosine and A2AR on antitumor T and natural killer (NK) cells.  Among the coadjuvants are (i) antagonists of A2AR, (ii) extracellular adenosine-degrading drugs, (iii) inhibitors of adenosine generation by CD39/CD73 ectoenzymes, and (iv) inhibitors of hypoxia-HIF-1α signaling.  Combining these coadjuvants with CTLA-4 and/or PD-1 blockade is expected to have additive or even synergistic effects of targeting two different antitumor protective mechanisms.  It is expected that even after multicombinatorial blockade of neg. immunol. regulators, the antitumor T and NK cells would still be vulnerable to inhibition by hypoxia and A2AR.  Yet to be tested is the potential capacity of coadjuvants to minimize the side effects of CTLA-4 and/or PD-1 blockade by decreasing the dose of blocking antibodies or by eliminating the need for dual blockade.  Cancer Immunol Res; 2(7); 598-605. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHkhcwpTVeg7Vg90H21EOLACvtfcHk0litQawtzJRW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWgtrzF&md5=9a7805b55c2849b47fd00df1ca38f413</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-14-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-14-0075%26sid%3Dliteratum%253Aachs%26aulast%3DSitkovsky%26aufirst%3DM.%2BV.%26aulast%3DHatfield%26aufirst%3DS.%26aulast%3DAbbott%26aufirst%3DR.%26aulast%3DBelikoff%26aufirst%3DB.%26aulast%3DLukashev%26aufirst%3DD.%26aulast%3DOhta%26aufirst%3DA.%26atitle%3DHostile%252C%2520hypoxia-A2-adenosinergic%2520tumor%2520biology%2520as%2520the%2520next%2520barrier%2520to%2520overcome%2520for%2520tumor%2520immunologists%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2%26spage%3D598%26epage%3D605%26doi%3D10.1158%2F2326-6066.CIR-14-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Purinergic regulation of the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/nri.2016.4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnri.2016.4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26922909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlKmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=177-192&author=C.+Cekicauthor=J.+Linden&title=Purinergic+regulation+of+the+immune+system&doi=10.1038%2Fnri.2016.4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Purinergic regulation of the immune system</span></div><div class="casAuthors">Cekic, Caglar; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">177-192</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cellular stress or apoptosis triggers the release of ATP, ADP and other nucleotides into the extracellular space.  Extracellular nucleotides function as autocrine and paracrine signalling mols. by activating cell-surface P2 purinergic receptors that elicit pro-inflammatory immune responses.  Over time, extracellular nucleotides are metabolized to adenosine, leading to reduced P2 signalling and increased signalling through anti-inflammatory adenosine (P1 purinergic) receptors.  Here, we review how local purinergic signalling changes over time during tissue responses to injury or disease, and we discuss the potential of targeting purinergic signalling pathways for the immunotherapeutic treatment of ischemia, organ transplantation, autoimmunity or cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod6c3DxezmqbVg90H21EOLACvtfcHk0lhStlBFuneQug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlKmurg%253D&md5=930862a0d6cfd16d6c3cdefc45094d0d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnri.2016.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2016.4%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DPurinergic%2520regulation%2520of%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2016%26volume%3D16%26spage%3D177%26epage%3D192%26doi%3D10.1038%2Fnri.2016.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoskin, D. W.</span></span> <span> </span><span class="NLM_article-title">The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2602</span>– <span class="NLM_lpage">2605</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9205063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2sXkt12qsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=2602-2605&author=J.+Blayauthor=T.+D.+Whiteauthor=D.+W.+Hoskin&title=The+extracellular+fluid+of+solid+carcinomas+contains+immunosuppressive+concentrations+of+adenosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine</span></div><div class="casAuthors">Blay, Jonathan; White, Thomas D.; Hoskin, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2602-2605</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purine nucleoside adenosine (9-β-D-ribofuranosyladenine) inhibits a no. of lymphocyte functions in vitro, including the ability of activated T lymphocytes and natural killer cells to adhere to and kill tumor targets.  Solid tumors, such as adenocarcinomas of the lung and colon, are frequently hypoxic and are, therefore, likely to exhibit increased adenine nucleotide breakdown through the 5'-nucleotidase pathway, yielding adenosine.  The authors examd. whether the concn. of adenosine in the extracellular fluid of such tumors is adequate to cause immunosuppression.  Murine tumors grown in syngeneic hosts or human tumors grown in immunodeficient nu/nu mice were subjected to microdialysis, and adenosine levels in the microdialyzate were measured by high-performance liq. chromatog.  Treatment of the tumor microdialyzates with adenosine deaminase eliminated the adenosine peak.  Recovery of adenosine ranged from 15 to 29%, depending on the microdialysis probe, and concns. of adenosine in tumors ranged from 0.2 to 2.4 μM with a mean of 0.5 μM.  In contrast, the adenosine concn. measured s.c. at the same location was 30 nM.  Inclusion of the adenosine deaminase inhibitor coformycin (10 μM) and the adenosine kinase inhibitor 5'-iodotubercidin (0.1 μM) in the microdialysis perfusion buffer increased extracellular adenosine concn. in tumors to as high as 13 μM.  These data show that extracellular adenosine levels in solid tumors are sufficient to suppress the local antitumor immune response and that interference with pathways of adenosine metab. causes marked increases in tumor extracellular adenosine concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ojmDg8ZxJLVg90H21EOLACvtfcHk0lhStlBFuneQug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt12qsr0%253D&md5=2660be28e3cf17a8788fd48ac37bb9e2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlay%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DT.%2BD.%26aulast%3DHoskin%26aufirst%3DD.%2BW.%26atitle%3DThe%2520extracellular%2520fluid%2520of%2520solid%2520carcinomas%2520contains%2520immunosuppressive%2520concentrations%2520of%2520adenosine%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D2602%26epage%3D2605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1007/s11302-012-9349-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs11302-012-9349-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23271562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVGjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=145-165&author=V.+Kumar&title=Adenosine+as+an+endogenous+immunoregulator+in+cancer+pathogenesis%3A+where+to+go%3F&doi=10.1007%2Fs11302-012-9349-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?</span></div><div class="casAuthors">Kumar, V.</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-165</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Cancer is a chronic disease and its pathogenesis is well correlated with infection and inflammation.  Adenosine is a purine nucleoside, which is produced under metabolic stress like hypoxic conditions.  Acute or chronic inflammatory conditions lead to the release of precursor adenine nucleotides (ATP (ATP), ADP (ADP) and adenosine monophosphate (AMP)) from cells, which are extracellularly catabolized into adenosine by extracellular ectonucleotidases, i.e., CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5'-ectonucleotidase.  It is now well-known that adenosine is secreted by cancer as well as immune cells during tumor pathogenesis under metabolic stress or hypoxia.  Once adenosine is released into the extracellular environment, it exerts various immunomodulatory effects via adenosine receptors (A1, A2A, A2B, and A3) expressed on various immune cells (i.e., macrophages, myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, dendritic cells (DCs), T cells, regulatory T cell (Tregs), etc.), which play very important roles in the pathogenesis of cancer.  This review is intended to summarize the role of inflammation and adenosine in the immunopathogenesis of tumor along with regulation of tumor-specific immune response and its modulation as an adjunct approach to tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXKJ8-GFdwnLVg90H21EOLACvtfcHk0lhStlBFuneQug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVGjsrs%253D&md5=5b0499a34d0940c5c17dbbbaec55ab11</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs11302-012-9349-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-012-9349-9%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DAdenosine%2520as%2520an%2520endogenous%2520immunoregulator%2520in%2520cancer%2520pathogenesis%253A%2520where%2520to%2520go%253F%26jtitle%3DPurinergic%2520Signalling%26date%3D2013%26volume%3D9%26spage%3D145%26epage%3D165%26doi%3D10.1007%2Fs11302-012-9349-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Häusler, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Barrio, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diessner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohschein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hönig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wischhusen, J.</span></span> <span> </span><span class="NLM_article-title">Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24489992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC2cvhsFajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=129-139&author=S.+F.+H%C3%A4uslerauthor=I.+M.+Del+Barrioauthor=J.+Diessnerauthor=R.+G.+Steinauthor=J.+Strohscheinauthor=A.+H%C3%B6nigauthor=J.+Dietlauthor=J.+Wischhusen&title=Anti-CD39+and+anti-CD73+antibodies+A1+and+7G2+improve+targeted+therapy+in+ovarian+cancer+by+blocking+adenosine-dependent+immune+evasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion</span></div><div class="casAuthors">Hausler Sebastian Fm; Del Barrio Itsaso Montalban; Wischhusen Jorg; Diessner Joachim; Strohschein Jenny; Honig Arnd; Dietl Johannes; Stein Roland G</div><div class="citationInfo"><span class="NLM_cas:title">American journal of translational research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-39</span>
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    </div><div class="casAbstract">The ectonucleotidases CD39 and CD73 degrade ATP to adenosine which inhibits immune responses via the A2A adenosine receptor (ADORA2A) on T and NK cells.  The current study investigates the potential therapeutic use of the specific anti CD39- and anti CD73-antibodies A1 (CD39) and 7G2 (CD73) as these two ectonucleotidases are overexpressed in ovarian cancer (OvCA).  As expected, NK cell cytotoxicity against the human ovarian cancer cell lines OAW-42 or SK-OV-3 was significantly increased in the presence of A1 or 7G2 antibody.  While this might partly be due to antibody-dependent cell-mediated cytotoxicity, a luciferase-dependent assay for quantifying biologically active adenosine further showed that A1 and 7G2 can inhibit CD39 and CD73-dependent adenosine-generation.  In turn, the reduction in adenosine levels achieved by addition of A1 and 7G2 to OAW-42 or SK-OV-3 cells was found to de-inhibit the proliferation of CD4(+) T cells in coculture with OvCA cells.  Likewise, blocking of CD39 and CD73 on OvCA cells via A1 and 7G2 led to an increased cytotoxicity of alloreactive primed T cells.  Thus, antibodies like A1 and 7G2 could improve targeted therapy in ovarian cancer not only by specifically labeling overexpressed antigens but also by blocking adenosine-dependent immune evasion in this immunogenic malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9fEm3gySkQb9KldV63DuefW6udTcc2eY6iyeMwzb-trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvhsFajtA%253D%253D&md5=125b94ca750f445adab3e01a03bf897e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A4usler%26aufirst%3DS.%2BF.%26aulast%3DDel%2BBarrio%26aufirst%3DI.%2BM.%26aulast%3DDiessner%26aufirst%3DJ.%26aulast%3DStein%26aufirst%3DR.%2BG.%26aulast%3DStrohschein%26aufirst%3DJ.%26aulast%3DH%25C3%25B6nig%26aufirst%3DA.%26aulast%3DDietl%26aufirst%3DJ.%26aulast%3DWischhusen%26aufirst%3DJ.%26atitle%3DAnti-CD39%2520and%2520anti-CD73%2520antibodies%2520A1%2520and%25207G2%2520improve%2520targeted%2520therapy%2520in%2520ovarian%2520cancer%2520by%2520blocking%2520adenosine-dependent%2520immune%2520evasion%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2014%26volume%3D6%26spage%3D129%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousineau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendoo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haibe-Kains, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mes-Masson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 is associated with poor prognosis in high-grade serous ovarian cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4494</span>– <span class="NLM_lpage">4503</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-14-3569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26363007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGnu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4494-4503&author=M.+Turcotteauthor=K.+Springauthor=S.+Pommeyauthor=G.+Chouinardauthor=I.+Cousineauauthor=J.+Georgeauthor=G.+M.+Chenauthor=D.+M.+Gendooauthor=B.+Haibe-Kainsauthor=T.+Karnauthor=K.+Rahimiauthor=C.+Le+Pageauthor=D.+Provencherauthor=A.+M.+Mes-Massonauthor=J.+Stagg&title=CD73+is+associated+with+poor+prognosis+in+high-grade+serous+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-14-3569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer</span></div><div class="casAuthors">Turcotte, Martin; Spring, Kathleen; Pommey, Sandra; Chouinard, Guillaume; Cousineau, Isabelle; George, Joshy; Chen, Gregory M.; Gendoo, Deena M. A.; Haibe-Kains, Benjamin; Karn, Thomas; Rahimi, Kurosh; Le Page, Cecile; Provencher, Diane; Mes-Masson, Anne-Marie; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4494-4503</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The cell surface nucleotidase CD73 is an immunosuppressive enzyme involved in tumor progression and metastasis.  Although preclin. studies suggest that CD73 can be targeted for cancer treatment, the clin. impact of CD73 in ovarian cancer remains unclear.  In this study, we investigated the prognostic value of CD73 in high-grade serous (HGS) ovarian cancer using gene and protein expression analyses.  Our results demonstrate that high levels of CD73 are significantly assocd. with shorter disease-free survival and overall survival in patients with HGS ovarian cancer.  Furthermore, high levels of CD73 expression in ovarian tumor cells abolished the good prognosis assocd. with intraepithelial CD8+ cells.  Notably, CD73 gene expression was highest in the C1/stromal mol. subtype of HGS ovarian cancer and pos. correlated with an epithelial-to-mesenchymal transition gene signature.  Moreover, in vitro studies revealed that CD73 and extracellular adenosine enhance ovarian tumor cell growth as well as expression of antiapoptotic BCL-2 family members.  Finally, in vivo coinjection of ID8 mouse ovarian tumor cells with mouse embryonic fibroblasts showed that CD73 expression in fibroblasts promotes tumor immune escape and thereby tumor growth.  In conclusion, our study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in HGS ovarian cancers.  Cancer Res; 75(21); 4494-503. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0cI-iFGChprVg90H21EOLACvtfcHk0li6NAfhlhNjwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGnu7vF&md5=168775cf106084e44de08a6f6a302255</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3569%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DK.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DChouinard%26aufirst%3DG.%26aulast%3DCousineau%26aufirst%3DI.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%2BM.%26aulast%3DGendoo%26aufirst%3DD.%2BM.%26aulast%3DHaibe-Kains%26aufirst%3DB.%26aulast%3DKarn%26aufirst%3DT.%26aulast%3DRahimi%26aufirst%3DK.%26aulast%3DLe%2BPage%26aufirst%3DC.%26aulast%3DProvencher%26aufirst%3DD.%26aulast%3DMes-Masson%26aufirst%3DA.%2BM.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520is%2520associated%2520with%2520poor%2520prognosis%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4494%26epage%3D4503%26doi%3D10.1158%2F0008-5472.CAN-14-3569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparwasser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2892</span>– <span class="NLM_lpage">2900</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-10-4246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21292811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2892-2900&author=J.+Staggauthor=U.+Divisekeraauthor=H.+Duretauthor=T.+Sparwasserauthor=M.+W.+Tengauthor=P.+K.+Darcyauthor=M.+J.+Smyth&title=CD73-deficient+mice+have+increased+antitumor+immunity+and+are+resistant+to+experimental+metastasis&doi=10.1158%2F0008-5472.CAN-10-4246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis</span></div><div class="casAuthors">Stagg, John; Divisekera, Upulie; Duret, Helene; Sparwasser, Tim; Teng, Michele W. L.; Darcy, Phillip K.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2892-2900</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CD73 is a cell-surface enzyme that suppresses immune responses by producing extracellular adenosine.  In this study, we employed CD73 gene-targeted mice to investigate the role of host-derived CD73 on antitumor immunity and tumor cell metastasis.  We found that CD73 ablation significantly suppressed the growth of ovalbumin-expressing MC38 colon cancer, EG7 lymphoma, AT-3 mammary tumors, and B16F10 melanoma.  The protective effect of CD73 deficiency on primary tumors was dependent on CD8+ T cells and assocd. with an increased frequency of antigen-specific CD8+ T cells in peripheral blood and tumors and increased antigen-specific IFN-γ prodn.  Replicate studies in bone marrow chimeras established that both hematopoietic and nonhematopoietic expression of CD73 was important to promote tumor immune escape.  Using adoptive reconstitution of T regulatory cell (Treg)-depleted DEREG (depletion of regulatory T cells) mice, we demonstrated that part of the protumorigenic effect of Tregs was dependent on their expression of CD73.  CD73-deficient mice were also protected against pulmonary metastasis of B16F10 melanoma cells after i.v. injection.  Unexpectedly, we found that the prometastatic effect of host-derived CD73 was dependent on CD73 expression on nonhematopoietic cells.  CD73 expression on nonhematopoietic cells, most likely endothelial cells, was crit. for promoting lung metastasis in a manner independent from immunosuppressive effects.  Notably, in vivo blockade of CD73 with a selective inhibitor or anti-CD73 monoclonal antibody significantly reduced tumor growth and metastasis of CD73-neg. tumors.  Taken together, our findings indicate that CD73 may be targeted at multiple levels to induce anticancer effects including at the level of tumor cells, Tregs, and nonhematopoietic cells.  Cancer Res; 71(8); 2892-900.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQxUwCZ8XerVg90H21EOLACvtfcHk0lixEi08oDIJ_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslWjs78%253D&md5=94cc37e9eb84e5e8cce990252cc0e7a2</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4246%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DDuret%26aufirst%3DH.%26aulast%3DSparwasser%26aufirst%3DT.%26aulast%3DTeng%26aufirst%3DM.%2BW.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DCD73-deficient%2520mice%2520have%2520increased%2520antitumor%2520immunity%2520and%2520are%2520resistant%2520to%2520experimental%2520metastasis%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2892%26epage%3D2900%26doi%3D10.1158%2F0008-5472.CAN-10-4246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryzhov, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickup, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chytil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorska, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feoktistov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novitskiy, S. V.</span></span> <span> </span><span class="NLM_article-title">Role of TGF-beta signaling in generation of CD39+CD73+ myeloid cells in tumors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">3155</span>– <span class="NLM_lpage">3164</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1400578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.4049%2Fjimmunol.1400578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25127858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2qurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=3155-3164&author=S.+V.+Ryzhovauthor=M.+W.+Pickupauthor=A.+Chytilauthor=A.+E.+Gorskaauthor=Q.+Zhangauthor=P.+Owensauthor=I.+Feoktistovauthor=H.+L.+Mosesauthor=S.+V.+Novitskiy&title=Role+of+TGF-beta+signaling+in+generation+of+CD39%2BCD73%2B+myeloid+cells+in+tumors&doi=10.4049%2Fjimmunol.1400578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors</span></div><div class="casAuthors">Ryzhov, Sergey V.; Pickup, Michael W.; Chytil, Anna; Gorska, Agnieszka E.; Zhang, Qinkun; Owens, Philip; Feoktistov, Igor; Moses, Harold L.; Novitskiy, Sergey V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3155-3164</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">There is growing evidence that generation of adenosine from ATP, which is mediated by the CD39/CD73 enzyme pair, predetermines immunosuppressive and proangiogenic properties of myeloid cells.  We have previously shown that the deletion of the TGF-β type II receptor gene (Tgfbr2) expression in myeloid cells is assocd. with decreased tumor growth, suggesting protumorigenic effect of TGF-β signaling.  In this study, we tested the hypothesis that TGF-β drives differentiation of myeloid-derived suppressor cells into protumorigenic terminally differentiated myeloid mononuclear cells (TDMMCs) characterized by high levels of cell-surface CD39/CD73 expression.  We found that TDMMCs represent a major cell subpopulation expressing high levels of both CD39 and CD73 in the tumor microenvironment.  In tumors isolated from mice with spontaneous tumor formation of mammary gland and conditional deletion of the type II TGF-β receptor in mammary epithelium, an increased level of TGF-β protein was assocd. with further increase in no. of CD39+CD73+ TDMMCs compared with MMTV-PyMT/TGFβRIIWT control tumors with intact TGF-β signaling.  Using genetic and pharmacol. approaches, we demonstrated that the TGF-β signaling mediates maturation of myeloid-derived suppressor cells into TDMMCs with high levels of cell surface CD39/CD73 expression and adenosine-generating capacity.  Disruption of TGF-β signaling in myeloid cells resulted in decreased accumulation of TDMMCs, expressing CD39 and CD73, and was accompanied by increased infiltration of T lymphocytes, reduced d. of blood vessels, and diminished progression of both Lewis lung carcinoma and spontaneous mammary carcinomas.  We propose that TGF-β signaling can directly induce the generation of CD39+CD73+ TDMMCs, thus contributing to the immunosuppressive, proangiogenic, and tumor-promoting effects of this pleiotropic effector in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWhuAg0SxIRLVg90H21EOLACvtfcHk0lixEi08oDIJ_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2qurvM&md5=829d2afc57700dbcff9d6827c5ad0531</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1400578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1400578%26sid%3Dliteratum%253Aachs%26aulast%3DRyzhov%26aufirst%3DS.%2BV.%26aulast%3DPickup%26aufirst%3DM.%2BW.%26aulast%3DChytil%26aufirst%3DA.%26aulast%3DGorska%26aufirst%3DA.%2BE.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DOwens%26aufirst%3DP.%26aulast%3DFeoktistov%26aufirst%3DI.%26aulast%3DMoses%26aufirst%3DH.%2BL.%26aulast%3DNovitskiy%26aufirst%3DS.%2BV.%26atitle%3DRole%2520of%2520TGF-beta%2520signaling%2520in%2520generation%2520of%2520CD39%252BCD73%252B%2520myeloid%2520cells%2520in%2520tumors%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D3155%26epage%3D3164%26doi%3D10.4049%2Fjimmunol.1400578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 therapy impairs tumor angiogenesis</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1466</span>– <span class="NLM_lpage">1473</span>, <span class="refDoi"> DOI: 10.1002/ijc.28456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1002%2Fijc.28456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23982901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVKnsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=1466-1473&author=B.+Allardauthor=M.+Turcotteauthor=K.+Springauthor=S.+Pommeyauthor=I.+Royalauthor=J.+Stagg&title=Anti-CD73+therapy+impairs+tumor+angiogenesis&doi=10.1002%2Fijc.28456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 therapy impairs tumor angiogenesis</span></div><div class="casAuthors">Allard, Bertrand; Turcotte, Martin; Spring, Kathleen; Pommey, Sandra; Royal, Isabelle; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1466-1473</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">CD73 is an ecto-nucleotidase overexpressed in various types of tumors that catabolizes the generation of extracellular adenosine, a potent immunosuppressor.  We and others have shown that targeted blockade of CD73 can rescue anti-tumor T cells from the immunosuppressive effects of extracellular adenosine.  Another important function of extracellular adenosine is to regulate adaptive responses to hypoxia.  However, the importance of CD73 for tumor angiogenesis and the effect of anti-CD73 therapy on tumor angiogenesis remain unknown.  In this study, we demonstrated that CD73 expression on tumor cells and host cells contribute to tumor angiogenesis.  Our data revealed that tumor-derived CD73 enhances the prodn. of vascular endothelial growth factor (VEGF) by tumor cells that host-derived CD73 is required for in vivo angiogenic responses and that endothelial cells require CD73 expression for tube formation and migration.  Notably, the pro-angiogeneic effects of CD73 relied on both enzymic and non-enzymic functions.  Using a mouse model of breast cancer, we demonstrated that targeted blockade of CD73 with a monoclonal antibody significantly decreased tumor VEGF levels and suppressed tumor angiogenesis in vivo.  Taken together, our study strongly suggests that targeted blockade of CD73 can significantly block tumor angiogenesis, and further supports its clin. development for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD0tXpGfw0W7Vg90H21EOLACvtfcHk0li6OsrnWJ68jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVKnsrnF&md5=888109a577d25c4b4ed0769a4b200439</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fijc.28456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28456%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DK.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DRoyal%26aufirst%3DI.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DAnti-CD73%2520therapy%2520impairs%2520tumor%2520angiogenesis%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2014%26volume%3D134%26spage%3D1466%26epage%3D1473%26doi%3D10.1002%2Fijc.28456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thibaudin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boidot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegran, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derangere, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limagne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladoire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apetoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiringhelli, F.</span></span> <span> </span><span class="NLM_article-title">Human ectonucleotidase-expressing CD25(high) Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1055444</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2015.1055444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1080%2F2162402X.2015.1055444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26942062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1Ogu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e1055444&author=M.+Thibaudinauthor=M.+Chaixauthor=R.+Boidotauthor=F.+Vegranauthor=V.+Derangereauthor=E.+Limagneauthor=H.+Bergerauthor=S.+Ladoireauthor=L.+Apetohauthor=F.+Ghiringhelli&title=Human+ectonucleotidase-expressing+CD25%28high%29+Th17+cells+accumulate+in+breast+cancer+tumors+and+exert+immunosuppressive+functions&doi=10.1080%2F2162402X.2015.1055444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions</span></div><div class="casAuthors">Thibaudin, Marion; Chaix, Marie; Boidot, Romain; Vegran, Frederique; Derangere, Valentin; Limagne, Emeric; Berger, Helene; Ladoire, Sylvain; Apetoh, Lionel; Ghiringhelli, Francois</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1055444/1-e1055444/12</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Th17 cells contribute to the development of some autoimmune and allergic diseases by driving tissue inflammation.  However, the function of Th17 cells during cancer progression remains controversial.  Here, we show that human memory CD25high Th17 cells suppress T cell immunity in breast cancer.  Ectonucleotidase-expressing Th17 cells accumulated in breast cancer tumors and suppressed CD4+ and CD8+ T cell activation.  These cells expressed both Rorγt and Foxp3 genes and secreted Th17 related cytokines.  We further found that CD39 ectonucleotisase expression on tumor-infiltrating Th17 cells was driven by TGF-β and IL-6.  Finally, immunohistochem. anal. of localized breast cancer revealed that high-tumor infiltration by IL-17+ cells was assocd. with a poor clin. outcome and impeded the favorable effect of high CD8+ infiltration.  Altogether, these findings suggest that intratumoral Th17 cells compromise anticancer immune responses in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrigQPxb4ZFs7Vg90H21EOLACvtfcHk0li6OsrnWJ68jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1Ogu7s%253D&md5=0a3f1bf8566b58d8a05fe761ab4476d2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2015.1055444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2015.1055444%26sid%3Dliteratum%253Aachs%26aulast%3DThibaudin%26aufirst%3DM.%26aulast%3DChaix%26aufirst%3DM.%26aulast%3DBoidot%26aufirst%3DR.%26aulast%3DVegran%26aufirst%3DF.%26aulast%3DDerangere%26aufirst%3DV.%26aulast%3DLimagne%26aufirst%3DE.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DLadoire%26aufirst%3DS.%26aulast%3DApetoh%26aufirst%3DL.%26aulast%3DGhiringhelli%26aufirst%3DF.%26atitle%3DHuman%2520ectonucleotidase-expressing%2520CD25%2528high%2529%2520Th17%2520cells%2520accumulate%2520in%2520breast%2520cancer%2520tumors%2520and%2520exert%2520immunosuppressive%2520functions%26jtitle%3DOncoimmunology%26date%3D2016%26volume%3D5%26spage%3De1055444%26doi%3D10.1080%2F2162402X.2015.1055444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choukèr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxt045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1093%2Fintimm%2Fdxt045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24150242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFKmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=83-91&author=A.+Ohtaauthor=M.+Madasuauthor=M.+Subramanianauthor=R.+Kiniauthor=G.+Jonesauthor=A.+Chouk%C3%A8rauthor=A.+Ohtaauthor=M.+Sitkovsky&title=Hypoxia-induced+and+A2A+adenosine+receptor-independent+T-cell+suppression+is+short+lived+and+easily+reversible&doi=10.1093%2Fintimm%2Fdxt045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible</span></div><div class="casAuthors">Ohta, Akio; Madasu, Manasa; Subramanian, Meenakshi; Kini, Radhika; Jones, Graham; Chouker, Alexander; Ohta, Akiko; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Hypoxia can induce adenosine-independent T-cell suppression in vivo and in vitro.  Tissue hypoxia plays a key role in establishing an immunosuppressive environment in vivo by, among other effects, increasing the level of extracellular adenosine, which then signals through A2A adenosine receptor (A2AR) to elicit its immunosuppressive effect.  Although the important role of the adenosine-A2AR interaction in limiting inflammation has been established, the current study revisited this issue by asking whether hypoxia can also exert its T-cell inhibitory effects even without A2AR.  A similar degree of hypoxia-triggered inhibition was obsd. in wild-type and A2AR-deficient T cells both in vitro and, after exposure of mice to a hypoxic atm., in vivo.  This A2AR-independent hypoxic T-cell suppression was qual. and mechanistically different from immunosuppression by A2AR stimulation.  The A2AR-independent hypoxic immunosuppression strongly reduced T-cell proliferation, while IFN-γ-producing activity was more susceptible to the A2AR-dependent inhibition.  In contrast to the sustained functional impairment after A2AR-mediated T-cell inhibition, the A2AR-independent inhibition under hypoxia was short lived, as evidenced by the quick recovery of IFN-γ-producing activity upon re-stimulation.  These data support the view that T-cell inhibition by hypoxia can be mediated by multiple mechanisms and that both A2AR and key mols. in the A2AR-independent T-cell inhibition should be targeted to overcome the hypoxia-related immunosuppression in infected tissues and tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmvOzAQPmO5LVg90H21EOLACvtfcHk0liR1xMmkxalPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFKmsbo%253D&md5=ce85083b79e8dc5b85def3e65963b4b8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxt045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxt045%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DMadasu%26aufirst%3DM.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DKini%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DChouk%25C3%25A8r%26aufirst%3DA.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DHypoxia-induced%2520and%2520A2A%2520adenosine%2520receptor-independent%2520T-cell%2520suppression%2520is%2520short%2520lived%2520and%2520easily%2520reversible%26jtitle%3DInt.%2520Immunol.%26date%3D2014%26volume%3D26%26spage%3D83%26epage%3D91%26doi%3D10.1093%2Fintimm%2Fdxt045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milenkovski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kershaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptor 2a blockade increases the efficacy of anti-Pd-1 through enhanced antitumor T-cell responses</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-14-0211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F2326-6066.CIR-14-0211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25672397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvV2msbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=506-517&author=P.+A.+Beavisauthor=N.+Milenkovskiauthor=M.+A.+Hendersonauthor=L.+B.+Johnauthor=B.+Allardauthor=S.+Loiauthor=M.+H.+Kershawauthor=J.+Staggauthor=P.+K.+Darcy&title=Adenosine+receptor+2a+blockade+increases+the+efficacy+of+anti-Pd-1+through+enhanced+antitumor+T-cell+responses&doi=10.1158%2F2326-6066.CIR-14-0211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses</span></div><div class="casAuthors">Beavis, Paul A.; Milenkovski, Nicole; Henderson, Melissa A.; John, Liza B.; Allard, Bertrand; Loi, Sherene; Kershaw, Michael H.; Stagg, John; Darcy, Phillip K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">506-517</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Beavis, Milenkovski, and colleagues reveal that adenosine receptor blockade enhanced anti-PD-1 efficacy against CD73+ tumors in twomouse models via augmentation of tumor-infiltrating CD8+ T-cell effector function by increasing IFNγ and Granzyme B prodn. and suggest CD73 expression as a biomarker for anti-PD-1 efficacy.  Immunotherapy is rapidly emerging as a cancer treatment with high potential.  Recent clin. trials with anti-CTLA-4 and anti-PD-1/PD-L1 antibodies (mAbs) suggest that targeting multiple immunosuppressive pathways may significantly improve patient survival.  The generation of adenosine by CD73 also suppresses antitumor immune responses through the activation of A2A receptors on T cells and natural killer (NK) cells.  We sought to det. whether blockade of A2A receptors could enhance the efficacy of anti-PD-1 mAb.  The expression of CD73 by tumor cells limited the efficacy of anti-PD-1 mAb in two tumor models, and this was alleviated with concomitant treatment with an A2A adenosine receptor antagonist.  The blockade of PD-1 enhanced A2A receptor expression on tumor-infiltrating CD8+ T cells, making them more susceptible to A2A-mediated suppression.  Thus, dual blockade of PD-1 and A2A significantly enhanced the expression of IFNγ and Granzyme B by tumor-infiltrating CD8+ T cells and, accordingly, increased growth inhibition of CD73+ tumors and survival of mice.  The results of our study indicate that CD73 expression may constitute a potential biomarker for the efficacy of anti-PD-1 mAb in patients with cancer and that the efficacy of anti-PD-1 mAb can be significantly enhanced by A2A antagonists.  We have therefore revealed a potentially novel biomarker for the efficacy of anti-PD-1 that warrants further investigation in patients.  Because our studies used SYN-115, a drug that has already undergone phase IIb testing in Parkinson disease, our findings have immediate translational relevance for patients with cancer.  Cancer Immunol Res; 3(5); 506-17. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0mXEGNShKXLVg90H21EOLACvtfcHk0liiMJ5HNrbRtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvV2msbY%253D&md5=2a5eaf10df8675fa514039c64acfc85f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-14-0211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-14-0211%26sid%3Dliteratum%253Aachs%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DMilenkovski%26aufirst%3DN.%26aulast%3DHenderson%26aufirst%3DM.%2BA.%26aulast%3DJohn%26aufirst%3DL.%2BB.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DKershaw%26aufirst%3DM.%2BH.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26atitle%3DAdenosine%2520receptor%25202a%2520blockade%2520increases%2520the%2520efficacy%2520of%2520anti-Pd-1%2520through%2520enhanced%2520antitumor%2520T-cell%2520responses%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2015%26volume%3D3%26spage%3D506%26epage%3D517%26doi%3D10.1158%2F2326-6066.CIR-14-0211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leclerc, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlebois, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 expression is an independent prognostic factor in prostate cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1078-0432.CCR-15-1181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26253870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=158-166&author=B.+G.+Leclercauthor=R.+Charleboisauthor=G.+Chouinardauthor=B.+Allardauthor=S.+Pommeyauthor=F.+Saadauthor=J.+Stagg&title=CD73+expression+is+an+independent+prognostic+factor+in+prostate+cancer&doi=10.1158%2F1078-0432.CCR-15-1181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer</span></div><div class="casAuthors">Leclerc, Bruno G.; Charlebois, Roxanne; Chouinard, Guillaume; Allard, Bertrand; Pommey, Sandra; Saad, Fred; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-166</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: CD73 is an adenosine-generating ecto-enzyme that suppresses antitumor immunity in mouse models of cancer, including prostate cancer.  Although high levels of CD73 are assocd. with poor prognosis in various types of cancer, the clin. impact of CD73 in prostate cancer remains unclear.  Exptl. Design: We evaluated the prognostic value of CD73 protein expression and CD8+ cell d. in 285 cases of prostate cancer on tissue microarray (TMA).  Normal adjacent and tumor tissues were evaluated in duplicates.  Results: Univariate and multivariate analyses revealed that high levels of CD73 in normal adjacent prostate epithelium were significantly assocd. with shorter biochem. recurrence (BCR)-free survival.  Notably, CD73 expression in normal epithelium conferred a neg. prognostic value to prostate-infiltrating CD8+ cells.  Surprisingly, high levels of CD73 in the tumor stroma were assocd. with longer BCR-free survival in univariate anal.  In vitro studies revealed that adenosine signaling inhibited NF-κB activity in human prostate cancer cells via A2B adenosine receptors.  Consistent with these results, CD73 expression in the prostate tumor stroma neg. correlated with p65 expression in the nuclei of prostate tumor cells.  Conclusions: Our study revealed that CD73 is an independent prognostic factor in prostate cancer.  Our data support a model in which CD73 expression in the prostate epithelium suppresses immunosurveillance by CD8+ T cells, whereas CD73 expression in the tumor stroma reduces NF-κB signaling in tumor cells via A2B adenosine receptor signaling.  CD73 expression, including in normal adjacent prostate epithelium, can thus effectively discriminate between aggressive and indolent forms of prostate cancer.  Clin Cancer Res; 22(1); 158-66. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9HCI_kLOGLVg90H21EOLACvtfcHk0ljMM6sYfIsWtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqsrk%253D&md5=f775efcc9f67005fcc4d0696399ab79f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1181%26sid%3Dliteratum%253Aachs%26aulast%3DLeclerc%26aufirst%3DB.%2BG.%26aulast%3DCharlebois%26aufirst%3DR.%26aulast%3DChouinard%26aufirst%3DG.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520expression%2520is%2520an%2520independent%2520prognostic%2520factor%2520in%2520prostate%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D158%26epage%3D166%26doi%3D10.1158%2F1078-0432.CCR-15-1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stannard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3652</span>– <span class="NLM_lpage">3658</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-14-0957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24986517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCqs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3652-3658&author=D.+Mittalauthor=A.+Youngauthor=K.+Stannardauthor=M.+Yongauthor=M.+W.+Tengauthor=B.+Allardauthor=J.+Staggauthor=M.+J.+Smyth&title=Antimetastatic+effects+of+blocking+PD-1+and+the+adenosine+A2A+receptor&doi=10.1158%2F0008-5472.CAN-14-0957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor</span></div><div class="casAuthors">Mittal, Deepak; Young, Arabella; Stannard, Kimberley; Yong, Michelle; Teng, Michele W. L.; Allard, Bertrand; Stagg, John; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3652-3658</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Adenosine targeting is an attractive new approach to cancer treatment, but no clin. study has yet examd. adenosine inhibition in oncol. despite the safe clin. profile of adenosine A2A receptor inhibitors (A2ARi) hi Parkinson disease.  Metastasis is the main cause of cancer-related deaths worldwide, and therefore we have studied exptl. and spontaneous mouse models of melanoma and breast cancer metastasis to demonstrate the efficacy and mechanism of a combination of A2ARi in combination with anti-PD-1 monoclonal antibody (mAb).  This combination significantly reduces metastatic burden and prolongs the life of mice compared with either monotherapy alone.  Importantly, the combination was only effective when the tumor expressed high levels of CD73, suggesting a tumor biomarker that at a min. could be used to stratify patients that might receive this combination.  The mechanism of the combination therapy was critically dependent on NK cells and IFNγ, and to a lesser extent, CD8+ T cells and the effector mol., perforin.  Overall, these results provide a strong rationale to use A2ARi with anti-PD-1 mAb for the treatment of minimal residual and metastatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW_l2JwbYd0bVg90H21EOLACvtfcHk0ljMM6sYfIsWtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCqs7fO&md5=9baa0050f726559abfa70b30f94419a5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0957%26sid%3Dliteratum%253Aachs%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DStannard%26aufirst%3DK.%26aulast%3DYong%26aufirst%3DM.%26aulast%3DTeng%26aufirst%3DM.%2BW.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DAntimetastatic%2520effects%2520of%2520blocking%2520PD-1%2520and%2520the%2520adenosine%2520A2A%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3652%26epage%3D3658%26doi%3D10.1158%2F0008-5472.CAN-14-0957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatfield, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaergaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukashev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belikoff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethumadhavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philbrook, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannici, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podack, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M. V.</span></span> <span> </span><span class="NLM_article-title">Immunological mechanisms of the antitumor effects of supplemental oxygenation</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">277ra30</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa1260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1126%2Fscitranslmed.aaa1260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25739764" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=277ra30&author=S.+M.+Hatfieldauthor=J.+Kjaergaardauthor=D.+Lukashevauthor=T.+H.+Schreiberauthor=B.+Belikoffauthor=R.+Abbottauthor=S.+Sethumadhavanauthor=P.+Philbrookauthor=K.+Koauthor=R.+Canniciauthor=M.+Thayerauthor=S.+Rodigauthor=J.+L.+Kutokauthor=E.+K.+Jacksonauthor=B.+Kargerauthor=E.+R.+Podackauthor=A.+Ohtaauthor=M.+V.+Sitkovsky&title=Immunological+mechanisms+of+the+antitumor+effects+of+supplemental+oxygenation&doi=10.1126%2Fscitranslmed.aaa1260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa1260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa1260%26sid%3Dliteratum%253Aachs%26aulast%3DHatfield%26aufirst%3DS.%2BM.%26aulast%3DKjaergaard%26aufirst%3DJ.%26aulast%3DLukashev%26aufirst%3DD.%26aulast%3DSchreiber%26aufirst%3DT.%2BH.%26aulast%3DBelikoff%26aufirst%3DB.%26aulast%3DAbbott%26aufirst%3DR.%26aulast%3DSethumadhavan%26aufirst%3DS.%26aulast%3DPhilbrook%26aufirst%3DP.%26aulast%3DKo%26aufirst%3DK.%26aulast%3DCannici%26aufirst%3DR.%26aulast%3DThayer%26aufirst%3DM.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26aulast%3DJackson%26aufirst%3DE.%2BK.%26aulast%3DKarger%26aufirst%3DB.%26aulast%3DPodack%26aufirst%3DE.%2BR.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DSitkovsky%26aufirst%3DM.%2BV.%26atitle%3DImmunological%2520mechanisms%2520of%2520the%2520antitumor%2520effects%2520of%2520supplemental%2520oxygenation%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26spage%3D277ra30%26doi%3D10.1126%2Fscitranslmed.aaa1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span> <span> </span><span class="NLM_article-title">Adenosine promotes Foxp3 expression in Treg cells in sepsis model by activating JNK/AP-1 pathway</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2284</span>– <span class="NLM_lpage">2292</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=27347335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVGnurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=2284-2292&author=R.+Baoauthor=J.+Houauthor=Y.+Liauthor=J.+Bianauthor=X.+Dengauthor=X.+Zhuauthor=T.+Yang&title=Adenosine+promotes+Foxp3+expression+in+Treg+cells+in+sepsis+model+by+activating+JNK%2FAP-1+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine promotes Foxp3 expression in Treg cells in sepsis model by activating JNK/AP-1 pathway</span></div><div class="casAuthors">Bao, Rui; Hou, Jiong; Li, Yan; Bian, Jinjun; Deng, Xiaoming; Zhu, Xiaoyan; Yang, Tao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2284-2292</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Objectives: Forkhead/winged helix transcription factor p3 (Foxp3) increases in CD4+CD25+Treg cells during sepsis; however, related mechanisms are unclear.  Our study aimed to explore the possible mol. mechanisms of high expression of Foxp3 in Treg cells during sepsis.  Methods: Sepsis was induced by cecal ligation and puncture (CLP) method.  CD4+CD25+Treg cells were isolated from peripheral blood and identified by flow cytometry (FCM).  Treg cells were cultured with or without adenosine, adenosine agonist, adenosine antagonist, SMAD family member 3 (Smad3) agonist (transforming growth factor (TGF)-β1), or C-Jun N-Terminal Kinase (JNK) inhibitor.Expression levels of Foxp3 and activator protein 1 (AP-1) were detd.  The binding of c-Fos or c-Jun to the Foxp3 promoter was then evaluated by the chromatin immunopptn. (ChIP) assay and quantified by quant. real-time PCR (qRT-PCR).  The mRNA and protein levels of Foxp3 were detd. after transfection with siRNA against c-Fos, Fra2, c-Jun or JunD.  Results: Pharmacol. inhibition of both adenosine and JNK reduced Foxp3 protein levels.  JNK/ AP-1 activation was involved in increased levels of Foxp3 protein in CD4+CD25+Treg cells.  AP-1 regulated activity of Foxp3 promoter in Treg cells, and the induction of c-Fos or c-Jun activity leads to elevated transcription of Foxp3 gene.  Knockdown of c-Fos, Fra-2, c-Jun, or JunD levels also reduced Foxp3 expression.  Conclusion: We confirm that adenosine plays significant roles in the high expression of Foxp3.  Adenosine promotes Foxp3 expression in Treg cells during sepsis via JNK/AP-1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7rlySesXzILVg90H21EOLACvtfcHk0lj9-vSwApfT-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVGnurs%253D&md5=fc3a84095b552880b32e7ec4783b2a8e</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DR.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DT.%26atitle%3DAdenosine%2520promotes%2520Foxp3%2520expression%2520in%2520Treg%2520cells%2520in%2520sepsis%2520model%2520by%2520activating%2520JNK%252FAP-1%2520pathway%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2016%26volume%3D8%26spage%3D2284%26epage%3D2292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7259</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-3583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-13-3583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25377469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOhtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=7250-7259&author=C.+Cekicauthor=Y.+J.+Dayauthor=D.+Sagauthor=J.+Linden&title=Myeloid+expression+of+adenosine+A2A+receptor+suppresses+T+and+NK+cell+responses+in+the+solid+tumor+microenvironment&doi=10.1158%2F0008-5472.CAN-13-3583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment</span></div><div class="casAuthors">Cekic, Caglar; Day, Yuan-Ji; Sag, Duygu; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7250-7259</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study provides a mechanistic rationale to reposition inhibitors of a certain class of cell surface adenosine receptors to block an important pathway of immune escape that is commonly activated in solid tumors, with immediate implications for clin. evaluation.  High concns. of adenosine in tumor microenvironments inhibit antitumor cytotoxic lymphocyte responses.  Although T cells express inhibitory adenosine A2A receptors (A2AR) that suppress their activation and inhibit immune killing of tumors, a role for myeloid cell A2ARs in suppressing the immune response to tumors has yet to be investigated.  In this study, we show that the growth of transplanted syngeneic B16F10 melanoma or Lewis lung carcinoma cells is slowed in Adora2af/f-LysMCre+/- mice, which selectively lack myeloid A2ARs.  Reduced melanoma growth is assocd. with significant increases in MHCII and IL12 expression in tumor-assocd. macrophages and with >90% redns. in IL10 expression in tumor-assocd. macrophages, dendritic cells (DC), and Ly6C+ or Ly6G+ myeloid-derived suppressor cells (MDSC).  Myeloid deletion of A2ARs significantly increases CD44 expression on tumor-assocd. T cells and natural killer (NK) cells.  Depletion of CD8+ T cells or NK cells in tumor-bearing mice indicates that both cell types initially contribute to slowing melanoma growth in mice lacking myeloid A2A receptors, but tumor suppression mediated by CD8+ T cells is more persistent.  Myeloid-selective A2AR deletion significantly reduces lung metastasis of melanomas that express luciferase (for in vivo tracking) and ovalbumin (as a model antigen).  Reduced metastasis is assocd. with increased nos. and activation of NK cells and antigen-specific CD8+ T cells in lung infiltrates.  Overall, the findings indicate that myeloid cell A2ARs have direct myelosuppressive effects that indirectly contribute to the suppression of T cells and NK cells in primary and metastatic tumor microenvironments.  The results indicate that tumor-assocd. myeloid cells, including macrophages, DCs, and MDSCs all express immunosuppressive A2ARs that are potential targets of adenosine receptor blockers to enhance immune killing of tumors.  Cancer Res; 74(24); 7250-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXEUi0VvnzKLVg90H21EOLACvtfcHk0liOChJvJukKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOhtrnL&md5=463ac7254c95ba8fcea06c7c32b045a4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-3583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-3583%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DDay%26aufirst%3DY.%2BJ.%26aulast%3DSag%26aufirst%3DD.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DMyeloid%2520expression%2520of%2520adenosine%2520A2A%2520receptor%2520suppresses%2520T%2520and%2520NK%2520cell%2520responses%2520in%2520the%2520solid%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D7250%26epage%3D7259%26doi%3D10.1158%2F0008-5472.CAN-13-3583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2371</span>– <span class="NLM_lpage">2382</span>, <span class="refDoi"> DOI: 10.1172/JCI45559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1172%2FJCI45559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21537079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVaitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2371-2382&author=L.+Wangauthor=J.+Fanauthor=L.+F.+Thompsonauthor=Y.+Zhangauthor=T.+Shinauthor=T.+J.+Curielauthor=B.+Zhang&title=CD73+has+distinct+roles+in+nonhematopoietic+and+hematopoietic+cells+to+promote+tumor+growth+in+mice&doi=10.1172%2FJCI45559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice</span></div><div class="casAuthors">Wang, Long; Fan, Jie; Thompson, Linda F.; Zhang, Yi; Shin, Tahiro; Curiel, Tyler J.; Zhang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2371-2382</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">CD73 is overexpressed in many types of human and mouse cancers and is implicated in the control of tumor progression.  However, the specific contribution from tumor or host CD73 expression to tumor growth remains unknown to date.  Here, we show that host CD73 promotes tumor growth in a T cell-dependent manner and that the optimal antitumor effect of CD73 blockade requires inhibiting both tumor and host CD73.  Notably, enzymic activity of CD73 on nonhematopoietic cells limited tumor-infiltrating T cells by controlling antitumor T cell homing to tumors in multiple mouse tumor models.  In contrast, CD73 on hematopoietic cells (including CD4+CD25+ Tregs) inhibited systemic antitumor T cell expansion and effector functions.  Thus, CD73 on hematopoietic and nonhematopoietic cells has distinct adenosinergic effects in regulating systemic and local antitumor T cell responses.  Importantly, pharmacol. blockade of CD73 using its selective inhibitor or an anti-CD73 mAb inhibited tumor growth and completely restored efficacy of adoptive T cell therapy in mice.  These findings suggest that both tumor and host CD73 cooperatively protect tumors from incoming antitumor T cells and show the potential of targeting CD73 as a cancer immunotherapy strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwVgJW9GQSfbVg90H21EOLACvtfcHk0liOChJvJukKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVaitro%253D&md5=175d9a4ca0c43f1a12bf4e8ce2462da7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1172%2FJCI45559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45559%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShin%26aufirst%3DT.%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%26atitle%3DCD73%2520has%2520distinct%2520roles%2520in%2520nonhematopoietic%2520and%2520hematopoietic%2520cells%2520to%2520promote%2520tumor%2520growth%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2371%26epage%3D2382%26doi%3D10.1172%2FJCI45559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Csóka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selmeczy, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koscsó, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Németh, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepka-Lenhart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gause, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibovich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">Adenosine promotes alternative macrophage activation via A2A and A2B receptors</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1096/fj.11-190934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1096%2Ffj.11-190934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21926236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlCnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=376-386&author=B.+Cs%C3%B3kaauthor=Z.+Selmeczyauthor=B.+Koscs%C3%B3author=Z.+H.+N%C3%A9methauthor=P.+Pacherauthor=P.+J.+Murrayauthor=D.+Kepka-Lenhartauthor=S.+M.+Morrisauthor=W.+C.+Gauseauthor=S.+J.+Leibovichauthor=G.+Hask%C3%B3&title=Adenosine+promotes+alternative+macrophage+activation+via+A2A+and+A2B+receptors&doi=10.1096%2Ffj.11-190934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine promotes alternative macrophage activation via A2A and A2B receptors</span></div><div class="casAuthors">Csoka, Balazs; Selmeczy, Zsolt; Koscso, Balazs; Nemeth, Zoltan H.; Pacher, Pal; Murray, Peter J.; Kepka-Lenhart, Diane; Morris, Sidney M., Jr.; Gause, William C.; Leibovich, S. Joseph; Hasko, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">376-386, 10.1096/fj.11-190934</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Adenosine has been implicated in suppressing the proinflammatory responses of classically activated macrophages induced by Th1 cytokines.  Alternative macrophage activation is induced by the Th2 cytokines interleukin (IL)-4 and IL-13; however, the role of adenosine in governing alternative macrophage activation is unknown.  We show here that adenosine treatment of IL-4- or IL-13-activated macrophages augments the expression of alternative macrophage markers arginase-1, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and macrophage galactose-type C-type lectin-1.  The stimulatory effect of adenosine required primarily A2B receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) increased both arginase activity (EC50 = 261.8 nM) and TIMP-1 prodn. (EC50 = 80.67 nM), and both pharmacol. and genetic blockade of A2B receptors prevented the effect of NECA.  A2A receptors also contributed to the adenosine augmentation of IL-4-induced TIMP-1 release, as both adenosine and NECA were less efficacious in augmenting TIMP-1 release by A2A receptor-deficient than control macrophages.  Of the transcription factors known to drive alternative macrophage activation, CCAAT-enhancer-binding protein β was required, while cAMP response element-binding protein and signal transducer and activator of transcription 6 were dispensable in mediating the effect of adenosine.  We propose that adenosine receptor activation suppresses inflammation and promotes tissue restitution, in part, by promoting alternative macrophage activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon6drkoEh9trVg90H21EOLACvtfcHk0li6R2z0hmHT3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlCnsg%253D%253D&md5=437030997ac372ce9c927d8c18e19c45</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1096%2Ffj.11-190934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.11-190934%26sid%3Dliteratum%253Aachs%26aulast%3DCs%25C3%25B3ka%26aufirst%3DB.%26aulast%3DSelmeczy%26aufirst%3DZ.%26aulast%3DKoscs%25C3%25B3%26aufirst%3DB.%26aulast%3DN%25C3%25A9meth%26aufirst%3DZ.%2BH.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DMurray%26aufirst%3DP.%2BJ.%26aulast%3DKepka-Lenhart%26aufirst%3DD.%26aulast%3DMorris%26aufirst%3DS.%2BM.%26aulast%3DGause%26aufirst%3DW.%2BC.%26aulast%3DLeibovich%26aufirst%3DS.%2BJ.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DAdenosine%2520promotes%2520alternative%2520macrophage%2520activation%2520via%2520A2A%2520and%2520A2B%2520receptors%26jtitle%3DFASEB%2520J.%26date%3D2012%26volume%3D26%26spage%3D376%26epage%3D386%26doi%3D10.1096%2Ffj.11-190934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novitskiy, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryzhov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaynagetdinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhomirov, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biaggioni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feoktistov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikov, M. M.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors in regulation of dendritic cell differentiation and function</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1831</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-02-136325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1182%2Fblood-2008-02-136325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=18559975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVylu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=1822-1831&author=S.+V.+Novitskiyauthor=S.+Ryzhovauthor=R.+Zaynagetdinovauthor=A.+E.+Goldsteinauthor=Y.+Huangauthor=O.+Y.+Tikhomirovauthor=M.+R.+Blackburnauthor=I.+Biaggioniauthor=D.+P.+Carboneauthor=I.+Feoktistovauthor=M.+M.+Dikov&title=Adenosine+receptors+in+regulation+of+dendritic+cell+differentiation+and+function&doi=10.1182%2Fblood-2008-02-136325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors in regulation of dendritic cell differentiation and function</span></div><div class="casAuthors">Novitskiy, Sergey V.; Ryzhov, Sergey; Zaynagetdinov, Rinat; Goldstein, Anna E.; Huang, Yuhui; Tikhomirov, Oleg Y.; Blackburn, Michael R.; Biaggioni, Italo; Carbone, David P.; Feoktistov, Igor; Dikov, Mikhail M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1822-1831</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Differentiation of functional dendritic cells (DCs) critically depends on the microenvironment.  DCs differentiate in hypoxic tumor sites and inflamed or damaged tissue.  Because local concns. of adenosine reach high physiol. relevant levels in these conditions, we assessed the expression of adenosine receptors and the effect of their activation on differentiation of human monocytes and mouse peritoneal macrophages and hematopoietic progenitor cells (HPCs) into myeloid DCs.  Stimulation of adenosine receptors skews DC differentiation toward a distinct cell population characterized by expression of both DC and monocyte/macrophage cell surface markers.  Pharmacol. anal. and expts. with cells from A2B adenosine receptor knockout mice identified A2B receptor as the mediator of adenosine effects on DCs.  Unlike normal myeloid DCs, adenosine-differentiated DCs have impaired allostimulatory activity and express high levels of angiogenic, proinflammatory, immune suppressor, and tolerogenic factors, including VEGF, IL-8, IL-6, IL-10, COX-2, TGF-β, and IDO.  They promoted tumor growth if injected into tumors implanted in mice.  Using adenosine desaminase knockout animals, we showed that DCs with proangiogenic phenotype are highly abundant under conditions assocd. with elevated levels of extracellular adenosine in vivo.  Adenosine signaling through A2B receptor is an important factor of aberrant DC differentiation and generation of tolerogenic, angiogenic, and proinflammatory cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgQtMbXlnZUbVg90H21EOLACvtfcHk0li6R2z0hmHT3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVylu7rF&md5=c5d285718ba75670e5f392736999a8f7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-02-136325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-02-136325%26sid%3Dliteratum%253Aachs%26aulast%3DNovitskiy%26aufirst%3DS.%2BV.%26aulast%3DRyzhov%26aufirst%3DS.%26aulast%3DZaynagetdinov%26aufirst%3DR.%26aulast%3DGoldstein%26aufirst%3DA.%2BE.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DTikhomirov%26aufirst%3DO.%2BY.%26aulast%3DBlackburn%26aufirst%3DM.%2BR.%26aulast%3DBiaggioni%26aufirst%3DI.%26aulast%3DCarbone%26aufirst%3DD.%2BP.%26aulast%3DFeoktistov%26aufirst%3DI.%26aulast%3DDikov%26aufirst%3DM.%2BM.%26atitle%3DAdenosine%2520receptors%2520in%2520regulation%2520of%2520dendritic%2520cell%2520differentiation%2520and%2520function%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D1822%26epage%3D1831%26doi%3D10.1182%2Fblood-2008-02-136325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrentraut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westrich, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltzschig, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clambey, E. T.</span></span> <span> </span><span class="NLM_article-title">Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e32416</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0032416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1371%2Fjournal.pone.0032416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22389701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ehsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e32416&author=H.+Ehrentrautauthor=J.+A.+Westrichauthor=H.+K.+Eltzschigauthor=E.+T.+Clambey&title=Adora2b+adenosine+receptor+engagement+enhances+regulatory+T+cell+abundance+during+endotoxin-induced+pulmonary+inflammation&doi=10.1371%2Fjournal.pone.0032416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation</span></div><div class="casAuthors">Ehrentraut, Heidi; Westrich, Joseph A.; Eltzschig, Holger K.; Clambey, Eric T.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e32416</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Anti-inflammatory signals play an essential role in constraining the magnitude of an inflammatory response.  Extracellular adenosine is a crit. tissue-protective factor, limiting the extent of inflammation.  Given the potent anti-inflammatory effects of extracellular adenosine, we sought to investigate how extracellular adenosine regulates T cell activation and differentiation.  Adenosine receptor activation by a pan adenosine-receptor agonist enhanced the abundance of murine regulatory T cells (Tregs), a cell type crit. in constraining inflammation.  Gene expression studies in both naive CD4 T cells and Tregs revealed that these cells expressed multiple adenosine receptors.  Based on recent studies implicating the Adora2b in endogenous anti-inflammatory responses during acute inflammation, we used a pharmacol. approach to specifically activate Adora2b.  Indeed, these studies revealed robust enhancement of Treg differentiation in wild-type mice, but not in Adora2b-/- T cells.  Finally, when we subjected Adora2b-deficient mice to endotoxin-induced pulmonary inflammation, we found that these mice experienced more severe inflammation, characterized by increased cell recruitment and increased fluid leakage into the airways.  Notably, Adora2b-deficient mice failed to induce Tregs after endotoxin-induced inflammation and instead had an enhanced recruitment of pro-inflammatory effector T cells.  In total, these data indicate that the Adora2b adenosine receptor serves a potent anti-inflammatory role, functioning at least in part through the enhancement of Tregs, to limit inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIRCjGWLan7Vg90H21EOLACvtfcHk0lhe93qYHIdAGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ehsb0%253D&md5=619fe098459b52fc5b89b6366ecb218e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0032416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0032416%26sid%3Dliteratum%253Aachs%26aulast%3DEhrentraut%26aufirst%3DH.%26aulast%3DWestrich%26aufirst%3DJ.%2BA.%26aulast%3DEltzschig%26aufirst%3DH.%2BK.%26aulast%3DClambey%26aufirst%3DE.%2BT.%26atitle%3DAdora2b%2520adenosine%2520receptor%2520engagement%2520enhances%2520regulatory%2520T%2520cell%2520abundance%2520during%2520endotoxin-induced%2520pulmonary%2520inflammation%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De32416%26doi%3D10.1371%2Fjournal.pone.0032416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronchese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukashev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apasov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">A2A adenosine receptor protects tumors from antitumor T cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">13132</span>– <span class="NLM_lpage">13137</span>, <span class="refDoi"> DOI: 10.1073/pnas.0605251103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1073%2Fpnas.0605251103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16916931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD28Xptlelsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=13132-13137&author=A.+Ohtaauthor=E.+Gorelikauthor=S.+J.+Prasadauthor=F.+Roncheseauthor=D.+Lukashevauthor=M.+K.+Wongauthor=X.+Huangauthor=S.+Caldwellauthor=K.+Liuauthor=P.+Smithauthor=J.+F.+Chenauthor=E.+K.+Jacksonauthor=S.+Apasovauthor=S.+Abramsauthor=M.+Sitkovsky&title=A2A+adenosine+receptor+protects+tumors+from+antitumor+T+cells&doi=10.1073%2Fpnas.0605251103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A2A adenosine receptor protects tumors from antitumor T cells</span></div><div class="casAuthors">Ohta, Akio; Gorelik, Elieser; Prasad, Simon J.; Ronchese, Franca; Lukashev, Dmitriy; Wong, Michael K. K.; Huang, Xiaojun; Caldwell, Sheila; Liu, Kebin; Smith, Patrick; Chen, Jiang-Fan; Jackson, Edwin; Apasov, Sergey; Abrams, Scott; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13132-13137</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The A2A adenosine receptor (A2AR) has been shown to be a crit. and nonredundant neg. regulator of immune cells in protecting normal tissues from inflammatory damage.  We hypothesized that A2AR also protects cancerous tissues by inhibiting incoming antitumor T lymphocytes.  Here we confirm this hypothesis by showing that genetic deletion of A2AR in the host resulted in rejection of established immunogenic tumors in ≈60% of A2AR-deficient mice with no rejection obsd. in control WT mice.  The use of antagonists, including caffeine, or targeting the A2 receptors by siRNA pretreatment of T cells improved the inhibition of tumor growth, destruction of metastases, and prevention of neovascularization by antitumor T cells.  The data suggest that effects of A2AR are T cell autonomous.  The inhibition of antitumor T cells via their A2AR in the adenosine-rich tumor microenvironment may explain the paradoxical coexistence of tumors and antitumor immune cells in some cancer patients (the "Hellstrom paradox").  We propose to target the hypoxia→adenosine→A2AR pathway as a cancer immunotherapy strategy to prevent the inhibition of antitumor T cells in the tumor microenvironment.  The same strategy may prevent the premature termination of immune response and improve the vaccine-induced development of antitumor and antiviral T cells.  The observations of autoimmunity during melanoma rejection in A2AR-deficient mice suggest that A2AR in T cells is also important in preventing autoimmunity.  Thus, although using the hypoxia→adenosine→A2AR pathway inhibitors may improve antitumor immunity, the recruitment of this pathway by selective drugs is expected to attenuate the autoimmune tissue damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor_lg2Eaf727Vg90H21EOLACvtfcHk0lhe93qYHIdAGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xptlelsrw%253D&md5=01291e44600fd286b82ea84f0d38aa7c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0605251103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0605251103%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DGorelik%26aufirst%3DE.%26aulast%3DPrasad%26aufirst%3DS.%2BJ.%26aulast%3DRonchese%26aufirst%3DF.%26aulast%3DLukashev%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCaldwell%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DJackson%26aufirst%3DE.%2BK.%26aulast%3DApasov%26aufirst%3DS.%26aulast%3DAbrams%26aufirst%3DS.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DA2A%2520adenosine%2520receptor%2520protects%2520tumors%2520from%2520antitumor%2520T%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D13132%26epage%3D13137%26doi%3D10.1073%2Fpnas.0605251103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paget, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span> <span> </span><span class="NLM_article-title">Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">14711</span>– <span class="NLM_lpage">14716</span>, <span class="refDoi"> DOI: 10.1073/pnas.1308209110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1073%2Fpnas.1308209110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23964122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVKksLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=14711-14716&author=P.+A.+Beavisauthor=U.+Divisekeraauthor=C.+Pagetauthor=M.+T.+Chowauthor=L.+B.+Johnauthor=C.+Devaudauthor=K.+Dwyerauthor=J.+Staggauthor=M.+J.+Smythauthor=P.+K.+Darcy&title=Blockade+of+A2A+receptors+potently+suppresses+the+metastasis+of+CD73%2B+tumors&doi=10.1073%2Fpnas.1308209110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors</span></div><div class="casAuthors">Beavis, Paul A.; Divisekera, Upulie; Paget, Christophe; Chow, Melvyn T.; John, Liza B.; Devaud, Christel; Dwyer, Karen; Stagg, John; Smyth, Mark J.; Darcy, Phillip K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">14711-14716,S14711/1-S14711/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">CD73 inhibits antitumor immunity through the activation of adenosine receptors expressed on multiple immune subsets.  CD73 also enhances tumor metastasis, although the nature of the immune subsets and adenosine receptor subtypes involved in this process are largely unknown.  In this study, the authors revealed that A2A/A2B receptor antagonists were effective in reducing the metastasis of tumors expressing CD73 endogenously (4T1.2 breast tumors) and when CD73 was ectopically expressed (B16F10 melanoma).  A2A-/- mice were strongly protected against tumor metastasis, indicating that host A2A receptors enhanced tumor metastasis.  A2A blockade enhanced natural killer (NK) cell maturation and cytotoxic function in vitro, reduced metastasis in a perforin-dependent manner, and enhanced NK cell expression of granzyme B in vivo, strongly suggesting that the antimetastatic effect of A2A blockade was due to enhanced NK cell function.  Interestingly, A2B blockade had no effect on NK cell cytotoxicity, indicating that an NK cell-independent mechanism also contributed to the increased metastasis of CD73+ tumors.  The authors' results thus revealed that CD73 promotes tumor metastasis through multiple mechanisms, including suppression of NK cell function.  Furthermore, the authors' data strongly suggest that A2A or A2B antagonists may be useful for the treatment of metastatic disease.  Overall, the authors' study has potential therapeutic implications given that A2A/A2B receptor antagonists have already entered clin. trials in other therapeutic settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYO0Dnl_qmy7Vg90H21EOLACvtfcHk0lhe93qYHIdAGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVKksLzL&md5=7b55e554c472a46e7f08c2fcb691f1f4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1308209110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1308209110%26sid%3Dliteratum%253Aachs%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DPaget%26aufirst%3DC.%26aulast%3DChow%26aufirst%3DM.%2BT.%26aulast%3DJohn%26aufirst%3DL.%2BB.%26aulast%3DDevaud%26aufirst%3DC.%26aulast%3DDwyer%26aufirst%3DK.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26atitle%3DBlockade%2520of%2520A2A%2520receptors%2520potently%2520suppresses%2520the%2520metastasis%2520of%2520CD73%252B%2520tumors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D14711%26epage%3D14716%26doi%3D10.1073%2Fpnas.1308209110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waickman, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alme, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senaldi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarek, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1007/s00262-011-1155-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs00262-011-1155-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22116345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFKqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=917-926&author=A.+T.+Waickmanauthor=A.+Almeauthor=L.+Senaldiauthor=P.+E.+Zarekauthor=M.+Hortonauthor=J.+D.+Powell&title=Enhancement+of+tumor+immunotherapy+by+deletion+of+the+A2A+adenosine+receptor&doi=10.1007%2Fs00262-011-1155-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor</span></div><div class="casAuthors">Waickman, Adam T.; Alme, Angela; Senaldi, Liana; Zarek, Paul E.; Horton, Maureen; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The A2A adenosine receptor plays a crit. and non-redundant role in suppressing inflammation at sites of hypoxia and tissue damage.  The tumor microenvironment has high levels of adenosine as a result of hypoxia and ectopic expression of enzymes responsible for the generation of extracellular adenosine.  Thus, we sought to det. the ability of A2A receptor null mice to immunol. reject tumors.  We obsd. that mice lacking the A2A adenosine receptor showed significantly delayed growth of lymphoma cells when compared to WT mice.  Furthermore, when immunized with a low dose of tumor or with an irradiated GM-CSF-secreting tumor vaccine, A2A receptor null mice showed significantly enhanced protection from a subsequent high-dose challenge from both immunogenic and poorly immunogenic tumor lines.  This increase in protection was accompanied by an increase in the no. of tumor-antigen-specific CD8 T cells at the vaccine-site draining lymph node.  Finally, we found that A2A receptor null mice displayed more robust anti-tumor responses than WT mice when they were treated with a sol. B7-DC/Fc fusion protein designed to antagonize B7-H1-mediated co-inhibition.  This combinatorial immunotherapy strategy could also be recapitulated with pharmacol. A2A receptor blockade paired with B7-DC/Fc administration.  In light of these data, we believe that blockade of the A2A adenosine receptor is an attractive target for tumor immunotherapy that synergizes with other immunomodulatory approaches currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLwuC7utbv-7Vg90H21EOLACvtfcHk0liN3Ysq91iFgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFKqu7s%253D&md5=6f3ac5af343eb37f6bac7109912f370d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00262-011-1155-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-011-1155-7%26sid%3Dliteratum%253Aachs%26aulast%3DWaickman%26aufirst%3DA.%2BT.%26aulast%3DAlme%26aufirst%3DA.%26aulast%3DSenaldi%26aufirst%3DL.%26aulast%3DZarek%26aufirst%3DP.%2BE.%26aulast%3DHorton%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DEnhancement%2520of%2520tumor%2520immunotherapy%2520by%2520deletion%2520of%2520the%2520A2A%2520adenosine%2520receptor%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2012%26volume%3D61%26spage%3D917%26epage%3D926%26doi%3D10.1007%2Fs00262-011-1155-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, S.</span></span> <span> </span><span class="NLM_article-title">Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24660106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVOksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=172-181&author=R.+Iannoneauthor=L.+Mieleauthor=P.+Maiolinoauthor=A.+Pintoauthor=S.+Morello&title=Adenosine+limits+the+therapeutic+effectiveness+of+anti-CTLA4+mAb+in+a+mouse+melanoma+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma mode</span></div><div class="casAuthors">Iannone, Raffaella; Miele, Lucio; Maiolino, Piera; Pinto, Aldo; Morello, Silvana</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-181, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Combination therapies for melanoma that target immune-regulatory networks are entering clin. practice and more are under investigation in preclin. or clin. studies.  Adenosine plays a key role in regulating melanoma progression.  We investigated the effectiveness of cytotoxic T lymphocyte-assocd. antigen 4 (CTLA-4) antibody (mAb) in combination with either modulators of adenosine receptors (AR) activation or an inhibitor of adenosine prodn. in a murine model of melanoma.  We found that treatment with APCP, selective inhibitor of the adenosine-generating nucleotidase CD73, enhanced the activity of anti-CTLA4 mAb, by improving tumor immune response.  Blockade of the adenosine A2a receptor (A2aR), which plays a crit. role in the regulation of T-cell functions, significantly reduced melanoma growth.  Most importantly, combination therapy including an A2aR antagonist with anti-CTLA4 mAb markedly inhibited tumor growth and enhanced anti-tumor immune responses.  Targeting A3R and CTLA4 was not as effective in limiting melanoma growth as targeting A2aR.  These data suggest that the efficacy of anti-CTLA4 melanoma therapy may be improved by targeting multiple mechanisms of immune suppression within tumor tissue, including CD73 or A2a receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzj-TJvGLs97Vg90H21EOLACvtfcHk0liN3Ysq91iFgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVOksrs%253D&md5=9df35166be411b35c4694eb1a4608581</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DMaiolino%26aufirst%3DP.%26aulast%3DPinto%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DS.%26atitle%3DAdenosine%2520limits%2520the%2520therapeutic%2520effectiveness%2520of%2520anti-CTLA4%2520mAb%2520in%2520a%2520mouse%2520melanoma%2520model%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2014%26volume%3D4%26spage%3D172%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuffrida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardiana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaney, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kats, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyorki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kershaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1172/JCI89455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1172%2FJCI89455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28165340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jsFahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=929-941&author=P.+A.+Beavisauthor=M.+A.+Hendersonauthor=L.+Giuffridaauthor=J.+K.+Millsauthor=K.+Sekauthor=R.+S.+Crossauthor=A.+J.+Davenportauthor=L.+B.+Johnauthor=S.+Mardianaauthor=C.+Y.+Slaneyauthor=R.+W.+Johnstoneauthor=J.+A.+Trapaniauthor=J.+Staggauthor=S.+Loiauthor=L.+Katsauthor=D.+Gyorkiauthor=M.+H.+Kershawauthor=P.+K.+Darcy&title=Targeting+the+adenosine+2A+receptor+enhances+chimeric+antigen+receptor+T+cell+efficacy&doi=10.1172%2FJCI89455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy</span></div><div class="casAuthors">Beavis Paul A; Henderson Melissa A; Giuffrida Lauren; Mills Jane K; Sek Kevin; Cross Ryan S; Davenport Alexander J; John Liza B; Mardiana Sherly; Slaney Clare Y; Johnstone Ricky W; Trapani Joseph A; Stagg John; Loi Sherene; Kats Lev; Gyorki David; Kershaw Michael H; Darcy Phillip K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">929-941</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chimeric antigen receptor (CAR) T cells have been highly successful in treating hematological malignancies, including acute and chronic lymphoblastic leukemia.  However, treatment of solid tumors using CAR T cells has been largely unsuccessful to date, partly because of tumor-induced immunosuppressive mechanisms, including adenosine production.  Previous studies have shown that adenosine generated by tumor cells potently inhibits endogenous antitumor T cell responses through activation of adenosine 2A receptors (A2ARs).  Herein, we have observed that CAR activation resulted in increased A2AR expression and suppression of both murine and human CAR T cells.  This was reversible using either A2AR antagonists or genetic targeting of A2AR using shRNA.  In 2 syngeneic HER2+ self-antigen tumor models, we found that either genetic or pharmacological targeting of the A2AR profoundly increased CAR T cell efficacy, particularly when combined with PD-1 blockade.  Mechanistically, this was associated with increased cytokine production of CD8+ CAR T cells and increased activation of both CD8+ and CD4+ CAR T cells.  Given the known clinical relevance of the CD73/adenosine pathway in several solid tumor types, and the initiation of phase I trials for A2AR antagonists in oncology, this approach has high translational potential to enhance CAR T cell efficacy in several cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRg-r0B0lykDP69nzq6467DfW6udTcc2eZAjyxQ7D3hhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jsFahtA%253D%253D&md5=c46df40ff3c7d438497ccb57ca149e5f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1172%2FJCI89455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI89455%26sid%3Dliteratum%253Aachs%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DHenderson%26aufirst%3DM.%2BA.%26aulast%3DGiuffrida%26aufirst%3DL.%26aulast%3DMills%26aufirst%3DJ.%2BK.%26aulast%3DSek%26aufirst%3DK.%26aulast%3DCross%26aufirst%3DR.%2BS.%26aulast%3DDavenport%26aufirst%3DA.%2BJ.%26aulast%3DJohn%26aufirst%3DL.%2BB.%26aulast%3DMardiana%26aufirst%3DS.%26aulast%3DSlaney%26aufirst%3DC.%2BY.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DTrapani%26aufirst%3DJ.%2BA.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DKats%26aufirst%3DL.%26aulast%3DGyorki%26aufirst%3DD.%26aulast%3DKershaw%26aufirst%3DM.%2BH.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26atitle%3DTargeting%2520the%2520adenosine%25202A%2520receptor%2520enhances%2520chimeric%2520antigen%2520receptor%2520T%2520cell%2520efficacy%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D929%26epage%3D941%26doi%3D10.1172%2FJCI89455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haibe-Kains, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">11091</span>– <span class="NLM_lpage">11096</span>, <span class="refDoi"> DOI: 10.1073/pnas.1222251110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1073%2Fpnas.1222251110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23776241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=11091-11096&author=S.+Loiauthor=S.+Pommeyauthor=B.+Haibe-Kainsauthor=P.+A.+Beavisauthor=P.+K.+Darcyauthor=M.+J.+Smythauthor=J.+Stagg&title=CD73+promotes+anthracycline+resistance+and+poor+prognosis+in+triple+negative+breast+cancer&doi=10.1073%2Fpnas.1222251110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</span></div><div class="casAuthors">Loi, Sherene; Pommey, Sandra; Haibe-Kains, Benjamin; Beavis, Paul A.; Darcy, Phillip K.; Smyth, Mark J.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11091-11096,S11091/1-S11091/21</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using gene-expression data from over 6,000 breast cancer patients, we report herein that high CD73 expression is assocd. with a poor prognosis in triple-neg. breast cancers (TNBC).  Because anthracycline-based chemotherapy regimens are std. treatment for TNBC, we investigated the relationship between CD73 and anthracycline efficacy.  In TNBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was significantly assocd. with a lower rate of pathol. complete response or the disappearance of invasive tumor at surgery.  Using mouse models of breast cancer, we demonstrated that CD73 overexpression in tumor cells conferred chemoresistance to doxorubicin, a commonly used anthracycline, by suppressing adaptive antitumor immune responses via activation of A2A adenosine receptors.  Targeted blockade of CD73 enhanced doxorubicin-mediated antitumor immune responses and significantly prolonged the survival of mice with established metastatic breast cancer.  Taken together, our data suggest that CD73 constitutes a therapeutic target in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6KtLUgWgbYbVg90H21EOLACvtfcHk0lhYDxMbwwYgXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLrO&md5=97b58f664273accfcab7096dcbc76db6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1222251110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1222251110%26sid%3Dliteratum%253Aachs%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DHaibe-Kains%26aufirst%3DB.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520promotes%2520anthracycline%2520resistance%2520and%2520poor%2520prognosis%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D11091%26epage%3D11096%26doi%3D10.1073%2Fpnas.1222251110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vecchio, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L.</span></span> <span> </span><span class="NLM_article-title">Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.230003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1124%2Fjpet.115.230003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26791603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVeksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2016&pages=36-44&author=E.+A.+Vecchioauthor=C.+Y.+R.+Tanauthor=K.+J.+Gregoryauthor=A.+Christopoulosauthor=P.+J.+Whiteauthor=L.+May&title=Ligand-independent+adenosine+A2B+receptor+constitutive+activity+as+a+promoter+of+prostate+cancer+cell+proliferation&doi=10.1124%2Fjpet.115.230003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation</span></div><div class="casAuthors">Vecchio, Elizabeth A.; Tan, Christina Y. R.; Gregory, Karen J.; Christopoulos, Arthur; White, Paul J.; May, Lauren T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aberrant ligand-independent G protein-coupled receptor constitutive activity has been implicated in the pathophysiol. of a no. of cancers.  The adenosine A2B receptor (A2BAR) is dynamically upregulated under pathol. conditions assocd. with a hypoxic microenvironment, including solid tumors.  This, in turn, may amplify ligand-independent A2BAR signal transduction.  The contribution of A2BAR constitutive activity to disease progression is currently unknown yet of fundamental importance, as the preferred therapeutic modality for drugs designed to reduce A2BAR constitutive activity would be inverse agonism as opposed to neutral antagonism.  The current study investigated A2BAR constitutive activity in a heterologous expression system and a native 22Rv1 human prostate cancer cell line exposed to hypoxic conditions (2% O2).  The A2BAR inverse agonists, ZM241385 [4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol] or PSB-603 (8-(4-(4-(4-chlorophenyl)piperazide-1-sulfonyl)phenyl)-1-propylxanthine), mediated a concn.-dependent decrease in baseline cAMP levels in both cellular systems.  Proliferation of multiple prostate cancer cell lines was also attenuated in the presence of PSB-603.  Importantly, both the decrease in baseline cAMP accumulation and the redn. of proliferation were not influenced by the addn. of adenosine deaminase, demonstrating that these effects are not dependent on stimulation of A2BARs by the endogenous agonist adenosine.  Our study is the first to reveal that wild-type human A2BARs have high constitutive activity in both model and native cells.  Furthermore, our findings demonstrate that this ligand-independent A2BAR constitutive activity is sufficient to promote prostate cancer cell proliferation in vitro.  More broadly, A2BAR constitutive activity may have wider, currently unappreciated implications in pathol. conditions assocd. with a hypoxic microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgR2SqHb3o7Vg90H21EOLACvtfcHk0liwAwP4bpStGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVeksbw%253D&md5=47cef2c343e8efedf7b9497f704e6a33</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.230003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.230003%26sid%3Dliteratum%253Aachs%26aulast%3DVecchio%26aufirst%3DE.%2BA.%26aulast%3DTan%26aufirst%3DC.%2BY.%2BR.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DMay%26aufirst%3DL.%26atitle%3DLigand-independent%2520adenosine%2520A2B%2520receptor%2520constitutive%2520activity%2520as%2520a%2520promoter%2520of%2520prostate%2520cancer%2520cell%2520proliferation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D357%26spage%3D36%26epage%3D44%26doi%3D10.1124%2Fjpet.115.230003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodorescu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strieter, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2B receptor blockade slows growth of bladder and breast tumors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1101845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.4049%2Fjimmunol.1101845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22116822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Gltr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2012&pages=198-205&author=C.+Cekicauthor=D.+Sagauthor=Y.+Liauthor=D.+Theodorescuauthor=R.+M.+Strieterauthor=J.+Linden&title=Adenosine+A2B+receptor+blockade+slows+growth+of+bladder+and+breast+tumors&doi=10.4049%2Fjimmunol.1101845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors</span></div><div class="casAuthors">Cekic, Caglar; Sag, Duygu; Li, Yuesheng; Theodorescu, Dan; Strieter, Robert M.; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">198-205</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The accumulation of high levels of adenosine in tumors activates A2A and A2B receptors on immune cells and inhibits their ability to suppress tumor growth.  Deletion of adenosine A2A receptors (A2AARs) has been reported to activate antitumor T cells, stimulate dendritic cell (DC) function, and inhibit angiogenesis.  In this study, we evaluated the effects of intermittent intratumor injection of a nonselective adenosine receptor antagonist, aminophylline (AMO; theophylline ethylenediamine) and, for the first time to our knowledge, a selective A2BAR antagonist, ATL801.  AMO and ATL801 slowed the growth of MB49 bladder and 4T1 breast tumors in syngeneic mice and reduced by 85% metastasizes of breast cancer cells from mammary fat to lung.  Based on expts. with A2AAR-/- or adenosine A2B receptor-/- mice, the effect of AMO injection was unexpectedly attributed to A2BAR and not to A2AAR blockade.  AMO and ATL801 significantly increased tumor levels of IFN-γ and the IFN-inducible chemokine CXCL10, which is a ligand for CXCR3.  This was assocd. with an increase in activated tumor-infiltrating CXCR3+ T cells and a decrease in endothelial cell precursors within tumors.  Tumor growth inhibition by AMO or ATL801 was eliminated in CXCR3-/- mice and RAG1-/- mice that lack mature T cells.  In RAG1-/- mice, A2BAR deletion enhanced CD86 expression on CD11b- DCs.  Bone marrow chimera expts. demonstrated that CXCR3 and A2BAR expression on bone marrow cells is required for the antitumor effects of AMO.  The data suggest that blockade of A2BARs enhances DC activation and CXCR3-dependent antitumor responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJWI-EUe7h3rVg90H21EOLACvtfcHk0liwAwP4bpStGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Gltr7E&md5=dce403f7ab9a9ae0e90df07cf4b9392c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1101845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1101845%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DSag%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTheodorescu%26aufirst%3DD.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2B%2520receptor%2520blockade%2520slows%2520growth%2520of%2520bladder%2520and%2520breast%2520tumors%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D188%26spage%3D198%26epage%3D205%26doi%3D10.4049%2Fjimmunol.1101845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, S.</span></span> <span> </span><span class="NLM_article-title">Blockade of A2B adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1400</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1593/neo.131748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1593%2Fneo.131748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24403862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWls73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1400-1409&author=R.+Iannoneauthor=L.+Mieleauthor=P.+Maiolinoauthor=A.+Pintoauthor=S.+Morello&title=Blockade+of+A2B+adenosine+receptor+reduces+tumor+growth+and+immune+suppression+mediated+by+myeloid-derived+suppressor+cells+in+a+mouse+model+of+melanoma&doi=10.1593%2Fneo.131748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma</span></div><div class="casAuthors">Iannone, Raffaella; Miele, Lucio; Maiolino, Piera; Pinto, Aldo; Morello, Silvana</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1400-1409, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">The A2b receptor (A2bR) belongs to the adenosine receptor family.  Emerging evidence suggest that A2bR is implicated in tumor progression in some murine tumor models, but the therapeutic potential of targeting A2bR in melanoma has not been examd.  This study first shows that melanoma-bearing mice treated with Bay 60-6583, a selective A2bR agonist, had increased melanoma growth.  This effect was assocd. with higher levels of immune regulatory mediators interleukin-10 (IL-10) and monocyte chemoattractant protein 1 (MCP-1) and accumulation of tumor-assocd. CD11b pos. Gr1 pos. cells (CD11b+Gr1+) myeloid-derived suppressor cells (MDSCs).  Depletion of CD11b+Gr1+ cells completely reversed the protumor activity of Bay 60-6583.  Conversely, pharmacol. blockade of A2bR with PSB1115 reversed immune suppression in the tumor microenvironment, leading to a significant melanoma growth delay.  PSB1115 treatment reduced both levels of IL-10 and MCP-1 and CD11b+Gr1+ cell no. in melanoma lesions.  These effects were assocd. with higher frequency of tumor-infiltrating CD8 pos. (CD8+) T cells and natural killer T (NKT) cells and increased levels of T helper 1 (Th1)-like cytokines.  Adoptive transfer of CD11b+Gr1+ cells abrogated the antitumor activity of PSB1115.  These data suggest that the antitumor activity of PSB1115 relies on its ability to lower accumulation of tumor-infiltrating MDSCs and restore an efficient antitumor T cell response.  The antitumor effect of PSB1115 was not obsd. in melanoma-bearing nude mice.  Furthermore, PSB1115 enhanced the antitumor efficacy of dacarbazine.These data indicate that A2bR antagonists such as PSB1115 should be investigated as adjuvants in the treatment of melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCc_1YKSaS8rVg90H21EOLACvtfcHk0liwAwP4bpStGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWls73K&md5=0b4cb56ad530f6cca9027d845a7577cc</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1593%2Fneo.131748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.131748%26sid%3Dliteratum%253Aachs%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DMaiolino%26aufirst%3DP.%26aulast%3DPinto%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DS.%26atitle%3DBlockade%2520of%2520A2B%2520adenosine%2520receptor%2520reduces%2520tumor%2520growth%2520and%2520immune%2520suppression%2520mediated%2520by%2520myeloid-derived%2520suppressor%2520cells%2520in%2520a%2520mouse%2520model%2520of%2520melanoma%26jtitle%3DNeoplasia%26date%3D2013%26volume%3D15%26spage%3D1400%26epage%3D1409%26doi%3D10.1593%2Fneo.131748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, S.</span></span> <span> </span><span class="NLM_article-title">Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">27478</span>– <span class="NLM_lpage">27489</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.18632%2Foncotarget.4393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26317647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC287ntVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=27478-27489&author=C.+Sorrentinoauthor=L.+Mieleauthor=A.+Portaauthor=A.+Pintoauthor=S.+Morello&title=Myeloid-derived+suppressor+cells+contribute+to+A2B+adenosine+receptor-induced+VEGF+production+and+angiogenesis+in+a+mouse+melanoma+model&doi=10.18632%2Foncotarget.4393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model</span></div><div class="casAuthors">Sorrentino Claudia; Porta Amalia; Pinto Aldo; Morello Silvana; Miele Lucio</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">27478-89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) is an angiogenic factor critically involved in tumor progression.  Adenosine A2B receptor plays a pivotal role in promoting tumor growth.  The aim of this study was to investigate the role of myeloid-derived suppressor cells (MDSCs) in the pro-angiogenic effects of A2B and to determine whether A2B blockade could enhance the effectiveness of anti-VEGF treatment.  Mice treated with Bay60-6583, a selective A2B receptor agonist, showed enhanced tumor VEGF-A expression and vessel density.  This effect was associated with accelerated tumor growth, which could be reversed with anti-VEGF treatment.  Bay60-6583 increased the accumulation of tumor CD11b+Gr1+ cells.  Depletion of MDSCs in mice significantly reduced A2B-induced VEGF production.  However, A2B receptor stimulation did not directly regulate VEGF expression in isolated tumor myeloid cells.  Mechanistically, Bay60-6583-treated melanoma tissues showed increased STAT3 activation.  Inhibition of STAT3 significantly decreased the pro-tumor activity of Bay60-6583 and reduced tumor VEGF expression.  Pharmacological blockade of A2B receptor with PSB1115 significantly reduced tumor growth by inhibiting tumor angiogenesis and increasing T cells numbers within the tumor microenvironment.  These effects are, at least in part, dependent on impaired tumor accumulation of Gr1+ cells upon A2B receptor blockade.  PSB1115 increased the effectiveness of anti-VEGF treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpoOT32a8a7wvupmecNw_lfW6udTcc2eaM73TxBQuG2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287ntVKrtA%253D%253D&md5=676b86b21bf78edea849235599f682b8</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4393%26sid%3Dliteratum%253Aachs%26aulast%3DSorrentino%26aufirst%3DC.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DPorta%26aufirst%3DA.%26aulast%3DPinto%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DS.%26atitle%3DMyeloid-derived%2520suppressor%2520cells%2520contribute%2520to%2520A2B%2520adenosine%2520receptor-induced%2520VEGF%2520production%2520and%2520angiogenesis%2520in%2520a%2520mouse%2520melanoma%2520model%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D27478%26epage%3D27489%26doi%3D10.18632%2Foncotarget.4393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Extracellular adenosine regulates naive T cell development and peripheral maintenance</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">2693</span>– <span class="NLM_lpage">2706</span>, <span class="refDoi"> DOI: 10.1084/jem.20130249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1084%2Fjem.20130249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24145516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=2693-2706&author=C.+Cekicauthor=D.+Sagauthor=Y.+J.+Dayauthor=J.+Linden&title=Extracellular+adenosine+regulates+naive+T+cell+development+and+peripheral+maintenance&doi=10.1084%2Fjem.20130249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular adenosine regulates naive T cell development and peripheral maintenance</span></div><div class="casAuthors">Cekic, Caglar; Sag, Duygu; Day, Yuan-Ji; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2693-2706</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Adenosine produced as a byproduct of metabolic activity is present in all tissues and produces dose-dependent suppression of TCR signaling.  Naive T cell maintenance depends on inhibition of TCR signals by environmental sensors, which are yet to be fully defined.  We produced mice with a floxed adenosine A2A receptor (A2AR) gene, Adora2a, and show that either global A2AR deletion or cre-mediated T cell deletion elicits a decline in the no. of naive but not memory T cells.  A2AR signaling maintains naive T cells in a quiescent state by inhibiting TCR-induced activation of the phosphatidylinositide 3-kinase (PI3K)-AKT pathway, thereby reducing IL-7Rα down-regulation and naive T cell apoptosis.  Patterns of IL-7Rα expression on T cells in chimeric mice reconstituted with Adora2a+/+ and Adora2a-/- bone marrow cells suggest that decreased IL-7Rα in naive T cells is a cell-intrinsic consequence of Adora2a deletion.  In addn., A2AR expression increases in early thymic T cell development and contributes to progression of double-neg. thymic precursors to single-pos. thymocytes with increased IL-7Rα expression.  Therefore, A2AR signaling regulates T cell development and maintenance to sustain normal nos. of naive T cells in the periphery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo74zbT0m4BIbVg90H21EOLACvtfcHk0lh5L1si88grcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsbfF&md5=2c4a497e4cfd0ec94d47eeec7ab07e29</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1084%2Fjem.20130249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20130249%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DSag%26aufirst%3DD.%26aulast%3DDay%26aufirst%3DY.%2BJ.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DExtracellular%2520adenosine%2520regulates%2520naive%2520T%2520cell%2520development%2520and%2520peripheral%2520maintenance%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D2693%26epage%3D2706%26doi%3D10.1084%2Fjem.20130249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">7239</span>– <span class="NLM_lpage">7249</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-3581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-13-3581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25341542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOhtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=7239-7249&author=C.+Cekicauthor=J.+Linden&title=Adenosine+A2A+receptors+intrinsically+regulate+CD8%2B+T+cells+in+the+tumor+microenvironment&doi=10.1158%2F0008-5472.CAN-13-3581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment</span></div><div class="casAuthors">Cekic, Caglar; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7239-7249</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted deletion of the adenosine A2A receptor, an important inhibitory receptor on T cells, paradoxically enhances the growth rate of solid tumors by impairing tumor-assocd. T-cell maintenance and effector/memory differentiation, with implications for clin. testing of A2A receptor antagonists to enhance cancer immunotherapy.  Adenosine A2A receptor (A2AR) blockade enhances innate and adaptive immune responses.  However, mouse genetic studies have shown that A2AR deletion does not inhibit the growth of all tumor types.  In the current study, we showed that growth rates for ectopic melanoma and bladder tumors are increased in Adora2a-/- mice within 2 wk of tumor inoculation.  A2AR deletion in the host reduced nos. of CD8+ T cells and effector-memory differentiation of all T cells.  To examine intrinsic functions in T cells, we generated mice harboring a T-cell-specific deletion of A2AR.  In this host strain, tumor-bearing mice displayed increased growth of ectopic melanomas, decreased nos. of tumor-assocd. T cells, reduced effector-memory differentiation, and reduced antiapoptotic IL7Rα (CD127) expression on antigen-experienced cells.  Intratumoral pharmacol. blockade similarly reduced CD8+ T-cell d. within tumors in wild-type hosts.  We found that A2AR-proficient CD8+ T cells specific for melanoma cells displayed a relative survival advantage in tumors.  Thus, abrogating A2AR signaling appeared to reduce IL7R expression, survival, and differentiation of T cells in the tumor microenvironment.  One implication of these results is that the antitumor effects of A2AR blockade that can be mediated by activation of cytotoxic T cells may be overcome in some tumor microenvironments as a result of impaired T-cell maintenance and effector-memory differentiation.  Thus, our findings imply that the efficacious application of A2AR inhibitors for cancer immunotherapy may require careful dose optimization to prevent activation-induced T-cell death in tumors.  Cancer Res; 74(24); 7239-49. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq94b5Vd4f577Vg90H21EOLACvtfcHk0liKFvKp9v4jiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOhtrnJ&md5=7bb588350820bf2f5392143546f1cc0a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-3581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-3581%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520receptors%2520intrinsically%2520regulate%2520CD8%252B%2520T%2520cells%2520in%2520the%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D7239%26epage%3D7249%26doi%3D10.1158%2F0008-5472.CAN-13-3581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Borstel, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evoniuk, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtman, R. J.</span></span> <span> </span><span class="NLM_article-title">Adenosine potentiates sympathomimetic effects of nicotinic agonists in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>236</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=3003340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaL28Xht1eks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=1986&pages=344-349&author=R.+W.+von%0ABorstelauthor=G.+E.+Evoniukauthor=R.+J.+Wurtman&title=Adenosine+potentiates+sympathomimetic+effects+of+nicotinic+agonists+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine potentiates sympathomimetic effects of nicotinic agonists in vivo</span></div><div class="casAuthors">Von Borstel, Reid W.; Evoniuk, Gary E.; Wurtman, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">344-9</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The effects of adenosine  [58-61-7] (or synthetic adenosine receptor agonists) on a variety of sympathomimetic responses to nicotine  [54-11-5] (or other nicotinic cholinergic agonists) were examd.  Indexes of sympathetic activity examd. were: blood pressure; heart rate; eyelid tension; and vas deferens perfusion pressure.  Elevation of arterial plasma adenosine from its basal level (∼1.5 μM) to 2-3 μM (by i.v. adenosine infusion) had no effect on the basal value of any of these indexes, but increased by 2.5-4-fold their peak responses to nicotine (40 μg/kg i.v.).  Adenosine also strongly enhanced sympathomimetic responses to inhaled cigarette smoke.  The adenosine receptor antagonist caffeine (10 mg/kg) suppressed the ability of adenosine to potentiate these responses to nicotine.  Pressor responses to the nicotinic cholinergic receptor agonists dimethylphenylpiperazinium iodide  [54-77-3], tetramethylammonium  [51-92-3], lobeline  [90-69-7], and cytisin  [485-35-8] were also potentiated by adenosine.  Low doses (0.25-5 μ/kg) of synthetic adenosine receptor agonists potentiated all 4 of the tested sympathomimetic responses to nicotine, exhibiting the rank order of potency: N-cyclopropylcarboxamidoadenosine  [50908-62-8] > 2-chloroadenosine  [146-77-0] > N6-R-phenylisopropyl adenosine  [38594-96-6] > N6-S-phenylisopropyladenosine  [38594-97-7].  The nonpurinergic vasodilator, Na nitroprusside, failed to potentiate responses to nicotine, suggesting that the influence of adenosine on responses to nicotine is not secondary to its direct circulatory effects.  Decentralization of the sympathetic ganglia that control eyelid tension and vas deferens perfusion pressure did not affect responses to nicotine or their potentiation by adenosine, confirming that the loci wherein both adenosine and nicotine act are within or distal to sympathetic ganglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXSNn8zKYGJLVg90H21EOLACvtfcHk0liKFvKp9v4jiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xht1eks74%253D&md5=f754595f152ebec01f1dffa03bb96c35</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BBorstel%26aufirst%3DR.%2BW.%26aulast%3DEvoniuk%26aufirst%3DG.%2BE.%26aulast%3DWurtman%26aufirst%3DR.%2BJ.%26atitle%3DAdenosine%2520potentiates%2520sympathomimetic%2520effects%2520of%2520nicotinic%2520agonists%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1986%26volume%3D236%26spage%3D344%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maenhaut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Sande, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderhaegen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S.</span></span> <span> </span><span class="NLM_article-title">RDC8 codes for an adenosine A2 receptor with physiological constitutive activity</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(05)80909-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2FS0006-291X%2805%2980909-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=2125216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK3MXps1Wrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=1990&pages=1169-1178&author=C.+Maenhautauthor=J.+Van+Sandeauthor=F.+Libertauthor=M.+Abramowiczauthor=M.+Parmentierauthor=J.+J.+Vanderhaegenauthor=J.+E.+Dumontauthor=G.+Vassartauthor=S.+Schiffmann&title=RDC8+codes+for+an+adenosine+A2+receptor+with+physiological+constitutive+activity&doi=10.1016%2FS0006-291X%2805%2980909-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">RDC8 codes for an adenosine A2 receptor with physiological constitutive activity</span></div><div class="casAuthors">Maenhaut, Carine; Van Sande, Jacqueline; Libert, Frederick; Abramowicz, Marc; Parmentier, Marc; Vanderhaegen, Jean Jacques; Dumont, Jacques E.; Vassart, Gilbert; Schiffmann, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1169-78</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">The cDNA of an unidentified recently cloned G protein-coupled receptor, RDC8, has been expressed in Y1 adrenal cells, in dog thyrocytes in primary culture, and in Xenopus oocytes.  In all these systems this resulted in the activation of adenylyl cyclase and of the cAMP cascade in the absence of any added external signal.  However, this physiol. constitutive activator was inhibited by adenosine deaminase and by inhibitors of the adenosine A2 receptor.  Cos 7 cells transfected with RDC8 cDNA constructs acquired binding characteristics of an adenosine A2 receptor.  Moreover, RDC8 mRNA and adenosine A2 receptors display a very similar distribution in the brain.  RDC8 therefore codes for an A2 adenosine receptor.  Whether the physiol. constitutive activation of this receptor is entirely explained by endogeneously produced adenosine is as yet unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKrLE25ynVkrVg90H21EOLACvtfcHk0liLBNEUFNAhTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXps1Wrtw%253D%253D&md5=e925e1af7ccff03114e94ae252121896</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2805%2980909-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252805%252980909-X%26sid%3Dliteratum%253Aachs%26aulast%3DMaenhaut%26aufirst%3DC.%26aulast%3DVan%2BSande%26aufirst%3DJ.%26aulast%3DLibert%26aufirst%3DF.%26aulast%3DAbramowicz%26aufirst%3DM.%26aulast%3DParmentier%26aufirst%3DM.%26aulast%3DVanderhaegen%26aufirst%3DJ.%2BJ.%26aulast%3DDumont%26aufirst%3DJ.%2BE.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DSchiffmann%26aufirst%3DS.%26atitle%3DRDC8%2520codes%2520for%2520an%2520adenosine%2520A2%2520receptor%2520with%2520physiological%2520constitutive%2520activity%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1990%26volume%3D173%26spage%3D1169%26epage%3D1178%26doi%3D10.1016%2FS0006-291X%2805%2980909-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furlong, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selbie, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shine, J.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of a human brain adenosine A2 receptor</span>. <i>Mol. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/0169-328X(92)90152-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2F0169-328X%2892%2990152-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1331670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK3sXit1Kiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1992&pages=62-66&author=T.+J.+Furlongauthor=K.+D.+Pierceauthor=L.+A.+Selbieauthor=J.+Shine&title=Molecular+characterization+of+a+human+brain+adenosine+A2+receptor&doi=10.1016%2F0169-328X%2892%2990152-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of a human brain adenosine A2 receptor</span></div><div class="casAuthors">Furlong, Timothy J.; Pierce, Kerrie D.; Selbie, Lisa A.; Shine, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">62-6</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    </div><div class="casAbstract">A cDNA encoding a G protein-coupled receptor of unknown ligand specificity was isolated from a human hippocampal cDNA library by virtue of the high degree of structural homol. between members of this receptor family.  The cloned receptor DNA was transfected into human embryonic kidney 293 cells.  Stably transfected cell lines bound a variety of adenosine agonists and antagonists with affinities characteristic of a brain adenosine A2a receptor.  The A2a specific agonist CGS21680 stimulated cAMP prodn. but did not alter intracellular calcium concns. in transfected 293 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLrHo7yhb7dLVg90H21EOLACvtfcHk0ljV303VUovjaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit1Kiu7s%253D&md5=7074217779407edb8a93652462529fd6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0169-328X%2892%2990152-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0169-328X%252892%252990152-2%26sid%3Dliteratum%253Aachs%26aulast%3DFurlong%26aufirst%3DT.%2BJ.%26aulast%3DPierce%26aufirst%3DK.%2BD.%26aulast%3DSelbie%26aufirst%3DL.%2BA.%26aulast%3DShine%26aufirst%3DJ.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520human%2520brain%2520adenosine%2520A2%2520receptor%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D1992%26volume%3D15%26spage%3D62%26epage%3D66%26doi%3D10.1016%2F0169-328X%2892%2990152-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaugeois, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrazzini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Yacoubi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderhaeghen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costentin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, M.</span></span> <span> </span><span class="NLM_article-title">Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1038/41771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2F41771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9262401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2sXlsFSjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=1997&pages=674-678&author=C.+Ledentauthor=J.+M.+Vaugeoisauthor=S.+N.+Schiffmannauthor=T.+Pedrazziniauthor=M.+El+Yacoubiauthor=J.+J.+Vanderhaeghenauthor=J.+Costentinauthor=J.+K.+Heathauthor=G.+Vassartauthor=M.+Parmentier&title=Aggressiveness%2C+hypoalgesia+and+high+blood+pressure+in+mice+lacking+the+adenosine+A2a+receptor&doi=10.1038%2F41771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor</span></div><div class="casAuthors">Ledent, Catherine; Vaugeois, Jean-Marie; Schiffmann, Serge N.; Pedrazzini, Thierry; El Yacoubi, Malika; Vanderhaeghen, Jean-Jacques; Costentin, Jean; Heath, John K.; Vassart, Gilbert; Parmentier, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">6643</span>),
    <span class="NLM_cas:pages">674-678</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Adenosine is released from metabolically active cells by facilitated diffusion, and is generated extracellularly by degrdn. of released ATP.  It is a potent biol. mediator that modulates the activity of numerous cell types, including various neuronal populations, platelets, neutrophils and mast cells, and smooth muscle cells in bronchi and vasculature.  Most of these effects help to protect cells and tissues during stress conditions such as ischemia.  Adenosine mediates its effects through four receptor subtypes: the A1, A2a, A2b and A3 receptors.  The A2a receptor (A2aR) is abundant in basal ganglia, vasculature and platelets, and stimulates adenylyl cyclase.  It is a major target of caffeine, the most widely used psychoactive drug.  Here the authors investigate the role of the A2a receptor by disrupting the gene in mice.  The authors found that A2aR-knockout (A2aR-/-) mice were viable and bred normally.  Their exploratory activity was reduced, whereas caffeine, which normally stimulates exploratory behavior, became a depressant of exploratory activity.  Knockout animals scored higher in anxiety tests, and male mice were much more aggressive towards intruders.  The response of A2aR-/- mice to acute pain stimuli was slower.  Blood pressure and heart rate were increased, as well as platelet aggregation.  The specific A2a agonist CGS 21680 lost its biol. activity in all systems tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0iq2QuhMaEbVg90H21EOLACvtfcHk0ljV303VUovjaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsFSjsLY%253D&md5=c383aa8b1552fe119691ac9f9877a8e9</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2F41771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F41771%26sid%3Dliteratum%253Aachs%26aulast%3DLedent%26aufirst%3DC.%26aulast%3DVaugeois%26aufirst%3DJ.%2BM.%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26aulast%3DPedrazzini%26aufirst%3DT.%26aulast%3DEl%2BYacoubi%26aufirst%3DM.%26aulast%3DVanderhaeghen%26aufirst%3DJ.%2BJ.%26aulast%3DCostentin%26aufirst%3DJ.%26aulast%3DHeath%26aufirst%3DJ.%2BK.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DParmentier%26aufirst%3DM.%26atitle%3DAggressiveness%252C%2520hypoalgesia%2520and%2520high%2520blood%2520pressure%2520in%2520mice%2520lacking%2520the%2520adenosine%2520A2a%2520receptor%26jtitle%3DNature%26date%3D1997%26volume%3D388%26spage%3D674%26epage%3D678%26doi%3D10.1038%2F41771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domenici, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popoli, P.</span></span> <span> </span><span class="NLM_article-title">The role of adenosine tone and adenosine receptors in huntington’s disease</span>. <i>J. Caffeine Adenosine Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1089/caff.2018.0006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1089%2Fcaff.2018.0006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30023989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWltr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=43-58&author=D.+Blumauthor=Y.+Chernauthor=M.+R.+Domeniciauthor=L.+Bueeauthor=C.+Y.+Linauthor=W.+Reaauthor=S.+Ferreauthor=P.+Popoli&title=The+role+of+adenosine+tone+and+adenosine+receptors+in+huntington%E2%80%99s+disease&doi=10.1089%2Fcaff.2018.0006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease</span></div><div class="casAuthors">Blum, David; Chern, Yijuang; Domenici, Maria Rosaria; Buee, Luc; Lin, Chien-Yu; Rea, William; Ferre, Sergi; Popoli, Patrizia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Caffeine and Adenosine Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">43-58</span>CODEN:
                <span class="NLM_cas:coden">JCARCW</span>;
        ISSN:<span class="NLM_cas:issn">2573-3400</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by a mutation in the IT15 gene that encodes for the huntingtin protein.  Mutated hungtingtin, although widely expressed in the brain, predominantly affects striato-pallidal neurons, particularly enriched with adenosine A2A receptors (A2AR), suggesting a possible involvement of adenosine and A2AR is the pathogenesis of HD.  In fact, polymorphic variation in the ADORA2A gene influences the age at onset in HD, and A2AR dynamics is altered by mutated huntingtin.  Basal levels of adenosine and adenosine receptors are involved in many processes crit. for neuronal function and homeostasis, including modulation of synaptic activity and excitotoxicity, the control of neurotrophin levels and functions, and the regulation of protein degrdn. mechanisms.  In the present review, we critically analyze the current literature involving the effect of altered adenosine tone and adenosine receptors in HD and discuss why therapeutics that modulate the adenosine system may represent a novel approach for the treatment of HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhCca2neQiG7Vg90H21EOLACvtfcHk0lg8tWEdG3iSlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWltr%252FL&md5=b94dfab0b86db5f4269a2a82999b965f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1089%2Fcaff.2018.0006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcaff.2018.0006%26sid%3Dliteratum%253Aachs%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DChern%26aufirst%3DY.%26aulast%3DDomenici%26aufirst%3DM.%2BR.%26aulast%3DBuee%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DRea%26aufirst%3DW.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DPopoli%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520adenosine%2520tone%2520and%2520adenosine%2520receptors%2520in%2520huntington%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Caffeine%2520Adenosine%2520Res.%26date%3D2018%26volume%3D8%26spage%3D43%26epage%3D58%26doi%3D10.1089%2Fcaff.2018.0006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arosio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gussago, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assolari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scortichini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mari, D.</span></span> <span> </span><span class="NLM_article-title">Down-regulation of adenosine A1 and A2A receptors in peripheral cells from idiopathic normal-pressure hydrocephalus patients</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2015.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.jns.2015.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26810542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2016&pages=196-199&author=M.+Casatiauthor=B.+Arosioauthor=C.+Gussagoauthor=E.+Ferriauthor=L.+Magniauthor=L.+Assolariauthor=V.+Scortichiniauthor=C.+Naniauthor=P.+D.+Rossiauthor=D.+Mari&title=Down-regulation+of+adenosine+A1+and+A2A+receptors+in+peripheral+cells+from+idiopathic+normal-pressure+hydrocephalus+patients&doi=10.1016%2Fj.jns.2015.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of adenosine A1 and A2A receptors in peripheral cells from idiopathic normal-pressure hydrocephalus patients</span></div><div class="casAuthors">Casati, Martina; Arosio, Beatrice; Gussago, Cristina; Ferri, Evelyn; Magni, Lorenzo; Assolari, Lara; Scortichini, Valeria; Nani, Carolina; Rossi, Paolo Dionigi; Mari, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196-199</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic normal-pressure hydrocephalus (iNPH) is a neurol. disease that usually develops in the elderly.  Natural history of iNPH is still unknown.  It has been hypothesized that cerebrovascular diseases could have a role in etiol. of chronic hydrocephalus and studies show an increased prevalence of cardiovascular diseases in iNPH patients.  Moreover, evidences show a possible alteration of immune system in iNPH patients.  Adenosine (Ado) is a metabolite produced in response to metabolic stress and injury.  Adenosine and its receptors play an important role in vascular protection and in the modulation of inflammatory reactions and neuroinflammation.  Our aim is to evaluate gene and protein expression of A1R and A2AR in the peripheral blood mononuclear cells (PBMCs) from iNPH patients compared to control subjects.  We investigate if Ado system, that plays an important role in central nervous system, in vascular system, and also in inflammation, is involved in pathophysiol. of iNPH disease.  Our anal. showed that A1R mRNA levels and A1R d. in PBMCs from iNPH patients were significantly lower than CT subjects (0.84 ± 0.12 and 2.42 ± 0.42, p < 0.001 and 0.31 ± 0.02 and 0.42 ± 0.04, p = 0.043; resp.).  About A2AR, the gene expression in PBMCs was significantly lower in iNPH than CT (0.65 ± 0.09 and 1.5 ± 0.14, p < 0.001) as well as there was a trend in protein expression: iNPH and CT (0.51 ± 0.05 and 0.62 ± 0.03; p = 0.172).  This preliminary study underlines the involvement of Ado system in iNPH disease whose pathophysiol. is still unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRAhRMcKQsXrVg90H21EOLACvtfcHk0ljlZLYFyNrIYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKnsLc%253D&md5=034f6169b287cb51e3794d0975dd205a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2015.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2015.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DCasati%26aufirst%3DM.%26aulast%3DArosio%26aufirst%3DB.%26aulast%3DGussago%26aufirst%3DC.%26aulast%3DFerri%26aufirst%3DE.%26aulast%3DMagni%26aufirst%3DL.%26aulast%3DAssolari%26aufirst%3DL.%26aulast%3DScortichini%26aufirst%3DV.%26aulast%3DNani%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DP.%2BD.%26aulast%3DMari%26aufirst%3DD.%26atitle%3DDown-regulation%2520of%2520adenosine%2520A1%2520and%2520A2A%2520receptors%2520in%2520peripheral%2520cells%2520from%2520idiopathic%2520normal-pressure%2520hydrocephalus%2520patients%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2016%26volume%3D361%26spage%3D196%26epage%3D199%26doi%3D10.1016%2Fj.jns.2015.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cieslak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wujak, M.</span></span> <span> </span><span class="NLM_article-title">Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1007/s11302-018-9633-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs11302-018-9633-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30430356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1SnsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1-15&author=M.+Cieslakauthor=K.+Roszekauthor=M.+Wujak&title=Purinergic+implication+in+amyotrophic+lateral+sclerosis-from+pathological+mechanisms+to+therapeutic+perspectives&doi=10.1007%2Fs11302-018-9633-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives</span></div><div class="casAuthors">Cieslak, M.; Roszek, K.; Wujak, M.</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a clin. heterogeneous disorder characterized by degeneration of upper motor neurons in the brainstem and lower motor neurons in the spinal cord.  Multiple mechanisms of motor neuron injury have been implicated, including more than 20 different genetic factors.  The pathogenesis of ALS consists of two stages: an early neuroprotective stage and a later neurotoxic.  During early phases of disease progression, the immune system through glial and T cell activities provides anti-inflammatory factors that sustain motor neuron viability.  As the disease progresses and motor neuron injury accelerates, a rapidly succeeding neurotoxic phase develops.  A well-orchestrated purine-mediated dialog among motor neurons, surrounding glia and immune cells control the beneficial and detrimental activities occurring in the nervous system.  In general, low ATP (ATP) concns. protect cells against excitotoxic stimuli through purinergic P2X4 receptor, whereas high concns. of ATP trigger toxic P2X7 receptor activation.  Finally, adenosine is also involved in ALS progression since A2A receptor antagonists prevent motor neuron death.  Given the complex cellular cross-talk occurring in ALS and the recognized function of extracellular nucleotides and adenosine in neuroglia communication, the comprehensive understanding of purinome dynamics might provide new research perspectives to decipher ALS and help to design more efficient and targeted drugs.  This review will focus on the purinergic players involved in ALS etiol. and disease progression and current therapeutic strategies to enhance neuroprotection and suppress neurotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFmoWpxuuNM7Vg90H21EOLACvtfcHk0ljlZLYFyNrIYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1SnsLrL&md5=a9ea6ebacfd9846942208736c3fcfd25</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs11302-018-9633-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-018-9633-4%26sid%3Dliteratum%253Aachs%26aulast%3DCieslak%26aufirst%3DM.%26aulast%3DRoszek%26aufirst%3DK.%26aulast%3DWujak%26aufirst%3DM.%26atitle%3DPurinergic%2520implication%2520in%2520amyotrophic%2520lateral%2520sclerosis-from%2520pathological%2520mechanisms%2520to%2520therapeutic%2520perspectives%26jtitle%3DPurinergic%2520Signalling%26date%3D2019%26volume%3D15%26spage%3D1%26epage%3D15%26doi%3D10.1007%2Fs11302-018-9633-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paganelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resseguier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlinge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malergue, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armangau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerbaul, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenouillet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guieu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruf, J.</span></span> <span> </span><span class="NLM_article-title">Specific pharmacological profile of A2A adenosine receptor predicts reduced fractional flow reserve in patients with suspected coronary artery disease</span>. <i>J. Am. Heart Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e008290</span>, <span class="refDoi"> DOI: 10.1161/JAHA.117.008290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1161%2FJAHA.117.008290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29654194" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=e008290&author=F.+Paganelliauthor=N.+Resseguierauthor=M.+Marlingeauthor=M.+Laineauthor=F.+Malergueauthor=N.+Kipsonauthor=P.+Armangauauthor=N.+Pezzoliauthor=F.+Kerbaulauthor=L.+Bonelloauthor=G.+Mottolaauthor=E.+Fenouilletauthor=R.+Guieuauthor=J.+Ruf&title=Specific+pharmacological+profile+of+A2A+adenosine+receptor+predicts+reduced+fractional+flow+reserve+in+patients+with+suspected+coronary+artery+disease&doi=10.1161%2FJAHA.117.008290"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1161%2FJAHA.117.008290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FJAHA.117.008290%26sid%3Dliteratum%253Aachs%26aulast%3DPaganelli%26aufirst%3DF.%26aulast%3DResseguier%26aufirst%3DN.%26aulast%3DMarlinge%26aufirst%3DM.%26aulast%3DLaine%26aufirst%3DM.%26aulast%3DMalergue%26aufirst%3DF.%26aulast%3DKipson%26aufirst%3DN.%26aulast%3DArmangau%26aufirst%3DP.%26aulast%3DPezzoli%26aufirst%3DN.%26aulast%3DKerbaul%26aufirst%3DF.%26aulast%3DBonello%26aufirst%3DL.%26aulast%3DMottola%26aufirst%3DG.%26aulast%3DFenouillet%26aufirst%3DE.%26aulast%3DGuieu%26aufirst%3DR.%26aulast%3DRuf%26aufirst%3DJ.%26atitle%3DSpecific%2520pharmacological%2520profile%2520of%2520A2A%2520adenosine%2520receptor%2520predicts%2520reduced%2520fractional%2520flow%2520reserve%2520in%2520patients%2520with%2520suspected%2520coronary%2520artery%2520disease%26jtitle%3DJ.%2520Am.%2520Heart%2520Assoc.%26date%3D2018%26volume%3D7%26spage%3De008290%26doi%3D10.1161%2FJAHA.117.008290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arosio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viazzoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastronardi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamaschini, L.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.3233/JAD-2010-090814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.3233%2FJAD-2010-090814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=20413899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFKgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=991-996&author=B.+Arosioauthor=C.+Viazzoliauthor=L.+Mastronardiauthor=C.+Bilottaauthor=C.+Verganiauthor=L.+Bergamaschini&title=Adenosine+A2A+receptor+expression+in+peripheral+blood+mononuclear+cells+of+patients+with+mild+cognitive+impairment&doi=10.3233%2FJAD-2010-090814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Expression in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment</span></div><div class="casAuthors">Arosio, Beatrice; Viazzoli, Chiara; Mastronardi, Luigina; Bilotta, Claudio; Vergani, Carlo; Bergamaschini, Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">991-996</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Adenosine suppresses immune responses through the adenosine A2A receptors (A2AR).  We evaluated the expression of A2AR in blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer's disease (AD), and controls in order to verify if it may help distinguish different forms of cognitive decline.  There was a significant linear increase in both mRNA levels and receptor d. from multiple cognitive domain MCI (mcd-MCI) to amnestic MCI (a-MCI), spanning through AD and controls, without any significant difference between the latter two groups of subjects.  These data, which need to be confirmed in a larger no. of patients, suggest that expression of A2AR in PBMCs may be a valuable means of differentiating a-MCI and mcd-MCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_TImartT_ybVg90H21EOLACvtfcHk0ljhfkYvTL6p8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFKgsbw%253D&md5=c62a92d7ab78f80930c219a7136e559f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-090814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-090814%26sid%3Dliteratum%253Aachs%26aulast%3DArosio%26aufirst%3DB.%26aulast%3DViazzoli%26aufirst%3DC.%26aulast%3DMastronardi%26aufirst%3DL.%26aulast%3DBilotta%26aufirst%3DC.%26aulast%3DVergani%26aufirst%3DC.%26aulast%3DBergamaschini%26aufirst%3DL.%26atitle%3DAdenosine%2520A2A%2520receptor%2520expression%2520in%2520peripheral%2520blood%2520mononuclear%2520cells%2520of%2520patients%2520with%2520mild%2520cognitive%2520impairment%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2010%26volume%3D20%26spage%3D991%26epage%3D996%26doi%3D10.3233%2FJAD-2010-090814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasko, G.</span></span> <span> </span><span class="NLM_article-title">The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1124/pr.117.014878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1124%2Fpr.117.014878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31235653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFersr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=345-382&author=L.+Antonioliauthor=C.+Blandizziauthor=P.+Pacherauthor=G.+Hasko&title=The+purinergic+system+as+a+pharmacological+target+for+the+treatment+of+immune-mediated+inflammatory+diseases&doi=10.1124%2Fpr.117.014878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases</span></div><div class="casAuthors">Antonioli, Luca; Blandizzi, Corrado; Pacher, Pal; Hasko, Gyoergy</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-382</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such asmultiple sclerosis, rheumatoidarthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus.  Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well.  The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, resp., as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body.  The purinergic signaling complex can regulate the development and course of IMIDs.  Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs.  In addn., we discuss the possible therapeutic applications of drugs acting on purinergic pathways,which have been entering clin. development, to manage patients suffering from IMIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEgKKRAYo4crVg90H21EOLACvtfcHk0ljhfkYvTL6p8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFersr%252FI&md5=7c0a822c268a67872d70748e0698e4da</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fpr.117.014878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.117.014878%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DBlandizzi%26aufirst%3DC.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DHasko%26aufirst%3DG.%26atitle%3DThe%2520purinergic%2520system%2520as%2520a%2520pharmacological%2520target%2520for%2520the%2520treatment%2520of%2520immune-mediated%2520inflammatory%2520diseases%26jtitle%3DPharmacol.%2520Rev.%26date%3D2019%26volume%3D71%26spage%3D345%26epage%3D382%26doi%3D10.1124%2Fpr.117.014878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albasanz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptors are up-regulated in Pick’s disease frontal cortex</span>. <i>Brain Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1111/j.1750-3639.2006.00026.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1111%2Fj.1750-3639.2006.00026.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=17107593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=249-255&author=J.+L.+Albasanzauthor=A.+Rodriguezauthor=I.+Ferrerauthor=M.+Martin&title=Adenosine+A2A+receptors+are+up-regulated+in+Pick%E2%80%99s+disease+frontal+cortex&doi=10.1111%2Fj.1750-3639.2006.00026.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptors are up-regulated in pick's disease frontal cortex</span></div><div class="casAuthors">Albasanz, Jose Luis; Rodriguez, Agustin; Ferrer, Isidro; Martin, Mairena</div><div class="citationInfo"><span class="NLM_cas:title">Brain Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">249-255</span>CODEN:
                <span class="NLM_cas:coden">BRPAE7</span>;
        ISSN:<span class="NLM_cas:issn">1015-6305</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Adenosine A2A receptors (A2AR) are highly expressed in striatum.  However, they are also present in extrastriatal structures.  A2AR were studied in post-mortem human frontal cortex from Pick's disease (PiD) and age-matched non-demented controls by radioligand binding assays, Western-blotting, real-time PCR and adenylyl cyclase activity detn.  Satn. binding assay using [3H]ZM 241385, a selective A2A antagonist, as radioligand revealed a significant increase in total adenosine A2AR nos. (Bmax) in frontal cortex from PiD samples (191% of control Bmax), suggesting up-regulation of this receptor.  A significant increase in the level of A2AR was also detected by Western-blotting.  Furthermore, expression of mRNA coding A2AR detd. by quant. real-time PCR was enhanced.  In agreement, stimulation of adenylyl cyclase by CGS 21680, a selective A2A receptor agonist, was significantly strengthened.  Up-regulation of A2B receptors and their corresponding mRNA was also obsd.  These results show that A2A adenosine receptor/adenylyl cyclase transduction pathway is up-regulated and sensitized in frontal cortex brain from PiD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOI4C5n7fB8LVg90H21EOLACvtfcHk0ljx4eTKGciM_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslKlsA%253D%253D&md5=8324c80877cfe6382a4a8217fbca0d98</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fj.1750-3639.2006.00026.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1750-3639.2006.00026.x%26sid%3Dliteratum%253Aachs%26aulast%3DAlbasanz%26aufirst%3DJ.%2BL.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DI.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DAdenosine%2520A2A%2520receptors%2520are%2520up-regulated%2520in%2520Pick%25E2%2580%2599s%2520disease%2520frontal%2520cortex%26jtitle%3DBrain%2520Pathol.%26date%3D2006%26volume%3D16%26spage%3D249%26epage%3D255%26doi%3D10.1111%2Fj.1750-3639.2006.00026.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuscano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trincavelli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerrai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciapparelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucacchini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dell’Osso, L.</span></span> <span> </span><span class="NLM_article-title">Upregulation of A2A adenosine receptors in platelets from patients affected by bipolar disorders under treatment with typical antipsychotics</span>. <i>J. Psychiatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.jpsychires.2004.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.jpsychires.2004.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16431220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FktlGitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2006&pages=81-88&author=C.+Martiniauthor=D.+Tuscanoauthor=M.+L.+Trincavelliauthor=E.+Cerraiauthor=M.+Bianchiauthor=A.+Ciapparelliauthor=L.+Alessioauthor=L.+Novelliauthor=M.+Catenaauthor=A.+Lucacchiniauthor=G.+B.+Cassanoauthor=L.+Dell%E2%80%99Osso&title=Upregulation+of+A2A+adenosine+receptors+in+platelets+from+patients+affected+by+bipolar+disorders+under+treatment+with+typical+antipsychotics&doi=10.1016%2Fj.jpsychires.2004.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of A2A adenosine receptors in platelets from patients affected by bipolar disorders under treatment with typical antipsychotics</span></div><div class="casAuthors">Martini Claudia; Tuscano Daniela; Trincavelli Maria Letizia; Cerrai Elisa; Bianchi Maria; Ciapparelli Antonio; Alessio Lucioni; Novelli Letizia; Catena Mario; Lucacchini Antonio; Cassano Giovanni Battista; Dell'Osso Liliana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-8</span>
        ISSN:<span class="NLM_cas:issn">0022-3956</span>.
    </div><div class="casAbstract">Antipsychotic drugs, potent dopamine receptor antagonists, are commonly used in the treatment of psychotic and affective illness.  The discovery of antagonistic interactions between A2A adenosine receptors (ARs) and D2 dopamine receptors (DRs) in the central nervous system suggests that the adenosine system may be involved in the pathogenesis of psychiatric and neurological disorders.  In the present study, we demonstrated for the first time that human platelets co-express A2A ARs and D2 DRs assembled into an heteromeric complexes.  We also investigated the effects of chronic treatment with either typical or atypical antipsychotics on A2A AR binding parameters and receptors responsiveness in human platelets from patients affected by bipolar disorder.  Chronic administration of typical antipsychotics induced a significant upregulation of A2A AR binding sites.  Since no effects on A2A AR were obtained following "in vitro" platelet treatment with a typical antipsychotic (haloperidol), we could exclude a direct effect of the drug on A2A AR at the peripheral level.  Moreover, typical antipsychotics induced a significant increase in the agonist potency to mediate A2A AR-G protein coupling.  On the contrary, chronic treatment with atypical antipsychotics did not induce any significant alterations in A2A AR equilibrium binding parameters and receptor responsiveness suggesting that typical but not atypical antipsychotic drugs induced a selective modification of A2A AR binding parameters in human platelets.  These results are in accordance with the literature data describing the selective A2A AR upregulation induced by typical antipsychotics in human striatum suggesting platelets as a peripheral model of the interactions between adenosine and dopamine system occurring in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBgNcglAeYobZpSb_XWfMrfW6udTcc2eYnkswCMdb_VLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FktlGitg%253D%253D&md5=339c714bf80780d222f57a1a46676112</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2004.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2004.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DTuscano%26aufirst%3DD.%26aulast%3DTrincavelli%26aufirst%3DM.%2BL.%26aulast%3DCerrai%26aufirst%3DE.%26aulast%3DBianchi%26aufirst%3DM.%26aulast%3DCiapparelli%26aufirst%3DA.%26aulast%3DAlessio%26aufirst%3DL.%26aulast%3DNovelli%26aufirst%3DL.%26aulast%3DCatena%26aufirst%3DM.%26aulast%3DLucacchini%26aufirst%3DA.%26aulast%3DCassano%26aufirst%3DG.%2BB.%26aulast%3DDell%25E2%2580%2599Osso%26aufirst%3DL.%26atitle%3DUpregulation%2520of%2520A2A%2520adenosine%2520receptors%2520in%2520platelets%2520from%2520patients%2520affected%2520by%2520bipolar%2520disorders%2520under%2520treatment%2520with%2520typical%2520antipsychotics%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2006%26volume%3D40%26spage%3D81%26epage%3D88%26doi%3D10.1016%2Fj.jpsychires.2004.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wielockx, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Eijk, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerretsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groeneveld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneses, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langereis, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zomer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riksen, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Hoeven, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltzschig, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickkers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kox, M.</span></span> <span> </span><span class="NLM_article-title">Short-term hypoxia dampens inflammation in vivo via enhanced adenosine release and adenosine 2b receptor stimulation</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2018.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.ebiom.2018.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29983349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FlvVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=144-156&author=D.+Kiersauthor=B.+Wielockxauthor=E.+Petersauthor=L.+T.+van+Eijkauthor=J.+Gerretsenauthor=A.+Johnauthor=E.+Janssenauthor=R.+Groeneveldauthor=M.+Petersauthor=L.+Damenauthor=A.+M.+Menesesauthor=A.+Krugerauthor=J.+D.+Langereisauthor=A.+L.+Zomerauthor=M.+R.+Blackburnauthor=L.+A.+Joostenauthor=M.+G.+Neteaauthor=N.+P.+Riksenauthor=J.+G.+van+der%0AHoevenauthor=G.+J.+Schefferauthor=H.+K.+Eltzschigauthor=P.+Pickkersauthor=M.+Kox&title=Short-term+hypoxia+dampens+inflammation+in+vivo+via+enhanced+adenosine+release+and+adenosine+2b+receptor+stimulation&doi=10.1016%2Fj.ebiom.2018.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Short-Term Hypoxia Dampens Inflammation in vivo via Enhanced Adenosine Release and Adenosine 2B Receptor Stimulation</span></div><div class="casAuthors">Kiers Dorien; Wielockx Ben; Meneses Ana M; Kruger Anja; Peters Esther; van Eijk Lucas T; Gerretsen Jelle; John Aaron; Janssen Emmy; Groeneveld Rianne; Peters Mara; Damen Lars; van der Hoeven Johannes G; Pickkers Peter; Langereis Jeroen D; Zomer Aldert L; Blackburn Michael R; Joosten Leo A; Netea Mihai G; Riksen Niels P; Scheffer Gert-Jan; Eltzschig Holger K; Kox Matthijs</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144-156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hypoxia and inflammation are closely intertwined phenomena.  Critically ill patients often suffer from systemic inflammatory conditions and concurrently experience short-lived hypoxia.  We evaluated the effects of short-term hypoxia on systemic inflammation, and show that it potently attenuates pro-inflammatory cytokine responses during murine endotoxemia.  These effects are independent of hypoxia-inducible factors (HIFs), but involve augmented adenosine levels, in turn resulting in an adenosine 2B receptor-mediated post-transcriptional increase of interleukin (IL)-10 production.  We translated our findings to humans using the experimental endotoxemia model, where short-term hypoxia resulted in enhanced plasma concentrations of adenosine, augmentation of endotoxin-induced circulating IL-10 levels, and concurrent attenuation of the pro-inflammatory cytokine response.  Again, HIFs were shown not to be involved.  Taken together, we demonstrate that short-term hypoxia dampens the systemic pro-inflammatory cytokine response through enhanced purinergic signaling in mice and men.  These effects may contribute to outcome and provide leads for immunomodulatory treatment strategies for critically ill patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRV7_vQIOrf5tLIORRPd5lbfW6udTcc2eYnkswCMdb_VLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FlvVKgtQ%253D%253D&md5=2710559b0830e4367ee47f08bd2000da</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2018.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2018.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DKiers%26aufirst%3DD.%26aulast%3DWielockx%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DE.%26aulast%3Dvan%2BEijk%26aufirst%3DL.%2BT.%26aulast%3DGerretsen%26aufirst%3DJ.%26aulast%3DJohn%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DE.%26aulast%3DGroeneveld%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DDamen%26aufirst%3DL.%26aulast%3DMeneses%26aufirst%3DA.%2BM.%26aulast%3DKruger%26aufirst%3DA.%26aulast%3DLangereis%26aufirst%3DJ.%2BD.%26aulast%3DZomer%26aufirst%3DA.%2BL.%26aulast%3DBlackburn%26aufirst%3DM.%2BR.%26aulast%3DJoosten%26aufirst%3DL.%2BA.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26aulast%3DRiksen%26aufirst%3DN.%2BP.%26aulast%3Dvan%2Bder%2BHoeven%26aufirst%3DJ.%2BG.%26aulast%3DScheffer%26aufirst%3DG.%2BJ.%26aulast%3DEltzschig%26aufirst%3DH.%2BK.%26aulast%3DPickkers%26aufirst%3DP.%26aulast%3DKox%26aufirst%3DM.%26atitle%3DShort-term%2520hypoxia%2520dampens%2520inflammation%2520in%2520vivo%2520via%2520enhanced%2520adenosine%2520release%2520and%2520adenosine%25202b%2520receptor%2520stimulation%26jtitle%3DEBioMedicine%26date%3D2018%26volume%3D33%26spage%3D144%26epage%3D156%26doi%3D10.1016%2Fj.ebiom.2018.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falconi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonito-Oliva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bartolomeo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massimini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattapposta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locuratolo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Addario, C.</span></span> <span> </span><span class="NLM_article-title">On the role of adenosine A2A receptor gene transcriptional regulation in Parkinson’s disease</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.3389/fnins.2019.00683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.3389%2Ffnins.2019.00683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31354407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BB3MvitFymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=683-683&author=A.+Falconiauthor=A.+Bonito-Olivaauthor=M.+Di+Bartolomeoauthor=M.+Massiminiauthor=F.+Fattappostaauthor=N.+Locuratoloauthor=E.+Daineseauthor=E.+Pascaleauthor=G.+Fisoneauthor=C.+D%E2%80%99Addario&title=On+the+role+of+adenosine+A2A+receptor+gene+transcriptional+regulation+in+Parkinson%E2%80%99s+disease&doi=10.3389%2Ffnins.2019.00683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinson's Disease</span></div><div class="casAuthors">Falconi Anastasia; Di Bartolomeo Martina; Massimini Marcella; Dainese Enrico; D'Addario Claudio; Bonito-Oliva Alessandra; Fisone Gilberto; Fattapposta Francesco; Locuratolo Nicoletta; Pascale Esterina; D'Addario Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">683</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Adenosine A2A receptors (A2ARs) have attracted considerable attention as an important molecular target for the design of Parkinson's disease (PD) therapeutic compounds.  Here, we studied the transcriptional regulation of the A2AR gene in human peripheral blood mononuclear cells (PBMCs) obtained from PD patients and in the striatum of the well-validated, 6-hydroxydopamine (6-OHDA)-induced PD mouse model.  We report an increase in A2AR mRNA expression and protein levels in both human cells and mice striata, and in the latter we could also observe a consistent reduction in DNA methylation at gene promoter and an increase in histone H3 acetylation at lysine 9.  Of particular relevance in clinical samples, we also observed higher levels in the receptor gene expression in younger subjects, as well as in those with less years from disease onset, and less severe disease according to clinical scores.  In conclusion, the present findings provide further evidence of the relevant role of A2AR in PD and, based on the clinical data, highlight its potential role as disease biomarker for PD especially at the initial stages of disease development.  Furthermore, our preclinical results also suggest selective epigenetic mechanisms targeting gene promoter as tool for the development of new treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAeEQq77nyFQ5nADWVYHg1fW6udTcc2eYyvsD00NBWD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvitFymtw%253D%253D&md5=2aa3f193e9addc8267a7c0ce681af4f2</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2019.00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2019.00683%26sid%3Dliteratum%253Aachs%26aulast%3DFalconi%26aufirst%3DA.%26aulast%3DBonito-Oliva%26aufirst%3DA.%26aulast%3DDi%2BBartolomeo%26aufirst%3DM.%26aulast%3DMassimini%26aufirst%3DM.%26aulast%3DFattapposta%26aufirst%3DF.%26aulast%3DLocuratolo%26aufirst%3DN.%26aulast%3DDainese%26aufirst%3DE.%26aulast%3DPascale%26aufirst%3DE.%26aulast%3DFisone%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Addario%26aufirst%3DC.%26atitle%3DOn%2520the%2520role%2520of%2520adenosine%2520A2A%2520receptor%2520gene%2520transcriptional%2520regulation%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DFront.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D683%26epage%3D683%26doi%3D10.3389%2Ffnins.2019.00683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Attraqchi, O. H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attimarad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopala, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Attraqchi, N. H. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor as a potential drug target - current status and future perspectives</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2716</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.2174/1381612825666190716113444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.2174%2F1381612825666190716113444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31333093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFOrsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=2716-2740&author=O.+H.+A.+Al-Attraqchiauthor=M.+Attimaradauthor=K.+N.+Venugopalaauthor=A.+Nairauthor=N.+H.+A.+Al-Attraqchi&title=Adenosine+A2A+receptor+as+a+potential+drug+target+-+current+status+and+future+perspectives&doi=10.2174%2F1381612825666190716113444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives</span></div><div class="casAuthors">Al-Attraqchi, Omar H. A.; Attimarad, Mahesh; Venugopala, Katharigatta N.; Nair, Anroop; Al-Attraqchi, Noor H. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2716-2740</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine receptors (ARs) are a class of G-protein coupled receptors (GPCRs) that are activated by the endogenous substance adenosine.  ARs are classified into 4 subtype receptors, namely, the A1, A2A, A2B and A3 receptors.  The wide distribution and expression of the ARs in various body tissues as well as the roles they have in controlling different functions in the body make them potential drug targets for the treatment of various pathol. conditions, such as cardiac diseases, cancer, Parkinson's disease, inflammation and glaucoma.  Therefore, in the past decades, there have been extensive investigations of ARs with a high no. of agonists and antagonists identified that can interact with these receptors.  This review shall discuss the A2A receptor (A2AAR) subtype of the ARs.  The structure, properties and the recent advances in the therapeutic potential of the receptor are discussed with an overview of the recent advances in the methods of studying the receptor.  Also, mol. modeling approaches utilized in the design of A2AAR ligands are highlighted with various recent examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVXNrbnwe1QbVg90H21EOLACvtfcHk0liKuNi7sL9y-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFOrsrnF&md5=9599e1c0fa09b706ed37cf23166d6915</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.2174%2F1381612825666190716113444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612825666190716113444%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Attraqchi%26aufirst%3DO.%2BH.%2BA.%26aulast%3DAttimarad%26aufirst%3DM.%26aulast%3DVenugopala%26aufirst%3DK.%2BN.%26aulast%3DNair%26aufirst%3DA.%26aulast%3DAl-Attraqchi%26aufirst%3DN.%2BH.%2BA.%26atitle%3DAdenosine%2520A2A%2520receptor%2520as%2520a%2520potential%2520drug%2520target%2520-%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2019%26volume%3D25%26spage%3D2716%26epage%3D2740%26doi%3D10.2174%2F1381612825666190716113444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayeem, M. A.</span></span> <span> </span><span class="NLM_article-title">Exploring adenosine receptor ligands: potential role in the treatment of cardiovascular diseases</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">917</span>, <span class="refDoi"> DOI: 10.3390/molecules22060917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.3390%2Fmolecules22060917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1arur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=917&author=W.+J.+Geldenhuysauthor=A.+Hanifauthor=J.+Yunauthor=M.+A.+Nayeem&title=Exploring+adenosine+receptor+ligands%3A+potential+role+in+the+treatment+of+cardiovascular+diseases&doi=10.3390%2Fmolecules22060917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring adenosine receptor ligands: potential role in the treatment of cardiovascular diseases</span></div><div class="casAuthors">Geldenhuys, Werner J.; Hanif, Ahmad; Yun, June; Nayeem, Mohammed A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">917/1-917/11</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cardiovascular diseases remain the no. one diseases affecting patients' morbidity and mortality.  The adenosine receptors are G-protein coupled receptors which have been of interest for drugs target for the treatment of multiple diseases ranging from cardiovascular to neurol.  Adenosine receptors have been connected to several biol. pathways affecting the physiol. and pathol. of the cardiovascular system.  In this review, we will cover the different adenosine receptor ligands that have been identified to interact with adenosine receptors and affect the vascular system.  These ligands will be evaluated from clin. as well as medicinal chem. perspectives with more emphasis on how structural changes in structure translate into ligand potency and efficacy.  Adenosine receptors represent a novel therapeutic target for development of treatment options treating a wide variety of diseases, including vascular disease and obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkryKf_Lr83rVg90H21EOLACvtfcHk0liKuNi7sL9y-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1arur3O&md5=048d90bdf6c8957dae91bd550aaf9a8b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22060917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22060917%26sid%3Dliteratum%253Aachs%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DHanif%26aufirst%3DA.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DNayeem%26aufirst%3DM.%2BA.%26atitle%3DExploring%2520adenosine%2520receptor%2520ligands%253A%2520potential%2520role%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D917%26doi%3D10.3390%2Fmolecules22060917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor antagonists and parkinson’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1021/cn2000537</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn2000537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=555-567&author=B.+C.+Shookauthor=P.+F.+Jackson&title=Adenosine+A2A+receptor+antagonists+and+parkinson%E2%80%99s+disease&doi=10.1021%2Fcn2000537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists and Parkinson's Disease</span></div><div class="casAuthors">Shook, Brian C.; Jackson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">555-567</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This Review summarizes and updates the work on adenosine A2A receptor antagonists for Parkinson's disease from 2006 to the present.  There have been numerous publications, patent applications, and press releases within this time frame that highlight new medicinal chem. approaches to this attractive and promising target to treat Parkinson's disease.  The Review is broken down by scaffold type and will discuss the efforts to optimize particular scaffolds for activity, pharmacokinetics, and other drug discovery parameters.  The majority of approaches focus on prepg. selective A2A antagonists, but a few approaches to dual A2A/A1 antagonists will also be highlighted.  The in vivo profiles of compds. will be highlighted and discussed to compare activities across different chem. series.  A clin. report and update will be given on compds. that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9jbqVC-a6P7Vg90H21EOLACvtfcHk0lgniV8ByAogrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D&md5=81746259f96dd1a270f12c3cb2dbe1d3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fcn2000537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn2000537%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520and%2520parkinson%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D555%26epage%3D567%26doi%3D10.1021%2Fcn2000537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armentero, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanciego, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span> <span> </span><span class="NLM_article-title">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson’s disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.pharmthera.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21810444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=280-299&author=M.+T.+Armenteroauthor=A.+Pinnaauthor=S.+Ferreauthor=J.+L.+Lanciegoauthor=C.+E.+Mullerauthor=R.+Franco&title=Past%2C+present+and+future+of+A2A+adenosine+receptor+antagonists+in+the+therapy+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pharmthera.2011.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease</span></div><div class="casAuthors">Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Lanciego, Jose Luis; Mueller, Christa E.; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-299</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clin. trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market.  The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia.  At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients.  However, a considerable body of data indicates that in addn. to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration.  Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community.  Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors.  Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2pOYdmdfQMLVg90H21EOLACvtfcHk0lgniV8ByAogrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP&md5=39fa871338516f7574deb7845029e624</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPast%252C%2520present%2520and%2520future%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520in%2520the%2520therapy%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D280%26epage%3D299%26doi%3D10.1016%2Fj.pharmthera.2011.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span> <span> </span><span class="NLM_article-title">Recent progress in the discovery of adenosine A2A receptor antagonists for the treatment of Parkinson’s disease</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=20597030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSju7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=466-480&author=U.+Shahauthor=R.+Hodgson&title=Recent+progress+in+the+discovery+of+adenosine+A2A+receptor+antagonists+for+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in the discovery of adenosine A2A receptor antagonists for the treatment of Parkinson's disease</span></div><div class="casAuthors">Shah, Unmesh; Hodgson, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466-480</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Antagonism of the A2A receptor has emerged as a promising non-dopaminergic approach for the potential treatment of Parkinson's disease (PD).  Several pharmaceutical and academic institutions have ongoing research programs in this area, and orally efficacious A2A receptor antagonists were advanced into clin. development.  Traditionally, antagonists of the A2A receptor are classified as xanthine and non-xanthine derivs.  This review provides a detailed summary of the recent SAR development that has led to the discovery of promising non-xanthine-based A2A receptor antagonists.  The current clin. status and the potential utility of A2A receptor antagonists in indications other than PD are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouWpTRXO9ll7Vg90H21EOLACvtfcHk0lheE5b3GUSeQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSju7zK&md5=1e9fb4644949ab0efeb9a208bdb1d3d7</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DU.%26aulast%3DHodgson%26aufirst%3DR.%26atitle%3DRecent%2520progress%2520in%2520the%2520discovery%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D466%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cristalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpini, R.</span></span> <span> </span><span class="NLM_article-title">Recent developments in adenosine A2A receptor ligands</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/978-3-540-89615-9_3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2F978-3-540-89615-9_3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=19639279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sktr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2009&pages=59-98&author=G.+Cristalliauthor=C.+E.+Mullerauthor=R.+Volpini&title=Recent+developments+in+adenosine+A2A+receptor+ligands&doi=10.1007%2F978-3-540-89615-9_3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in adenosine A2A receptor ligands</span></div><div class="casAuthors">Cristalli, Gloria; Muller, Christa E.; Volpini, Rosaria</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">Adenosine Receptors in Health and Disease</span>),
    <span class="NLM_cas:pages">59-98</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The development of potent and selective agonists and antagonists of adenosine receptors (ARs) has been a target of medicinal chem. research for several decades, and recently the US Food and Drug Administration has approved Lexiscan, an adenosine deriv. substituted at the 2 position, for use as a pharmacol. stress agent in radionuclide myocardial perfusion imaging.  Currently, some other adenosine A2A receptor (A2AAR) agonists and antagonists are undergoing preclin. testing and clin. trials.  While agonists are potent antiinflammatory agents also showing hypotensive effects, antagonists are being developed for the treatment of Parkinson's disease.  However, since there are still major problems in this field, including side effects, low brain penetration (for the targeting of CNS diseases), short half-life, or lack of in vivo effects, the design and development of new AR ligands is a hot research topic.  This review presents an update on the medicinal chem. of A2AAR agonists and antagonists, and stresses the strong need for more selective ligands at the human A2AAR subtype, in particular in the case of agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZlneM0HaH4rVg90H21EOLACvtfcHk0lheE5b3GUSeQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sktr7E&md5=95c3e8fde30c9094d81cea882987ae64</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-89615-9_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-89615-9_3%26sid%3Dliteratum%253Aachs%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DVolpini%26aufirst%3DR.%26atitle%3DRecent%2520developments%2520in%2520adenosine%2520A2A%2520receptor%2520ligands%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2009%26volume%3D193%26spage%3D59%26epage%3D98%26doi%3D10.1007%2F978-3-540-89615-9_3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span> <span> </span><span class="NLM_article-title">Adenosine, adenosine A2A antagonists, and Parkinson’s disease</span>. <i>Parkinsonism Relat. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">406</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/j.parkreldis.2008.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.parkreldis.2008.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=19446490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BD1MvksVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=406-413&author=P.+Jennerauthor=A.+Moriauthor=R.+Hauserauthor=M.+Morelliauthor=B.+B.+Fredholmauthor=J.+F.+Chen&title=Adenosine%2C+adenosine+A2A+antagonists%2C+and+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.parkreldis.2008.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine, adenosine A 2A antagonists, and Parkinson's disease</span></div><div class="casAuthors">Jenner P; Mori A; Hauser R; Morelli M; Fredholm B B; Chen J F</div><div class="citationInfo"><span class="NLM_cas:title">Parkinsonism & related disorders</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">406-13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adenosine derived from the degradation of ATP/AMP functions as a signalling molecule in the nervous system through the occupation of A1, A2, and A3 adenosine receptors.  Adenosine A(2A) receptors have a selective localization to the basal ganglia and specifically to the indirect output pathway, and as a consequence offer a unique opportunity to modulate the output from the striatum that is believed critical to the occurrence of motor components of PD.  Indeed, the ability of A(2A) antagonists to modulate basal ganglia neurotransmission has been shown to be associated with improved motor function in experimental models of PD.  This suggests that A(2A) antagonists would be effective as a symptomatic treatment in humans without provoking marked dyskinesia.  Indeed, the A(2A) antagonist istradefylline reduces OFF time in moderate- to late-stage patients with PD already receiving dopaminergic therapy, with an increase in non-troublesome dyskinesia.  Adenosine and adenosine receptors also exert actions relevant to pathogenesis in PD, raising the possibility of their use as neuroprotective agents.  Both epidemiologic evidence and the current preclinical data strongly support a role for A(2A) antagonists in protecting dopaminergic neurons and influencing the onset and progression of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsdd-F41SVOmBAiYWy6n3SfW6udTcc2ebf5gJTGGRYMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvksVWnsg%253D%253D&md5=3c823d672ed66ea92ef6876eedf544a5</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.parkreldis.2008.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.parkreldis.2008.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DJenner%26aufirst%3DP.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DHauser%26aufirst%3DR.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26atitle%3DAdenosine%252C%2520adenosine%2520A2A%2520antagonists%252C%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DParkinsonism%2520Relat.%2520Disord.%26date%3D2009%26volume%3D15%26spage%3D406%26epage%3D413%26doi%3D10.1016%2Fj.parkreldis.2008.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vu, C.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the design and optimization of adenosine A2A receptor antagonists</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16022182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFCgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=458-468&author=C.+Vu&title=Recent+advances+in+the+design+and+optimization+of+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the design and optimization of adenosine A2A receptor antagonists</span></div><div class="casAuthors">Vu, Chi B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">458-468</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  In recent years, the adenosine A2A receptor has gained interest as a potential therapeutic target for alleviating the symptoms of Parkinson's disease.  Adenosine A2A receptor antagonists are orally effective in a variety of rodent models of Parkinson's disease.  Traditionally, adenosine A2A receptor antagonists are divided into 2 general classes, xanthine or non-xanthine derivs.  Extensive optimization among the xanthine derivs. has already led to the clin. candidate KW-6002 (Kyowa Hakko Kogyo Co Ltd).  However, there is increasing interest among researchers in this field to explore other classes of compds. as potential antagonists for this particular receptor.  This review highlights the more recent developments in the design and optimization of non-xanthine derivs. as adenosine A2A receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFVWEy9JKDtbVg90H21EOLACvtfcHk0libSbPjK3qrcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFCgt7c%253D&md5=3d081bf399a0984379c193565a58d337</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DC.%26atitle%3DRecent%2520advances%2520in%2520the%2520design%2520and%2520optimization%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2005%26volume%3D8%26spage%3D458%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1007/s40263-014-0161-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs40263-014-0161-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24687255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWhtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=455-474&author=A.+Pinna&title=Adenosine+A2A+receptor+antagonists+in+Parkinson%E2%80%99s+disease%3A+progress+in+clinical+trials+from+the+newly+approved+istradefylline+to+drugs+in+early+development+and+those+already+discontinued&doi=10.1007%2Fs40263-014-0161-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued</span></div><div class="casAuthors">Pinna, Annalisa</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-474</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine, glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and contribute to its symptomatol.  Thus, the progress of non-dopaminergic therapies for PD has attracted much interest in recent years.  Among new classes of drugs, adenosine A2A antagonists have emerged as promising candidates.  The development of new highly selective adenosine A2A receptor antagonists, and their encouraging anti-parkinsonian responses in animal models of PD, has provided a rationale for clin. trials to evaluate the therapeutic potential and the safety of these agents in patients with PD.  To date, the clin. research regarding A2A antagonists and their potential utilization in PD therapy continues to evolve between drugs just or previously discontinued (preladenant and vipadenant), new derivs. in development (tozadenant, PBF-509, ST1535, ST4206 and V81444) and the relatively old drug istradefylline, which has finally been licensed as an anti-parkinsonian drug in Japan.  All these compds. have been shown to have a good safety profile and be well tolerated.  Moreover, results from phase II and III trials also demonstrate that A2A antagonists are effective in reducing off-time, without worsening troublesome dyskinesia, and in increasing on-time with a mild increase of non-troublesome dyskinesia, in patients at an advanced stage of PD treated with L-DOPA.  In addn., early findings suggest that A2A antagonists might also be efficacious as monotherapy in patients at an early stage of PD.  This review summarizes pharmacol. and clin. data available on istradefylline, tozadenant, PBF-509, ST1535, ST4206, V81444, preladenant and vipadenant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9RSy9sahNnbVg90H21EOLACvtfcHk0libSbPjK3qrcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWhtLc%253D&md5=1c12ad215ddb2384ec190027d23a3216</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2Fs40263-014-0161-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-014-0161-7%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520progress%2520in%2520clinical%2520trials%2520from%2520the%2520newly%2520approved%2520istradefylline%2520to%2520drugs%2520in%2520early%2520development%2520and%2520those%2520already%2520discontinued%26jtitle%3DCNS%2520Drugs%26date%3D2014%26volume%3D28%26spage%3D455%26epage%3D474%26doi%3D10.1007%2Fs40263-014-0161-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burbiel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">Multigram-scale synthesis, stability and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson’s disease</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">3308</span>– <span class="NLM_lpage">3318</span>, <span class="refDoi"> DOI: 10.1021/jo0358574</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0358574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFarsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3308-3318&author=J.+Hockemeyerauthor=J.+Burbielauthor=C.+E.+M%C3%BCller&title=Multigram-scale+synthesis%2C+stability+and+photoreactions+of+A2A+adenosine+receptor+antagonists+with+8-styrylxanthine+structure%3A+potential+drugs+for+Parkinson%E2%80%99s+disease&doi=10.1021%2Fjo0358574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Multigram-Scale Syntheses, Stability, and Photoreactions of A2A Adenosine Receptor Antagonists with 8-Styrylxanthine Structure: Potential Drugs for Parkinson's Disease</span></div><div class="casAuthors">Hockemeyer, Joerg; Burbiel, Joachim C.; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3308-3318</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The improved multigram-scale syntheses of the important 8-styrylxanthine A2A adenosine receptor antagonist MSX-2 [I, R = CH2C≡CH, R1 = (CH2)3OH, R2 = H], its water-sol. prodrug MXS-3 [I, R = CH2C≡CH, R1 = (CH2)3OP(O)(OH)2, R2 = H], and KW-6002 [I, R = R1 = Et, R2 = OMe] are described.  N-Alkylation reactions at different positions of the uracil ring were optimized.  Two different methods for xanthine formation from 6-amino-5-cinnamoylaminouracil precursors were investigated: (a) the elimination of water by alk. catalysis and (b) hexamethyldisilazane as a condensing agent; the latter was found to be superior.  The photosensitivity of the 8-styrylxanthines was studied.  The (E)-configurated stryrylxanthine MSX-2 isomerized in dild. soln., and the resulting (Z)-isomer was isolated and characterized.  Furthermore, solid 8-styrylxanthines can dimerize upon exposure to daylight or irradn. with UV light.  The resulting cyclobutane derivs. with head-to-tail (syn) configuration exhibited a considerably lower A2A adenosine receptor affinity than their parent compds.  The dimerization product of MSX-2 was a moderately potent nonselective A1 and A2A antagonist (Ki(A1) = 273 nM, Ki (A2A) = 175 nM) while the dimer of KW-6002 was inactive at A1 and only weakly active at A2A adenosine receptors (Ki = 1.57 μM).  The light sensitivity of 8-styrylxanthine derivs., not only in soln., but also in the solid state, has to be considered when using those compds. as pharmacol. tools or drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH59mwpE6WRLVg90H21EOLACvtfcHk0libSbPjK3qrcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFarsro%253D&md5=b76c488fd1df3d5c31b3911bf1b27d6b</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjo0358574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0358574%26sid%3Dliteratum%253Aachs%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DBurbiel%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DMultigram-scale%2520synthesis%252C%2520stability%2520and%2520photoreactions%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520with%25208-styrylxanthine%2520structure%253A%2520potential%2520drugs%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3308%26epage%3D3318%26doi%3D10.1021%2Fjo0358574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kjaergaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">A2A adenosine receptor gene deletion or synthetic A2A antagonist liberate tumor-reactive CD8(+) T cells from tumor-induced immunosuppression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1700850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.4049%2Fjimmunol.1700850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29802128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Oqu7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2018&pages=782-791&author=J.+Kjaergaardauthor=S.+Hatfieldauthor=G.+Jonesauthor=A.+Ohtaauthor=M.+Sitkovsky&title=A2A+adenosine+receptor+gene+deletion+or+synthetic+A2A+antagonist+liberate+tumor-reactive+CD8%28%2B%29+T+cells+from+tumor-induced+immunosuppression&doi=10.4049%2Fjimmunol.1700850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression</span></div><div class="casAuthors">Kjaergaard, Jorgen; Hatfield, Stephen; Jones, Graham; Ohta, Akio; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">782-791</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Tumor hypoxia-driven accumulation of extracellular adenosine was shown to facilitate tumor evasion by engaging the immunosuppressive, intracellular cAMP-elevating A2 adenosine receptors (A2R) on tumor-reactive effector T cells, but there remains a need for careful evaluation of the limiting factors and properties of A2R blockade-enabled antitumor immunity.  In studies of A2AR and/or A2BR gene-deficient mice, we found that A2AR deletion-but not A2BR deletion-liberates endogenous CD8+ T cell antitumor immunity against weakly immunogenic MCA205 sarcomas.  Studies of adoptively transferred A2AR-/-, A2BR-/-, or A2AR-/-/A2BR-/- tumor-reactive T cells confirmed that immunosuppression in the tumor microenvironment was mediated by A2AR on CD8+ T cells.  Treatment with A2AR antagonist mimicked A2AR gene deletion in adoptive T cell immunotherapy.  This therapeutic benefit of targeting A2AR was independent of the anatomical location of tumor growth.  The enhanced antitumor reactivity also led to the eradication of established intracranial tumors, which was assocd. with mouse survival and the maintenance of long-lasting, tumor-specific immunol. memory.  The blockade of the A2AR on adoptively transferred T cells by synthetic A2AR antagonist led to higher levels of IFN-γ secretion by tumor-infiltrating CD8+ T cells.  These data clarify the mechanism of hypoxia-driven immunosuppression in the tumor microenvironment by A2AR on tumor-reactive CD8+ T cells and show that selective A2AR antagonists can be effective in improving the outcomes of T cell-based immunotherapies.  Demonstration of the T cell dose dependency of tumor rejection points to a major limitation of current cancer immunotherapies, in which the presence of sufficient nos. of tumor-reactive T cells in a patient is not known.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPGcoGQnU2n7Vg90H21EOLACvtfcHk0lhjsX5hRHH-Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Oqu7jF&md5=ff4a23b4ef75b4e8df36e42a3945389e</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1700850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1700850%26sid%3Dliteratum%253Aachs%26aulast%3DKjaergaard%26aufirst%3DJ.%26aulast%3DHatfield%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DA2A%2520adenosine%2520receptor%2520gene%2520deletion%2520or%2520synthetic%2520A2A%2520antagonist%2520liberate%2520tumor-reactive%2520CD8%2528%252B%2529%2520T%2520cells%2520from%2520tumor-induced%2520immunosuppression%26jtitle%3DJ.%2520Immunol.%26date%3D2018%26volume%3D201%26spage%3D782%26epage%3D791%26doi%3D10.4049%2Fjimmunol.1700850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A. D.</span>; <span class="NLM_string-name">Robert, F.</span>; <span class="NLM_string-name">Baum, P. R.</span>; <span class="NLM_string-name">Odegard, V.</span></span> <span> </span><span class="NLM_article-title">Application of Istradefylline in Preparation of Medicine for Treating Tumor</span>. PCT Int. Appl. <span class="NLM_patent">WO2019084060 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+A.+D.+Thompson&author=F.+Robert&author=P.+R.+Baum&author=V.+Odegard&title=Application+of+Istradefylline+in+Preparation+of+Medicine+for+Treating+Tumor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DP.%2BA.%2BD.%26atitle%3DApplication%2520of%2520Istradefylline%2520in%2520Preparation%2520of%2520Medicine%2520for%2520Treating%2520Tumor%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunwalder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Psychoyos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cash, W. D.</span></span> <span> </span><span class="NLM_article-title">Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>241</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">420</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=2883298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaL2sXksFWrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=1987&pages=415-420&author=M.+Williamsauthor=J.+Francisauthor=G.+Ghaiauthor=A.+Braunwalderauthor=S.+Psychoyosauthor=G.+A.+Stoneauthor=W.+D.+Cash&title=Biochemical+characterization+of+the+triazoloquinazoline%2C+CGS+15943%2C+a+novel%2C+non-xanthine+adenosine+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical characterization of the triazoloquinazoline CGS 15943A, a novel, nonxanthine adenosine antagonist</span></div><div class="casAuthors">Williams, Michael; Francis, John; Ghai, Geetha; Braunwalder, Albert; Psychoyos, Stacy; Stone, George A.; Cash, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">415-20</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">CGS 15943A (I), a triazoloquinazoline, is a potent and selective adenosine receptor antagonist as assessed by its effects on radioligand binding and adenosine-stimulated adenylate cyclase activity in guinea pig synaptoneurosomes.  At the adenosine A-1 receptor labeled with [3H]cyclohexyladenosine, I had an IC50 value of 20 nM.  At the striatal A-2 receptor labeled with [3H]5'-N-ethylcarboxamidoadenosine (in the presence of a low concn. of cyclopentyladenosine to block A-1 receptors labeled by this nonselective adenosine agonist), I had an IC50 value of 3 nM, indicating that the compd. had some degree of selectivity for the A-2 receptor.  Anal. of the effect of the compd. on the satn. isotherms for each of the receptors indicated that it was a competitive antagonist at the brain A-1 receptor but that it was noncompetitive at the striatal A-2 receptor.  I was a potent adenosine antagonist in the adenosine-stimulated adenylate cyclase system in guinea pig synaptoneurosomes, where the compd. was found to have an IC50 value of 30 to 70 nM against the increase in cAMP evoked by 5 μM adenosine.  I had no effect on the binding of [3H]nitrobenzylthioinosine, a ligand thought to bind to adenosine uptake sites, and, at a concn. of 10 μM, had no effect on beef heart type III phosphodiesterase activity.  In assessing its activity in binding assays for 21 other putative neurotransmitters, I showed no appreciable activity at concns. up to 10 μM, although it was able to inhibit the binding of [3H]flunitrazepam to the central benzodiazepine receptor with an IC50 value of 1020 nM.  I is a potent adenosine antagonist.  Since it is not a xanthine with the underlying assocn. of phosphodiesterase-inhibitory properties, it may be useful in evaluating the role of adenosine in mammalian tissue function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7D611Hdrm6rVg90H21EOLACvtfcHk0ljuryEb-ZM8KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXksFWrtLc%253D&md5=15287d69f1c5ae5a413f665c137353a7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DGhai%26aufirst%3DG.%26aulast%3DBraunwalder%26aufirst%3DA.%26aulast%3DPsychoyos%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DG.%2BA.%26aulast%3DCash%26aufirst%3DW.%2BD.%26atitle%3DBiochemical%2520characterization%2520of%2520the%2520triazoloquinazoline%252C%2520CGS%252015943%252C%2520a%2520novel%252C%2520non-xanthine%2520adenosine%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1987%26volume%3D241%26spage%3D415%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gatta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Giudice, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borioni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionisotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2 receptor antagonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/0223-5234(93)90087-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2F0223-5234%2893%2990087-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2cXjt1entrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1993&pages=569-576&author=F.+Gattaauthor=M.+R.+Del+Giudiceauthor=A.+Borioniauthor=P.+A.+Boreaauthor=S.+Dionisottiauthor=E.+Ongini&title=Synthesis+of+imidazo%5B1%2C2-c%5Dpyrazolo%5B4%2C3-e%5Dpyrimidines%2C+pyrazolo%5B4%2C3-e%5D1%2C2%2C4-triazolo%5B1%2C5-c%5Dpyrimidines+and+1%2C2%2C4-triazolo%5B5%2C1-i%5Dpurines%3A+new+potent+adenosine+A2+receptor+antagonists&doi=10.1016%2F0223-5234%2893%2990087-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2 receptor antagonists</span></div><div class="casAuthors">Gatta, F.; Del Giudice, M. R.; Borioni, A.; Borea, P. A.; Dionisotti, S.; Ongini, E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">569-76</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">A no. of 2- or 4-fluorobenzyl derivs. of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine and 1,2,4-triazolo[5,1-i]purine have been synthesized.  The interaction with the adenosine A2 and A1 receptors was evaluated using selected biol. assays.  The highest degree of activity was displayed by the 5-amino-2-(2-furyl)-7-(or 8-)-fluorobenzylpyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine I and II (R = 2- and 4-F) and -3-fluorobenzyl-1,2,4-triazolo[5,1-i]purines III (R = 2- and 4-F).  The compd. II (R = 4-F) was the most potent A2 antagonist in the authors' series with a selectivity similar to that of the ref. compd. CGS 15943, but with 75-fold more activity in the platelet aggregation model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVxyuCXbfN5bVg90H21EOLACvtfcHk0ljuryEb-ZM8KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjt1entrg%253D&md5=4efd3e9be2319b631598a20b43b80e91</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2F0223-5234%2893%2990087-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0223-5234%252893%252990087-U%26sid%3Dliteratum%253Aachs%26aulast%3DGatta%26aufirst%3DF.%26aulast%3DDel%2BGiudice%26aufirst%3DM.%2BR.%26aulast%3DBorioni%26aufirst%3DA.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DDionisotti%26aufirst%3DS.%26aulast%3DOngini%26aufirst%3DE.%26atitle%3DSynthesis%2520of%2520imidazo%255B1%252C2-c%255Dpyrazolo%255B4%252C3-e%255Dpyrimidines%252C%2520pyrazolo%255B4%252C3-e%255D1%252C2%252C4-triazolo%255B1%252C5-c%255Dpyrimidines%2520and%25201%252C2%252C4-triazolo%255B5%252C1-i%255Dpurines%253A%2520new%2520potent%2520adenosine%2520A2%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1993%26volume%3D28%26spage%3D569%26epage%3D576%26doi%3D10.1016%2F0223-5234%2893%2990087-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappaterra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionisotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2539</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)80279-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2FS0960-894X%2801%2980279-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2MXit1Orsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=2539-2544&author=P.+G.+Baraldiauthor=S.+Manfrediniauthor=D.+Simoniauthor=L.+Zappaterraauthor=C.+Zocchiauthor=S.+Dionisottiauthor=E.+Ongini&title=Synthesis+of+new+pyrazolo%5B4%2C3-e%5D1%2C2%2C4-triazolo%5B1%2C5-c%5D+pyrimidine+and+1%2C2%2C3-triazolo%5B4%2C5-e%5D1%2C2%2C4-triazolo%5B1%2C5-c%5D+pyrimidine+displaying+potent+and+selective+activity+as+A2a+adenosine+receptor+antagonists&doi=10.1016%2FS0960-894X%2801%2980279-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c]pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Manfredini, Stefano; Simoni, Daniele; Zappaterra, Laura; Zocchi, Cristina; Dionisotti, Silvio; Ongini, Ennio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2539-44</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c]pyrimidines were prepd. and evaluated for their activity as adenosine A2a receptor antagonists.  In the present study, 5-amino-7-(phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261) was identified as potent and selective adenosine A2a antagonist in binding assays (Ki = 2.3 nM, Ki ratio: A2/A2a = 52.6).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXHpSXE_jS2rVg90H21EOLACvtfcHk0lg40oMMHPw0xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1Orsr4%253D&md5=14674c4312f72b1e58e859f70b7d5d4c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980279-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980279-1%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DManfredini%26aufirst%3DS.%26aulast%3DSimoni%26aufirst%3DD.%26aulast%3DZappaterra%26aufirst%3DL.%26aulast%3DZocchi%26aufirst%3DC.%26aulast%3DDionisotti%26aufirst%3DS.%26aulast%3DOngini%26aufirst%3DE.%26atitle%3DSynthesis%2520of%2520new%2520pyrazolo%255B4%252C3-e%255D1%252C2%252C4-triazolo%255B1%252C5-c%255D%2520pyrimidine%2520and%25201%252C2%252C3-triazolo%255B4%252C5-e%255D1%252C2%252C4-triazolo%255B1%252C5-c%255D%2520pyrimidine%2520displaying%2520potent%2520and%2520selective%2520activity%2520as%2520A2a%2520adenosine%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1994%26volume%3D4%26spage%3D2539%26epage%3D2544%26doi%3D10.1016%2FS0960-894X%2801%2980279-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2255</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-09-3109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=20179192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFygt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2245-2255&author=D.+Jinauthor=J.+Fanauthor=L.+Wangauthor=L.+F.+Thompsonauthor=A.+Liuauthor=B.+J.+Danielauthor=T.+Shinauthor=T.+J.+Curielauthor=B.+Zhang&title=CD73+on+tumor+cells+impairs+antitumor+T-cell+responses%3A+a+novel+mechanism+of+tumor-induced+immune+suppression&doi=10.1158%2F0008-5472.CAN-09-3109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression</span></div><div class="casAuthors">Jin, Dachuan; Fan, Jie; Wang, Long; Thompson, Linda F.; Liu, Aijie; Daniel, Benjamin J.; Shin, Tahiro; Curiel, Tyler J.; Zhang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2245-2255</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CD73, originally defined as a lymphocyte differentiation antigen, is thought to function as a cosignaling mol. on T lymphocytes and an adhesion mol. that is required for lymphocyte binding to endothelium.  We show here that CD73 is widely expressed on many tumor cell lines and is upregulated in cancerous tissues.  Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP breakdown to immunosuppressive adenosine, we hypothesized that CD73-generated adenosine prevents tumor destruction by inhibiting antitumor immunity.  We confirmed this hypothesis by showing that combining tumor CD73 knockdown and tumor-specific T-cell transfer cured all tumor-bearing mice.  In striking contrast, there was no therapeutic benefit of adoptive T-cell immunotherapy in mice bearing tumors without CD73 knockdown.  Moreover, blockade of the A2A adenosine receptor with a selective antagonist also augmented the efficacy of adoptive T-cell therapy.  These findings identify a potential mechanism for CD73-mediated tumor immune evasion and point to a novel cancer immunotherapy strategy by targeting the enzymic activity of tumor CD73.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKSNnpdNVOrbVg90H21EOLACvtfcHk0ljF5K_3HVhLAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFygt7w%253D&md5=222edb4bbc4908588cafc8a9789dce0d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3109%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DThompson%26aufirst%3DL.%2BF.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DDaniel%26aufirst%3DB.%2BJ.%26aulast%3DShin%26aufirst%3DT.%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%26atitle%3DCD73%2520on%2520tumor%2520cells%2520impairs%2520antitumor%2520T-cell%2520responses%253A%2520a%2520novel%2520mechanism%2520of%2520tumor-induced%2520immune%2520suppression%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2245%26epage%3D2255%26doi%3D10.1158%2F0008-5472.CAN-09-3109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shryock, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowdy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacciari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spalluto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monopoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belardinelli, L.</span></span> <span> </span><span class="NLM_article-title">A<sub>2A</sub>-adenosine receptor reserve for coronary vasodilation</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.98.7.711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1161%2F01.CIR.98.7.711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9715864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK1cXlslWltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1998&pages=711-718&author=J.+C.+Shryockauthor=S.+Snowdyauthor=P.+G.+Baraldiauthor=B.+Cacciariauthor=G.+Spallutoauthor=A.+Monopoliauthor=E.+Onginiauthor=S.+P.+Bakerauthor=L.+Belardinelli&title=A2A-adenosine+receptor+reserve+for+coronary+vasodilation&doi=10.1161%2F01.CIR.98.7.711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A2A-adenosine receptor reserve for coronary vasodilation</span></div><div class="casAuthors">Shryock, John C.; Snowdy, Stephen; Baraldi, Pier Giovanni; Cacciari, Barbara; Spalluto, Giampiero; Monopoli, Angela; Ongini, Ennio; Baker, Stephen P.; Belardinelli, Luiz</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">711-718</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Adenosine is a potent coronary vasodilator and causes an increase of coronary blood flow by activation of A2A-adenosine receptors (A2A-AdoRs).  The purpose of this study was to test the hypothesis that the high potency of adenosine and adenosine analogs to cause coronary vasodilation is explained by the presence of a large A2A-AdoR reserve ("spare receptors").  A novel, irreversible antagonist of A2A-AdoRs was used to inactivate receptors and reduce the response to agonist.  Agonist-induced increases of coronary conductance before and after exposure of hearts to the irreversible antagonist were compared.  Three agonists were studied: CGS 21680, adenosine, and 2-chloro-N6-cyclopentyladenosine (CCPA).  Data were analyzed to det. agonist KA (equil. dissocn. const.) and EC50 values.  Values of KA for activation of A2A-AdoRs by CGS 21680, adenosine, and CCPA were 105, 1800, and 2630 nmol/L, resp.  In contrast, values of EC50 for CGS 21680, adenosine, and CCPA to increase coronary conductance were 1.5, 85, and 243 nmol/L, resp.  By use of the law of mass action, it was calcd. that half-maximal responses to CGS 21680, adenosine, and CCPA occurred when only 1.3%, 5%, and 9%, resp., of A2A-AdoRs were occupied by agonist.  Thus, the receptor reserves for the 3 A2A-AdoR agonists were large.  The receptor reserve for A2A-AdoRs inducing an increase of coronary conductance can explain both the high potency of adenosine to cause coronary vasodilation and the observation that an A2A-AdoR agonist can cause coronary vasodilation without systemic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQyNzlsplKLVg90H21EOLACvtfcHk0ljF5K_3HVhLAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlslWltb0%253D&md5=1871328e347731d240b749553c1a63a6</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.98.7.711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.98.7.711%26sid%3Dliteratum%253Aachs%26aulast%3DShryock%26aufirst%3DJ.%2BC.%26aulast%3DSnowdy%26aufirst%3DS.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DCacciari%26aufirst%3DB.%26aulast%3DSpalluto%26aufirst%3DG.%26aulast%3DMonopoli%26aufirst%3DA.%26aulast%3DOngini%26aufirst%3DE.%26aulast%3DBaker%26aufirst%3DS.%2BP.%26aulast%3DBelardinelli%26aufirst%3DL.%26atitle%3DA2A-adenosine%2520receptor%2520reserve%2520for%2520coronary%2520vasodilation%26jtitle%3DCirculation%26date%3D1998%26volume%3D98%26spage%3D711%26epage%3D718%26doi%3D10.1161%2F01.CIR.98.7.711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caulkett, P. W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPartlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, B.</span></span> <span> </span><span class="NLM_article-title">Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]triazolo[1,5-a][1,3,5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1039/p19950000801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1039%2Fp19950000801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2MXltFOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&pages=801-808&author=P.+W.+R.+Caulkettauthor=G.+Jonesauthor=M.+McPartlinauthor=N.+D.+Renshawauthor=S.+K.+Stewartauthor=B.+Wright&title=Adenine+isosteres+with+bridgehead+nitrogen.+Part+1.+Two+independent+syntheses+of+the+%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazine+ring+system+leading+to+a+range+of+substituents+in+the+2%2C+5+and+7+positions&doi=10.1039%2Fp19950000801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]traizolo[1,5-a][1,3,5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions</span></div><div class="casAuthors">Caulkett, Peter W. R.; Jones, Geraint; McPartlin, Mary; Renshaw, Nigel D.; Stewart, Sarah K.; Wright, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">801-8</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Condensation of a 3-substituted 5-amino-1,2,4-triazole with an N-cyanocarbonimidate gave the title compds., in most cases as a mixt. of isomers; sepn. and elaboration then gave [1,2,4]triazolo[1,5-a][1,3,5]triazines bearing a range of substituents in the 5 and 7 positions.  Under milder reaction conditions, less stable isomeric products (e.g., the [1,2,4]triazolo[4,3-a][1,3,5]triazine ring system or an uncyclized N-cyano intermediate) was isolated and shown to rearrange to the [1,5-a] isomer.  A second synthesis was described in which a 2-hydrazido-1,3,5-triazine was cyclodehydrated to give a single isomer with identical substituents in the 5 and 7 positions; the large difference in reactivity between these allows selective replacement at the 7-position with nucleophile.  Addnl., the second synthesis was more readily adaptable to the introduction of substituents at the 2 position of the bicyclic nucleus.  7-Amino-2-(2-furyl)-5-phenoxy[1,2,4]triazolo[1,5-a][1,3,5]triazine was prepd. independently by both synthetic sequences and its structure verified by X-ray crystallog. anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr04m7BOaXYCLVg90H21EOLACvtfcHk0liB9dlIuC5q9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltFOrsbc%253D&md5=7ff740514304fb8d3398102b62fc25b5</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1039%2Fp19950000801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp19950000801%26sid%3Dliteratum%253Aachs%26aulast%3DCaulkett%26aufirst%3DP.%2BW.%2BR.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DMcPartlin%26aufirst%3DM.%26aulast%3DRenshaw%26aufirst%3DN.%2BD.%26aulast%3DStewart%26aufirst%3DS.%2BK.%26aulast%3DWright%26aufirst%3DB.%26atitle%3DAdenine%2520isosteres%2520with%2520bridgehead%2520nitrogen.%2520Part%25201.%2520Two%2520independent%2520syntheses%2520of%2520the%2520%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazine%2520ring%2520system%2520leading%2520to%2520a%2520range%2520of%2520substituents%2520in%2520the%25202%252C%25205%2520and%25207%2520positions%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1995%26spage%3D801%26epage%3D808%26doi%3D10.1039%2Fp19950000801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, A.</span>; <span class="NLM_string-name">Moreau, J. L.</span>; <span class="NLM_string-name">Poli, S. M.</span>; <span class="NLM_string-name">Riemer, C.</span>; <span class="NLM_string-name">Steward, L.</span></span> <span> </span><span class="NLM_article-title">4-Hydroxy-4-methyl-piperidine-1-carboxylic Acid (4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide</span>. U.S. Pat. Appl. Publ. <span class="NLM_patent">US20050261289 A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=A.+Flohr&author=J.+L.+Moreau&author=S.+M.+Poli&author=C.+Riemer&author=L.+Steward&title=4-Hydroxy-4-methyl-piperidine-1-carboxylic+Acid+%284-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl%29-amide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlohr%26aufirst%3DA.%26atitle%3D4-Hydroxy-4-methyl-piperidine-1-carboxylic%2520Acid%2520%25284-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl%2529-amide%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span>ClinicalTrials.gov
home page. <a href="https://clinicaltrials.gov/ct2/results?cond=&amp;term=SYN115&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://clinicaltrials.gov/ct2/results?cond=&term=SYN115&cntry=&state=&city=&dist=</a> (accessed Jun 17, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov%0Ahome+page.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DSYN115%26cntry%3D%26state%3D%26city%3D%26dist%3D+%28accessed+Jun+17%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaakola, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1217</span>, <span class="refDoi"> DOI: 10.1126/science.1164772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1126%2Fscience.1164772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=18832607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlyqtbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1211-1217&author=V.+P.+Jaakolaauthor=M.+T.+Griffithauthor=M.+A.+Hansonauthor=V.+Cherezovauthor=E.+Y.+T.+Chienauthor=J.+R.+Laneauthor=A.+P.+Ijzermanauthor=R.+C.+Stevens&title=The+2.6+angstrom+crystal+structure+of+a+human+A2A+adenosine+receptor+bound+to+an+antagonist&doi=10.1126%2Fscience.1164772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist</span></div><div class="casAuthors">Jaakola, Veli-Pekka; Griffith, Mark T.; Hanson, Michael A.; Cherezov, Vadim; Chien, Ellen Y. T.; Lane, J. Robert; IJzerman, Adriaan P.; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5905</span>),
    <span class="NLM_cas:pages">1211-1217</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The adenosine class of heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) mediates the important role of extracellular adenosine in many physiol. processes and is antagonized by caffeine.  The authors have detd. the crystal structure of the human A2A adenosine receptor, in complex with a high-affinity subtype-selective antagonist, ZM241385, to 2.6 angstrom resoln.  Four disulfide bridges in the extracellular domain, combined with a subtle repacking of the transmembrane helixes relative to the adrenergic and rhodopsin receptor structures, define a pocket distinct from that of other structurally detd. GPCRs.  The arrangement allows for the binding of the antagonist in an extended conformation, perpendicular to the membrane plane.  The binding site highlights an integral role for the extracellular loops, together with the helical core, in ligand recognition by this class of GPCRs and suggests a role for ZM241385 in restricting the movement of a tryptophan residue important in the activation mechanism of the class A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7QL4wN4TdhrVg90H21EOLACvtfcHk0liHA6HAX5blgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlyqtbfN&md5=5bdb862b41f345c244f3c162e058206b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164772%26sid%3Dliteratum%253Aachs%26aulast%3DJaakola%26aufirst%3DV.%2BP.%26aulast%3DGriffith%26aufirst%3DM.%2BT.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DThe%25202.6%2520angstrom%2520crystal%2520structure%2520of%2520a%2520human%2520A2A%2520adenosine%2520receptor%2520bound%2520to%2520an%2520antagonist%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1211%26epage%3D1217%26doi%3D10.1126%2Fscience.1164772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhukov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1898</span>– <span class="NLM_lpage">1903</span>, <span class="refDoi"> DOI: 10.1021/jm201376w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201376w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVGqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1898-1903&author=M.+Congreveauthor=S.+P.+Andrewsauthor=A.+S.+Dor%C3%A9author=K.+Hollensteinauthor=E.+Hurrellauthor=C.+J.+Langmeadauthor=J.+S.+Masonauthor=I.+W.+Ngauthor=B.+Tehanauthor=A.+Zhukovauthor=M.+Weirauthor=F.+H.+Marshall&title=Discovery+of+1%2C2%2C4-triazine+derivatives+as+adenosine+A2A+antagonists+using+structure+based+drug+design&doi=10.1021%2Fjm201376w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design</span></div><div class="casAuthors">Congreve, Miles; Andrews, Stephen P.; Dore, Andrew S.; Hollenstein, Kaspar; Hurrell, Edward; Langmead, Christopher J.; Mason, Jonathan S.; Ng, Irene W.; Tehan, Benjamin; Zhukov, Andrei; Weir, Malcolm; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1898-1903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent, ligand efficient, selective, and orally efficacious 1,2,4-triazine derivs. have been identified using structure based drug design approaches as antagonists of the adenosine A2A receptor.  The X-ray crystal structures of compds. 4e and 4g (I) bound to the GPCR illustrate that the mols. bind deeply inside the orthosteric binding cavity.  In vivo pharmacokinetic and efficacy data for compd. 4k are presented, demonstrating the potential of this series of compds. for the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpddydZvtRPv7Vg90H21EOLACvtfcHk0liuEP1BLCW4hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVGqsw%253D%253D&md5=71d76db8a22bf82f11d3632d2917e155</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm201376w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201376w%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DHurrell%26aufirst%3DE.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DNg%26aufirst%3DI.%2BW.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DZhukov%26aufirst%3DA.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DDiscovery%2520of%25201%252C2%252C4-triazine%2520derivatives%2520as%2520adenosine%2520A2A%2520antagonists%2520using%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1898%26epage%3D1903%26doi%3D10.1021%2Fjm201376w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span> <span> </span><span class="NLM_article-title">Controlling the dissociation of ligands from the adenosine A2A receptor through modulation of salt bridge strength</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6470</span>– <span class="NLM_lpage">6479</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00653</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00653" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6470-6479&author=E.+Segalaauthor=D.+Guoauthor=R.+K.+Y.+Chengauthor=A.+Bortolatoauthor=F.+Deflorianauthor=A.+S.+Dor%C3%A9author=J.+C.+Erreyauthor=L.+H.+Heitmanauthor=A.+P.+Ijzermanauthor=F.+H.+Marshallauthor=R.+M.+Cooke&title=Controlling+the+dissociation+of+ligands+from+the+adenosine+A2A+receptor+through+modulation+of+salt+bridge+strength&doi=10.1021%2Facs.jmedchem.6b00653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength</span></div><div class="casAuthors">Segala, Elena; Guo, Dong; Cheng, Robert K. Y.; Bortolato, Andrea; Deflorian, Francesca; Dore, Andrew S.; Errey, James C.; Heitman, Laura H.; IJzerman, Adriaan P.; Marshall, Fiona H.; Cooke, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6470-6479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The assocn. and dissocn. kinetics of ligands binding to proteins vary considerably, but the mechanisms behind this variability are poorly understood, limiting their utilization for drug discovery.  This is particularly so for G protein-coupled receptors (GPCRs) where high resoln. structural information is only beginning to emerge.  Engineering the human A2A adenosine receptor has allowed structures to be solved in complex with the ref. compd. ZM241385 and four related ligands at high resoln.  Differences between the structures are limited, with the most pronounced being the interaction of each ligand with a salt bridge on the extracellular side of the receptor.  Mutagenesis expts. confirm the role of this salt bridge in controlling the dissocn. kinetics of the ligands from the receptor, while mol. dynamics simulations demonstrate the ability of ligands to modulate salt bridge stability.  These results shed light on a structural determinant of ligand dissocn. kinetics and identify a means by which this property may be optimized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_RuyZEvv2gLVg90H21EOLACvtfcHk0liuEP1BLCW4hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFygu7w%253D&md5=c3b2db16aef190ae6c213a3a7ba133ba</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00653%26sid%3Dliteratum%253Aachs%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DR.%2BK.%2BY.%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26atitle%3DControlling%2520the%2520dissociation%2520of%2520ligands%2520from%2520the%2520adenosine%2520A2A%2520receptor%2520through%2520modulation%2520of%2520salt%2520bridge%2520strength%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6470%26epage%3D6479%26doi%3D10.1021%2Facs.jmedchem.6b00653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lebon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span> <span> </span><span class="NLM_article-title">Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>474</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">525</span>, <span class="refDoi"> DOI: 10.1038/nature10136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnature10136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21593763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFyqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=474&publication_year=2011&pages=521-525&author=G.+Lebonauthor=T.+Warneauthor=P.+C.+Edwardsauthor=K.+Bennettauthor=C.+J.+Langmeadauthor=A.+G.+W.+Leslieauthor=C.+G.+Tate&title=Agonist-bound+adenosine+A2A+receptor+structures+reveal+common+features+of+GPCR+activation&doi=10.1038%2Fnature10136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation</span></div><div class="casAuthors">Lebon, Guillaume; Warne, Tony; Edwards, Patricia C.; Bennett, Kirstie; Langmead, Christopher J.; Leslie, Andrew G. W.; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">474</span>
        (<span class="NLM_cas:issue">7352</span>),
    <span class="NLM_cas:pages">521-525</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Adenosine receptors and β-adrenoceptors are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins on binding the agonists adenosine or noradrenaline, resp.  GPCRs have similar structures consisting of seven transmembrane helixes that contain well-conserved sequence motifs, indicating that they are probably activated by a common mechanism.  Recent structures of β-adrenoceptors highlight residues in transmembrane region 5 that initially bind specifically to agonists rather than to antagonists, indicating that these residues have an important role in agonist-induced activation of receptors.  Here we present two crystal structures of the thermostabilized human adenosine A2A receptor (A2AR-GL31) bound to its endogenous agonist adenosine and the synthetic agonist NECA.  The structures represent an intermediate conformation between the inactive and active states, because they share all the features of GPCRs that are thought to be in a fully activated state, except that the cytoplasmic end of transmembrane helix 6 partially occludes the G-protein-binding site.  The adenine substituent of the agonists binds in a similar fashion to the chem. related region of the inverse agonist ZM241385 (ref. 8).  Both agonists contain a ribose group, not found in ZM241385, which extends deep into the ligand-binding pocket where it makes polar interactions with conserved residues in H7 (Ser 2777.42 and His 2787.43; superscripts refer to Ballesteros-Weinstein numbering) and non-polar interactions with residues in H3.  In contrast, the inverse agonist ZM241385 does not interact with any of these residues and comparison with the agonist-bound structures indicates that ZM241385 sterically prevents the conformational change in H5 and therefore it acts as an inverse agonist.  Comparison of the agonist-bound structures of A2AR with the agonist-bound structures of β-adrenoceptors indicates that the contraction of the ligand-binding pocket caused by the inward motion of helixes 3, 5 and 7 may be a common feature in the activation of all GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1rCKkCsE9CrVg90H21EOLACvtfcHk0liLIjSTunVZ4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFyqsrg%253D&md5=1b8161216b878db48ad33d7e8e007dc7</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnature10136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10136%26sid%3Dliteratum%253Aachs%26aulast%3DLebon%26aufirst%3DG.%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DTate%26aufirst%3DC.%2BG.%26atitle%3DAgonist-bound%2520adenosine%2520A2A%2520receptor%2520structures%2520reveal%2520common%2520features%2520of%2520GPCR%2520activation%26jtitle%3DNature%26date%3D2011%26volume%3D474%26spage%3D521%26epage%3D525%26doi%3D10.1038%2Fnature10136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lebon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of CGS21680 binding to the human adenosine A2A receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1124/mol.114.097360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1124%2Fmol.114.097360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25762024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=907-915&author=G.+Lebonauthor=P.+C.+Edwardsauthor=A.+G.+W.+Leslieauthor=C.+G.+Tate&title=Molecular+determinants+of+CGS21680+binding+to+the+human+adenosine+A2A+receptor&doi=10.1124%2Fmol.114.097360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of CGS21680 binding to the human adenosine A2A receptor</span></div><div class="casAuthors">Lebon, Guillaume; Edwards, Patricia C.; Leslie, Andrew G. W.; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">907-915</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adenosine A2A receptor (A2AR) plays a key role in transmembrane signaling mediated by the endogenous agonist adenosine.  Here, we describe the crystal structure of human A2AR thermostabilized in an active-like conformation bound to the selective agonist 2-[p-(2-carboxyethyl)phenylethyl-amino]-5'-N-ethylcarboxamido adenosine (CGS21680) at a resoln. of 2.6 Å.  Comparison of A2AR structures bound to either CGS21680, 5'-N-ethylcarboxamido adenosine (NECA), UK432097 [6-(2,2-diphenylethylamino)-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-tetrahydrofuran-2-yl]-N-[2-[[1-(2-pyridyl)-4-piperidyl] carbamoylamino]ethyl]purine-2-carboxamide], or adenosine shows that the adenosine moiety of the ligands binds to the receptor in an identical fashion.  However, an extension in CGS21680 compared with adenosine, the (2-carboxyethyl)phenylethylamino group, binds in an extended vestibule formed from transmembrane regions 2 and 7 (TM2 and TM7) and extracellular loops 2 and 3 (EL2 and EL3).  The (2-carboxyethyl)phenylethylamino group makes van der Waals contacts with side chains of amino acid residues Glu169EL2, His264EL3, Leu2677.32, and Ile2747.39, and the amine group forms a hydrogen bond with the side chain of Ser672.65.  Of these residues, only Ile2747.39 is absolutely conserved across the human adenosine receptor subfamily.  The major difference between the structures of A2AR bound to either adenosine or CGS21680 is that the binding pocket narrows at the extracellular surface when CGS21680 is bound, due to an inward tilt of TM2 in that region.  This conformation is stabilized by hydrogen bonds formed by the side chain of Ser672.65 to CGS21680, either directly or via an ordered water mol.  Mutation of amino acid residues Ser672.65, Glu169EL2, and His264EL3, and anal. of receptor activation either in the presence or absence of ligands implicates this region in modulating the level of basal activity of A2AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbUSE2hiL30bVg90H21EOLACvtfcHk0lg2wvnXzZF6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wlu7c%253D&md5=156b7c2ef575df49e4a354029f435b7d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.097360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.097360%26sid%3Dliteratum%253Aachs%26aulast%3DLebon%26aufirst%3DG.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DTate%26aufirst%3DC.%2BG.%26atitle%3DMolecular%2520determinants%2520of%2520CGS21680%2520binding%2520to%2520the%2520human%2520adenosine%2520A2A%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D907%26epage%3D915%26doi%3D10.1124%2Fmol.114.097360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nehmé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span> <span> </span><span class="NLM_article-title">Structure of the adenosine A2A receptor bound to an engineered G protein</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>536</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1038/nature18966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnature18966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=27462812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GrurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=536&publication_year=2016&pages=104-107&author=B.+Carpenterauthor=R.+Nehm%C3%A9author=T.+Warneauthor=A.+G.+W.+Leslieauthor=C.+G.+Tate&title=Structure+of+the+adenosine+A2A+receptor+bound+to+an+engineered+G+protein&doi=10.1038%2Fnature18966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the adenosine A2A receptor bound to an engineered G protein</span></div><div class="casAuthors">Carpenter, Byron; Nehme, Rony; Warne, Tony; Leslie, Andrew G. W.; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">536</span>
        (<span class="NLM_cas:issue">7614</span>),
    <span class="NLM_cas:pages">104-107</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are essential components of the signalling network throughout the body.  To understand the mol. mechanism of G-protein-mediated signalling, solved structures of receptors in inactive conformations and in the active conformation coupled to a G protein are necessary.  Here we present the structure of the adenosine A2A receptor (A2AR) bound to an engineered G protein, mini-Gs, at 3.4 Å resoln.  Mini-Gs binds to A2AR through an extensive interface (1,048 Å2) that is similar, but not identical, to the interface between Gs and the β2-adrenergic receptor.  The transition of the receptor from an agonist-bound active-intermediate state to an active G-protein-bound state is characterized by a 14 Å shift of the cytoplasmic end of transmembrane helix 6 (H6) away from the receptor core, slight changes in the positions of the cytoplasmic ends of H5 and H7 and rotamer changes of the amino acid side chains Arg3.50, Tyr5.58 and Tyr7.53.  There are no substantial differences in the extracellular half of the receptor around the ligand binding pocket.  The A2AR-mini-Gs structure highlights both the diversity and similarity in G-protein coupling to GPCRs and hints at the potential complexity of the mol. basis for G-protein specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr75HihlyPssrVg90H21EOLACvtfcHk0lg2wvnXzZF6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GrurbP&md5=f5a720baaefe45f5bf4491dfe1fb8a15</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnature18966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18966%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DB.%26aulast%3DNehm%25C3%25A9%26aufirst%3DR.%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DTate%26aufirst%3DC.%2BG.%26atitle%3DStructure%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520bound%2520to%2520an%2520engineered%2520G%2520protein%26jtitle%3DNature%26date%3D2016%26volume%3D536%26spage%3D104%26epage%3D107%26doi%3D10.1038%2Fnature18966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines xac and caffeine</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1016/j.str.2011.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.str.2011.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21885291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaru7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1283-1293&author=A.+S.+Dor%C3%A9author=N.+Robertsonauthor=J.+C.+Erreyauthor=I.+Ngauthor=K.+Hollensteinauthor=B.+Tehanauthor=E.+Hurrellauthor=K.+Bennettauthor=M.+Congreveauthor=F.+Magnaniauthor=C.+G.+Tateauthor=M.+Weirauthor=F.+H.+Marshall&title=Structure+of+the+adenosine+A2A+receptor+in+complex+with+ZM241385+and+the+xanthines+xac+and+caffeine&doi=10.1016%2Fj.str.2011.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine</span></div><div class="casAuthors">Dore, Andrew S.; Robertson, Nathan; Errey, James C.; Ng, Irene; Hollenstein, Kaspar; Tehan, Ben; Hurrell, Edward; Bennett, Kirstie; Congreve, Miles; Magnani, Francesca; Tate, Christopher G.; Weir, Malcolm; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1283-1293</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Methylxanthines, including caffeine and theophylline, are among the most widely consumed stimulant drugs in the world.  These effects are mediated primarily via blockade of adenosine receptors.  Xanthine analogs with improved properties have been developed as potential treatments for diseases such as Parkinson's disease.  Here we report the structures of a thermostabilized adenosine A2A receptor in complex with the xanthines xanthine amine congener and caffeine, as well as the A2A selective inverse agonist ZM241385.  The receptor is crystd. in the inactive state conformation as defined by the presence of a salt bridge known as the ionic lock.  The complete third intracellular loop, responsible for G protein coupling, is visible consisting of extended helixes 5 and 6.  The structures provide new insight into the features that define the ligand binding pocket of the adenosine receptor for ligands of diverse chemotypes as well as the cytoplasmic regions that interact with signal transduction proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWsexwFu6LD7Vg90H21EOLACvtfcHk0lg2wvnXzZF6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaru7fE&md5=a25db14aa70c2b42b9c3eb98c3c16bae</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2011.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2011.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DNg%26aufirst%3DI.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DHurrell%26aufirst%3DE.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMagnani%26aufirst%3DF.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520in%2520complex%2520with%2520ZM241385%2520and%2520the%2520xanthines%2520xac%2520and%2520caffeine%26jtitle%3DStructure%26date%3D2011%26volume%3D19%26spage%3D1283%26epage%3D1293%26doi%3D10.1016%2Fj.str.2011.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olieric, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brünle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gashi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworkowski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panepucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skopintsev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panneels, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schertler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Standfuss, J.</span></span> <span> </span><span class="NLM_article-title">Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">542</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00630-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fs41467-017-00630-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28912485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1cboslKltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=542&author=T.+Weinertauthor=N.+Oliericauthor=R.+Chengauthor=S.+Br%C3%BCnleauthor=D.+Jamesauthor=D.+Ozerovauthor=D.+Gashiauthor=L.+Veraauthor=M.+Marshauthor=K.+Jaegerauthor=F.+Dworkowskiauthor=E.+Panepucciauthor=S.+Basuauthor=P.+Skopintsevauthor=A.+S.+Dor%C3%A9author=T.+Gengauthor=R.+M.+Cookeauthor=M.+Liangauthor=A.+E.+Protaauthor=V.+Panneelsauthor=P.+Noglyauthor=U.+Ermlerauthor=G.+Schertlerauthor=M.+Hennigauthor=M.+O.+Steinmetzauthor=M.+Wangauthor=J.+Standfuss&title=Serial+millisecond+crystallography+for+routine+room-temperature+structure+determination+at+synchrotrons&doi=10.1038%2Fs41467-017-00630-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons</span></div><div class="casAuthors">Weinert Tobias; Olieric Natacha; James Daniel; Gashi Dardan; Jaeger Kathrin; Skopintsev Petr; Prota Andrea E; Panneels Valerie; Nogly Przemyslaw; Schertler Gebhard; Steinmetz Michel O; Standfuss Jorg; Cheng Robert; Hennig Michael; Brunle Steffen; Ermler Ulrich; Ozerov Dmitry; Gashi Dardan; Vera Laura; Marsh May; Dworkowski Florian; Panepucci Ezequiel; Basu Shibom; Wang Meitian; Dore Andrew S; Geng Tian; Cooke Robert M; Liang Mengning; Schertler Gebhard; Steinmetz Michel O</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">542</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Historically, room-temperature structure determination was succeeded by cryo-crystallography to mitigate radiation damage.  Here, we demonstrate that serial millisecond crystallography at a synchrotron beamline equipped with high-viscosity injector and high frame-rate detector allows typical crystallographic experiments to be performed at room-temperature.  Using a crystal scanning approach, we determine the high-resolution structure of the radiation sensitive molybdenum storage protein, demonstrate soaking of the drug colchicine into tubulin and native sulfur phasing of the human G protein-coupled adenosine receptor.  Serial crystallographic data for molecular replacement already converges in 1,000-10,000 diffraction patterns, which we collected in 3 to maximally 82 minutes.  Compared with serial data we collected at a free-electron laser, the synchrotron data are of slightly lower resolution, however fewer diffraction patterns are needed for de novo phasing.  Overall, the data we collected by room-temperature serial crystallography are of comparable quality to cryo-crystallographic data and can be routinely collected at synchrotrons.Serial crystallography was developed for protein crystal data collection with X-ray free-electron lasers.  Here the authors present several examples which show that serial crystallography using high-viscosity injectors can also be routinely employed for room-temperature data collection at synchrotrons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2XuDrQ2dPti6Ufuk_1xoTfW6udTcc2eZCRbMZbuXw0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cboslKltg%253D%253D&md5=2fc0843781c5237cc59b3b64fffc4106</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00630-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00630-4%26sid%3Dliteratum%253Aachs%26aulast%3DWeinert%26aufirst%3DT.%26aulast%3DOlieric%26aufirst%3DN.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DBr%25C3%25BCnle%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DOzerov%26aufirst%3DD.%26aulast%3DGashi%26aufirst%3DD.%26aulast%3DVera%26aufirst%3DL.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DJaeger%26aufirst%3DK.%26aulast%3DDworkowski%26aufirst%3DF.%26aulast%3DPanepucci%26aufirst%3DE.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DSkopintsev%26aufirst%3DP.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DGeng%26aufirst%3DT.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DLiang%26aufirst%3DM.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DPanneels%26aufirst%3DV.%26aulast%3DNogly%26aufirst%3DP.%26aulast%3DErmler%26aufirst%3DU.%26aulast%3DSchertler%26aufirst%3DG.%26aulast%3DHennig%26aufirst%3DM.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DStandfuss%26aufirst%3DJ.%26atitle%3DSerial%2520millisecond%2520crystallography%2520for%2520routine%2520room-temperature%2520structure%2520determination%2520at%2520synchrotrons%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D542%26doi%3D10.1038%2Fs41467-017-00630-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimazu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terakado
Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doak, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nango, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabashi, M.</span></span> <span> </span><span class="NLM_article-title">High-viscosity sample-injection device for serial femtosecond crystallography at atmospheric pressure</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1107/S1600576719012846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1107%2FS1600576719012846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31798359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1GqtrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2019&pages=1280-1288&author=Y.+Shimazuauthor=K.+Tonoauthor=T.+Tanakaauthor=Y.+Yamanakaauthor=T.+Nakaneauthor=C.+Moriauthor=K.+Terakado%0AKimuraauthor=T.+Fujiwaraauthor=M.+Sugaharaauthor=R.+Tanakaauthor=R.+B.+Doakauthor=T.+Shimamuraauthor=S.+Iwataauthor=E.+Nangoauthor=M.+Yabashi&title=High-viscosity+sample-injection+device+for+serial+femtosecond+crystallography+at+atmospheric+pressure&doi=10.1107%2FS1600576719012846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">High-viscosity sample-injection device for serial femtosecond crystallography at atmospheric pressure</span></div><div class="casAuthors">Shimazu, Yoshiaki; Tono, Kensuke; Tanaka, Tomoyuki; Yamanaka, Yasuaki; Nakane, Takanori; Mori, Chihiro; Terakado Kimura, Kanako; Fujiwara, Takaaki; Sugahara, Michihiro; Tanaka, Rie; Doak, R. Bruce; Shimamura, Tatsuro; Iwata, So; Nango, Eriko; Yabashi, Makina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1280-1288</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">1600-5767</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A sample-injection device has been developed at SPring-8 Angstrom Compact Free-Electron Laser (SACLA) for serial femtosecond crystallog. (SFX) at atm. pressure.  Microcrystals embedded in a highly viscous carrier are stably delivered from a capillary nozzle with the aid of a coaxial gas flow and a suction device.  The cartridge-type sample reservoir is easily replaceable and facilitates sample reloading or exchange.  The reservoir is positioned in a cooling jacket with a temp.-regulated water flow, which is useful to prevent drastic changes in the sample temp. during data collection.  This work demonstrates that the injector successfully worked in SFX of the human A2A adenosine receptor complexed with an antagonist, ZM241385, in lipidic cubic phase and for hen egg-white lysozyme microcrystals in a grease carrier.  The injection device has also been applied to many kinds of proteins, not only for static structural analyses but also for dynamics studies using pump-probe techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzrUpnaK2sn7Vg90H21EOLACvtfcHk0liJsWv7OAsdww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1GqtrnP&md5=2341d4739df5d5e733c6d8962c4033ec</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1107%2FS1600576719012846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1600576719012846%26sid%3Dliteratum%253Aachs%26aulast%3DShimazu%26aufirst%3DY.%26aulast%3DTono%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DYamanaka%26aufirst%3DY.%26aulast%3DNakane%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DC.%26aulast%3DTerakado%2BKimura%26aufirst%3DK.%26aulast%3DFujiwara%26aufirst%3DT.%26aulast%3DSugahara%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DDoak%26aufirst%3DR.%2BB.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DIwata%26aufirst%3DS.%26aulast%3DNango%26aufirst%3DE.%26aulast%3DYabashi%26aufirst%3DM.%26atitle%3DHigh-viscosity%2520sample-injection%2520device%2520for%2520serial%2520femtosecond%2520crystallography%2520at%2520atmospheric%2520pressure%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2019%26volume%3D52%26spage%3D1280%26epage%3D1288%26doi%3D10.1107%2FS1600576719012846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiez-Vandal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span> <span> </span><span class="NLM_article-title">Structures of human A1 and A2A adenosine receptors with xanthines reveal determinants of selectivity</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1275</span>– <span class="NLM_lpage">1285</span>, <span class="refDoi"> DOI: 10.1016/j.str.2017.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.str.2017.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28712806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOlsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1275-1285&author=R.+K.+Y.+Chengauthor=E.+Segalaauthor=N.+Robertsonauthor=F.+Deflorianauthor=A.+S.+Dor%C3%A9author=J.+C.+Erreyauthor=C.+Fiez-Vandalauthor=F.+H.+Marshallauthor=R.+M.+Cooke&title=Structures+of+human+A1+and+A2A+adenosine+receptors+with+xanthines+reveal+determinants+of+selectivity&doi=10.1016%2Fj.str.2017.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of Human A1 and A2a Adenosine Receptors with Xanthines Reveal Determinants of Selectivity</span></div><div class="casAuthors">Cheng, Robert K. Y.; Segala, Elena; Robertson, Nathan; Deflorian, Francesca; Dore, Andrew S.; Errey, James C.; Fiez-Vandal, Cedric; Marshall, Fiona H.; Cooke, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1275-1285.e4</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The adenosine A1 and A2a receptors belong to the purinergic family of G protein-coupled receptors, and regulate diverse functions of the cardiovascular, respiratory, renal, inflammation, and CNS.  Xanthines such as caffeine and theophylline are weak, non-selective antagonists of adenosine receptors.  Here we report the structure of a thermostabilized human A1 receptor at 3.3 Å resoln. with PSB36, an A1-selective xanthine-based antagonist.  This is compared with structures of the A2a receptor with PSB36 (2.8 Å resoln.), caffeine (2.1 Å), and theophylline (2.0 Å) to highlight features of ligand recognition which are common across xanthines.  The structures of A1R and A2aR were analyzed to identify the differences that are important selectivity determinants for xanthine ligands, and the role of T2707.35 in A1R (M2707.35 in A2aR) in conferring selectivity was confirmed by mutagenesis.  The structural differences confirmed to lead to selectivity can be utilized in the design of new subtype-selective A1R or A2aR antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDdYCktAYdKLVg90H21EOLACvtfcHk0lgySwBdJ_eNDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOlsbfJ&md5=e759fd60b25beac2d9429809f3b51b02</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2017.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2017.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DR.%2BK.%2BY.%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DFiez-Vandal%26aufirst%3DC.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26atitle%3DStructures%2520of%2520human%2520A1%2520and%2520A2A%2520adenosine%2520receptors%2520with%2520xanthines%2520reveal%2520determinants%2520of%2520selectivity%26jtitle%3DStructure%26date%3D2017%26volume%3D25%26spage%3D1275%26epage%3D1285%26doi%3D10.1016%2Fj.str.2017.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattedi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasio, F. L.</span></span> <span> </span><span class="NLM_article-title">Understanding ligand binding selectivity in a prototypical GPCR family</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2830</span>– <span class="NLM_lpage">2836</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.9b00298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.9b00298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVehurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=2830-2836&author=G.+Mattediauthor=F.+Deflorianauthor=J.+S.+Masonauthor=C.+de+Graafauthor=F.+L.+Gervasio&title=Understanding+ligand+binding+selectivity+in+a+prototypical+GPCR+family&doi=10.1021%2Facs.jcim.9b00298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Ligand Binding Selectivity in a Prototypical GPCR Family</span></div><div class="casAuthors">Mattedi, Giulio; Deflorian, Francesca; Mason, Jonathan S.; de Graaf, Chris; Gervasio, Francesco L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2830-2836</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adenosine receptors are involved in many pathol. conditions and are thus promising drug targets.  However, developing drugs that target this GPCR subfamily is a challenging task.  A no. of drug candidates fail due to lack of selectivity which results in unwanted side effects.  The extensive structural similarity of adenosine receptors complicates the design of selective ligands.  The problem of selective targeting is a general concern in GPCRs, and in this respect adenosine receptors are a prototypical example.  Here we use enhanced sampling simulations to decipher the determinants of selectivity of ligands in A2a and A1 adenosine receptors.  Our model shows how small differences in the binding pocket and in the water network around the ligand can be leveraged to achieve selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbIs4oEcJQ3rVg90H21EOLACvtfcHk0lgySwBdJ_eNDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVehurzE&md5=18d573fcaf6a87e58d7b954db1aefacb</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.9b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.9b00298%26sid%3Dliteratum%253Aachs%26aulast%3DMattedi%26aufirst%3DG.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DGervasio%26aufirst%3DF.%2BL.%26atitle%3DUnderstanding%2520ligand%2520binding%2520selectivity%2520in%2520a%2520prototypical%2520GPCR%2520family%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2019%26volume%3D59%26spage%3D2830%26epage%3D2836%26doi%3D10.1021%2Facs.jcim.9b00298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachhawat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M. L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2066</span>– <span class="NLM_lpage">2071</span>, <span class="refDoi"> DOI: 10.1073/pnas.1621423114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1073%2Fpnas.1621423114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28167788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=2066-2071&author=B.+Sunauthor=P.+Bachhawatauthor=M.+L.-H.+Chuauthor=M.+Woodauthor=T.+Ceskaauthor=Z.+A.+Sandsauthor=J.+Mercierauthor=F.+Lebonauthor=T.+S.+Kobilkaauthor=B.+K.+Kobilka&title=Crystal+structure+of+the+adenosine+A2A+receptor+bound+to+an+antagonist+reveals+a+potential+allosteric+pocket&doi=10.1073%2Fpnas.1621423114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket</span></div><div class="casAuthors">Sun, Bingfa; Bachhawat, Priti; Chu, Matthew Ling-Hon; Wood, Martyn; Ceska, Tom; Sands, Zara A.; Mercier, Joel; Lebon, Florence; Kobilka, Tong Sun; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2066-2071</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The adenosine A2A receptor (A2AR) has long been implicated in cardiovascular disorders.  As more selective A2AR ligands are being identified, its roles in other disorders, such as Parkinson's disease, are starting to emerge, and A2AR antagonists are important drug candidates for non-dopaminergic anti-Parkinson treatment.  Here, the authors report the crystal structure of A2A receptor bound to compd. 1, a novel A2AR/N-methyl-D-aspartate (NMDA) receptor subtype 2B (NR2B; NMDA receptor 2B) dual antagonist and potential anti-Parkinson candidate compd., at 3.5 Å resoln.  The A2A receptor with a cytochrome b562-RIL (BRIL) fusion (A2AR-BRIL) in intracellular loop 3 (ICL3) was crystd. in detergent micelles using vapor-phase diffusion.  Whereas A2AR-BRIL bound to antagonist ZM241385 was previously been crystd. in the lipidic cubic phase (LCP), structural differences in the compd. 1-bound A2AR-BRIL prevented formation of the lattice obsd. with the ZM241385-bound receptor.  The crystals grew with a type II crystal lattice in contrast to the typical type I packing seen from membrane protein structures crystd. in LCP.  Compd. 1 bound in a position that overlapped with the native ligand, adenosine, but its methoxyphenyl group extended to an exosite not previously obsd. in other A2AR structures.  Structural anal. revealed that compd. 1 binding resulted in the unique conformations of 2 Tyr residues (Tyr91.35 and Tyr2717.36) which are crit. for the formation of the exosite.  The structure revealed insights into antagonist binding that were not obsd. in other A2AR structures, highlighting flexibility in the binding pocket that may facilitate the development of A2AR-selective compds. for the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5SraoNhZQ0bVg90H21EOLACvtfcHk0li6Wp5jOcABuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCksb8%253D&md5=58ac85e930066ef7a6788c4d7f3a72b3</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1621423114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1621423114%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DBachhawat%26aufirst%3DP.%26aulast%3DChu%26aufirst%3DM.%2BL.-H.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DCeska%26aufirst%3DT.%26aulast%3DSands%26aufirst%3DZ.%2BA.%26aulast%3DMercier%26aufirst%3DJ.%26aulast%3DLebon%26aufirst%3DF.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520bound%2520to%2520an%2520antagonist%2520reveals%2520a%2520potential%2520allosteric%2520pocket%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D2066%26epage%3D2071%26doi%3D10.1073%2Fpnas.1621423114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span>; <span class="NLM_string-name">Macleod, C.</span>; <span class="NLM_string-name">Moulton, B.</span>; <span class="NLM_string-name">Lenagh-Snow, G.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine Derivatives and Their Use Use for the Treatment of Cancer</span>. PCT Int. Appl. <span class="NLM_patent">WO2019122932 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+McCarthy&author=C.+Macleod&author=B.+Moulton&author=G.+Lenagh-Snow&title=Pyrimidine+Derivatives+and+Their+Use+Use+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DC.%26atitle%3DPyrimidine%2520Derivatives%2520and%2520Their%2520Use%2520Use%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beatty, J.</span>; <span class="NLM_string-name">Debien, L.</span>; <span class="NLM_string-name">Jeffrey, J.</span>; <span class="NLM_string-name">Leleti, M. R.</span>; <span class="NLM_string-name">Mandal, D.</span>; <span class="NLM_string-name">Miles, D.</span>; <span class="NLM_string-name">Powers, J.</span>; <span class="NLM_string-name">Rosen, B.</span>; <span class="NLM_string-name">Thomas-Tran, R.</span>; <span class="NLM_string-name">Sharif, E.</span></span> <span> </span><span class="NLM_article-title">Preparation of Azolopyrimidine for the Treatment of Cancer and Immune Related Disorders</span>. PCT Int. Appl. <span class="NLM_patent">WO2018136700 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Beatty&author=L.+Debien&author=J.+Jeffrey&author=M.+R.+Leleti&author=D.+Mandal&author=D.+Miles&author=J.+Powers&author=B.+Rosen&author=R.+Thomas-Tran&author=E.+Sharif&title=Preparation+of+Azolopyrimidine+for+the+Treatment+of+Cancer+and+Immune+Related+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeatty%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520Azolopyrimidine%2520for%2520the%2520Treatment%2520of%2520Cancer%2520and%2520Immune%2520Related%2520Disorders%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido-Shaqfeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the potent and selective A2R antagonist AB928 for the treatment of cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4572</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-4572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2017-4572" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4572&author=M.+J.+Waltersauthor=J.+B.+Tanauthor=A.+Beckerauthor=F.+Yiauthor=T.+Parkauthor=M.+R.+Leletiauthor=B.+Rosenauthor=E.+Sharifauthor=L.+Debienauthor=S.+Youngauthor=W.+H.+Limauthor=S.+Garrido-Shaqfehauthor=J.+C.+Jaenauthor=J.+P.+Powers&title=Characterization+of+the+potent+and+selective+A2R+antagonist+AB928+for+the+treatment+of+cancer&doi=10.1158%2F1538-7445.AM2017-4572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-4572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-4572%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26aulast%3DTan%26aufirst%3DJ.%2BB.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DYi%26aufirst%3DF.%26aulast%3DPark%26aufirst%3DT.%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26aulast%3DRosen%26aufirst%3DB.%26aulast%3DSharif%26aufirst%3DE.%26aulast%3DDebien%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DW.%2BH.%26aulast%3DGarrido-Shaqfeh%26aufirst%3DS.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520potent%2520and%2520selective%2520A2R%2520antagonist%2520AB928%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4572%26doi%3D10.1158%2F1538-7445.AM2017-4572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Direnzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piovesan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handlos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, E. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. J.</span></span> <span> </span><span class="NLM_article-title">AB928, a dual antagonist of the A2AR and A2BR adenosine receptors, relieves adenosine-mediated immune suppression</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">A162</span>, <span class="refDoi"> DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F2326-6074.CRICIMTEATIAACR18-A162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30602507" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=A162&author=D.+Direnzoauthor=D.+Piovesanauthor=J.+Tanauthor=D.+H.+Milesauthor=M.+R.+Leletiauthor=T.+Parkauthor=F.+Sorianoauthor=B.+Handlosauthor=J.+L.+Jeffreyauthor=E.+U.+Sharifauthor=B.+R.+Rosenauthor=U.+Schindlerauthor=J.+P.+Powersauthor=M.+J.+Walters&title=AB928%2C+a+dual+antagonist+of+the+A2AR+and+A2BR+adenosine+receptors%2C+relieves+adenosine-mediated+immune+suppression&doi=10.1158%2F2326-6074.CRICIMTEATIAACR18-A162"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F2326-6074.CRICIMTEATIAACR18-A162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6074.CRICIMTEATIAACR18-A162%26sid%3Dliteratum%253Aachs%26aulast%3DDirenzo%26aufirst%3DD.%26aulast%3DPiovesan%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DMiles%26aufirst%3DD.%2BH.%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26aulast%3DPark%26aufirst%3DT.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DHandlos%26aufirst%3DB.%26aulast%3DJeffrey%26aufirst%3DJ.%2BL.%26aulast%3DSharif%26aufirst%3DE.%2BU.%26aulast%3DRosen%26aufirst%3DB.%2BR.%26aulast%3DSchindler%26aufirst%3DU.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26atitle%3DAB928%252C%2520a%2520dual%2520antagonist%2520of%2520the%2520A2AR%2520and%2520A2BR%2520adenosine%2520receptors%252C%2520relieves%2520adenosine-mediated%2520immune%2520suppression%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26spage%3DA162%26doi%3D10.1158%2F2326-6074.CRICIMTEATIAACR18-A162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piovesan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Direnzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span> <span> </span><span class="NLM_article-title">Combining adenosine receptor inhibition, with AB928, and chemotherapy results in greater immune activation and tumor control</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5556</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-5556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2018-5556" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5556&author=M.+J.+Waltersauthor=D.+Piovesanauthor=J.+Tanauthor=D.+Direnzoauthor=F.+Yinauthor=D.+Milesauthor=M.+R.+Leletiauthor=T.+Parkauthor=F.+Sorianoauthor=E.+Sharifauthor=U.+Schindlerauthor=J.+P.+Powers&title=Combining+adenosine+receptor+inhibition%2C+with+AB928%2C+and+chemotherapy+results+in+greater+immune+activation+and+tumor+control&doi=10.1158%2F1538-7445.AM2018-5556"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-5556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-5556%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26aulast%3DPiovesan%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DDirenzo%26aufirst%3DD.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26aulast%3DPark%26aufirst%3DT.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DSharif%26aufirst%3DE.%26aulast%3DSchindler%26aufirst%3DU.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DCombining%2520adenosine%2520receptor%2520inhibition%252C%2520with%2520AB928%252C%2520and%2520chemotherapy%2520results%2520in%2520greater%2520immune%2520activation%2520and%2520tumor%2520control%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5556%26doi%3D10.1158%2F1538-7445.AM2018-5556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakunnel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M.</span></span> <span> </span><span class="NLM_article-title">Final results of the phase 1 study in healthy volunteers of AB928, a dual antagonist of the A2AR and A2BR adenosine receptors being studied as an activator of anti-tumor immune response</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">viii665</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy303.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1093%2Fannonc%2Fmdy303.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=viii665&author=L.+C.+Seitzauthor=D.+Ashokauthor=M.+Leletiauthor=J.+Powersauthor=B.+Rosenauthor=D.+Milesauthor=E.+Sharifauthor=L.+Jinauthor=A.+Parkauthor=S.+Youngauthor=A.+Riegerauthor=U.+Schindlerauthor=J.+Karakunnelauthor=M.+Walters&title=Final+results+of+the+phase+1+study+in+healthy+volunteers+of+AB928%2C+a+dual+antagonist+of+the+A2AR+and+A2BR+adenosine+receptors+being+studied+as+an+activator+of+anti-tumor+immune+response&doi=10.1093%2Fannonc%2Fmdy303.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy303.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy303.050%26sid%3Dliteratum%253Aachs%26aulast%3DSeitz%26aufirst%3DL.%2BC.%26aulast%3DAshok%26aufirst%3DD.%26aulast%3DLeleti%26aufirst%3DM.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DB.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DSharif%26aufirst%3DE.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DRieger%26aufirst%3DA.%26aulast%3DSchindler%26aufirst%3DU.%26aulast%3DKarakunnel%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DM.%26atitle%3DFinal%2520results%2520of%2520the%2520phase%25201%2520study%2520in%2520healthy%2520volunteers%2520of%2520AB928%252C%2520a%2520dual%2520antagonist%2520of%2520the%2520A2AR%2520and%2520A2BR%2520adenosine%2520receptors%2520being%2520studied%2520as%2520an%2520activator%2520of%2520anti-tumor%2520immune%2520response%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3Dviii665%26doi%3D10.1093%2Fannonc%2Fmdy303.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakunnel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, A.</span></span> <span> </span><span class="NLM_article-title">AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2604</span>, <span class="refDoi"> DOI: 10.1200/JCO.2019.37.15_suppl.2604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1200%2FJCO.2019.37.15_suppl.2604" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=2604&author=J.+D.+Powderlyauthor=P.+L.+de+Souzaauthor=R.+Gutierrezauthor=L.+Horvathauthor=L.+Seitzauthor=D.+Ashokauthor=A.+Parkauthor=M.+J.+Waltersauthor=J.+J.+Karakunnelauthor=W.+Berryauthor=A.+Riegerauthor=A.+Garofaloauthor=D.+W.+Laiauthor=A.+Chaudhry&title=AB928%2C+a+novel+dual+adenosine+receptor+antagonist%2C+combined+with+chemotherapy+or+AB122+%28anti-PD-1%29+in+patients+%28pts%29+with+advanced+tumors%3A+Preliminary+results+from+ongoing+phase+I+studies&doi=10.1200%2FJCO.2019.37.15_suppl.2604"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.2604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.2604%26sid%3Dliteratum%253Aachs%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BSouza%26aufirst%3DP.%2BL.%26aulast%3DGutierrez%26aufirst%3DR.%26aulast%3DHorvath%26aufirst%3DL.%26aulast%3DSeitz%26aufirst%3DL.%26aulast%3DAshok%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26aulast%3DKarakunnel%26aufirst%3DJ.%2BJ.%26aulast%3DBerry%26aufirst%3DW.%26aulast%3DRieger%26aufirst%3DA.%26aulast%3DGarofalo%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DD.%2BW.%26aulast%3DChaudhry%26aufirst%3DA.%26atitle%3DAB928%252C%2520a%2520novel%2520dual%2520adenosine%2520receptor%2520antagonist%252C%2520combined%2520with%2520chemotherapy%2520or%2520AB122%2520%2528anti-PD-1%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520tumors%253A%2520Preliminary%2520results%2520from%2520ongoing%2520phase%2520I%2520studies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D2604%26doi%3D10.1200%2FJCO.2019.37.15_suppl.2604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span>; <span class="NLM_string-name">Miles, D. H.</span>; <span class="NLM_string-name">Powers, J. P.</span>; <span class="NLM_string-name">Rosen, B. R.</span>; <span class="NLM_string-name">Sharif, E. U.</span>; <span class="NLM_string-name">Thomas-Tran, R.</span></span> <span> </span><span class="NLM_article-title">Quinazoline-pyridine Derivatives for the Treatment of Cancer-Related Disorders and Their Preparation</span>. PCT Int. Appl. <span class="NLM_patent">WO2018204661 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+R.+Leleti&author=D.+H.+Miles&author=J.+P.+Powers&author=B.+R.+Rosen&author=E.+U.+Sharif&author=R.+Thomas-Tran&title=Quinazoline-pyridine+Derivatives+for+the+Treatment+of+Cancer-Related+Disorders+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26atitle%3DQuinazoline-pyridine%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Cancer-Related%2520Disorders%2520and%2520Their%2520Preparation%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span>; <span class="NLM_string-name">Miles, D. H.</span>; <span class="NLM_string-name">Powers, J. P.</span>; <span class="NLM_string-name">Rosen, B. R.</span>; <span class="NLM_string-name">Sharif, E. U.</span>; <span class="NLM_string-name">Thomas-Tran, R.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline-pyrazole Derivatives for the Treatment of Cancer-related Disorders</span>. PCT Int. Appl. <span class="NLM_patent">WO2018213377 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+R.+Leleti&author=D.+H.+Miles&author=J.+P.+Powers&author=B.+R.+Rosen&author=E.+U.+Sharif&author=R.+Thomas-Tran&title=Preparation+of+Quinazoline-pyrazole+Derivatives+for+the+Treatment+of+Cancer-related+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26atitle%3DPreparation%2520of%2520Quinazoline-pyrazole%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Cancer-related%2520Disorders%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botting, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerpiniere, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightowler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAteer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padfield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reece, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selwood, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. M.</span></span> <span> </span><span class="NLM_article-title">Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1021/jm800961g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800961g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFSjtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=33-47&author=R.+J.+Gillespieauthor=S.+J.+Bamfordauthor=R.+Bottingauthor=M.+Comerauthor=S.+Dennyauthor=S.+Gaurauthor=M.+Griffinauthor=A.+M.+Jordanauthor=A.+R.+Knightauthor=J.+Lerpiniereauthor=S.+Leonardiauthor=S.+Lightowlerauthor=S.+McAteerauthor=A.+Merrettauthor=A.+Misraauthor=A.+Padfieldauthor=M.+Reeceauthor=M.+Saadiauthor=D.+L.+Selwoodauthor=G.+C.+Strattonauthor=D.+Surryauthor=R.+Toddauthor=X.+Tongauthor=V.+Rustonauthor=R.+Uptonauthor=S.+M.+Weiss&title=Antagonists+of+the+human+A2A+adenosine+receptor.+4.+Design%2C+synthesis%2C+and+preclinical+evaluation+of+7-aryltriazolo%5B4%2C5-d%5Dpyrimidines&doi=10.1021%2Fjm800961g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines</span></div><div class="casAuthors">Gillespie, Roger J.; Bamford, Samantha J.; Botting, Ruth; Comer, Mike; Denny, Sarah; Gaur, Suneel; Griffin, Michael; Jordan, Allan M.; Knight, Anthony R.; Lerpiniere, Joanne; Leonardi, Stefania; Lightowler, Sean; McAteer, Steven; Merrett, Angela; Misra, Anil; Padfield, Antony; Reece, Mark; Saadi, Mona; Selwood, Daniel L.; Stratton, Gemma C.; Surry, Dominic; Todd, Richard; Tong, Xin; Ruston, Vicki; Upton, Rebecca; Weiss, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-47</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonism of the human A2A receptor has been implicated as a point of therapeutic intervention in the alleviation of the symptoms assocd. with Parkinson's disease.  This is thought to occur, at least in part, by increasing the sensitivity of the dopaminergic neurons to the residual, depleted levels of striatal dopamine.  We herein describe a novel series of functionalized triazolo[4,5-d]pyrimidine derivs. that display functional antagonism of the A2A receptor.  Optimization of these compds. has resulted in improvements in potency, selectivity, and the pharmacokinetic properties of key derivs.  These efforts have led to the discovery of I (V2006/BIIB014), which demonstrates strong oral activity in commonly used models of Parkinson's disease.  Furthermore, this deriv. has shown excellent preclin. pharmacokinetics and has successfully completed phase I clin. studies.  This compd. is presently undergoing further clin. evaluation in collaboration with Biogen Idec.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6pAUuqxmjkLVg90H21EOLACvtfcHk0liJLJUiMhCgwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFSjtbrP&md5=74142663769a86d6cacc6dce252757eb</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm800961g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800961g%26sid%3Dliteratum%253Aachs%26aulast%3DGillespie%26aufirst%3DR.%2BJ.%26aulast%3DBamford%26aufirst%3DS.%2BJ.%26aulast%3DBotting%26aufirst%3DR.%26aulast%3DComer%26aufirst%3DM.%26aulast%3DDenny%26aufirst%3DS.%26aulast%3DGaur%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DM.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DKnight%26aufirst%3DA.%2BR.%26aulast%3DLerpiniere%26aufirst%3DJ.%26aulast%3DLeonardi%26aufirst%3DS.%26aulast%3DLightowler%26aufirst%3DS.%26aulast%3DMcAteer%26aufirst%3DS.%26aulast%3DMerrett%26aufirst%3DA.%26aulast%3DMisra%26aufirst%3DA.%26aulast%3DPadfield%26aufirst%3DA.%26aulast%3DReece%26aufirst%3DM.%26aulast%3DSaadi%26aufirst%3DM.%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26aulast%3DStratton%26aufirst%3DG.%2BC.%26aulast%3DSurry%26aufirst%3DD.%26aulast%3DTodd%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DRuston%26aufirst%3DV.%26aulast%3DUpton%26aufirst%3DR.%26aulast%3DWeiss%26aufirst%3DS.%2BM.%26atitle%3DAntagonists%2520of%2520the%2520human%2520A2A%2520adenosine%2520receptor.%25204.%2520Design%252C%2520synthesis%252C%2520and%2520preclinical%2520evaluation%2520of%25207-aryltriazolo%255B4%252C5-d%255Dpyrimidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D33%26epage%3D47%26doi%3D10.1021%2Fjm800961g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rucktooa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span> <span> </span><span class="NLM_article-title">Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-18570-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fs41598-017-18570-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29311713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1MzosFaktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=41&author=P.+Rucktooaauthor=R.+K.+Y.+Chengauthor=E.+Segalaauthor=T.+Gengauthor=J.+C.+Erreyauthor=G.+A.+Brownauthor=R.+M.+Cookeauthor=F.+H.+Marshallauthor=A.+S.+Dor%C3%A9&title=Towards+high+throughput+GPCR+crystallography%3A+In+Meso+soaking+of+Adenosine+A2A+Receptor+crystals&doi=10.1038%2Fs41598-017-18570-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals</span></div><div class="casAuthors">Rucktooa Prakash; Cheng Robert K Y; Segala Elena; Geng Tian; Errey James C; Brown Giles A; Cooke Robert M; Marshall Fiona H; Dore Andrew S; Cheng Robert K Y</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Here we report an efficient method to generate multiple co-structures of the A2A G protein-coupled receptor (GPCR) with small-molecules from a single preparation of a thermostabilised receptor crystallised in Lipidic Cubic Phase (LCP).  Receptor crystallisation is achieved following purification using a low affinity "carrier" ligand (theophylline) and crystals are then soaked in solutions containing the desired (higher affinity) compounds.  Complete datasets to high resolution can then be collected from single crystals and seven structures are reported here of which three are novel.  The method significantly improves structural throughput for ligand screening using stabilised GPCRs, thereby actively driving Structure-Based Drug Discovery (SBDD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT__KWoaDFa1cScOqQTSkOffW6udTcc2eb7cUCrR-6-rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzosFaktQ%253D%253D&md5=835858f9d8557f79e9325b41fe7e9a89</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-18570-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-18570-w%26sid%3Dliteratum%253Aachs%26aulast%3DRucktooa%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DR.%2BK.%2BY.%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DGeng%26aufirst%3DT.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DG.%2BA.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26atitle%3DTowards%2520high%2520throughput%2520GPCR%2520crystallography%253A%2520In%2520Meso%2520soaking%2520of%2520Adenosine%2520A2A%2520Receptor%2520crystals%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D41%26doi%3D10.1038%2Fs41598-017-18570-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, S. J.</span>; <span class="NLM_string-name">Gillespie, R. J.</span>; <span class="NLM_string-name">Todd, R. S.</span></span> <span> </span><span class="NLM_article-title">Triazolo[4,5-d]pyramidine Derivatives, their Preparation, and Use as Purine Receptor Antagonists for Treating Movement Disorders and Other Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO2009156737 A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+J.+Bamford&author=R.+J.+Gillespie&author=R.+S.+Todd&title=Triazolo%5B4%2C5-d%5Dpyramidine+Derivatives%2C+their+Preparation%2C+and+Use+as+Purine+Receptor+Antagonists+for+Treating+Movement+Disorders+and+Other+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBamford%26aufirst%3DS.%2BJ.%26atitle%3DTriazolo%255B4%252C5-d%255Dpyramidine%2520Derivatives%252C%2520their%2520Preparation%252C%2520and%2520Use%2520as%2520Purine%2520Receptor%2520Antagonists%2520for%2520Treating%2520Movement%2520Disorders%2520and%2520Other%2520Diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willingham, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccione, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaffery, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span> <span> </span><span class="NLM_article-title">A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(l)1 and anti-CTLA-4 in preclinical models</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-18-0056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F2326-6066.CIR-18-0056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30131376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1emt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=1136-1149&author=S.+B.+Willinghamauthor=P.+Y.+Hoauthor=A.+Hotsonauthor=C.+Hillauthor=E.+C.+Piccioneauthor=J.+Hsiehauthor=L.+Liuauthor=J.+J.+Buggyauthor=I.+McCafferyauthor=R.+A.+Miller&title=A2AR+antagonism+with+CPI-444+induces+antitumor+responses+and+augments+efficacy+to+anti-PD-%28l%291+and+anti-CTLA-4+in+preclinical+models&doi=10.1158%2F2326-6066.CIR-18-0056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models</span></div><div class="casAuthors">Willingham, Stephen B.; Ho, Po Y.; Hotson, Andrew; Hill, Craig; Piccione, Emily C.; Hsieh, Jessica; Liu, Liang; Buggy, Joseph J.; McCaffery, Ian; Miller, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1136-1149</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Adenosine signaling through A2A receptors (A2AR) expressed on immune cells suppresses antitumor immunity.  CPI-444 is a potent, selective, oral A2AR antagonist.  Blockade of A2AR with CPI-444 restored T-cell signaling, IL2, and IFNγ prodn. that were suppressed by adenosine analogs in vitro.  CPI-444 treatment led to dose-dependent inhibition of tumor growth in multiple syngeneic mouse tumor models.  Concns. of extracellular adenosine in the tumor microenvironment, measured using microdialysis, were approx. 100-150 nmol/L and were higher than corresponding s.c. tissue.  Combining CPI-444 with anti-PD-L1 or anti-CTLA-4 treatment eliminated tumors in up to 90% of treated mice, including restoration of immune responses in models that incompletely responded to anti-PD-L1 or anti-CTLA-4 monotherapy.  Tumor growth was fully inhibited when mice with cleared tumors were later rechallenged, indicating that CPI-444 induced systemic antitumor immune memory.  CD8[suplus] T-cell depletion abrogated the efficacy of CPI-444 with and without anti-PD-L1 treatment, demonstrating a role for CD8[suplus] T cells in mediating primary and secondary immune responses.  The antitumor efficacy of CPI-444 with and without anti-PD-L1 was assocd. with increased T-cell activation, a compensatory increase in CD73 expression, and induction of a Th1 gene expression signature consistent with immune activation.  These results suggest a broad role for adenosine-mediated immunosuppression in tumors and justify the further evaluation of CPI-444 as a therapeutic agent in patients with solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5x2Tft7FzvrVg90H21EOLACvtfcHk0lhKoQDrnR77YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1emt7k%253D&md5=effa3cf830866317986507d2e061aa5d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0056%26sid%3Dliteratum%253Aachs%26aulast%3DWillingham%26aufirst%3DS.%2BB.%26aulast%3DHo%26aufirst%3DP.%2BY.%26aulast%3DHotson%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DC.%26aulast%3DPiccione%26aufirst%3DE.%2BC.%26aulast%3DHsieh%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DMcCaffery%26aufirst%3DI.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26atitle%3DA2AR%2520antagonism%2520with%2520CPI-444%2520induces%2520antitumor%2520responses%2520and%2520augments%2520efficacy%2520to%2520anti-PD-%2528l%25291%2520and%2520anti-CTLA-4%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2018%26volume%3D6%26spage%3D1136%26epage%3D1149%26doi%3D10.1158%2F2326-6066.CIR-18-0056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquerre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versluys, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poussereau-Pomie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paillasse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swindells, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisztwan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel non-brain penetrant A2AR inhibitor and proof-of-concept of CD73 and A2AR/CD73 small-molecule inhibitors for cancer immunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">3768</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-3768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2018-3768" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=3768&author=P.+Fonsauthor=A.+Bellauthor=M.+Esquerreauthor=S.+Versluysauthor=F.+Bertrandauthor=C.+Poussereau-Pomieauthor=A.+Schreyerauthor=R.+Coxauthor=J.+Besnardauthor=M.+Paillasseauthor=M.+Swindellsauthor=J.+Lisztwanauthor=C.+Johnstoneauthor=M.+Whittakerauthor=A.+Hopkins&title=Identification+of+a+novel+non-brain+penetrant+A2AR+inhibitor+and+proof-of-concept+of+CD73+and+A2AR%2FCD73+small-molecule+inhibitors+for+cancer+immunotherapy&doi=10.1158%2F1538-7445.AM2018-3768"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-3768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-3768%26sid%3Dliteratum%253Aachs%26aulast%3DFons%26aufirst%3DP.%26aulast%3DBell%26aufirst%3DA.%26aulast%3DEsquerre%26aufirst%3DM.%26aulast%3DVersluys%26aufirst%3DS.%26aulast%3DBertrand%26aufirst%3DF.%26aulast%3DPoussereau-Pomie%26aufirst%3DC.%26aulast%3DSchreyer%26aufirst%3DA.%26aulast%3DCox%26aufirst%3DR.%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DPaillasse%26aufirst%3DM.%26aulast%3DSwindells%26aufirst%3DM.%26aulast%3DLisztwan%26aufirst%3DJ.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DM.%26aulast%3DHopkins%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520novel%2520non-brain%2520penetrant%2520A2AR%2520inhibitor%2520and%2520proof-of-concept%2520of%2520CD73%2520and%2520A2AR%252FCD73%2520small-molecule%2520inhibitors%2520for%2520cancer%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D3768%26doi%3D10.1158%2F1538-7445.AM2018-3768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubukov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for allosteric regulation of GPCRs by sodium ions</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1126/science.1219218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1126%2Fscience.1219218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22798613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2012&pages=232-236&author=W.+Liuauthor=E.+Chunauthor=A.+A.+Thompsonauthor=P.+Chubukovauthor=F.+Xuauthor=V.+Katritchauthor=G.+W.+Hanauthor=C.+B.+Rothauthor=L.+H.+Heitmanauthor=A.+P.+Ijzermanauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structural+basis+for+allosteric+regulation+of+GPCRs+by+sodium+ions&doi=10.1126%2Fscience.1219218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions</span></div><div class="casAuthors">Liu, Wei; Chun, Eugene; Thompson, Aaron A.; Chubukov, Pavel; Xu, Fei; Katritch, Vsevolod; Han, Gye Won; Roth, Christopher B.; Heitman, Laura H.; IJzerman, Adriaan P.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">6091</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Pharmacol. responses of G protein-coupled receptors (GPCRs) can be fine-tuned by allosteric modulators.  Structural studies of such effects have been limited due to the medium resoln. of GPCR structures.  We reengineered the human A2A adenosine receptor by replacing its third intracellular loop with apocytochrome b562RIL and solved the structure at 1.8 angstrom resoln.  The high-resoln. structure allowed us to identify 57 ordered water mols. inside the receptor comprising three major clusters.  The central cluster harbors a putative sodium ion bound to the highly conserved aspartate residue Asp2.50.  Addnl., two cholesterols stabilize the conformation of helix VI, and one of 23 ordered lipids intercalates inside the ligand-binding pocket.  These high-resoln. details shed light on the potential role of structured water mols., sodium ions, and lipids/cholesterol in GPCR stabilization and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvcjQimGnIMLVg90H21EOLACvtfcHk0lhKoQDrnR77YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKqtbs%253D&md5=782b2235b76ef77b11b6456f8e4485e1</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1126%2Fscience.1219218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1219218%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChun%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DA.%2BA.%26aulast%3DChubukov%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DRoth%26aufirst%3DC.%2BB.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructural%2520basis%2520for%2520allosteric%2520regulation%2520of%2520GPCRs%2520by%2520sodium%2520ions%26jtitle%3DScience%26date%3D2012%26volume%3D337%26spage%3D232%26epage%3D236%26doi%3D10.1126%2Fscience.1219218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of novel highly potent A2A adenosine receptor antagonists for cancerimmunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">4110</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-4140" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4110&author=K.+Leeauthor=S.+Junauthor=E.+Byunauthor=H.+Leeauthor=Y.+Leeauthor=M.+Moonauthor=Y.-Y.+Kimauthor=H.+J.+Kangauthor=Y.+Ahnauthor=Y.+Kimauthor=K.+H.+Suh&title=Discovery+and+characterization+of+novel+highly+potent+A2A+adenosine+receptor+antagonists+for+cancerimmunotherapy&doi=10.1158%2F1538-7445.AM2019-4140"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4140%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%26aulast%3DJun%26aufirst%3DS.%26aulast%3DByun%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DMoon%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DY.-Y.%26aulast%3DKang%26aufirst%3DH.%2BJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520novel%2520highly%2520potent%2520A2A%2520adenosine%2520receptor%2520antagonists%2520for%2520cancerimmunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D4110%26doi%3D10.1158%2F1538-7445.AM2019-4140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houthuys, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyawouame, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deregnaucourt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiercz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detheux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quéva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span> <span> </span><span class="NLM_article-title">A novel adenosine A2A receptor antagonist optimized for high potency in adenosine-rich tumor microenvironment boosts anti-tumor immunity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1683</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-1683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2017-1683" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1683&author=E.+Houthuysauthor=M.+Brouwerauthor=F.+Nyawouameauthor=R.+Pirsonauthor=R.+Marillierauthor=T.+Deregnaucourtauthor=J.+Marchanteauthor=J.+Swierczauthor=C.+Moulinauthor=V.+Bolauthor=G.+Driessensauthor=M.+Detheuxauthor=C.+Qu%C3%A9vaauthor=S.+Crosignaniauthor=B.+Gomes&title=A+novel+adenosine+A2A+receptor+antagonist+optimized+for+high+potency+in+adenosine-rich+tumor+microenvironment+boosts+anti-tumor+immunity&doi=10.1158%2F1538-7445.AM2017-1683"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-1683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-1683%26sid%3Dliteratum%253Aachs%26aulast%3DHouthuys%26aufirst%3DE.%26aulast%3DBrouwer%26aufirst%3DM.%26aulast%3DNyawouame%26aufirst%3DF.%26aulast%3DPirson%26aufirst%3DR.%26aulast%3DMarillier%26aufirst%3DR.%26aulast%3DDeregnaucourt%26aufirst%3DT.%26aulast%3DMarchante%26aufirst%3DJ.%26aulast%3DSwiercz%26aufirst%3DJ.%26aulast%3DMoulin%26aufirst%3DC.%26aulast%3DBol%26aufirst%3DV.%26aulast%3DDriessens%26aufirst%3DG.%26aulast%3DDetheux%26aufirst%3DM.%26aulast%3DQu%25C3%25A9va%26aufirst%3DC.%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DGomes%26aufirst%3DB.%26atitle%3DA%2520novel%2520adenosine%2520A2A%2520receptor%2520antagonist%2520optimized%2520for%2520high%2520potency%2520in%2520adenosine-rich%2520tumor%2520microenvironment%2520boosts%2520anti-tumor%2520immunity%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D1683%26doi%3D10.1158%2F1538-7445.AM2017-1683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houthuys, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basilico, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deregnaucourt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detheux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiercz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span> <span> </span><span class="NLM_article-title">EOS100850, a non-brain penetrant highly selective A2A receptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">3261</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-3261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-3261" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=3261&author=E.+Houthuysauthor=P.+Basilicoauthor=M.+Brouwerauthor=T.+Deregnaucourtauthor=M.+Detheuxauthor=G.+Driessensauthor=B.+Gomesauthor=X.+Leroyauthor=J.+Marchanteauthor=R.+Marillierauthor=J.+Swierczauthor=S.+Crosignani&title=EOS100850%2C+a+non-brain+penetrant+highly+selective+A2A+receptor+antagonist%2C+uniquely+maintains+high+potency+within+the+adenosine+rich+tumor+microenvironment&doi=10.1158%2F1538-7445.AM2019-3261"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-3261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-3261%26sid%3Dliteratum%253Aachs%26aulast%3DHouthuys%26aufirst%3DE.%26aulast%3DBasilico%26aufirst%3DP.%26aulast%3DBrouwer%26aufirst%3DM.%26aulast%3DDeregnaucourt%26aufirst%3DT.%26aulast%3DDetheux%26aufirst%3DM.%26aulast%3DDriessens%26aufirst%3DG.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DLeroy%26aufirst%3DX.%26aulast%3DMarchante%26aufirst%3DJ.%26aulast%3DMarillier%26aufirst%3DR.%26aulast%3DSwiercz%26aufirst%3DJ.%26aulast%3DCrosignani%26aufirst%3DS.%26atitle%3DEOS100850%252C%2520a%2520non-brain%2520penetrant%2520highly%2520selective%2520A2A%2520receptor%2520antagonist%252C%2520uniquely%2520maintains%2520high%2520potency%2520within%2520the%2520adenosine%2520rich%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D3261%26doi%3D10.1158%2F1538-7445.AM2019-3261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preillon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederix, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basilico, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houthuys, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span> <span> </span><span class="NLM_article-title">EOS100850, an A2A receptor antagonist with prolonged pharmacodynamic activity, mediates the generation of specific durable immune responses in a murine breast cancer model</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">4147</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-4147" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4147&author=R.+Pirsonauthor=A.+C.+Michauxauthor=D.+Jamartauthor=J.+Preillonauthor=K.+Frederixauthor=P.+Basilicoauthor=C.+Martinoliauthor=X.+Leroyauthor=G.+Driessensauthor=E.+Houthuysauthor=S.+Chappelauthor=S.+Crosignaniauthor=R.+Marillier&title=EOS100850%2C+an+A2A+receptor+antagonist+with+prolonged+pharmacodynamic+activity%2C+mediates+the+generation+of+specific+durable+immune+responses+in+a+murine+breast+cancer+model&doi=10.1158%2F1538-7445.AM2019-4147"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4147%26sid%3Dliteratum%253Aachs%26aulast%3DPirson%26aufirst%3DR.%26aulast%3DMichaux%26aufirst%3DA.%2BC.%26aulast%3DJamart%26aufirst%3DD.%26aulast%3DPreillon%26aufirst%3DJ.%26aulast%3DFrederix%26aufirst%3DK.%26aulast%3DBasilico%26aufirst%3DP.%26aulast%3DMartinoli%26aufirst%3DC.%26aulast%3DLeroy%26aufirst%3DX.%26aulast%3DDriessens%26aufirst%3DG.%26aulast%3DHouthuys%26aufirst%3DE.%26aulast%3DChappel%26aufirst%3DS.%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DMarillier%26aufirst%3DR.%26atitle%3DEOS100850%252C%2520an%2520A2A%2520receptor%2520antagonist%2520with%2520prolonged%2520pharmacodynamic%2520activity%252C%2520mediates%2520the%2520generation%2520of%2520specific%2520durable%2520immune%2520responses%2520in%2520a%2520murine%2520breast%2520cancer%2520model%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D4147%26doi%3D10.1158%2F1538-7445.AM2019-4147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span>; <span class="NLM_string-name">Gomes, B.</span>; <span class="NLM_string-name">Houthuys, E.</span></span> <span> </span><span class="NLM_article-title">2-Oxothiazole Derivatives as A2A Inhibitors for the Use in the Treatment of Cancers</span>. PCT Int. Appl. <span class="NLM_patent">WO2018178338 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Crosignani&author=B.+Gomes&author=E.+Houthuys&title=2-Oxothiazole+Derivatives+as+A2A+Inhibitors+for+the+Use+in+the+Treatment+of+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26atitle%3D2-Oxothiazole%2520Derivatives%2520as%2520A2A%2520Inhibitors%2520for%2520the%2520Use%2520in%2520the%2520Treatment%2520of%2520Cancers%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertorelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varty, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachowicz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forlani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredduzzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impagnatiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolussi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neustadt, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggiani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.149617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1124%2Fjpet.108.149617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=19332567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=294-303&author=R.+A.+Hodgsonauthor=R.+Bertorelliauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=A.+Forlaniauthor=S.+Fredduzziauthor=M.+E.+Cohen-Williamsauthor=G.+A.+Higginsauthor=F.+Impagnatielloauthor=E.+Nicolussiauthor=L.+E.+Parraauthor=C.+Fosterauthor=Y.+Zhaiauthor=B.+R.+Neustadtauthor=A.+W.+Stamfordauthor=E.+M.+Parkerauthor=A.+Reggianiauthor=J.+C.+Hunter&title=Characterization+of+the+potent+and+highly+selective+A2A+receptor+antagonists+preladenant+and+SCH+412348+%5B7-%5B2-%5B4-2%2C4-Difluorophenyl%5D-1-piperazinyl%5Dethyl%5D-2-%282-furanyl%29-7H-pyrazolo%5B4%2C3-e%5D%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-c%5Dpyrimidin-5-amine%5D+in+rodent+models+of+movement+disorders+and+depression&doi=10.1124%2Fjpet.108.149617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span></div><div class="casAuthors">Hodgson, Robert A.; Bertorelli, Rosalia; Varty, Geoffrey B.; Lachowicz, Jean E.; Forlani, Angelo; Fredduzzi, Silva; Cohen-Williams, Mary E.; Higgins, Guy A.; Impagnatiello, Francesco; Nicolussi, Elisa; Parra, Leonard E.; Foster, Carolyn; Zhai, Ying; Neustadt, Bernie R.; Stamford, Andrew W.; Parker, Eric M.; Reggiani, Angelo; Hunter, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adenosine A2A receptor has been implicated in the underlying biol. of various neurol. and psychiatric disorders, including Parkinson's disease (PD) and depression.  Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] are potent competitive antagonists of the human A2A receptor (Ki = 1.1 and 0.6 nM, resp.) and have > 1000-fold selectivity over all other adenosine receptors, making these compds. the most selective A2A receptor antagonists reported to date.  Both compds. attenuate hypolocomotion induced by the A2A receptor agonist CGS-21680 [2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine], suggesting that they inhibit A2A receptor activity in vivo.  Their high degree of selectivity and robust in vivo activity make preladenant and SCH 412348 useful tools to investigate the role of the A2A receptor system in animal models of PD and depression.  Oral administration of preladenant and SCH 412348 (0.1-1 mg/kg) to rats potentiated 3,4-dihydroxy-L-phenylalanine (L-Dopa)-induced contralateral rotations after 6-hydroxydopamine lesions in the medial forebrain bundle and potently attenuated the cataleptic effects of haloperidol.  Preladenant (1 mg/kg) inhibited L-Dopa-induced behavioral sensitization after repeated daily administration, which suggests a reduced risk of the development of dyskinesias.  Finally, preladenant and SCH 412348 exhibited antidepressant-like profiles in models of behavioral despair, namely the mouse tail suspension test and the mouse and rat forced swim test.  These studies demonstrate that preladenant and SCH 412348 are potent and selective A2A receptor antagonists and provide further evidence of the potential therapeutic benefits of A2A receptor inhibition in PD (with reduced risk of dyskinesias) and depression (one of the primary nonmotor symptoms of PD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNkJMOfNlLc7Vg90H21EOLACvtfcHk0lhP-IBBiFaj9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D&md5=b8ce809c2d57a994d201ecca4daa39a3</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.149617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.149617%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DForlani%26aufirst%3DA.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DCohen-Williams%26aufirst%3DM.%2BE.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DNicolussi%26aufirst%3DE.%26aulast%3DParra%26aufirst%3DL.%2BE.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DReggiani%26aufirst%3DA.%26aulast%3DHunter%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520the%2520potent%2520and%2520highly%2520selective%2520A2A%2520receptor%2520antagonists%2520preladenant%2520and%2520SCH%2520412348%2520%255B7-%255B2-%255B4-2%252C4-Difluorophenyl%255D-1-piperazinyl%255Dethyl%255D-2-%25282-furanyl%2529-7H-pyrazolo%255B4%252C3-e%255D%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-c%255Dpyrimidin-5-amine%255D%2520in%2520rodent%2520models%2520of%2520movement%2520disorders%2520and%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D294%26epage%3D303%26doi%3D10.1124%2Fjpet.108.149617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanzer, E. M.</span>; <span class="NLM_string-name">Schiemann, K.</span>; <span class="NLM_string-name">Klein, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Thiazolopyridine Derivatives as Adenosine Receptor Antagonists for the Treatment of Hyperproliferative or Infectious Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO2019025099 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+M.+Tanzer&author=K.+Schiemann&author=M.+Klein&title=Preparation+of+Thiazolopyridine+Derivatives+as+Adenosine+Receptor+Antagonists+for+the+Treatment+of+Hyperproliferative+or+Infectious+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTanzer%26aufirst%3DE.%2BM.%26atitle%3DPreparation%2520of%2520Thiazolopyridine%2520Derivatives%2520as%2520Adenosine%2520Receptor%2520Antagonists%2520for%2520the%2520Treatment%2520of%2520Hyperproliferative%2520or%2520Infectious%2520Diseases%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanzer, E. M.</span>; <span class="NLM_string-name">Schiemann, K.</span>; <span class="NLM_string-name">Klein, M.</span></span> <span> </span><span class="NLM_article-title">Benzimidazole Derivatives as Adenosine Receptor Antagonists and Their Preparation</span>. PCT Int. Appl. <span class="NLM_patent">WO2019038215 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+M.+Tanzer&author=K.+Schiemann&author=M.+Klein&title=Benzimidazole+Derivatives+as+Adenosine+Receptor+Antagonists+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTanzer%26aufirst%3DE.%2BM.%26atitle%3DBenzimidazole%2520Derivatives%2520as%2520Adenosine%2520Receptor%2520Antagonists%2520and%2520Their%2520Preparation%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanzer, E. M.</span>; <span class="NLM_string-name">Schiemann, K.</span>; <span class="NLM_string-name">Klein, M.</span></span> <span> </span><span class="NLM_article-title">Quinoxaline Derivatives as Adenosine Receptor Antagonists and Their Preparation</span>. PCT Int. Appl. <span class="NLM_patent">WO2019038214 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+M.+Tanzer&author=K.+Schiemann&author=M.+Klein&title=Quinoxaline+Derivatives+as+Adenosine+Receptor+Antagonists+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTanzer%26aufirst%3DE.%2BM.%26atitle%3DQuinoxaline%2520Derivatives%2520as%2520Adenosine%2520Receptor%2520Antagonists%2520and%2520Their%2520Preparation%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crespo
Crespo, M. I.</span>; <span class="NLM_string-name">Prat, Q. M.</span>; <span class="NLM_string-name">Gual Roig, S.</span>; <span class="NLM_string-name">Castro Palomino
Laria, J. C.</span>; <span class="NLM_string-name">Slee, D. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2,6-Bis(heteroaryl)-4-aminopyrimidines as Adenosine Receptor Antagonists</span>. PCT Int. Appl. <span class="NLM_patent">WO2005058883 A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+I.+Crespo%0ACrespo&author=Q.+M.+Prat&author=S.+Gual+Roig&author=J.+C.+Castro+Palomino%0ALaria&author=D.+H.+Slee&title=Preparation+of+2%2C6-Bis%28heteroaryl%29-4-aminopyrimidines+as+Adenosine+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrespo%2BCrespo%26aufirst%3DM.%2BI.%26atitle%3DPreparation%2520of%25202%252C6-Bis%2528heteroaryl%2529-4-aminopyrimidines%2520as%2520Adenosine%2520Receptor%2520Antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho Gomez, J. A.</span>; <span class="NLM_string-name">Castro Palomino
Laria, J. C.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-Aminopyrimidine Derivatives and Their Use as Therapeutic Adenosine A2A Receptor Antagonists</span>. PCT Int. Appl. <span class="NLM_patent">WO2011121418 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+A.+Camacho+Gomez&author=J.+C.+Castro+Palomino%0ALaria&title=Preparation+of+4-Aminopyrimidine+Derivatives+and+Their+Use+as+Therapeutic+Adenosine+A2A+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%2BGomez%26aufirst%3DJ.%2BA.%26atitle%3DPreparation%2520of%25204-Aminopyrimidine%2520Derivatives%2520and%2520Their%2520Use%2520as%2520Therapeutic%2520Adenosine%2520A2A%2520Receptor%2520Antagonists%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mediavilla-Varela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noyes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span> <span> </span><span class="NLM_article-title">A novel antagonist of the immune checkpoint protein adenosine a2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/j.neo.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.neo.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28582704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=530-536&author=M.+Mediavilla-Varelaauthor=J.+Castroauthor=A.+Chiapporiauthor=D.+Noyesauthor=D.+C.+Hernandezauthor=B.+Allardauthor=J.+Staggauthor=S.+J.+Antonia&title=A+novel+antagonist+of+the+immune+checkpoint+protein+adenosine+a2a+receptor+restores+tumor-infiltrating+lymphocyte+activity+in+the+context+of+the+tumor+microenvironment&doi=10.1016%2Fj.neo.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment</span></div><div class="casAuthors">Mediavilla-Varela, Melanie; Castro, Julio; Chiappori, Alberto; Noyes, David; Hernandez, Dalia C.; Stagg, John; Antonia, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">530-536</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BACKGROUND: Therapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with various tumor types.  The success of these studies has led to the development of various antibodies/inhibitors for the different checkpoint proteins involved in immune evasion of the tumor.  Adenosine present in high concns. in the tumor microenvironment activates the immune checkpoint adenosine A2a receptor (A2aR), leading to the suppression of antitumor responses.  Inhibition of this checkpoint has the potential to enhance antitumor T-cell responsiveness.  METHODS: We developed a novel A2aR antagonist (PBF-509) and tested its antitumor response in vitro, in a mouse model, and in non-small cell lung cancer patient samples.  RESULTS: Our studies showed that PBF-509 is highly specific to the A2aR as well as inhibitory of A2aR function in an in vitro model.  In a mouse model, we found that lung metastasis was decreased after treatment with PBF-509 compared with its control.  Furthermore, freshly resected tumor-infiltrating lymphocytes from lung cancer patients showed increased A2aR expression in CD4+ cells and variable expression in CD8+ cells.  Ex vivo studies showed an increased responsiveness of human tumor-infiltrating lymphocytes when PBF-509 was combined with anti-PD-1 or anti-PD-L1.  CONCLUSIONS: Our studies demonstrate that inhibition of the A2aR using the novel inhibitor PBF-509 could lead to novel immunotherapeutic strategies in non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmcbcq1F7t-rVg90H21EOLACvtfcHk0lglY65jSStBYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsr0%253D&md5=71f91937d08afe3424abb5556e1993ac</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DMediavilla-Varela%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DNoyes%26aufirst%3DD.%26aulast%3DHernandez%26aufirst%3DD.%2BC.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26atitle%3DA%2520novel%2520antagonist%2520of%2520the%2520immune%2520checkpoint%2520protein%2520adenosine%2520a2a%2520receptor%2520restores%2520tumor-infiltrating%2520lymphocyte%2520activity%2520in%2520the%2520context%2520of%2520the%2520tumor%2520microenvironment%26jtitle%3DNeoplasia%26date%3D2017%26volume%3D19%26spage%3D530%26epage%3D536%26doi%3D10.1016%2Fj.neo.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bilic, S.</span>; <span class="NLM_string-name">Camacho Gomez, J. A.</span>; <span class="NLM_string-name">Cameron, J. S.</span>; <span class="NLM_string-name">Castro-Palomino Laria, J. C.</span>; <span class="NLM_string-name">Howard, D. R.</span></span> <span> </span><span class="NLM_article-title">1-(4-Amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol for Use in Treating Cancer</span>. PCT Int. Appl. <span class="NLM_patent">WO2018146612 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Bilic&author=J.+A.+Camacho+Gomez&author=J.+S.+Cameron&author=J.+C.+Castro-Palomino+Laria&author=D.+R.+Howard&title=1-%284-Amino-5-bromo-6-%281H-pyrazol-1-yl%29pyrimidin-2-yl%29-1H-pyrazol-4-ol+for+Use+in+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBilic%26aufirst%3DS.%26atitle%3D1-%25284-Amino-5-bromo-6-%25281H-pyrazol-1-yl%2529pyrimidin-2-yl%2529-1H-pyrazol-4-ol%2520for%2520Use%2520in%2520Treating%2520Cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galezowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegrzyn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commandeur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedzic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowogrodzki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeremeta-Spisak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzielak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Łozińska-Raj, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wronowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swirski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radzimierski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziembik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierzwicka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojcik-Jaszczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gocek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grycuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierzchala, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of novel dual A2A /A2B adenosine receptor antagonists for cancer immunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">3770</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-3770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2018-3770" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=3770&author=M.+Galezowskiauthor=P.+Wegrzynauthor=A.+Bobowskaauthor=C.+Commandeurauthor=K.+Dziedzicauthor=M.+Nowogrodzkiauthor=A.+Obaraauthor=J.+Szeremeta-Spisakauthor=A.+Dzielakauthor=I.+%C5%81ozi%C5%84ska-Rajauthor=M.+Dudekauthor=A.+Janigaauthor=J.+Reusauthor=M.+Wronowskiauthor=M.+Swirskiauthor=A.+Radzimierskiauthor=M.+Ziembikauthor=J.+Mierzwickaauthor=K.+Wojcik-Jaszczynskaauthor=E.+Gocekauthor=K.+Grycukauthor=A.+Golasauthor=O.+Pierzchalaauthor=J.+Zachmannauthor=M.+Nowak&title=Characterization+of+novel+dual+A2A+%2FA2B+adenosine+receptor+antagonists+for+cancer+immunotherapy&doi=10.1158%2F1538-7445.AM2018-3770"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-3770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-3770%26sid%3Dliteratum%253Aachs%26aulast%3DGalezowski%26aufirst%3DM.%26aulast%3DWegrzyn%26aufirst%3DP.%26aulast%3DBobowska%26aufirst%3DA.%26aulast%3DCommandeur%26aufirst%3DC.%26aulast%3DDziedzic%26aufirst%3DK.%26aulast%3DNowogrodzki%26aufirst%3DM.%26aulast%3DObara%26aufirst%3DA.%26aulast%3DSzeremeta-Spisak%26aufirst%3DJ.%26aulast%3DDzielak%26aufirst%3DA.%26aulast%3D%25C5%2581ozi%25C5%2584ska-Raj%26aufirst%3DI.%26aulast%3DDudek%26aufirst%3DM.%26aulast%3DJaniga%26aufirst%3DA.%26aulast%3DReus%26aufirst%3DJ.%26aulast%3DWronowski%26aufirst%3DM.%26aulast%3DSwirski%26aufirst%3DM.%26aulast%3DRadzimierski%26aufirst%3DA.%26aulast%3DZiembik%26aufirst%3DM.%26aulast%3DMierzwicka%26aufirst%3DJ.%26aulast%3DWojcik-Jaszczynska%26aufirst%3DK.%26aulast%3DGocek%26aufirst%3DE.%26aulast%3DGrycuk%26aufirst%3DK.%26aulast%3DGolas%26aufirst%3DA.%26aulast%3DPierzchala%26aufirst%3DO.%26aulast%3DZachmann%26aufirst%3DJ.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520novel%2520dual%2520A2A%2520%252FA2B%2520adenosine%2520receptor%2520antagonists%2520for%2520cancer%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D3770%26doi%3D10.1158%2F1538-7445.AM2018-3770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galezowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegrzyn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedzic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeremeta-Spisak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowogrodzki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozinska-Raj, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wronowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zastawna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkiewicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogacki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziembik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grycuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiatrowska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewandowska, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkiewicz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzozka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">Novel dual A2A A2B adenosine receptor antagonists for cancer immunotherapy: in vitro and in vivo characterization</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">4135</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-4135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31209060" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4135&author=M.+Galezowskiauthor=P.+Wegrzynauthor=A.+Bobowskaauthor=K.+Dziedzicauthor=J.+Szeremeta-Spisakauthor=M.+Nowogrodzkiauthor=G.+Satalaauthor=A.+Obaraauthor=I.+Lozinska-Rajauthor=M.+Dudekauthor=A.+Janigaauthor=J.+Reusauthor=M.+Wronowskiauthor=M.+Zastawnaauthor=G.+Statkiewiczauthor=M.+Rogackiauthor=M.+Ziembikauthor=K.+Grycukauthor=F.+Soukouauthor=K.+Michalikauthor=A.+Adamusauthor=K.+Wiatrowskaauthor=N.+Lewandowskaauthor=A.+Golasauthor=O.+Haberkiewiczauthor=R.+Porterauthor=K.+Brzozkaauthor=M.+Nowak&title=Novel+dual+A2A+A2B+adenosine+receptor+antagonists+for+cancer+immunotherapy%3A+in+vitro+and+in+vivo+characterization&doi=10.1158%2F1538-7445.AM2019-4135"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4135%26sid%3Dliteratum%253Aachs%26aulast%3DGalezowski%26aufirst%3DM.%26aulast%3DWegrzyn%26aufirst%3DP.%26aulast%3DBobowska%26aufirst%3DA.%26aulast%3DDziedzic%26aufirst%3DK.%26aulast%3DSzeremeta-Spisak%26aufirst%3DJ.%26aulast%3DNowogrodzki%26aufirst%3DM.%26aulast%3DSatala%26aufirst%3DG.%26aulast%3DObara%26aufirst%3DA.%26aulast%3DLozinska-Raj%26aufirst%3DI.%26aulast%3DDudek%26aufirst%3DM.%26aulast%3DJaniga%26aufirst%3DA.%26aulast%3DReus%26aufirst%3DJ.%26aulast%3DWronowski%26aufirst%3DM.%26aulast%3DZastawna%26aufirst%3DM.%26aulast%3DStatkiewicz%26aufirst%3DG.%26aulast%3DRogacki%26aufirst%3DM.%26aulast%3DZiembik%26aufirst%3DM.%26aulast%3DGrycuk%26aufirst%3DK.%26aulast%3DSoukou%26aufirst%3DF.%26aulast%3DMichalik%26aufirst%3DK.%26aulast%3DAdamus%26aufirst%3DA.%26aulast%3DWiatrowska%26aufirst%3DK.%26aulast%3DLewandowska%26aufirst%3DN.%26aulast%3DGolas%26aufirst%3DA.%26aulast%3DHaberkiewicz%26aufirst%3DO.%26aulast%3DPorter%26aufirst%3DR.%26aulast%3DBrzozka%26aufirst%3DK.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DNovel%2520dual%2520A2A%2520A2B%2520adenosine%2520receptor%2520antagonists%2520for%2520cancer%2520immunotherapy%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D4135%26doi%3D10.1158%2F1538-7445.AM2019-4135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bobowska, A.</span>; <span class="NLM_string-name">Galezowski, M.</span>; <span class="NLM_string-name">Nowak, M.</span>; <span class="NLM_string-name">Commandeur, C.</span>; <span class="NLM_string-name">Szeremeta-Spisak, J.</span>; <span class="NLM_string-name">Nowogrodzki, M.</span>; <span class="NLM_string-name">Obara, A.</span>; <span class="NLM_string-name">Dzielak, A.</span>; <span class="NLM_string-name">Lozinska, I.</span>; <span class="NLM_string-name">Dudek, M.</span>; <span class="NLM_string-name">Janiga, A.</span>; <span class="NLM_string-name">Reus, J.</span>; <span class="NLM_string-name">Wronowski, M.</span>; <span class="NLM_string-name">Zastawna, M.</span>; <span class="NLM_string-name">Radzimierski, A.</span>; <span class="NLM_string-name">Swirski, M.</span>; <span class="NLM_string-name">Zachmann, J.</span>; <span class="NLM_string-name">Fabritius, C.-H.</span>; <span class="NLM_string-name">Porter, R.</span>; <span class="NLM_string-name">Fogt, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazo[1,2-a]pyrazines as Adenosine A2A Receptor Modulators for the Treatment of Various Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO2019002606 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+Bobowska&author=M.+Galezowski&author=M.+Nowak&author=C.+Commandeur&author=J.+Szeremeta-Spisak&author=M.+Nowogrodzki&author=A.+Obara&author=A.+Dzielak&author=I.+Lozinska&author=M.+Dudek&author=A.+Janiga&author=J.+Reus&author=M.+Wronowski&author=M.+Zastawna&author=A.+Radzimierski&author=M.+Swirski&author=J.+Zachmann&author=C.-H.+Fabritius&author=R.+Porter&author=J.+Fogt&title=Preparation+of+Imidazo%5B1%2C2-a%5Dpyrazines+as+Adenosine+A2A+Receptor+Modulators+for+the+Treatment+of+Various+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBobowska%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Imidazo%255B1%252C2-a%255Dpyrazines%2520as%2520Adenosine%2520A2A%2520Receptor%2520Modulators%2520for%2520the%2520Treatment%2520of%2520Various%2520Diseases%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhukov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span> <span> </span><span class="NLM_article-title">Identification of novel adenosine A2A receptor antagonists by virtual screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1904</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1021/jm201455y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201455y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1904-1909&author=C.+J.+Langmeadauthor=S.+P.+Andrewsauthor=M.+Congreveauthor=J.+C.+Erreyauthor=E.+Hurrellauthor=F.+H.+Marshallauthor=J.+S.+Masonauthor=C.+M.+Richardsonauthor=N.+Robertsonauthor=A.+Zhukovauthor=M.+Weir&title=Identification+of+novel+adenosine+A2A+receptor+antagonists+by+virtual+screening&doi=10.1021%2Fjm201455y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screening</span></div><div class="casAuthors">Langmead, Christopher J.; Andrews, Stephen P.; Congreve, Miles; Errey, James C.; Hurrell, Edward; Marshall, Fiona H.; Mason, Jonathan S.; Richardson, Christine M.; Robertson, Nathan; Zhukov, Andrei; Weir, Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1904-1909</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Virtual screening was performed against exptl. enabled homol. models of the adenosine A2A receptor, identifying a diverse range of ligand efficient antagonists (hit rate 9%).  By use of ligand docking and Biophys. Mapping (BPM), hits 1 and 5 were optimized to potent and selective lead mols. (11-13 from 5, pKI = 7.5-8.5, 13- to >100-fold selective vs. adenosine A1; 14-16 from 1, pKI = 7.9-9.0, 19- to 59-fold selective).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroN2ZrmhhzurVg90H21EOLACvtfcHk0liTp8SJzaPynA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOqug%253D%253D&md5=89f18c8a19339aeb6d082bbb8bb0c830</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm201455y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201455y%26sid%3Dliteratum%253Aachs%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DHurrell%26aufirst%3DE.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DC.%2BM.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DZhukov%26aufirst%3DA.%26aulast%3DWeir%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520novel%2520adenosine%2520A2A%2520receptor%2520antagonists%2520by%2520virtual%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1904%26epage%3D1909%26doi%3D10.1021%2Fjm201455y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M. S.</span>; <span class="NLM_string-name">Andrews, S. P.</span>; <span class="NLM_string-name">Mason, J. S.</span>; <span class="NLM_string-name">Richardson, C. M.</span>; <span class="NLM_string-name">Brown, G. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1,2,4-Triazin-3-amine Derivatives as A1 and A2a Receptor Inhibitors Useful in the Treatment of Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO2011095625 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+S.+Congreve&author=S.+P.+Andrews&author=J.+S.+Mason&author=C.+M.+Richardson&author=G.+A.+Brown&title=Preparation+of+1%2C2%2C4-Triazin-3-amine+Derivatives+as+A1+and+A2a+Receptor+Inhibitors+Useful+in+the+Treatment+of+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%2BS.%26atitle%3DPreparation%2520of%25201%252C2%252C4-Triazin-3-amine%2520Derivatives%2520as%2520A1%2520and%2520A2a%2520Receptor%2520Inhibitors%2520Useful%2520in%2520the%2520Treatment%2520of%2520Diseases%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span>Protein
Data Bank home page. <a href="http://www.rcsb.org/structure/6GT3" class="extLink">http://www.rcsb.org/structure/6GT3</a> (accessed Jun 17, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Protein%0AData+Bank+home+page.+http%3A%2F%2Fwww.rcsb.org%2Fstructure%2F6GT3+%28accessed+Jun+17%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, D. A.</span></span> <span> </span><span class="NLM_article-title">The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">Lb</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-LB-192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-LB-192" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=Lb-192&author=C.+Barbonauthor=A.+Borodovskyauthor=Y.+Wangauthor=L.+Prickettauthor=K.+Sachsenmeierauthor=A.+Schullerauthor=W.+Shaoauthor=C.+Barrettauthor=S.+Fawellauthor=D.+A.+Mele&title=The+A2AR+antagonist+AZD4635+prevents+adenosine-mediated+immunosuppression+of+CD103%2B+dendritic+cells&doi=10.1158%2F1538-7445.AM2019-LB-192"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-LB-192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-LB-192%26sid%3Dliteratum%253Aachs%26aulast%3DBarbon%26aufirst%3DC.%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPrickett%26aufirst%3DL.%26aulast%3DSachsenmeier%26aufirst%3DK.%26aulast%3DSchuller%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DBarrett%26aufirst%3DC.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DMele%26aufirst%3DD.%2BA.%26atitle%3DThe%2520A2AR%2520antagonist%2520AZD4635%2520prevents%2520adenosine-mediated%2520immunosuppression%2520of%2520CD103%252B%2520dendritic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DLb%26epage%3D192%26doi%3D10.1158%2F1538-7445.AM2019-LB-192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DelSignore, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strittmatter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sah, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5580</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-5580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2017-5580" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=5580&author=A.+Borodovskyauthor=Y.+Wangauthor=M.+Yeauthor=J.+C.+Shawauthor=K.+F.+Sachsenmeierauthor=N.+Dengauthor=K.+J.+DelSignoreauthor=A.+J.+Fretlandauthor=J.+D.+Clarkeauthor=R.+J.+Goodwinauthor=N.+Strittmatterauthor=C.+Hayauthor=V.+R.+Sahauthor=D.+Lawsonauthor=C.+Reimerauthor=M.+Congreveauthor=J.+S.+Masonauthor=F.+H.+Marshallauthor=P.+Lyneauthor=R.+Woessner&title=Preclinical+pharmacodynamics+and+antitumor+activity+of+AZD4635%2C+a+novel+adenosine+2A+receptor+inhibitor+that+reverses+adenosine+mediated+T+cell+suppression&doi=10.1158%2F1538-7445.AM2017-5580"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-5580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-5580%26sid%3Dliteratum%253Aachs%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DShaw%26aufirst%3DJ.%2BC.%26aulast%3DSachsenmeier%26aufirst%3DK.%2BF.%26aulast%3DDeng%26aufirst%3DN.%26aulast%3DDelSignore%26aufirst%3DK.%2BJ.%26aulast%3DFretland%26aufirst%3DA.%2BJ.%26aulast%3DClarke%26aufirst%3DJ.%2BD.%26aulast%3DGoodwin%26aufirst%3DR.%2BJ.%26aulast%3DStrittmatter%26aufirst%3DN.%26aulast%3DHay%26aufirst%3DC.%26aulast%3DSah%26aufirst%3DV.%2BR.%26aulast%3DLawson%26aufirst%3DD.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DPreclinical%2520pharmacodynamics%2520and%2520antitumor%2520activity%2520of%2520AZD4635%252C%2520a%2520novel%2520adenosine%25202A%2520receptor%2520inhibitor%2520that%2520reverses%2520adenosine%2520mediated%2520T%2520cell%2520suppression%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D5580%26doi%3D10.1158%2F1538-7445.AM2017-5580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlix, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugundu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linghu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrop, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M. S.</span></span> <span> </span><span class="NLM_article-title">Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">Ct026</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-CT026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-CT026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=Ct026&author=J.+Bendellauthor=T.+Bauerauthor=M.+Patelauthor=G.+Falchookauthor=J.+L.+Karlixauthor=E.+Limauthor=G.+Mugunduauthor=P.+D.+Mitchellauthor=G.+P.+Pouliotauthor=G.+Moorthyauthor=B.+Linghuauthor=L.+McGrathauthor=B.+Harropauthor=W.+Shaoauthor=C.+G.+Drakeauthor=K.+Sachsenmeierauthor=M.+S.+Merchant&title=Evidence+of+immune+activation+in+the+first-in-human+Phase+Ia+dose+escalation+study+of+the+adenosine+2a+receptor+antagonist%2C+AZD4635%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1538-7445.AM2019-CT026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-CT026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-CT026%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DKarlix%26aufirst%3DJ.%2BL.%26aulast%3DLim%26aufirst%3DE.%26aulast%3DMugundu%26aufirst%3DG.%26aulast%3DMitchell%26aufirst%3DP.%2BD.%26aulast%3DPouliot%26aufirst%3DG.%2BP.%26aulast%3DMoorthy%26aufirst%3DG.%26aulast%3DLinghu%26aufirst%3DB.%26aulast%3DMcGrath%26aufirst%3DL.%26aulast%3DHarrop%26aufirst%3DB.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DSachsenmeier%26aufirst%3DK.%26aulast%3DMerchant%26aufirst%3DM.%2BS.%26atitle%3DEvidence%2520of%2520immune%2520activation%2520in%2520the%2520first-in-human%2520Phase%2520Ia%2520dose%2520escalation%2520study%2520of%2520the%2520adenosine%25202a%2520receptor%2520antagonist%252C%2520AZD4635%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DCt026%26doi%3D10.1158%2F1538-7445.AM2019-CT026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span>Sosei
Heptares home page. <a href="https://www.soseiheptares.com/uploads/publications/BioCentury%20March%20%2026%202018%20-%20Optimism%20for%20A2A.pdf" class="extLink">https://www.soseiheptares.com/uploads/publications/BioCentury%20March%20%2026%202018%20-%20Optimism%20for%20A2A.pdf</a> (accessed Jun 17, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sosei%0AHeptares+home+page.+https%3A%2F%2Fwww.soseiheptares.com%2Fuploads%2Fpublications%2FBioCentury%2520March%2520%252026%25202018%2520-%2520Optimism%2520for%2520A2A.pdf+%28accessed+Jun+17%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuya Kate  Huang</span>, <span class="hlFld-ContribAuthor ">Aditya  Pandey</span>, <span class="hlFld-ContribAuthor ">Duy Phuoc  Tran</span>, <span class="hlFld-ContribAuthor ">Nicolas L.  Villanueva</span>, <span class="hlFld-ContribAuthor ">Akio  Kitao</span>, <span class="hlFld-ContribAuthor ">Roger K.  Sunahara</span>, <span class="hlFld-ContribAuthor ">Adnan  Sljoka</span>, <span class="hlFld-ContribAuthor ">R. Scott  Prosser</span>. </span><span class="cited-content_cbyCitation_article-title">Delineating the conformational landscape of the adenosine A2A receptor during G protein coupling. </span><span class="cited-content_cbyCitation_journal-name">Cell</span><span> <strong>2021,</strong> <em>184 </em>
                                    (7)
                                     , 1884-1894.e14. <a href="https://doi.org/10.1016/j.cell.2021.02.041" title="DOI URL">https://doi.org/10.1016/j.cell.2021.02.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cell.2021.02.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cell.2021.02.041%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%26atitle%3DDelineating%252Bthe%252Bconformational%252Blandscape%252Bof%252Bthe%252Badenosine%252BA2A%252Breceptor%252Bduring%252BG%252Bprotein%252Bcoupling%26aulast%3DHuang%26aufirst%3DShuya%2BKate%26date%3D2021%26volume%3D184%26issue%3D7%26spage%3D1884%26epage%3D1894.e14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dana R.  Renk</span>, <span class="hlFld-ContribAuthor ">Marcel  Skraban</span>, <span class="hlFld-ContribAuthor ">Dirk  Bier</span>, <span class="hlFld-ContribAuthor ">Annette  Schulze</span>, <span class="hlFld-ContribAuthor ">Erika  Wabbals</span>, <span class="hlFld-ContribAuthor ">Franziska  Wedekind</span>, <span class="hlFld-ContribAuthor ">Felix  Neumaier</span>, <span class="hlFld-ContribAuthor ">Bernd  Neumaier</span>, <span class="hlFld-ContribAuthor ">Marcus  Holschbach</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113214. <a href="https://doi.org/10.1016/j.ejmech.2021.113214" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113214%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BTozadenant%252Banalogues%252Bas%252Badenosine%252BA2A%252Breceptor%252Bligands%26aulast%3DRenk%26aufirst%3DDana%2BR.%26date%3D2021%26volume%3D214%26spage%3D113214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Volker  Schirrmacher</span>. </span><span class="cited-content_cbyCitation_article-title">Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2020,</strong> <em>8 </em>
                                    (11)
                                     , 526. <a href="https://doi.org/10.3390/biomedicines8110526" title="DOI URL">https://doi.org/10.3390/biomedicines8110526</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines8110526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines8110526%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DMitochondria%252Bat%252BWork%25253A%252BNew%252BInsights%252Binto%252BRegulation%252Band%252BDysregulation%252Bof%252BCellular%252BEnergy%252BSupply%252Band%252BMetabolism%26aulast%3DSchirrmacher%26aufirst%3DVolker%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D11%26spage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Immune checkpoint signaling pathways in the TME and relevant intervention strategies for cancer immunotherapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Previously reported A<sub>2A</sub>R antagonists that were subsequently analyzed in antitumor immunological models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structures of ZM241385, caffeine, and tozadenant. The receptor is colored gray. Residues and side chains that interact with the ligand are shown as sticks and colored by element (carbon, gray; nitrogen, blue; oxygen, red; sulfur, yellow). Polar contacts are presented as dashed lines, and water molecules are shown as red spheres. The ligands are shown as sticks, and PDB codes are shown in the figure: (A) ZM241385, the salt bridge is intact; (B) ZM241385, the salt bridge is broken; (C) caffeine, the two distinct binding orientations in the structure are overlaid; (D) tozadenant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Selected A<sub>2A</sub>R antagonists from AdoRx Therapeutics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Selected A<sub>2A</sub>R antagonists from Arcus Biosciences.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A, C) Selected A<sub>2A</sub>R antagonists from Vernalis, Evotec/Exscientia, and Hanmi. (B) Cocrystal structure of vipadenant bound to A<sub>2A</sub>R. The ligand is shown as sticks, and the PDB code is shown in the figure. The receptor is shown as a cartoon and colored gray, whereas residues and side chains that interact with the ligand are shown as sticks and colored by element. Polar contacts are presented as dashed lines and water molecules are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Selected A<sub>2A</sub>R antagonists from iTeos Therapeutics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Selected A<sub>2A</sub>R antagonists from Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Selected A<sub>2A</sub>R antagonists from Novartis/Palobiofarma.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/medium/jm0c00237_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A, B) Selected A<sub>2A</sub>R antagonists from Selvita and Sosei Heptares/AstraZeneca. (C) The clinical candidate AZD4635 was discovered using SBDD. The ligands are shown as sticks, and PDB codes are shown in the figure: 3UZA-<b>47</b> and 6GT3-<b>48</b>. The receptor is shown as a cartoon and colored gray, whereas residues and side chains that interact with the ligand are shown as sticks and colored by element. Polar contacts are presented as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00237/20201105/images/large/jm0c00237_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00237&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 146 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarhini, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panelli, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarour, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H. J.</span></span> <span> </span><span class="NLM_article-title">Next generation of immunotherapy for melanoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3445</span>– <span class="NLM_lpage">3455</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.14.6423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1200%2FJCO.2007.14.6423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=18612161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvVWitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3445-3455&author=J.+M.+Kirkwoodauthor=A.+A.+Tarhiniauthor=M.+C.+Panelliauthor=S.+J.+Moschosauthor=H.+M.+Zarourauthor=L.+H.+Butterfieldauthor=H.+J.+Gogas&title=Next+generation+of+immunotherapy+for+melanoma&doi=10.1200%2FJCO.2007.14.6423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Next generation of immunotherapy for melanoma</span></div><div class="casAuthors">Kirkwood, John M.; Tarhini, Ahmad A.; Panelli, Monica C.; Moschos, Stergios J.; Zarour, Hassane M.; Butterfield, Lisa H.; Gogas, Helen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3445-3455</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose Immunotherapy has a long history with striking but limited success in patients with melanoma.  To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States.  Design Tumor evasion of host immune responses, and strategies for overcoming tumor-induced immunosuppression are reviewed.  Several novel immunotherapies currently in worldwide phase III clin. testing for melanoma are discussed.  Results The limitations of immunotherapy for melanoma stem from tumor-induced mechanisms of immune evasion that render the host tolerant of tumor antigens.  For example, melanoma inhibits the maturation of antigen-presenting cells, preventing full T-cell activation and downregulating the effector antitumor immune response.  New immunotherapies targeting crit. regulatory elements of the immune system may overcome tolerance and promote a more effective antitumor immune response.  These include monoclonal antibodies that block the cytotoxic T lymphocyte-assocd. antigen 4 (CTLA4) and toll-like receptor 9 (TLR9) agonists.  Blockade of CTLA4 prevents inhibitory signals that downregulate T-cell activation.  TLR9 agonists stimulate dendritic cell maturation and ultimately induce a more effective immune response.  These approaches have been shown to stimulate acute immune activation with concomitant appearance of transient adverse events mediated by the immune system.  The pattern and duration of immune responses assocd. with these new modalities differ from those assocd. with cytokines and cytotoxic agents.  In addn., vaccines are being developed that may ultimately target melanoma either alone or in combination with these immunomodulatory therapies.  Conclusion The successes of cytokine and interferon therapy of melanoma, coupled with an array of new approaches, are generating new enthusiasm for the immunotherapy of melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyeng-cXpDZLVg90H21EOLACvtfcHk0ljtV6AcyaLMPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvVWitrY%253D&md5=bc7e4b7b8d72758e8ca3762b3079880c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.6423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.6423%26sid%3Dliteratum%253Aachs%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DTarhini%26aufirst%3DA.%2BA.%26aulast%3DPanelli%26aufirst%3DM.%2BC.%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DZarour%26aufirst%3DH.%2BM.%26aulast%3DButterfield%26aufirst%3DL.%2BH.%26aulast%3DGogas%26aufirst%3DH.%2BJ.%26atitle%3DNext%2520generation%2520of%2520immunotherapy%2520for%2520melanoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3445%26epage%3D3455%26doi%3D10.1200%2FJCO.2007.14.6423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalabi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard-Lucey, V. M.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of the clinical immuno-oncology landscape</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1093%2Fannonc%2Fmdx755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29228097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzgt1ejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=84-91&author=J.+Tangauthor=A.+Shalabiauthor=V.+M.+Hubbard-Lucey&title=Comprehensive+analysis+of+the+clinical+immuno-oncology+landscape&doi=10.1093%2Fannonc%2Fmdx755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of the clinical immuno-oncology landscape</span></div><div class="casAuthors">Tang J; Shalabi A; Hubbard-Lucey V M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Advances from immuno-oncology (IO) are changing the standard of care of many types of cancer, and the paradigm of cancer treatments and drug development is being rewritten on a regular basis.  Moreover, an unprecedented number of new investigational agents and companies are entering the field of IO.  As such, it has become challenging for oncology physicians conducting clinical trials, industry veterans developing IO drugs, and even regulators reviewing novel IO agents to keep track of the rapidly evolving landscape.  To help the key stake holders in the field understand the latest IO landscape, we sought to present an unbiased, neutral, scientifically curated, and timely updated analysis of all the current IO agents in clinical development and the clinical trials testing these agents.  We based our analyses on information collected from numerous trusted and publicly available sources.  We have developed two databases.  One database tracks 2004 IO agents (940 in clinical stage and 1064 in preclinical stage) against 303 targets, from 864 companies; the other tracks 3042 active clinical trials of these agents with a target enrollment of 577 076 patients.  This report provides key analyses of these data.  Furthermore, we will discuss a number of important and actionable trends in the current IO landscape: a large number of companies developing agents against the same IO targets; a rapid increase in the number of anti-PD-1/L1 combination studies, many of which are testing the same combinations and following inefficient patterns; and a significant increase in the number of small, investigator-initiated studies.  For each of the findings, we speculate the causes and discuss a few initiatives that aim to address some of these challenges.  Finally, by making these landscape analyses available, we aspire to inform the cancer community as they seek to strive for efficiencies and innovation while avoiding duplication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDxZXleW3oBeQ4Pl9hzjQhfW6udTcc2eZUauIzuNHOP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzgt1ejug%253D%253D&md5=b8f7bb2b63892317cfdb0fe26f2860c9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx755%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DShalabi%26aufirst%3DA.%26aulast%3DHubbard-Lucey%26aufirst%3DV.%2BM.%26atitle%3DComprehensive%2520analysis%2520of%2520the%2520clinical%2520immuno-oncology%2520landscape%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3D84%26epage%3D91%26doi%3D10.1093%2Fannonc%2Fmdx755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marin-Acevedo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dholaria, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soyano, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chumsri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span> <span> </span><span class="NLM_article-title">Next generation of immune checkpoint therapy in cancer: new developments and challenges</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">39</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0582-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1186%2Fs13045-018-0582-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29544515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=39&author=J.+A.+Marin-Acevedoauthor=B.+Dholariaauthor=A.+E.+Soyanoauthor=K.+L.+Knutsonauthor=S.+Chumsriauthor=Y.+Lou&title=Next+generation+of+immune+checkpoint+therapy+in+cancer%3A+new+developments+and+challenges&doi=10.1186%2Fs13045-018-0582-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Next generation of immune checkpoint therapy in cancer: new developments and challenges</span></div><div class="casAuthors">Marin-Acevedo, Julian A.; Dholaria, Bhagirathbhai; Soyano, Aixa E.; Knutson, Keith L.; Chumsri, Saranya; Lou, Yanyan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39/1-39/20</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response.  In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response.  Immune checkpoint therapies act by blocking or stimulating these pathways and enhance the body's immunol. activity against tumors.  Cytotoxic T lymphocyte-assocd. mol.-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death ligand-1(PD-L1) are the most widely studied and recognized inhibitory checkpoint pathways.  Drugs blocking these pathways are currently utilized for a wide variety of malignancies and have demonstrated durable clin. activities in a subset of cancer patients.  This approach is rapidly extending beyond CTLA-4 and PD-1/PD-L1.  New inhibitory pathways are under investigation, and drugs blocking LAG-3, TIM-3, TIGIT, VISTA, or B7/H3 are being investigated.  Furthermore, agonists of stimulatory checkpoint pathways such as OX40, ICOS, GITR, 4-1BB, CD40, or mols. targeting tumor microenvironment components like IDO or TLR are under investigation.  In this article, we have provided a comprehensive review of immune checkpoint pathways involved in cancer immunotherapy, and discuss their mechanisms and the therapeutic interventions currently under investigation in phase I/II clin. trials.  We also reviewed the limitations, toxicities, and challenges and outline the possible future research directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXlwLaO-CI8bVg90H21EOLACvtfcHk0lidB2PrHFvVsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqur0%253D&md5=129ab4c9c697f1205e079af49a154ea0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0582-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0582-8%26sid%3Dliteratum%253Aachs%26aulast%3DMarin-Acevedo%26aufirst%3DJ.%2BA.%26aulast%3DDholaria%26aufirst%3DB.%26aulast%3DSoyano%26aufirst%3DA.%2BE.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DChumsri%26aufirst%3DS.%26aulast%3DLou%26aufirst%3DY.%26atitle%3DNext%2520generation%2520of%2520immune%2520checkpoint%2520therapy%2520in%2520cancer%253A%2520new%2520developments%2520and%2520challenges%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D39%26doi%3D10.1186%2Fs13045-018-0582-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targets in immuno-oncology</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.chembiol.2017.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28938090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1148-1160&author=D.+Dhanakauthor=J.+P.+Edwardsauthor=A.+Nguyenauthor=P.+J.+Tummino&title=Small-molecule+targets+in+immuno-oncology&doi=10.1016%2Fj.chembiol.2017.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Targets in Immuno-Oncology</span></div><div class="casAuthors">Dhanak, Dashyant; Edwards, James P.; Nguyen, Ancho; Tummino, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1148-1160</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in understanding the role and mol. mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clin. practice in the treatment of cancer.  Presently, multiple biol. drugs targeting the immune checkpoint proteins PD(L)1 or CTLA4 have been approved and/or are in advanced stages of clin. development for many cancers.  In addn., combination therapy with these agents and other immunomodulators is being intensively explored with the aim of improving primary response rates or prolonging overall survival.  The effectiveness of cancer immunotherapy with biologics is spurring research in alternate approaches including small-mol.-mediated targeting of intracellular pathways modulating the innate and adaptive immune response.  This focus of this review is on some of the key intracellular pathways where the development of a small-mol. therapeutic is attractive, tractable, and potentially synergistic with extracellular biol.-mediated immune checkpoint blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSIXjWBbl9wbVg90H21EOLACvtfcHk0lidB2PrHFvVsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurnL&md5=7f0f2368bec10000a87a3234bb82c035</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26atitle%3DSmall-molecule%2520targets%2520in%2520immuno-oncology%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D1148%26epage%3D1160%26doi%3D10.1016%2Fj.chembiol.2017.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule immuno-oncology therapy: advances, challenges and new directions</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190308131805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.2174%2F1568026619666190308131805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30854972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGhtL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=180-185&author=S.+Chenauthor=Z.+Songauthor=A.+Zhang&title=Small-molecule+immuno-oncology+therapy%3A+advances%2C+challenges+and+new+directions&doi=10.2174%2F1568026619666190308131805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions</span></div><div class="casAuthors">Chen, Shulun; Song, Zilan; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">180-185</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Oncol. immunotherapy has gained significant advances in recent years and benefits cancer patients with superior efficacy and superior clin. responses.  Currently over ten immune checkpoint antibodies targeting CTLA-4 and PD-1/PD-L1 have received regulatory approval worldwide and over thousands are under active clin. trials.  However, compared to the rapid advance of Monoclonal Antibody (mAb), studies on immunotherapeutic small mols. have far lagged behind.  Small mol. immunotherapy not only can target immunosuppressive mechanisms similar to mAbs, but also can stimulate intracellular pathways downstream of checkpoint proteins in innate or adaptive immune cells that mAbs are unable to access.  Therefore, small mol. immunotherapy can provide an alternative treatment modality either alone or complementary to or synergistic with extracellular checkpoint mAbs to address low clin. response and drug resistance.  Fortunately, remarkable progress has achieved recently in the pursuit of small mol. immunotherapy.  This review intends to provide a timely highlight on those clin. investigated small mols. targeting PD-1/PD-L1, IDO1, and STING.  The most advanced IDO1 inhibitor epacadostat have been aggressively progressed into multiple clin. testings.  Small mol. PD-1/PD-L1 inhibitors and STING activators are still in a premature state and their decisive application needs to wait for the ongoing clin. outcomes.  Since no small mol. immunotherapy has been approved yet, the future research should continue to focus on discovery of novel small mols. with distinct chemo-types and higher potency, identification of biomarkers to precisely stratify patients, as well as validation of many other immune-therapeutic targets, such as LAG3, KIRs, TIM-3, VISTA, B7-H3, and TIGIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIg_rDysKA6LVg90H21EOLACvtfcHk0lizmXd_3AaDzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGhtL7E&md5=944b0fc0de82574b1a24f3e910eaccf4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190308131805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190308131805%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSmall-molecule%2520immuno-oncology%2520therapy%253A%2520advances%252C%2520challenges%2520and%2520new%2520directions%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D180%26epage%3D185%26doi%3D10.2174%2F1568026619666190308131805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinska-Szostak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlicki, Ł.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarganes-Tzitzikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Bioactive macrocyclic inhibitors of the Pd-1/Pd-L1 immune checkpoint</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">13732</span>– <span class="NLM_lpage">13735</span>, <span class="refDoi"> DOI: 10.1002/anie.201707707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1002%2Fanie.201707707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOit7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=13732-13735&author=K.+Magiera-Mularzauthor=L.+Skalniakauthor=K.+M.+Zakauthor=B.+Musielakauthor=E.+Rudzinska-Szostakauthor=%C5%81.+Berlickiauthor=J.+Kocikauthor=P.+Grudnikauthor=D.+Salaauthor=T.+Zarganes-Tzitzikasauthor=S.+Shaabaniauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Bioactive+macrocyclic+inhibitors+of+the+Pd-1%2FPd-L1+immune+checkpoint&doi=10.1002%2Fanie.201707707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint</span></div><div class="casAuthors">Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Zak, Krzysztof M.; Musielak, Bogdan; Rudzinska-Szostak, Ewa; Berlicki, Lukasz; Kocik, Justyna; Grudnik, Przemyslaw; Sala, Dominik; Zarganes-Tzitzikas, Tryfon; Shaabani, Shabnam; Doemling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">13732-13735</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Blockade of the immunoinhibitory PD-1/PD-L1 pathway using monoclonal antibodies has shown impressive results with durable clin. antitumor responses.  Anti-PD-1 and anti-PD-L1 antibodies have now been approved for the treatment of a no. of tumor types, whereas the development of small mols. targeting immune checkpoints lags far behind.  We characterized two classes of macrocyclic-peptide inhibitors directed at the PD-1/PD-L1 pathway.  We show that these macrocyclic compds. act by directly binding to PD-L1 and that they are capable of antagonizing PD-L1 signaling and, similarly to antibodies, can restore the function of T-cells.  We also provide the crystal structures of two of these small-mol. inhibitors bound to PD-L1.  The structures provide a rationale for the checkpoint inhibition by these small mols., and a description of their small mol./PD-L1 interfaces provides a blueprint for the design of small-mol. inhibitors of the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxuarSIlQEobVg90H21EOLACvtfcHk0lizmXd_3AaDzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOit7%252FO&md5=b1634408007340ca0990d2607c96c1a9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fanie.201707707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201707707%26sid%3Dliteratum%253Aachs%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DRudzinska-Szostak%26aufirst%3DE.%26aulast%3DBerlicki%26aufirst%3D%25C5%2581.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DZarganes-Tzitzikas%26aufirst%3DT.%26aulast%3DShaabani%26aufirst%3DS.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DBioactive%2520macrocyclic%2520inhibitors%2520of%2520the%2520Pd-1%252FPd-L1%2520immune%2520checkpoint%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D13732%26epage%3D13735%26doi%3D10.1002%2Fanie.201707707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huck, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kötzner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbahns, K.</span></span> <span> </span><span class="NLM_article-title">Small molecules drive big improvements in immuno-oncology therapies</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4412</span>– <span class="NLM_lpage">4428</span>, <span class="refDoi"> DOI: 10.1002/anie.201707816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1002%2Fanie.201707816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlWqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=4412-4428&author=B.+R.+Huckauthor=L.+K%C3%B6tznerauthor=K.+Urbahns&title=Small+molecules+drive+big+improvements+in+immuno-oncology+therapies&doi=10.1002%2Fanie.201707816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Drive Big Improvements in Immuno-Oncology Therapies</span></div><div class="casAuthors">Huck, Bayard R.; Koetzner, Lisa; Urbahns, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4412-4428</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Immunooncol. therapies have the potential to revolutionize the armamentarium of available cancer treatments.  To further improve clin. response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment.  This Review highlights the significance of small mols. in this approach, which holds promise to provide increased benefit to cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobJKXxvd05sLVg90H21EOLACvtfcHk0lh22kBMGiwr_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlWqsbo%253D&md5=bef3a381977686b5bdb432a76364b066</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fanie.201707816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201707816%26sid%3Dliteratum%253Aachs%26aulast%3DHuck%26aufirst%3DB.%2BR.%26aulast%3DK%25C3%25B6tzner%26aufirst%3DL.%26aulast%3DUrbahns%26aufirst%3DK.%26atitle%3DSmall%2520molecules%2520drive%2520big%2520improvements%2520in%2520immuno-oncology%2520therapies%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D4412%26epage%3D4428%26doi%3D10.1002%2Fanie.201707816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huizinga, H. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span> <span> </span><span class="NLM_article-title">A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015–2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1512706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1080%2F13543776.2018.1512706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30107136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OltrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=665-678&author=S.+Shaabaniauthor=H.+P.+S.+Huizingaauthor=R.+Buteraauthor=A.+Kouchiauthor=K.+Guzikauthor=K.+Magiera-Mularzauthor=T.+A.+Holakauthor=A.+D%C3%B6mling&title=A+patent+review+on+PD-1%2FPD-L1+antagonists%3A+small+molecules%2C+peptides%2C+and+macrocycles+%282015%E2%80%932018%29&doi=10.1080%2F13543776.2018.1512706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)</span></div><div class="casAuthors">Shaabani, Shabnam; Huizinga, Harmen P. S.; Butera, Roberto; Kouchi, Ariana; Guzik, Katarzyna; Magiera-Mularz, Katarzyna; Holak, Tad A.; Doemling, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">665-678</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The protein-protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clin. practice.  However, only a small percentage of cancer patients benefit from PD1/PD-L1 directed mAbs.  Moreover, some patients experience immune related side effects upon treatment with these mAbs.  Recently, several at.-resoln. structures of human PD1/PD-L1, and small mols., peptides and mAbs with PD-L1 and PD1 open the field for structure based drug design.  Small mols. and peptides targeting PD1/PD-L1 promise to enhance tumor activity while showing less immune related side effects.  We reviewed the small mols. classes and peptides targeting PD1/PD-L1.  Currently approved PD1/PD-L1 directed therapeutics show room for improvement.  Three classes of non mAb small mol. classes have been discovered so far: (cyclic) peptides as direct competitive PD1/PD-L1 antagonists; small mols. disrupting PD1/PD-L1 and inducing a PD-L1 dimerization; and a small mol. class of unknown mode-of-action.  An example of the later group CA-170 is currently investigated in a Phase 1 trial in patients with advanced solid tumors and lymphomas.  Potential advantages of small mols. over mAbs include high distribution and better tumor penetration, improved PK/PD, less side effects and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ3xRey_KylLVg90H21EOLACvtfcHk0lh22kBMGiwr_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OltrbF&md5=a07b11ef81736c8f2c3258229ae3177d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1512706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1512706%26sid%3Dliteratum%253Aachs%26aulast%3DShaabani%26aufirst%3DS.%26aulast%3DHuizinga%26aufirst%3DH.%2BP.%2BS.%26aulast%3DButera%26aufirst%3DR.%26aulast%3DKouchi%26aufirst%3DA.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26atitle%3DA%2520patent%2520review%2520on%2520PD-1%252FPD-L1%2520antagonists%253A%2520small%2520molecules%252C%2520peptides%252C%2520and%2520macrocycles%2520%25282015%25E2%2580%25932018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D665%26epage%3D678%26doi%3D10.1080%2F13543776.2018.1512706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span>ClinicalTrials.gov
home page. <a href="https://clinicaltrials.gov/ct2/show/NCT02812875?term=NCT02812875&amp;draw=2&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02812875?term=NCT02812875&draw=2&rank=1</a> (accessed Jun 17, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov%0Ahome+page.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02812875%3Fterm%3DNCT02812875%26draw%3D2%26rank%3D1+%28accessed+Jun+17%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00990</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1715-1730&author=T.+Wangauthor=X.+Wuauthor=C.+Guoauthor=K.+Zhangauthor=J.+Xuauthor=Z.+Liauthor=S.+Jiang&title=Development+of+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+signaling+pathway&doi=10.1021%2Facs.jmedchem.8b00990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway</span></div><div class="casAuthors">Wang, Tianyu; Wu, Xiaoxing; Guo, Changying; Zhang, Kuojun; Xu, Jinyi; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1715-1730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The clin. success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy.  Currently, most drugs targeting this pathway are monoclonal antibodies.  Small-mol. inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include prodn. difficulties and their long half-life.  Recently, progress has been reported on anti-PD-1/PD-L1 small-mol. inhibitors.  In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-mol. inhibitors.  The structures and the preclin. and clin. studies of several peptide-based small-mol. candidate compds. in clin. trials are discussed.  We also illustrate the design strategies underlying reported nonpeptidic small-mol. inhibitors and provide insight into possible future exploration.  Development of small-mol. drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonItidshja8LVg90H21EOLACvtfcHk0lhVaASWSsGEsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL&md5=2fc7ee8e9bb8d37c7569913a4529d753</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00990%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520signaling%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1715%26epage%3D1730%26doi%3D10.1021%2Facs.jmedchem.8b00990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakharia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1007/s00281-018-0702-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs00281-018-0702-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30203227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=41-48&author=A.+J.+Mullerauthor=M.+G.+Manfrediauthor=Y.+Zakhariaauthor=G.+C.+Prendergast&title=Inhibiting+IDO+pathways+to+treat+cancer%3A+lessons+from+the+ECHO-301+trial+and+beyond&doi=10.1007%2Fs00281-018-0702-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond</span></div><div class="casAuthors">Muller, Alexander J.; Manfredi, Mark G.; Zakharia, Yousef; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  With immunotherapy enjoying a rapid resurgence based on the achievement of durable remissions in some patients with agents that derepress immune function, commonly referred to as "checkpoint inhibitors," enormous attention developed around the IDO1 enzyme as a metabolic mediator of immune escape in cancer.  In particular, outcomes of multiple phase 1/2 trials encouraged the idea that small mol. inhibitors of IDO1 may improve patient responses to anti-PD1 immune checkpoint therapy.  However, recent results from ECHO-301, the first large phase 3 trial to evaluate an IDO1-selective enzyme inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in advanced melanoma, showed no indication that epacadostat provided an increased benefit.  Here it discuss several caveats assocd. with this failed trial.  First is the uncertainty as to whether the target was adequately inhibited.  In particular, there remains a lack of direct evidence regarding the degree of IDO1 inhibition within the tumor, and previous trial data suggest that sufficient drug exposure may not have been achieved at the dose tested in ECHO-301.  Second, while there is a mechanistic rationale for the combination tested, the preclin. data were not particularly compelling.  More efficacious combinations have been demonstrated with DNA damaging modalities which may therefore be a more attractive alternative.  Third, as a highly selective IDO1 inhibitor, epacadostat was advanced aggressively despite preclin. genetic evidence of tumors bypassing IDO1 blockade.  Indeed, a well-grounded literature starting in 2011 points to targeting strategies that account for both IDO and tryptophan 2,3-dioxygenase as more appealing directions to pursue, including dual inhibitors and inhibitors of nodal downstream effector pathways such as aryl hydrocarbon receptor blockade.  Overall, the clin. readout from a single trial with significant limitations is by no means a definitive test for the field.  While biomarker information yet to be gleaned from ECHO-301 may yet reveal useful information regarding IDO1 pathway drugs, better rationalized compds. and better rationalized trial designs will be important in the future to accurately gage medical impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-55ynvYhvLVg90H21EOLACvtfcHk0lhVaASWSsGEsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI&md5=b672f039dcfd843d6c849167846e13a5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00281-018-0702-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-018-0702-0%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DManfredi%26aufirst%3DM.%2BG.%26aulast%3DZakharia%26aufirst%3DY.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibiting%2520IDO%2520pathways%2520to%2520treat%2520cancer%253A%2520lessons%2520from%2520the%2520ECHO-301%2520trial%2520and%2520beyond%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2019%26volume%3D41%26spage%3D41%26epage%3D48%26doi%3D10.1007%2Fs00281-018-0702-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1021/cr0682195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0682195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=238-263&author=P.+G.+Baraldiauthor=M.+A.+Tabriziauthor=S.+Gessiauthor=P.+A.+Borea&title=Adenosine+receptor+antagonists%3A+translating+medicinal+chemistry+and+pharmacology+into+clinical+utility&doi=10.1021%2Fcr0682195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Tabrizi, Mojgan Aghazadeh; Gessi, Stefania; Borea, Pier Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-263</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the chem. and pharmacol. of adenosine A1, A2A, A2B and A3 receptor antagonists and their therapeutic potential in clin. developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXhQGKqAVLbVg90H21EOLACvtfcHk0lhwd1StQuoQeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1OisQ%253D%253D&md5=1ae9e978507a1bbe7ab7aea0bdb33bb8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fcr0682195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0682195%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DGessi%26aufirst%3DS.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DAdenosine%2520receptor%2520antagonists%253A%2520translating%2520medicinal%2520chemistry%2520and%2520pharmacology%2520into%2520clinical%2520utility%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D238%26epage%3D263%26doi%3D10.1021%2Fcr0682195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Lera Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor as a drug discovery target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3623</span>– <span class="NLM_lpage">3650</span>, <span class="refDoi"> DOI: 10.1021/jm4011669</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011669" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3623-3650&author=M.+de%0ALera+Ruizauthor=Y.+H.+Limauthor=J.+Zheng&title=Adenosine+A2A+receptor+as+a+drug+discovery+target&doi=10.1021%2Fjm4011669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor as a Drug Discovery Target</span></div><div class="casAuthors">de Lera Ruiz, Manuel; Lim, Yeon-Hee; Zheng, Junying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3623-3650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The adenosine A2A receptor is a G-protein-coupled receptor (GPCR) that has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications.  Herein the authors describe adenosine A2A receptor distribution, signaling pathways, pharmacol., and mol. structure, followed by a summary and SAR discussion of the most relevant series of adenosine A2A agonists and antagonists.  This review also provides an update of the A2A ligands that are undergoing or have undergone clin. studies, including the two currently marketed agonists adenosine and regadenoson.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUPGC7zBCkbVg90H21EOLACvtfcHk0lhBLj9IxcNTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7bJ&md5=846641d1ac3ad16b6335af6b4df15f08</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm4011669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011669%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%2BRuiz%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DY.%2BH.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520receptor%2520as%2520a%2520drug%2520discovery%2520target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3623%26epage%3D3650%26doi%3D10.1021%2Fjm4011669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Structurally enabled discovery of adenosine A2A receptor antagonists</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.6b00119</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00119" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWkur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=21-37&author=A.+Jazayeriauthor=S.+P.+Andrewsauthor=F.+H.+Marshall&title=Structurally+enabled+discovery+of+adenosine+A2A+receptor+antagonists&doi=10.1021%2Facs.chemrev.6b00119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists</span></div><div class="casAuthors">Jazayeri, Ali; Andrews, Stephen P.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-37</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past decade there has been a revolution in the field of G protein-coupled receptor (GPCR) structural biol.  Many years of innovative research from different areas have come together to fuel this significant change in the fortunes of this field, which for many years was characterized by the paucity of high-resoln. structures.  The detn. to succeed has been in part due to the recognized importance of these proteins as drug targets, and although the pharmaceutical industry has been focusing on these receptors, it can be justifiably argued and demonstrated that many of the approved and com. successful GPCR drugs can be significantly improved to increase efficacy and/or reduce undesired side effects.  In addn., many validated targets in this class remain to be drugged.  It is widely recognized that application of structure-based drug design approaches can help medicinal chemists a long way toward discovering better drugs.  The achievement of structural biologists in providing high-resoln. insight is beginning to transform drug discovery efforts, and there are a no. of GPCR drugs that have been discovered by use of structural information that are in clin. development.  This review aims to highlight the key developments that have brought success to GPCR structure resoln. efforts and exemplify the practical application of structural information for the discovery of adenosine A2A receptor antagonists that have potential to treat multiple conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMOXpKZXAHwrVg90H21EOLACvtfcHk0lhBLj9IxcNTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWkur3L&md5=5e0a332b9f43eae4854f1681a79ff184</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00119%26sid%3Dliteratum%253Aachs%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructurally%2520enabled%2520discovery%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D21%26epage%3D37%26doi%3D10.1021%2Facs.chemrev.6b00119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatfield, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.coph.2016.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=27429212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFegurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=90-96&author=S.+M.+Hatfieldauthor=M.+Sitkovsky&title=A2A+adenosine+receptor+antagonists+to+weaken+the+hypoxia-HIF-1%CE%B1+driven+immunosuppression+and+improve+immunotherapies+of+cancer&doi=10.1016%2Fj.coph.2016.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer</span></div><div class="casAuthors">Hatfield, Stephen M.; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90-96</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Hypoxic and adenosine rich tumor microenvironments represent an important barrier that must be overcome to enable T and NK cells to reject tumors.  The A2A adenosine receptor (A2AR) on activated immune cells was identified as a crit. and non-redundant mediator of physiol. immunosuppression.  Observations showing that tumor-protecting A2AR also suppress and redirect the anti-tumor immune response pointed to the importance of inhibiting this pathway to improve cancer immunotherapy.  We advocated (i) blocking immunosuppressive adenosine-A2AR-cAMP-mediated intracellular signaling by A2AR antagonists and (ii) weakening hypoxia-HIF-1α-mediated accumulation of extracellular adenosine by oxygenation agents that also inhibits CD39/CD73 adenosine-generating enzymes.  In view of commencing clin. trials of synthetic A2AR antagonists in combination with cancer immunotherapies, we discuss their promise and exclusion criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHOKqtoNK0LbVg90H21EOLACvtfcHk0lgaFPj8dVt_Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFegurzJ&md5=2a5f9a1d5184083a06e736cb768f2599</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DHatfield%26aufirst%3DS.%2BM.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DA2A%2520adenosine%2520receptor%2520antagonists%2520to%2520weaken%2520the%2520hypoxia-HIF-1%25CE%25B1%2520driven%2520immunosuppression%2520and%2520improve%2520immunotherapies%2520of%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D29%26spage%3D90%26epage%3D96%26doi%3D10.1016%2Fj.coph.2016.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span> <span> </span><span class="NLM_article-title">Targeting adenosine A2A receptor antagonism for treatment of cancer</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1534825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1080%2F17460441.2018.1534825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30336706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSlsr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=997-1003&author=M.+Congreveauthor=G.+A.+Brownauthor=A.+Borodovskyauthor=M.+L.+Lamb&title=Targeting+adenosine+A2A+receptor+antagonism+for+treatment+of+cancer&doi=10.1080%2F17460441.2018.1534825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting adenosine A2A receptor antagonism for treatment of cancer</span></div><div class="casAuthors">Congreve, Miles; Brown, Giles A.; Borodovsky, Alexandra; Lamb, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">997-1003</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A Receptor (A2AR) antagonists are an emerging class of agents that treat cancers, both as a monotherapy and in combination with other therapeutic agents.  Several studies support the accumulation of extracellular adenosine in the tumor microenvironment as a crit. mechanism in immune evasion implicating A2AR antagonists for use in immuno-oncol.  In this perspective article, the authors briefly outline the history of the A2AR antagonist field for central nervous system indications and give their perspective on the status of agents progressing today in oncol.  A brief description of the biol. rationale in oncol. is given.  A particular focus of this article is progress in A2AR structure detn. and its impact on Structure-Based Drug Design.  Thus understanding of the A2AR antagonist mechanism of action has changed and is now being clin. validated by several key companies in the oncol. field.  This area is likely to rapidly develop over the next 1-2 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsUKYxjhu-TbVg90H21EOLACvtfcHk0lgaFPj8dVt_Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSlsr7J&md5=d45041fe45a473e6750fd2195be826de</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1534825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1534825%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DG.%2BA.%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26atitle%3DTargeting%2520adenosine%2520A2A%2520receptor%2520antagonism%2520for%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D997%26epage%3D1003%26doi%3D10.1080%2F17460441.2018.1534825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merighi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincenzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessi, S.</span></span> <span> </span><span class="NLM_article-title">Targeting A3 and A2A adenosine receptors in the fight against cancer</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1080/14728222.2019.1630380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1080%2F14728222.2019.1630380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31189400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=669-678&author=S.+Merighiauthor=E.+Battistelloauthor=L.+Giacomelliauthor=K.+Varaniauthor=F.+Vincenziauthor=P.+A.+Boreaauthor=S.+Gessi&title=Targeting+A3+and+A2A+adenosine+receptors+in+the+fight+against+cancer&doi=10.1080%2F14728222.2019.1630380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting A3 and A2A adenosine receptors in the fight against cancer</span></div><div class="casAuthors">Merighi, Stefania; Battistello, Enrica; Giacomelli, Luca; Varani, Katia; Vincenzi, Fabrizio; Borea, Pier Andrea; Gessi, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">669-678</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  There is a vicious cycle of tumor hypoxia, high adenosine levels, immune suppression and cancer growth that involves the use of adenosine receptor ligands in tumors.  After several years of research, the candidates emerging as promising new anticancer drugs are A3 adenosine receptor agonists and A2A receptor antagonists.  The authors give an updated overview of the field related to A3 receptor agonists and A2A receptor antagonists in cancer and propose their perspectives on the status of these compds. in oncol.  The rationale for the modulation of adenosine receptors in cancer is addressed, starting from the first in vitro evidence of their efficacy up to the animal and clin. studies.  A3 and A2A receptors are attractive targets in oncol. therapy due to their involvement in cancer progression and immune-resistance.  Of relevance, the A3 subtype is also a tumor marker to be used in a personalized drug treatment program while the A2A receptor, playing a non-redundant role in immunomodulation, may be blocked in combination with checkpoint inhibitors to improve their efficacy.  The future will reveal how successful this approach is in the fight against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLmD7ZrrPY47Vg90H21EOLACvtfcHk0lgO_rbFWXEV4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKjsbfL&md5=05f51bbcd65ad3d79770f188db174e03</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F14728222.2019.1630380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2019.1630380%26sid%3Dliteratum%253Aachs%26aulast%3DMerighi%26aufirst%3DS.%26aulast%3DBattistello%26aufirst%3DE.%26aulast%3DGiacomelli%26aufirst%3DL.%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DVincenzi%26aufirst%3DF.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DGessi%26aufirst%3DS.%26atitle%3DTargeting%2520A3%2520and%2520A2A%2520adenosine%2520receptors%2520in%2520the%2520fight%2520against%2520cancer%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2019%26volume%3D23%26spage%3D669%26epage%3D678%26doi%3D10.1080%2F14728222.2019.1630380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drury, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szent-Györgyi, A.</span></span> <span> </span><span class="NLM_article-title">The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1929</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.1929.sp002608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1113%2Fjphysiol.1929.sp002608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16994064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaA3cXis1aitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1929&pages=213-237&author=A.+N.+Druryauthor=A.+Szent-Gy%C3%B6rgyi&title=The+physiological+activity+of+adenine+compounds+with+especial+reference+to+their+action+upon+the+mammalian+heart&doi=10.1113%2Fjphysiol.1929.sp002608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart</span></div><div class="casAuthors">Drury, A. N.; Szent-Gyorgyi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">1929</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">213-37</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">A substance, which gave oil hydrolysis adenine, a pentose and H3PO4, was isolated from heart muscle.  It appeared to be adenylic acid having a physiol. action identical with adenylic acid and with adenosine prepd. from yeast nucleic acid.  The physiol. effects are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruSBD-A05bQbVg90H21EOLACvtfcHk0lgO_rbFWXEV4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA3cXis1aitQ%253D%253D&md5=c30c03073b42a0825ed6db7c9e756cc3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.1929.sp002608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.1929.sp002608%26sid%3Dliteratum%253Aachs%26aulast%3DDrury%26aufirst%3DA.%2BN.%26aulast%3DSzent-Gy%25C3%25B6rgyi%26aufirst%3DA.%26atitle%3DThe%2520physiological%2520activity%2520of%2520adenine%2520compounds%2520with%2520especial%2520reference%2520to%2520their%2520action%2520upon%2520the%2520mammalian%2520heart%26jtitle%3DJ.%2520Physiol.%26date%3D1929%26volume%3D68%26spage%3D213%26epage%3D237%26doi%3D10.1113%2Fjphysiol.1929.sp002608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bodin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span> <span> </span><span class="NLM_article-title">Increased release of ATP from endothelial cells during acute inflammation</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1007/s000110050341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs000110050341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9754870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK1cXls1CntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1998&pages=351-354&author=P.+Bodinauthor=G.+Burnstock&title=Increased+release+of+ATP+from+endothelial+cells+during+acute+inflammation&doi=10.1007%2Fs000110050341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Increased release of ATP from endothelial cells during acute inflammation</span></div><div class="casAuthors">Bodin, P.; Burnstock, G.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">351-354</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">The effects of lipopolysaccharide (LPS), a potent inflammatory mediator, on the shear stress stimulated release of ATP were investigated on endothelial cells.  Human umbilical vein endothelial cells (HUVEC) in primary cultures were subjected to shear stress using a cone and plate app.  ATP released by the cells was measured by luminometry, using a luciferin-luciferase assay.  Under shear stress alone (25 dyn/cm2), ATP accumulates into the culture medium and reaches a max. after 3-5 min of stimulation (121.7 pmol/mL).  The shear stress-stimulated release of ATP was increased after a 4 h pre-incubation of endothelial cells with 50 μg/mL (314.4 pmol/mL) and 10 μg/mL lipopolysaccharide (207.7 pmol/mL).  Dexamethasone inhibited the effects of lipopolysaccharide.  These results show that non-damaged endothelial cells release ATP under exptl. inflammatory conditions and support an early role of extracellular ATP in the inflammatory process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdMdGxEFsl2LVg90H21EOLACvtfcHk0lgO_rbFWXEV4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1CntLg%253D&md5=5de42506ac8a2e05dc0206424f4a5d2f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs000110050341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs000110050341%26sid%3Dliteratum%253Aachs%26aulast%3DBodin%26aufirst%3DP.%26aulast%3DBurnstock%26aufirst%3DG.%26atitle%3DIncreased%2520release%2520of%2520ATP%2520from%2520endothelial%2520cells%2520during%2520acute%2520inflammation%26jtitle%3DInflammation%2520Res.%26date%3D1998%26volume%3D47%26spage%3D351%26epage%3D354%26doi%3D10.1007%2Fs000110050341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AP, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1211%2F0022357011775631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=11734617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=527-552&author=B.+B.+Fredholmauthor=I.+J.+APauthor=K.+A.+Jacobsonauthor=K.+N.+Klotzauthor=J.+Linden&title=International+Union+of+Pharmacology.+XXV.+Nomenclature+and+classification+of+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors</span></div><div class="casAuthors">Fredholm, Bertil B.; IJzerman, Adriaan P.; Jacobson, Kenneth A.; Klotz, Karl-Norbert; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">527-552</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Four adenosine receptors have been cloned and characterized from several mammalian species.  The receptors are named adenosine A1, A2A, A2B, and A3.  The A2A and A2B receptors preferably interact with members of the Gs family of G proteins and the A1 and A3 receptors with Gi/o proteins.  However, other G protein interactions have also been described.  Adenosine is the preferred endogenous agonist at all these receptors, but inosine can also activate the A3 receptor.  The levels of adenosine seen under basal conditions are sufficient to cause some activation of all the receptors, at least where they are abundantly expressed.  Adenosine levels during, e.g., ischemia can activate all receptors even when expressed in low abundance.  Accordingly, expts. with receptor antagonists and mice with targeted disruption of adenosine A1, A2A, and A3 expression reveal roles for these receptors under physiol. and particularly pathophysiol. conditions.  There are pharmacol. tools that can be used to classify A1, A2A, and A3 receptors but few drugs that interact selectively with A2B receptors.  Testable models of the interaction of these drugs with their receptors have been generated by site-directed mutagenesis and homol.-based modeling.  Both agonists and antagonists are being developed as potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOCrJphTwDrVg90H21EOLACvtfcHk0ljHWX5lxAdYMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D&md5=060ea8a3d7b07fdc4b2c8acc3b4d4745</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1211%2F0022357011775631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357011775631%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DAP%26aufirst%3DI.%2BJ.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXV.%2520Nomenclature%2520and%2520classification%2520of%2520adenosine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D527%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghisu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Tacca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span> <span> </span><span class="NLM_article-title">Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2008.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.pharmthera.2008.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=18848843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWrs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2008&pages=233-253&author=L.+Antonioliauthor=M.+Fornaiauthor=R.+Colucciauthor=N.+Ghisuauthor=M.+Tuccoriauthor=M.+Del+Taccaauthor=C.+Blandizzi&title=Regulation+of+enteric+functions+by+adenosine%3A+pathophysiological+and+pharmacological+implications&doi=10.1016%2Fj.pharmthera.2008.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications</span></div><div class="casAuthors">Antonioli, Luca; Fornai, Matteo; Colucci, Rocchina; Ghisu, Narcisa; Tuccori, Marco; Del Tacca, Mario; Blandizzi, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-253</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The wide distribution of ATP and adenosine receptors as well as enzymes for purine metab. in different gut regions suggests a complex role for these mediators in the regulation of gastrointestinal functions.  Studies in rodents have shown a significant involvement of adenosine in the control of intestinal secretion, motility and sensation, via activation of A1, A2A, A2B or A3 purinergic receptors, as well as the participation of ATP in the regulation of enteric functions, through the recruitment of P2X and P2Y receptors.  Increasing interest is being focused on the involvement of ATP and adenosine in the pathophysiol. of intestinal disorders, with particular regard for inflammatory bowel diseases (IBDs), intestinal ischemia, post-operative ileus and related dysfunctions, such as gut dysmotility, diarrhea and abdominal discomfort/pain.  Current knowledge suggests that adenosine contributes to the modulation of enteric immune and inflammatory responses, leading to anti-inflammatory actions.  There is evidence supporting a role of adenosine in the alterations of enteric motor and secretory activity assocd. with bowel inflammation.  In particular, several studies have highlighted the importance of adenosine in diarrhea, since this nucleoside participates actively in the cross-talk between immune and epithelial cells in the presence of diarrhoeogenic stimuli.  In addn., adenosine exerts complex regulatory actions on pain transmission at peripheral and spinal sites.  The present review illustrates current information on the role played by adenosine in the regulation of enteric functions, under normal or pathol. conditions, and discusses pharmacol. interventions on adenosine pathways as novel therapeutic options for the management of gut disorders and related abdominal symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHBJtp93EULVg90H21EOLACvtfcHk0ljHWX5lxAdYMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWrs7fF&md5=f150ca845905466fd9b23d74224407f5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DFornai%26aufirst%3DM.%26aulast%3DColucci%26aufirst%3DR.%26aulast%3DGhisu%26aufirst%3DN.%26aulast%3DTuccori%26aufirst%3DM.%26aulast%3DDel%2BTacca%26aufirst%3DM.%26aulast%3DBlandizzi%26aufirst%3DC.%26atitle%3DRegulation%2520of%2520enteric%2520functions%2520by%2520adenosine%253A%2520pathophysiological%2520and%2520pharmacological%2520implications%26jtitle%3DPharmacol.%2520Ther.%26date%3D2008%26volume%3D120%26spage%3D233%26epage%3D253%26doi%3D10.1016%2Fj.pharmthera.2008.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kull, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, W.</span></span> <span> </span><span class="NLM_article-title">Structure and function of adenosine receptors and their genes</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1007/s002100000313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs002100000313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=11111830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFCru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2000&pages=364-374&author=B.+B.+Fredholmauthor=G.+Arslanauthor=L.+Halldnerauthor=B.+Kullauthor=G.+Schulteauthor=W.+Wasserman&title=Structure+and+function+of+adenosine+receptors+and+their+genes&doi=10.1007%2Fs002100000313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of adenosine receptors and their genes</span></div><div class="casAuthors">Fredholm, Bertil B.; Arslan, Giulia; Halldner, Linda; Kull, Bjorn; Schulte, Gunnar; Wasserman, Wyeth</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">364-374</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with 130 refs.  Four adenosine receptors have been cloned from many mammalian and some non-mammalian species.  In each case the translated part of the receptor is encoded by two sep. exons.  Two sep. promoters regulate the A1 receptor expression, and a similar situation may pertain also for the other receptors.  The receptors are expressed in a cell and tissue specific manner, even though A1 and A2B receptors are found in many different cell types.  Emerging data indicate that the receptor protein is targeted to specific parts of the cell.  A1 and A3 receptors activate the Gi family of G proteins, whereas A2A and A2B receptors activate the Gs family.  However, other G proteins can also be activated even though the physiol. significance of this is unknown.  Following the activation of G proteins several cellular effector pathways can be affected.  Signaling via adenosine receptors is also known to interact in functionally important ways with signaling initiated via other receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqi7IPIpeDOLVg90H21EOLACvtfcHk0ljHWX5lxAdYMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFCru7g%253D&md5=26a3b7f257b3748da01ab4ef33a81953</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs002100000313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002100000313%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DArslan%26aufirst%3DG.%26aulast%3DHalldner%26aufirst%3DL.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DSchulte%26aufirst%3DG.%26aulast%3DWasserman%26aufirst%3DW.%26atitle%3DStructure%2520and%2520function%2520of%2520adenosine%2520receptors%2520and%2520their%2520genes%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2000%26volume%3D362%26spage%3D364%26epage%3D374%26doi%3D10.1007%2Fs002100000313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ralevic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span> <span> </span><span class="NLM_article-title">Receptors for purines and pyrimidines</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">492</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9755289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK1cXmvFamur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1998&pages=413-492&author=V.+Ralevicauthor=G.+Burnstock&title=Receptors+for+purines+and+pyrimidines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Receptors for purines and pyrimidines</span></div><div class="casAuthors">Ralevic, Vera; Burnstock, Geoffrey</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-492</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review, with >1000 refs.  Extracellular purines (adenosine, ADP, and ATP) and pyrimidines (UDP and UTP) are important signaling mols. that mediate diverse biol. effects via cell-surface receptors termed purine receptors.  In this review particular emphasis is placed on the discrepancy between the pharmacol. properties and native and recombinant receptors for these agents.  There are two main families of purine receptors, adenosine or P1 receptors, and P2 receptors, recognizing primary ATP, ADP, UTP, and UDP.  Adenosine/P1 receptors have been further subdivided, according to convergent mol., biochem., and pharmacol. evidence into four subtypes, A1, A2A, A2B and A3, all of which couple to G proteins.  Based on differences in mol. structure and signal transduction mechanisms, P2 receptors divide naturally into two families of ligand-gated ion channels and G protein-coupled receptors termed P2X and P2Y receptors, resp.; to date seven mammalian P2X receptors (P2X1-7) and five mammalian P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11) have been cloned, characterized and accepted as valid members of the P2 receptor family.  As correlates between cloned and endogenous receptors are established, the structural subdivision will replace an earlier system of subclassification identifying endogenous P2X, P2Y, P2U, P2T, and P2Z receptors principally according to their pharmacol. profiles.  A prominent issue addressed in this review is the apparent mismatch of pharmacol. data in biol. tissue relating to the P2 receptor subtypes classified on the basis of mol. structure.  While it is logically satisfying to base receptor subclassification on amino acid sequencing where differences of 30-40% are generally regarded as justification for subtyping, it would seem that differences in sequence of less than 50% (even single point mutations) can result in substantial differences in pharmacol. profile.  Thus, receptor heterogeneity among species, together with receptor coexpression and the possible expression of new receptor subtypes that have not yet been cloned, complicates interpretation of pharmacol. responses in some tissues.  Thus, it will become apparent in the present review that , at least with the use of currently available, largely unselective agonists and antagonists, some response profiles do not fit those expected for the known P2 receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY-5Zb4ISCA7Vg90H21EOLACvtfcHk0lhwpe_8v64DWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvFamur0%253D&md5=9163ccc1e49f176eff77388a15690b1d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRalevic%26aufirst%3DV.%26aulast%3DBurnstock%26aufirst%3DG.%26atitle%3DReceptors%2520for%2520purines%2520and%2520pyrimidines%26jtitle%3DPharmacol.%2520Rev.%26date%3D1998%26volume%3D50%26spage%3D413%26epage%3D492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. G.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors as therapeutic targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrd1983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnrd1983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16518376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=247-264&author=K.+A.+Jacobsonauthor=Z.+G.+Gao&title=Adenosine+receptors+as+therapeutic+targets&doi=10.1038%2Fnrd1983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as therapeutic targets</span></div><div class="casAuthors">Jacobson, Kenneth A.; Gao, Zhan-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-264</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world.  There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischemic diseases, sleep disorders, immune and inflammatory disorders and cancer.  After more than three decades of medicinal chem. research, a considerable no. of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clin. evaluated, although none has yet received regulatory approval.  However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoG29EyQFoSbVg90H21EOLACvtfcHk0lhwpe_8v64DWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr4%253D&md5=85ad553154bd61f24a6bb594f960f9bc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd1983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1983%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26atitle%3DAdenosine%2520receptors%2520as%2520therapeutic%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D247%26epage%3D264%26doi%3D10.1038%2Fnrd1983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltzschig, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors as drug targets--what are the challenges?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1038/nrd3955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnrd3955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23535933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Glsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=265-286&author=J.+F.+Chenauthor=H.+K.+Eltzschigauthor=B.+B.+Fredholm&title=Adenosine+receptors+as+drug+targets%2D%2Dwhat+are+the+challenges%3F&doi=10.1038%2Fnrd3955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as drug targets - what are the challenges?</span></div><div class="casAuthors">Chen, Jiang-Fan; Eltzschig, Holger K.; Fredholm, Bertil B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">265-286</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine signalling has long been a target for drug development, with adenosine itself or its derivs. being used clin. since the 1940s.  In addn., methylxanthines such as caffeine have profound biol. effects as antagonists at adenosine receptors.  Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors.  There is strong evidence that adenosine has a functional role in many diseases, and several pharmacol. compds. specifically targeting individual adenosine receptors - either directly or indirectly - have now entered the clinic.  However, only one adenosine receptor-specific agent - the adenosine A2A receptor agonist regadenoson (Lexiscan; Astellas Pharma) - has so far gained approval from the US Food and Drug Administration (FDA).  Here, we focus on the biol. of adenosine signalling to identify hurdles in the development of addnl. pharmacol. compds. targeting adenosine receptors and discuss strategies to overcome these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqhEzWXi1WS7Vg90H21EOLACvtfcHk0lhwpe_8v64DWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Glsrs%253D&md5=898fee7a68273ebfbd5a1d3dca307dc5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3955%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DEltzschig%26aufirst%3DH.%2BK.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DAdenosine%2520receptors%2520as%2520drug%2520targets--what%2520are%2520the%2520challenges%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D265%26epage%3D286%26doi%3D10.1038%2Fnrd3955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Immunosuppressive activities of adenosine in cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.coph.2016.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=27209048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslagtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=7-16&author=B.+Allardauthor=P.+A.+Beavisauthor=P.+K.+Darcyauthor=J.+Stagg&title=Immunosuppressive+activities+of+adenosine+in+cancer&doi=10.1016%2Fj.coph.2016.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Immunosuppressive activities of adenosine in cancer</span></div><div class="casAuthors">Allard, Bertrand; Beavis, Paul A.; Darcy, Phillip K.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7-16</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Multiple immunosuppressive mechanisms impede anti-tumor immunity.  Among them, the accumulation of extracellular adenosine is a potent and widespread strategy exploited by tumors to escape immunosurveillance through the activation of purinergic receptors.  In the immune system, engagement of A2a and A2b adenosine receptors is a crit. regulatory mechanism that protects tissues against excessive immune reactions.  In tumors, this pathway is hijacked and hinders anti-tumor immunity, promoting cancer progression.  Different groups have highlighted the therapeutic potential of blocking CD73-dependent adenosine-mediated immunosuppression to reinstate anti-tumor immunity.  Phase clin. trials evaluating anti-CD73 antibodies and A2a receptor antagonists in cancer patients are currently ongoing.  We here review the recent literature on the immunosuppressive effects of extracellular adenosine and discuss the development of adenosine inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYRzXPb0hO57Vg90H21EOLACvtfcHk0lgH0NAMJ2cRdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslagtrk%253D&md5=70aeee8a8e49cae26f539a446900bbee</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DImmunosuppressive%2520activities%2520of%2520adenosine%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D29%26spage%3D7%26epage%3D16%26doi%3D10.1016%2Fj.coph.2016.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emens, L. A.</span></span> <span> </span><span class="NLM_article-title">Targeting adenosine for cancer immunotherapy</span>. <i>J. Immunotherapy Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s40425-018-0360-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1186%2Fs40425-018-0360-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29914571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosFamtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=57&author=R.+D.+Leoneauthor=L.+A.+Emens&title=Targeting+adenosine+for+cancer+immunotherapy&doi=10.1186%2Fs40425-018-0360-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting adenosine for cancer immunotherapy</span></div><div class="casAuthors">Leone Robert D; Emens Leisha A; Emens Leisha A</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer therapy.  To extend the impact of immunotherapy to more patients and a broader range of cancers, targeting additional mechanisms of tumor immune evasion will be critical.  Adenosine signaling has emerged as a key metabolic pathway that regulates tumor immunity.  Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment.  Hypoxia, high cell turnover, and expression of CD39 and CD73 are important factors in adenosine production.  Adenosine signaling through the A2a receptor expressed on immune cells potently dampens immune responses in inflamed tissues.  In this article, we will describe the role of adenosine signaling in regulating tumor immunity, highlighting potential therapeutic targets in the pathway.  We will also review preclinical data for each target and provide an update of current clinical activity within the field.  Together, current data suggest that rational combination immunotherapy strategies that incorporate inhibitors of the hypoxia-CD39-CD73-A2aR pathway have great promise for further improving clinical outcomes in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-_cHN3uno-2Zyxfu64m4ffW6udTcc2eZVoYL-Ee3Mirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosFamtw%253D%253D&md5=589bd113854d2c7b520182c688a2b348</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2Fs40425-018-0360-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-018-0360-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DR.%2BD.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26atitle%3DTargeting%2520adenosine%2520for%2520cancer%2520immunotherapy%26jtitle%3DJ.%2520Immunotherapy%2520Cancer%26date%3D2018%26volume%3D6%26spage%3D57%26doi%3D10.1186%2Fs40425-018-0360-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diniz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptor ligands on cancer therapy: a review of patent literature</span>. <i>Recent Pat. Anti-Cancer Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.2174/1574892812666171108115959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.2174%2F1574892812666171108115959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29119938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1antro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=40-69&author=J.+B.+Sousaauthor=P.+Frescoauthor=C.+Dinizauthor=J.+Goncalves&title=Adenosine+receptor+ligands+on+cancer+therapy%3A+a+review+of+patent+literature&doi=10.2174%2F1574892812666171108115959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature</span></div><div class="casAuthors">Sousa, Joana B.; Fresco, Paula; Diniz, Carmen; Goncalves, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on Anti-Cancer Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-69</span>CODEN:
                <span class="NLM_cas:coden">RPADDY</span>;
        ISSN:<span class="NLM_cas:issn">1574-8928</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine is a purine, with an adenine group and a ribose sugar, formed endogenously by ATP catabolism both intracellularly and extracellularly.  Among the medicinal features of adenosine and its receptors (A1, A2A, A2B and A3), anticancer activity has been an intense field of research.  The present review focuses on the patent literature from 2002 onwards (2002-May 2017).  Patents were searched and downloaded from the open access patent data bases and are available online.  A significant no. of patents (65) have been published on adenosine receptor ligands claiming anticancer activity, or presenting new methods of prepn. or treatment thereof, from 2002-2017 (May).  From these, 35 were published highlighting the promising attributes of compds./ methods to fight cancer.  Most of the compds. act as adenosine A3 receptor agonists, while others act as antagonists for the other adenosine receptor subtypes.  The signaling events triggered by activation of adenosine A3 receptor or by blockade of adenosine A1, A2A and A2B receptors can reverse an environment from being pro-cancer to an anti-cancer in the body.  The promising anticancer effects mediated by adenosine receptor ligands put them in the forefront as new drug candidates.  The present compilation can be worthy to medicinal chemists, pharmacologists, biochemists and other researchers focusing on the putative anticancer activity of adenosine receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVYkWyOZz0NLVg90H21EOLACvtfcHk0lgPfyc3ozN1Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1antro%253D&md5=f1b4db6d480cb190418dddf35e74b396</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F1574892812666171108115959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1574892812666171108115959%26sid%3Dliteratum%253Aachs%26aulast%3DSousa%26aufirst%3DJ.%2BB.%26aulast%3DFresco%26aufirst%3DP.%26aulast%3DDiniz%26aufirst%3DC.%26aulast%3DGoncalves%26aufirst%3DJ.%26atitle%3DAdenosine%2520receptor%2520ligands%2520on%2520cancer%2520therapy%253A%2520a%2520review%2520of%2520patent%2520literature%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D40%26epage%3D69%26doi%3D10.2174%2F1574892812666171108115959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">The blockade of immune checkpoints in cancer immunotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrc3239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnrc3239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22437870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVegtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=252-264&author=D.+M.+Pardoll&title=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&doi=10.1038%2Fnrc3239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The blockade of immune checkpoints in cancer immunotherapy</span></div><div class="casAuthors">Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">252-264</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Among the most promising approaches to activating therapeutic antitumor immunity is the blockade of immune checkpoints.  Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiol. immune responses in peripheral tissues in order to minimize collateral tissue damage.  It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens.  Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors.  Cytotoxic T-lymphocyte-assocd. antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval.  Preliminary clin. findings with blockers of addnl. immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumor immunity with the potential to produce durable clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosDPsOq8t6CrVg90H21EOLACvtfcHk0lgPfyc3ozN1Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVegtrw%253D&md5=d278a058ffb1ccd3f678c1ae3ac0e55e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnrc3239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3239%26sid%3Dliteratum%253Aachs%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DThe%2520blockade%2520of%2520immune%2520checkpoints%2520in%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D252%26epage%3D264%26doi%3D10.1038%2Fnrc3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belikoff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukashev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span> <span> </span><span class="NLM_article-title">Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-14-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F2326-6066.CIR-14-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24990240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWgtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=598-605&author=M.+V.+Sitkovskyauthor=S.+Hatfieldauthor=R.+Abbottauthor=B.+Belikoffauthor=D.+Lukashevauthor=A.+Ohta&title=Hostile%2C+hypoxia-A2-adenosinergic+tumor+biology+as+the+next+barrier+to+overcome+for+tumor+immunologists&doi=10.1158%2F2326-6066.CIR-14-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists</span></div><div class="casAuthors">Sitkovsky, Michail V.; Hatfield, Stephen; Abbott, Robert; Belikoff, Bryan; Lukashev, Dmitriy; Ohta, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">598-605</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as crit. and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity.  However, this immunosuppressive mechanism can be highjacked by bacteria and tumors to provide misguided protection for pathogens and cancerous tissues.  Inhibitors of the hypoxia-A2-adenosinergic pathway represent a conceptually novel type of immunol. coadjuvants that could be combined with cancer vaccines, adoptive cell transfer, and/or blockade of neg. immunol. regulators to further prolong patient survival and to minimize treatment-related side effects.  In support of this approach are preclin. studies and findings that some human cancers are resistant to chemotherapies and immunotherapies due to the tumor-generated extracellular adenosine and A2AR on antitumor T and natural killer (NK) cells.  Among the coadjuvants are (i) antagonists of A2AR, (ii) extracellular adenosine-degrading drugs, (iii) inhibitors of adenosine generation by CD39/CD73 ectoenzymes, and (iv) inhibitors of hypoxia-HIF-1α signaling.  Combining these coadjuvants with CTLA-4 and/or PD-1 blockade is expected to have additive or even synergistic effects of targeting two different antitumor protective mechanisms.  It is expected that even after multicombinatorial blockade of neg. immunol. regulators, the antitumor T and NK cells would still be vulnerable to inhibition by hypoxia and A2AR.  Yet to be tested is the potential capacity of coadjuvants to minimize the side effects of CTLA-4 and/or PD-1 blockade by decreasing the dose of blocking antibodies or by eliminating the need for dual blockade.  Cancer Immunol Res; 2(7); 598-605. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHkhcwpTVeg7Vg90H21EOLACvtfcHk0lgIqtV_Budvlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWgtrzF&md5=9a7805b55c2849b47fd00df1ca38f413</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-14-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-14-0075%26sid%3Dliteratum%253Aachs%26aulast%3DSitkovsky%26aufirst%3DM.%2BV.%26aulast%3DHatfield%26aufirst%3DS.%26aulast%3DAbbott%26aufirst%3DR.%26aulast%3DBelikoff%26aufirst%3DB.%26aulast%3DLukashev%26aufirst%3DD.%26aulast%3DOhta%26aufirst%3DA.%26atitle%3DHostile%252C%2520hypoxia-A2-adenosinergic%2520tumor%2520biology%2520as%2520the%2520next%2520barrier%2520to%2520overcome%2520for%2520tumor%2520immunologists%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2%26spage%3D598%26epage%3D605%26doi%3D10.1158%2F2326-6066.CIR-14-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Purinergic regulation of the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/nri.2016.4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnri.2016.4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26922909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlKmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=177-192&author=C.+Cekicauthor=J.+Linden&title=Purinergic+regulation+of+the+immune+system&doi=10.1038%2Fnri.2016.4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Purinergic regulation of the immune system</span></div><div class="casAuthors">Cekic, Caglar; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">177-192</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cellular stress or apoptosis triggers the release of ATP, ADP and other nucleotides into the extracellular space.  Extracellular nucleotides function as autocrine and paracrine signalling mols. by activating cell-surface P2 purinergic receptors that elicit pro-inflammatory immune responses.  Over time, extracellular nucleotides are metabolized to adenosine, leading to reduced P2 signalling and increased signalling through anti-inflammatory adenosine (P1 purinergic) receptors.  Here, we review how local purinergic signalling changes over time during tissue responses to injury or disease, and we discuss the potential of targeting purinergic signalling pathways for the immunotherapeutic treatment of ischemia, organ transplantation, autoimmunity or cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod6c3DxezmqbVg90H21EOLACvtfcHk0liNfh5ZAGBHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlKmurg%253D&md5=930862a0d6cfd16d6c3cdefc45094d0d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnri.2016.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2016.4%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DPurinergic%2520regulation%2520of%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2016%26volume%3D16%26spage%3D177%26epage%3D192%26doi%3D10.1038%2Fnri.2016.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoskin, D. W.</span></span> <span> </span><span class="NLM_article-title">The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2602</span>– <span class="NLM_lpage">2605</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9205063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2sXkt12qsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=2602-2605&author=J.+Blayauthor=T.+D.+Whiteauthor=D.+W.+Hoskin&title=The+extracellular+fluid+of+solid+carcinomas+contains+immunosuppressive+concentrations+of+adenosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine</span></div><div class="casAuthors">Blay, Jonathan; White, Thomas D.; Hoskin, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2602-2605</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purine nucleoside adenosine (9-β-D-ribofuranosyladenine) inhibits a no. of lymphocyte functions in vitro, including the ability of activated T lymphocytes and natural killer cells to adhere to and kill tumor targets.  Solid tumors, such as adenocarcinomas of the lung and colon, are frequently hypoxic and are, therefore, likely to exhibit increased adenine nucleotide breakdown through the 5'-nucleotidase pathway, yielding adenosine.  The authors examd. whether the concn. of adenosine in the extracellular fluid of such tumors is adequate to cause immunosuppression.  Murine tumors grown in syngeneic hosts or human tumors grown in immunodeficient nu/nu mice were subjected to microdialysis, and adenosine levels in the microdialyzate were measured by high-performance liq. chromatog.  Treatment of the tumor microdialyzates with adenosine deaminase eliminated the adenosine peak.  Recovery of adenosine ranged from 15 to 29%, depending on the microdialysis probe, and concns. of adenosine in tumors ranged from 0.2 to 2.4 μM with a mean of 0.5 μM.  In contrast, the adenosine concn. measured s.c. at the same location was 30 nM.  Inclusion of the adenosine deaminase inhibitor coformycin (10 μM) and the adenosine kinase inhibitor 5'-iodotubercidin (0.1 μM) in the microdialysis perfusion buffer increased extracellular adenosine concn. in tumors to as high as 13 μM.  These data show that extracellular adenosine levels in solid tumors are sufficient to suppress the local antitumor immune response and that interference with pathways of adenosine metab. causes marked increases in tumor extracellular adenosine concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ojmDg8ZxJLVg90H21EOLACvtfcHk0liNfh5ZAGBHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt12qsr0%253D&md5=2660be28e3cf17a8788fd48ac37bb9e2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlay%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DT.%2BD.%26aulast%3DHoskin%26aufirst%3DD.%2BW.%26atitle%3DThe%2520extracellular%2520fluid%2520of%2520solid%2520carcinomas%2520contains%2520immunosuppressive%2520concentrations%2520of%2520adenosine%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D2602%26epage%3D2605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1007/s11302-012-9349-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs11302-012-9349-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23271562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVGjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=145-165&author=V.+Kumar&title=Adenosine+as+an+endogenous+immunoregulator+in+cancer+pathogenesis%3A+where+to+go%3F&doi=10.1007%2Fs11302-012-9349-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?</span></div><div class="casAuthors">Kumar, V.</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-165</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Cancer is a chronic disease and its pathogenesis is well correlated with infection and inflammation.  Adenosine is a purine nucleoside, which is produced under metabolic stress like hypoxic conditions.  Acute or chronic inflammatory conditions lead to the release of precursor adenine nucleotides (ATP (ATP), ADP (ADP) and adenosine monophosphate (AMP)) from cells, which are extracellularly catabolized into adenosine by extracellular ectonucleotidases, i.e., CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5'-ectonucleotidase.  It is now well-known that adenosine is secreted by cancer as well as immune cells during tumor pathogenesis under metabolic stress or hypoxia.  Once adenosine is released into the extracellular environment, it exerts various immunomodulatory effects via adenosine receptors (A1, A2A, A2B, and A3) expressed on various immune cells (i.e., macrophages, myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, dendritic cells (DCs), T cells, regulatory T cell (Tregs), etc.), which play very important roles in the pathogenesis of cancer.  This review is intended to summarize the role of inflammation and adenosine in the immunopathogenesis of tumor along with regulation of tumor-specific immune response and its modulation as an adjunct approach to tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXKJ8-GFdwnLVg90H21EOLACvtfcHk0liNfh5ZAGBHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVGjsrs%253D&md5=5b0499a34d0940c5c17dbbbaec55ab11</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs11302-012-9349-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-012-9349-9%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DAdenosine%2520as%2520an%2520endogenous%2520immunoregulator%2520in%2520cancer%2520pathogenesis%253A%2520where%2520to%2520go%253F%26jtitle%3DPurinergic%2520Signalling%26date%3D2013%26volume%3D9%26spage%3D145%26epage%3D165%26doi%3D10.1007%2Fs11302-012-9349-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Häusler, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Barrio, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diessner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohschein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hönig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wischhusen, J.</span></span> <span> </span><span class="NLM_article-title">Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24489992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC2cvhsFajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=129-139&author=S.+F.+H%C3%A4uslerauthor=I.+M.+Del+Barrioauthor=J.+Diessnerauthor=R.+G.+Steinauthor=J.+Strohscheinauthor=A.+H%C3%B6nigauthor=J.+Dietlauthor=J.+Wischhusen&title=Anti-CD39+and+anti-CD73+antibodies+A1+and+7G2+improve+targeted+therapy+in+ovarian+cancer+by+blocking+adenosine-dependent+immune+evasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion</span></div><div class="casAuthors">Hausler Sebastian Fm; Del Barrio Itsaso Montalban; Wischhusen Jorg; Diessner Joachim; Strohschein Jenny; Honig Arnd; Dietl Johannes; Stein Roland G</div><div class="citationInfo"><span class="NLM_cas:title">American journal of translational research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-39</span>
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    </div><div class="casAbstract">The ectonucleotidases CD39 and CD73 degrade ATP to adenosine which inhibits immune responses via the A2A adenosine receptor (ADORA2A) on T and NK cells.  The current study investigates the potential therapeutic use of the specific anti CD39- and anti CD73-antibodies A1 (CD39) and 7G2 (CD73) as these two ectonucleotidases are overexpressed in ovarian cancer (OvCA).  As expected, NK cell cytotoxicity against the human ovarian cancer cell lines OAW-42 or SK-OV-3 was significantly increased in the presence of A1 or 7G2 antibody.  While this might partly be due to antibody-dependent cell-mediated cytotoxicity, a luciferase-dependent assay for quantifying biologically active adenosine further showed that A1 and 7G2 can inhibit CD39 and CD73-dependent adenosine-generation.  In turn, the reduction in adenosine levels achieved by addition of A1 and 7G2 to OAW-42 or SK-OV-3 cells was found to de-inhibit the proliferation of CD4(+) T cells in coculture with OvCA cells.  Likewise, blocking of CD39 and CD73 on OvCA cells via A1 and 7G2 led to an increased cytotoxicity of alloreactive primed T cells.  Thus, antibodies like A1 and 7G2 could improve targeted therapy in ovarian cancer not only by specifically labeling overexpressed antigens but also by blocking adenosine-dependent immune evasion in this immunogenic malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9fEm3gySkQb9KldV63DuefW6udTcc2eavSyApzR0vxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvhsFajtA%253D%253D&md5=125b94ca750f445adab3e01a03bf897e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A4usler%26aufirst%3DS.%2BF.%26aulast%3DDel%2BBarrio%26aufirst%3DI.%2BM.%26aulast%3DDiessner%26aufirst%3DJ.%26aulast%3DStein%26aufirst%3DR.%2BG.%26aulast%3DStrohschein%26aufirst%3DJ.%26aulast%3DH%25C3%25B6nig%26aufirst%3DA.%26aulast%3DDietl%26aufirst%3DJ.%26aulast%3DWischhusen%26aufirst%3DJ.%26atitle%3DAnti-CD39%2520and%2520anti-CD73%2520antibodies%2520A1%2520and%25207G2%2520improve%2520targeted%2520therapy%2520in%2520ovarian%2520cancer%2520by%2520blocking%2520adenosine-dependent%2520immune%2520evasion%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2014%26volume%3D6%26spage%3D129%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousineau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendoo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haibe-Kains, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mes-Masson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 is associated with poor prognosis in high-grade serous ovarian cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4494</span>– <span class="NLM_lpage">4503</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-14-3569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26363007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGnu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4494-4503&author=M.+Turcotteauthor=K.+Springauthor=S.+Pommeyauthor=G.+Chouinardauthor=I.+Cousineauauthor=J.+Georgeauthor=G.+M.+Chenauthor=D.+M.+Gendooauthor=B.+Haibe-Kainsauthor=T.+Karnauthor=K.+Rahimiauthor=C.+Le+Pageauthor=D.+Provencherauthor=A.+M.+Mes-Massonauthor=J.+Stagg&title=CD73+is+associated+with+poor+prognosis+in+high-grade+serous+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-14-3569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer</span></div><div class="casAuthors">Turcotte, Martin; Spring, Kathleen; Pommey, Sandra; Chouinard, Guillaume; Cousineau, Isabelle; George, Joshy; Chen, Gregory M.; Gendoo, Deena M. A.; Haibe-Kains, Benjamin; Karn, Thomas; Rahimi, Kurosh; Le Page, Cecile; Provencher, Diane; Mes-Masson, Anne-Marie; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4494-4503</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The cell surface nucleotidase CD73 is an immunosuppressive enzyme involved in tumor progression and metastasis.  Although preclin. studies suggest that CD73 can be targeted for cancer treatment, the clin. impact of CD73 in ovarian cancer remains unclear.  In this study, we investigated the prognostic value of CD73 in high-grade serous (HGS) ovarian cancer using gene and protein expression analyses.  Our results demonstrate that high levels of CD73 are significantly assocd. with shorter disease-free survival and overall survival in patients with HGS ovarian cancer.  Furthermore, high levels of CD73 expression in ovarian tumor cells abolished the good prognosis assocd. with intraepithelial CD8+ cells.  Notably, CD73 gene expression was highest in the C1/stromal mol. subtype of HGS ovarian cancer and pos. correlated with an epithelial-to-mesenchymal transition gene signature.  Moreover, in vitro studies revealed that CD73 and extracellular adenosine enhance ovarian tumor cell growth as well as expression of antiapoptotic BCL-2 family members.  Finally, in vivo coinjection of ID8 mouse ovarian tumor cells with mouse embryonic fibroblasts showed that CD73 expression in fibroblasts promotes tumor immune escape and thereby tumor growth.  In conclusion, our study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in HGS ovarian cancers.  Cancer Res; 75(21); 4494-503. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0cI-iFGChprVg90H21EOLACvtfcHk0licFEiCyQ6HFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGnu7vF&md5=168775cf106084e44de08a6f6a302255</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3569%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DK.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DChouinard%26aufirst%3DG.%26aulast%3DCousineau%26aufirst%3DI.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%2BM.%26aulast%3DGendoo%26aufirst%3DD.%2BM.%26aulast%3DHaibe-Kains%26aufirst%3DB.%26aulast%3DKarn%26aufirst%3DT.%26aulast%3DRahimi%26aufirst%3DK.%26aulast%3DLe%2BPage%26aufirst%3DC.%26aulast%3DProvencher%26aufirst%3DD.%26aulast%3DMes-Masson%26aufirst%3DA.%2BM.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520is%2520associated%2520with%2520poor%2520prognosis%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4494%26epage%3D4503%26doi%3D10.1158%2F0008-5472.CAN-14-3569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparwasser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2892</span>– <span class="NLM_lpage">2900</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-10-4246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21292811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2892-2900&author=J.+Staggauthor=U.+Divisekeraauthor=H.+Duretauthor=T.+Sparwasserauthor=M.+W.+Tengauthor=P.+K.+Darcyauthor=M.+J.+Smyth&title=CD73-deficient+mice+have+increased+antitumor+immunity+and+are+resistant+to+experimental+metastasis&doi=10.1158%2F0008-5472.CAN-10-4246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis</span></div><div class="casAuthors">Stagg, John; Divisekera, Upulie; Duret, Helene; Sparwasser, Tim; Teng, Michele W. L.; Darcy, Phillip K.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2892-2900</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CD73 is a cell-surface enzyme that suppresses immune responses by producing extracellular adenosine.  In this study, we employed CD73 gene-targeted mice to investigate the role of host-derived CD73 on antitumor immunity and tumor cell metastasis.  We found that CD73 ablation significantly suppressed the growth of ovalbumin-expressing MC38 colon cancer, EG7 lymphoma, AT-3 mammary tumors, and B16F10 melanoma.  The protective effect of CD73 deficiency on primary tumors was dependent on CD8+ T cells and assocd. with an increased frequency of antigen-specific CD8+ T cells in peripheral blood and tumors and increased antigen-specific IFN-γ prodn.  Replicate studies in bone marrow chimeras established that both hematopoietic and nonhematopoietic expression of CD73 was important to promote tumor immune escape.  Using adoptive reconstitution of T regulatory cell (Treg)-depleted DEREG (depletion of regulatory T cells) mice, we demonstrated that part of the protumorigenic effect of Tregs was dependent on their expression of CD73.  CD73-deficient mice were also protected against pulmonary metastasis of B16F10 melanoma cells after i.v. injection.  Unexpectedly, we found that the prometastatic effect of host-derived CD73 was dependent on CD73 expression on nonhematopoietic cells.  CD73 expression on nonhematopoietic cells, most likely endothelial cells, was crit. for promoting lung metastasis in a manner independent from immunosuppressive effects.  Notably, in vivo blockade of CD73 with a selective inhibitor or anti-CD73 monoclonal antibody significantly reduced tumor growth and metastasis of CD73-neg. tumors.  Taken together, our findings indicate that CD73 may be targeted at multiple levels to induce anticancer effects including at the level of tumor cells, Tregs, and nonhematopoietic cells.  Cancer Res; 71(8); 2892-900.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQxUwCZ8XerVg90H21EOLACvtfcHk0lgitCoHYsK0mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslWjs78%253D&md5=94cc37e9eb84e5e8cce990252cc0e7a2</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4246%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DDuret%26aufirst%3DH.%26aulast%3DSparwasser%26aufirst%3DT.%26aulast%3DTeng%26aufirst%3DM.%2BW.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DCD73-deficient%2520mice%2520have%2520increased%2520antitumor%2520immunity%2520and%2520are%2520resistant%2520to%2520experimental%2520metastasis%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2892%26epage%3D2900%26doi%3D10.1158%2F0008-5472.CAN-10-4246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryzhov, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickup, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chytil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorska, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feoktistov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novitskiy, S. V.</span></span> <span> </span><span class="NLM_article-title">Role of TGF-beta signaling in generation of CD39+CD73+ myeloid cells in tumors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">3155</span>– <span class="NLM_lpage">3164</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1400578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.4049%2Fjimmunol.1400578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25127858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2qurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=3155-3164&author=S.+V.+Ryzhovauthor=M.+W.+Pickupauthor=A.+Chytilauthor=A.+E.+Gorskaauthor=Q.+Zhangauthor=P.+Owensauthor=I.+Feoktistovauthor=H.+L.+Mosesauthor=S.+V.+Novitskiy&title=Role+of+TGF-beta+signaling+in+generation+of+CD39%2BCD73%2B+myeloid+cells+in+tumors&doi=10.4049%2Fjimmunol.1400578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors</span></div><div class="casAuthors">Ryzhov, Sergey V.; Pickup, Michael W.; Chytil, Anna; Gorska, Agnieszka E.; Zhang, Qinkun; Owens, Philip; Feoktistov, Igor; Moses, Harold L.; Novitskiy, Sergey V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3155-3164</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">There is growing evidence that generation of adenosine from ATP, which is mediated by the CD39/CD73 enzyme pair, predetermines immunosuppressive and proangiogenic properties of myeloid cells.  We have previously shown that the deletion of the TGF-β type II receptor gene (Tgfbr2) expression in myeloid cells is assocd. with decreased tumor growth, suggesting protumorigenic effect of TGF-β signaling.  In this study, we tested the hypothesis that TGF-β drives differentiation of myeloid-derived suppressor cells into protumorigenic terminally differentiated myeloid mononuclear cells (TDMMCs) characterized by high levels of cell-surface CD39/CD73 expression.  We found that TDMMCs represent a major cell subpopulation expressing high levels of both CD39 and CD73 in the tumor microenvironment.  In tumors isolated from mice with spontaneous tumor formation of mammary gland and conditional deletion of the type II TGF-β receptor in mammary epithelium, an increased level of TGF-β protein was assocd. with further increase in no. of CD39+CD73+ TDMMCs compared with MMTV-PyMT/TGFβRIIWT control tumors with intact TGF-β signaling.  Using genetic and pharmacol. approaches, we demonstrated that the TGF-β signaling mediates maturation of myeloid-derived suppressor cells into TDMMCs with high levels of cell surface CD39/CD73 expression and adenosine-generating capacity.  Disruption of TGF-β signaling in myeloid cells resulted in decreased accumulation of TDMMCs, expressing CD39 and CD73, and was accompanied by increased infiltration of T lymphocytes, reduced d. of blood vessels, and diminished progression of both Lewis lung carcinoma and spontaneous mammary carcinomas.  We propose that TGF-β signaling can directly induce the generation of CD39+CD73+ TDMMCs, thus contributing to the immunosuppressive, proangiogenic, and tumor-promoting effects of this pleiotropic effector in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWhuAg0SxIRLVg90H21EOLACvtfcHk0liXKdstA7RcKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2qurvM&md5=829d2afc57700dbcff9d6827c5ad0531</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1400578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1400578%26sid%3Dliteratum%253Aachs%26aulast%3DRyzhov%26aufirst%3DS.%2BV.%26aulast%3DPickup%26aufirst%3DM.%2BW.%26aulast%3DChytil%26aufirst%3DA.%26aulast%3DGorska%26aufirst%3DA.%2BE.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DOwens%26aufirst%3DP.%26aulast%3DFeoktistov%26aufirst%3DI.%26aulast%3DMoses%26aufirst%3DH.%2BL.%26aulast%3DNovitskiy%26aufirst%3DS.%2BV.%26atitle%3DRole%2520of%2520TGF-beta%2520signaling%2520in%2520generation%2520of%2520CD39%252BCD73%252B%2520myeloid%2520cells%2520in%2520tumors%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D3155%26epage%3D3164%26doi%3D10.4049%2Fjimmunol.1400578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 therapy impairs tumor angiogenesis</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1466</span>– <span class="NLM_lpage">1473</span>, <span class="refDoi"> DOI: 10.1002/ijc.28456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1002%2Fijc.28456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23982901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVKnsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=1466-1473&author=B.+Allardauthor=M.+Turcotteauthor=K.+Springauthor=S.+Pommeyauthor=I.+Royalauthor=J.+Stagg&title=Anti-CD73+therapy+impairs+tumor+angiogenesis&doi=10.1002%2Fijc.28456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 therapy impairs tumor angiogenesis</span></div><div class="casAuthors">Allard, Bertrand; Turcotte, Martin; Spring, Kathleen; Pommey, Sandra; Royal, Isabelle; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1466-1473</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">CD73 is an ecto-nucleotidase overexpressed in various types of tumors that catabolizes the generation of extracellular adenosine, a potent immunosuppressor.  We and others have shown that targeted blockade of CD73 can rescue anti-tumor T cells from the immunosuppressive effects of extracellular adenosine.  Another important function of extracellular adenosine is to regulate adaptive responses to hypoxia.  However, the importance of CD73 for tumor angiogenesis and the effect of anti-CD73 therapy on tumor angiogenesis remain unknown.  In this study, we demonstrated that CD73 expression on tumor cells and host cells contribute to tumor angiogenesis.  Our data revealed that tumor-derived CD73 enhances the prodn. of vascular endothelial growth factor (VEGF) by tumor cells that host-derived CD73 is required for in vivo angiogenic responses and that endothelial cells require CD73 expression for tube formation and migration.  Notably, the pro-angiogeneic effects of CD73 relied on both enzymic and non-enzymic functions.  Using a mouse model of breast cancer, we demonstrated that targeted blockade of CD73 with a monoclonal antibody significantly decreased tumor VEGF levels and suppressed tumor angiogenesis in vivo.  Taken together, our study strongly suggests that targeted blockade of CD73 can significantly block tumor angiogenesis, and further supports its clin. development for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD0tXpGfw0W7Vg90H21EOLACvtfcHk0liXKdstA7RcKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVKnsrnF&md5=888109a577d25c4b4ed0769a4b200439</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fijc.28456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28456%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DK.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DRoyal%26aufirst%3DI.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DAnti-CD73%2520therapy%2520impairs%2520tumor%2520angiogenesis%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2014%26volume%3D134%26spage%3D1466%26epage%3D1473%26doi%3D10.1002%2Fijc.28456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thibaudin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boidot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegran, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derangere, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limagne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladoire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apetoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiringhelli, F.</span></span> <span> </span><span class="NLM_article-title">Human ectonucleotidase-expressing CD25(high) Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1055444</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2015.1055444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1080%2F2162402X.2015.1055444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26942062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1Ogu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e1055444&author=M.+Thibaudinauthor=M.+Chaixauthor=R.+Boidotauthor=F.+Vegranauthor=V.+Derangereauthor=E.+Limagneauthor=H.+Bergerauthor=S.+Ladoireauthor=L.+Apetohauthor=F.+Ghiringhelli&title=Human+ectonucleotidase-expressing+CD25%28high%29+Th17+cells+accumulate+in+breast+cancer+tumors+and+exert+immunosuppressive+functions&doi=10.1080%2F2162402X.2015.1055444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions</span></div><div class="casAuthors">Thibaudin, Marion; Chaix, Marie; Boidot, Romain; Vegran, Frederique; Derangere, Valentin; Limagne, Emeric; Berger, Helene; Ladoire, Sylvain; Apetoh, Lionel; Ghiringhelli, Francois</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1055444/1-e1055444/12</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Th17 cells contribute to the development of some autoimmune and allergic diseases by driving tissue inflammation.  However, the function of Th17 cells during cancer progression remains controversial.  Here, we show that human memory CD25high Th17 cells suppress T cell immunity in breast cancer.  Ectonucleotidase-expressing Th17 cells accumulated in breast cancer tumors and suppressed CD4+ and CD8+ T cell activation.  These cells expressed both Rorγt and Foxp3 genes and secreted Th17 related cytokines.  We further found that CD39 ectonucleotisase expression on tumor-infiltrating Th17 cells was driven by TGF-β and IL-6.  Finally, immunohistochem. anal. of localized breast cancer revealed that high-tumor infiltration by IL-17+ cells was assocd. with a poor clin. outcome and impeded the favorable effect of high CD8+ infiltration.  Altogether, these findings suggest that intratumoral Th17 cells compromise anticancer immune responses in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrigQPxb4ZFs7Vg90H21EOLACvtfcHk0liXKdstA7RcKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1Ogu7s%253D&md5=0a3f1bf8566b58d8a05fe761ab4476d2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2015.1055444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2015.1055444%26sid%3Dliteratum%253Aachs%26aulast%3DThibaudin%26aufirst%3DM.%26aulast%3DChaix%26aufirst%3DM.%26aulast%3DBoidot%26aufirst%3DR.%26aulast%3DVegran%26aufirst%3DF.%26aulast%3DDerangere%26aufirst%3DV.%26aulast%3DLimagne%26aufirst%3DE.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DLadoire%26aufirst%3DS.%26aulast%3DApetoh%26aufirst%3DL.%26aulast%3DGhiringhelli%26aufirst%3DF.%26atitle%3DHuman%2520ectonucleotidase-expressing%2520CD25%2528high%2529%2520Th17%2520cells%2520accumulate%2520in%2520breast%2520cancer%2520tumors%2520and%2520exert%2520immunosuppressive%2520functions%26jtitle%3DOncoimmunology%26date%3D2016%26volume%3D5%26spage%3De1055444%26doi%3D10.1080%2F2162402X.2015.1055444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choukèr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxt045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1093%2Fintimm%2Fdxt045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24150242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFKmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=83-91&author=A.+Ohtaauthor=M.+Madasuauthor=M.+Subramanianauthor=R.+Kiniauthor=G.+Jonesauthor=A.+Chouk%C3%A8rauthor=A.+Ohtaauthor=M.+Sitkovsky&title=Hypoxia-induced+and+A2A+adenosine+receptor-independent+T-cell+suppression+is+short+lived+and+easily+reversible&doi=10.1093%2Fintimm%2Fdxt045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible</span></div><div class="casAuthors">Ohta, Akio; Madasu, Manasa; Subramanian, Meenakshi; Kini, Radhika; Jones, Graham; Chouker, Alexander; Ohta, Akiko; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Hypoxia can induce adenosine-independent T-cell suppression in vivo and in vitro.  Tissue hypoxia plays a key role in establishing an immunosuppressive environment in vivo by, among other effects, increasing the level of extracellular adenosine, which then signals through A2A adenosine receptor (A2AR) to elicit its immunosuppressive effect.  Although the important role of the adenosine-A2AR interaction in limiting inflammation has been established, the current study revisited this issue by asking whether hypoxia can also exert its T-cell inhibitory effects even without A2AR.  A similar degree of hypoxia-triggered inhibition was obsd. in wild-type and A2AR-deficient T cells both in vitro and, after exposure of mice to a hypoxic atm., in vivo.  This A2AR-independent hypoxic T-cell suppression was qual. and mechanistically different from immunosuppression by A2AR stimulation.  The A2AR-independent hypoxic immunosuppression strongly reduced T-cell proliferation, while IFN-γ-producing activity was more susceptible to the A2AR-dependent inhibition.  In contrast to the sustained functional impairment after A2AR-mediated T-cell inhibition, the A2AR-independent inhibition under hypoxia was short lived, as evidenced by the quick recovery of IFN-γ-producing activity upon re-stimulation.  These data support the view that T-cell inhibition by hypoxia can be mediated by multiple mechanisms and that both A2AR and key mols. in the A2AR-independent T-cell inhibition should be targeted to overcome the hypoxia-related immunosuppression in infected tissues and tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmvOzAQPmO5LVg90H21EOLACvtfcHk0ljZDUm6kuY3gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFKmsbo%253D&md5=ce85083b79e8dc5b85def3e65963b4b8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxt045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxt045%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DMadasu%26aufirst%3DM.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DKini%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DChouk%25C3%25A8r%26aufirst%3DA.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DHypoxia-induced%2520and%2520A2A%2520adenosine%2520receptor-independent%2520T-cell%2520suppression%2520is%2520short%2520lived%2520and%2520easily%2520reversible%26jtitle%3DInt.%2520Immunol.%26date%3D2014%26volume%3D26%26spage%3D83%26epage%3D91%26doi%3D10.1093%2Fintimm%2Fdxt045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milenkovski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kershaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptor 2a blockade increases the efficacy of anti-Pd-1 through enhanced antitumor T-cell responses</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-14-0211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F2326-6066.CIR-14-0211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25672397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvV2msbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=506-517&author=P.+A.+Beavisauthor=N.+Milenkovskiauthor=M.+A.+Hendersonauthor=L.+B.+Johnauthor=B.+Allardauthor=S.+Loiauthor=M.+H.+Kershawauthor=J.+Staggauthor=P.+K.+Darcy&title=Adenosine+receptor+2a+blockade+increases+the+efficacy+of+anti-Pd-1+through+enhanced+antitumor+T-cell+responses&doi=10.1158%2F2326-6066.CIR-14-0211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses</span></div><div class="casAuthors">Beavis, Paul A.; Milenkovski, Nicole; Henderson, Melissa A.; John, Liza B.; Allard, Bertrand; Loi, Sherene; Kershaw, Michael H.; Stagg, John; Darcy, Phillip K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">506-517</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Beavis, Milenkovski, and colleagues reveal that adenosine receptor blockade enhanced anti-PD-1 efficacy against CD73+ tumors in twomouse models via augmentation of tumor-infiltrating CD8+ T-cell effector function by increasing IFNγ and Granzyme B prodn. and suggest CD73 expression as a biomarker for anti-PD-1 efficacy.  Immunotherapy is rapidly emerging as a cancer treatment with high potential.  Recent clin. trials with anti-CTLA-4 and anti-PD-1/PD-L1 antibodies (mAbs) suggest that targeting multiple immunosuppressive pathways may significantly improve patient survival.  The generation of adenosine by CD73 also suppresses antitumor immune responses through the activation of A2A receptors on T cells and natural killer (NK) cells.  We sought to det. whether blockade of A2A receptors could enhance the efficacy of anti-PD-1 mAb.  The expression of CD73 by tumor cells limited the efficacy of anti-PD-1 mAb in two tumor models, and this was alleviated with concomitant treatment with an A2A adenosine receptor antagonist.  The blockade of PD-1 enhanced A2A receptor expression on tumor-infiltrating CD8+ T cells, making them more susceptible to A2A-mediated suppression.  Thus, dual blockade of PD-1 and A2A significantly enhanced the expression of IFNγ and Granzyme B by tumor-infiltrating CD8+ T cells and, accordingly, increased growth inhibition of CD73+ tumors and survival of mice.  The results of our study indicate that CD73 expression may constitute a potential biomarker for the efficacy of anti-PD-1 mAb in patients with cancer and that the efficacy of anti-PD-1 mAb can be significantly enhanced by A2A antagonists.  We have therefore revealed a potentially novel biomarker for the efficacy of anti-PD-1 that warrants further investigation in patients.  Because our studies used SYN-115, a drug that has already undergone phase IIb testing in Parkinson disease, our findings have immediate translational relevance for patients with cancer.  Cancer Immunol Res; 3(5); 506-17. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0mXEGNShKXLVg90H21EOLACvtfcHk0ljZDUm6kuY3gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvV2msbY%253D&md5=2a5eaf10df8675fa514039c64acfc85f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-14-0211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-14-0211%26sid%3Dliteratum%253Aachs%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DMilenkovski%26aufirst%3DN.%26aulast%3DHenderson%26aufirst%3DM.%2BA.%26aulast%3DJohn%26aufirst%3DL.%2BB.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DKershaw%26aufirst%3DM.%2BH.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26atitle%3DAdenosine%2520receptor%25202a%2520blockade%2520increases%2520the%2520efficacy%2520of%2520anti-Pd-1%2520through%2520enhanced%2520antitumor%2520T-cell%2520responses%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2015%26volume%3D3%26spage%3D506%26epage%3D517%26doi%3D10.1158%2F2326-6066.CIR-14-0211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leclerc, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlebois, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 expression is an independent prognostic factor in prostate cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1078-0432.CCR-15-1181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26253870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=158-166&author=B.+G.+Leclercauthor=R.+Charleboisauthor=G.+Chouinardauthor=B.+Allardauthor=S.+Pommeyauthor=F.+Saadauthor=J.+Stagg&title=CD73+expression+is+an+independent+prognostic+factor+in+prostate+cancer&doi=10.1158%2F1078-0432.CCR-15-1181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer</span></div><div class="casAuthors">Leclerc, Bruno G.; Charlebois, Roxanne; Chouinard, Guillaume; Allard, Bertrand; Pommey, Sandra; Saad, Fred; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-166</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: CD73 is an adenosine-generating ecto-enzyme that suppresses antitumor immunity in mouse models of cancer, including prostate cancer.  Although high levels of CD73 are assocd. with poor prognosis in various types of cancer, the clin. impact of CD73 in prostate cancer remains unclear.  Exptl. Design: We evaluated the prognostic value of CD73 protein expression and CD8+ cell d. in 285 cases of prostate cancer on tissue microarray (TMA).  Normal adjacent and tumor tissues were evaluated in duplicates.  Results: Univariate and multivariate analyses revealed that high levels of CD73 in normal adjacent prostate epithelium were significantly assocd. with shorter biochem. recurrence (BCR)-free survival.  Notably, CD73 expression in normal epithelium conferred a neg. prognostic value to prostate-infiltrating CD8+ cells.  Surprisingly, high levels of CD73 in the tumor stroma were assocd. with longer BCR-free survival in univariate anal.  In vitro studies revealed that adenosine signaling inhibited NF-κB activity in human prostate cancer cells via A2B adenosine receptors.  Consistent with these results, CD73 expression in the prostate tumor stroma neg. correlated with p65 expression in the nuclei of prostate tumor cells.  Conclusions: Our study revealed that CD73 is an independent prognostic factor in prostate cancer.  Our data support a model in which CD73 expression in the prostate epithelium suppresses immunosurveillance by CD8+ T cells, whereas CD73 expression in the tumor stroma reduces NF-κB signaling in tumor cells via A2B adenosine receptor signaling.  CD73 expression, including in normal adjacent prostate epithelium, can thus effectively discriminate between aggressive and indolent forms of prostate cancer.  Clin Cancer Res; 22(1); 158-66. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9HCI_kLOGLVg90H21EOLACvtfcHk0li1iISK2-HP0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqsrk%253D&md5=f775efcc9f67005fcc4d0696399ab79f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1181%26sid%3Dliteratum%253Aachs%26aulast%3DLeclerc%26aufirst%3DB.%2BG.%26aulast%3DCharlebois%26aufirst%3DR.%26aulast%3DChouinard%26aufirst%3DG.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520expression%2520is%2520an%2520independent%2520prognostic%2520factor%2520in%2520prostate%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D158%26epage%3D166%26doi%3D10.1158%2F1078-0432.CCR-15-1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stannard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3652</span>– <span class="NLM_lpage">3658</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-14-0957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24986517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCqs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3652-3658&author=D.+Mittalauthor=A.+Youngauthor=K.+Stannardauthor=M.+Yongauthor=M.+W.+Tengauthor=B.+Allardauthor=J.+Staggauthor=M.+J.+Smyth&title=Antimetastatic+effects+of+blocking+PD-1+and+the+adenosine+A2A+receptor&doi=10.1158%2F0008-5472.CAN-14-0957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor</span></div><div class="casAuthors">Mittal, Deepak; Young, Arabella; Stannard, Kimberley; Yong, Michelle; Teng, Michele W. L.; Allard, Bertrand; Stagg, John; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3652-3658</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Adenosine targeting is an attractive new approach to cancer treatment, but no clin. study has yet examd. adenosine inhibition in oncol. despite the safe clin. profile of adenosine A2A receptor inhibitors (A2ARi) hi Parkinson disease.  Metastasis is the main cause of cancer-related deaths worldwide, and therefore we have studied exptl. and spontaneous mouse models of melanoma and breast cancer metastasis to demonstrate the efficacy and mechanism of a combination of A2ARi in combination with anti-PD-1 monoclonal antibody (mAb).  This combination significantly reduces metastatic burden and prolongs the life of mice compared with either monotherapy alone.  Importantly, the combination was only effective when the tumor expressed high levels of CD73, suggesting a tumor biomarker that at a min. could be used to stratify patients that might receive this combination.  The mechanism of the combination therapy was critically dependent on NK cells and IFNγ, and to a lesser extent, CD8+ T cells and the effector mol., perforin.  Overall, these results provide a strong rationale to use A2ARi with anti-PD-1 mAb for the treatment of minimal residual and metastatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW_l2JwbYd0bVg90H21EOLACvtfcHk0li1iISK2-HP0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCqs7fO&md5=9baa0050f726559abfa70b30f94419a5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0957%26sid%3Dliteratum%253Aachs%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DStannard%26aufirst%3DK.%26aulast%3DYong%26aufirst%3DM.%26aulast%3DTeng%26aufirst%3DM.%2BW.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DAntimetastatic%2520effects%2520of%2520blocking%2520PD-1%2520and%2520the%2520adenosine%2520A2A%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3652%26epage%3D3658%26doi%3D10.1158%2F0008-5472.CAN-14-0957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatfield, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaergaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukashev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belikoff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethumadhavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philbrook, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannici, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podack, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M. V.</span></span> <span> </span><span class="NLM_article-title">Immunological mechanisms of the antitumor effects of supplemental oxygenation</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">277ra30</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa1260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1126%2Fscitranslmed.aaa1260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25739764" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=277ra30&author=S.+M.+Hatfieldauthor=J.+Kjaergaardauthor=D.+Lukashevauthor=T.+H.+Schreiberauthor=B.+Belikoffauthor=R.+Abbottauthor=S.+Sethumadhavanauthor=P.+Philbrookauthor=K.+Koauthor=R.+Canniciauthor=M.+Thayerauthor=S.+Rodigauthor=J.+L.+Kutokauthor=E.+K.+Jacksonauthor=B.+Kargerauthor=E.+R.+Podackauthor=A.+Ohtaauthor=M.+V.+Sitkovsky&title=Immunological+mechanisms+of+the+antitumor+effects+of+supplemental+oxygenation&doi=10.1126%2Fscitranslmed.aaa1260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa1260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa1260%26sid%3Dliteratum%253Aachs%26aulast%3DHatfield%26aufirst%3DS.%2BM.%26aulast%3DKjaergaard%26aufirst%3DJ.%26aulast%3DLukashev%26aufirst%3DD.%26aulast%3DSchreiber%26aufirst%3DT.%2BH.%26aulast%3DBelikoff%26aufirst%3DB.%26aulast%3DAbbott%26aufirst%3DR.%26aulast%3DSethumadhavan%26aufirst%3DS.%26aulast%3DPhilbrook%26aufirst%3DP.%26aulast%3DKo%26aufirst%3DK.%26aulast%3DCannici%26aufirst%3DR.%26aulast%3DThayer%26aufirst%3DM.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26aulast%3DJackson%26aufirst%3DE.%2BK.%26aulast%3DKarger%26aufirst%3DB.%26aulast%3DPodack%26aufirst%3DE.%2BR.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DSitkovsky%26aufirst%3DM.%2BV.%26atitle%3DImmunological%2520mechanisms%2520of%2520the%2520antitumor%2520effects%2520of%2520supplemental%2520oxygenation%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26spage%3D277ra30%26doi%3D10.1126%2Fscitranslmed.aaa1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span> <span> </span><span class="NLM_article-title">Adenosine promotes Foxp3 expression in Treg cells in sepsis model by activating JNK/AP-1 pathway</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2284</span>– <span class="NLM_lpage">2292</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=27347335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVGnurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=2284-2292&author=R.+Baoauthor=J.+Houauthor=Y.+Liauthor=J.+Bianauthor=X.+Dengauthor=X.+Zhuauthor=T.+Yang&title=Adenosine+promotes+Foxp3+expression+in+Treg+cells+in+sepsis+model+by+activating+JNK%2FAP-1+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine promotes Foxp3 expression in Treg cells in sepsis model by activating JNK/AP-1 pathway</span></div><div class="casAuthors">Bao, Rui; Hou, Jiong; Li, Yan; Bian, Jinjun; Deng, Xiaoming; Zhu, Xiaoyan; Yang, Tao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2284-2292</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Objectives: Forkhead/winged helix transcription factor p3 (Foxp3) increases in CD4+CD25+Treg cells during sepsis; however, related mechanisms are unclear.  Our study aimed to explore the possible mol. mechanisms of high expression of Foxp3 in Treg cells during sepsis.  Methods: Sepsis was induced by cecal ligation and puncture (CLP) method.  CD4+CD25+Treg cells were isolated from peripheral blood and identified by flow cytometry (FCM).  Treg cells were cultured with or without adenosine, adenosine agonist, adenosine antagonist, SMAD family member 3 (Smad3) agonist (transforming growth factor (TGF)-β1), or C-Jun N-Terminal Kinase (JNK) inhibitor.Expression levels of Foxp3 and activator protein 1 (AP-1) were detd.  The binding of c-Fos or c-Jun to the Foxp3 promoter was then evaluated by the chromatin immunopptn. (ChIP) assay and quantified by quant. real-time PCR (qRT-PCR).  The mRNA and protein levels of Foxp3 were detd. after transfection with siRNA against c-Fos, Fra2, c-Jun or JunD.  Results: Pharmacol. inhibition of both adenosine and JNK reduced Foxp3 protein levels.  JNK/ AP-1 activation was involved in increased levels of Foxp3 protein in CD4+CD25+Treg cells.  AP-1 regulated activity of Foxp3 promoter in Treg cells, and the induction of c-Fos or c-Jun activity leads to elevated transcription of Foxp3 gene.  Knockdown of c-Fos, Fra-2, c-Jun, or JunD levels also reduced Foxp3 expression.  Conclusion: We confirm that adenosine plays significant roles in the high expression of Foxp3.  Adenosine promotes Foxp3 expression in Treg cells during sepsis via JNK/AP-1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7rlySesXzILVg90H21EOLACvtfcHk0lgdq0ZOHpXAVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVGnurs%253D&md5=fc3a84095b552880b32e7ec4783b2a8e</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DR.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DT.%26atitle%3DAdenosine%2520promotes%2520Foxp3%2520expression%2520in%2520Treg%2520cells%2520in%2520sepsis%2520model%2520by%2520activating%2520JNK%252FAP-1%2520pathway%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2016%26volume%3D8%26spage%3D2284%26epage%3D2292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7259</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-3583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-13-3583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25377469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOhtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=7250-7259&author=C.+Cekicauthor=Y.+J.+Dayauthor=D.+Sagauthor=J.+Linden&title=Myeloid+expression+of+adenosine+A2A+receptor+suppresses+T+and+NK+cell+responses+in+the+solid+tumor+microenvironment&doi=10.1158%2F0008-5472.CAN-13-3583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment</span></div><div class="casAuthors">Cekic, Caglar; Day, Yuan-Ji; Sag, Duygu; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7250-7259</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study provides a mechanistic rationale to reposition inhibitors of a certain class of cell surface adenosine receptors to block an important pathway of immune escape that is commonly activated in solid tumors, with immediate implications for clin. evaluation.  High concns. of adenosine in tumor microenvironments inhibit antitumor cytotoxic lymphocyte responses.  Although T cells express inhibitory adenosine A2A receptors (A2AR) that suppress their activation and inhibit immune killing of tumors, a role for myeloid cell A2ARs in suppressing the immune response to tumors has yet to be investigated.  In this study, we show that the growth of transplanted syngeneic B16F10 melanoma or Lewis lung carcinoma cells is slowed in Adora2af/f-LysMCre+/- mice, which selectively lack myeloid A2ARs.  Reduced melanoma growth is assocd. with significant increases in MHCII and IL12 expression in tumor-assocd. macrophages and with >90% redns. in IL10 expression in tumor-assocd. macrophages, dendritic cells (DC), and Ly6C+ or Ly6G+ myeloid-derived suppressor cells (MDSC).  Myeloid deletion of A2ARs significantly increases CD44 expression on tumor-assocd. T cells and natural killer (NK) cells.  Depletion of CD8+ T cells or NK cells in tumor-bearing mice indicates that both cell types initially contribute to slowing melanoma growth in mice lacking myeloid A2A receptors, but tumor suppression mediated by CD8+ T cells is more persistent.  Myeloid-selective A2AR deletion significantly reduces lung metastasis of melanomas that express luciferase (for in vivo tracking) and ovalbumin (as a model antigen).  Reduced metastasis is assocd. with increased nos. and activation of NK cells and antigen-specific CD8+ T cells in lung infiltrates.  Overall, the findings indicate that myeloid cell A2ARs have direct myelosuppressive effects that indirectly contribute to the suppression of T cells and NK cells in primary and metastatic tumor microenvironments.  The results indicate that tumor-assocd. myeloid cells, including macrophages, DCs, and MDSCs all express immunosuppressive A2ARs that are potential targets of adenosine receptor blockers to enhance immune killing of tumors.  Cancer Res; 74(24); 7250-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXEUi0VvnzKLVg90H21EOLACvtfcHk0lgdq0ZOHpXAVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOhtrnL&md5=463ac7254c95ba8fcea06c7c32b045a4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-3583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-3583%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DDay%26aufirst%3DY.%2BJ.%26aulast%3DSag%26aufirst%3DD.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DMyeloid%2520expression%2520of%2520adenosine%2520A2A%2520receptor%2520suppresses%2520T%2520and%2520NK%2520cell%2520responses%2520in%2520the%2520solid%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D7250%26epage%3D7259%26doi%3D10.1158%2F0008-5472.CAN-13-3583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2371</span>– <span class="NLM_lpage">2382</span>, <span class="refDoi"> DOI: 10.1172/JCI45559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1172%2FJCI45559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21537079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVaitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2371-2382&author=L.+Wangauthor=J.+Fanauthor=L.+F.+Thompsonauthor=Y.+Zhangauthor=T.+Shinauthor=T.+J.+Curielauthor=B.+Zhang&title=CD73+has+distinct+roles+in+nonhematopoietic+and+hematopoietic+cells+to+promote+tumor+growth+in+mice&doi=10.1172%2FJCI45559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice</span></div><div class="casAuthors">Wang, Long; Fan, Jie; Thompson, Linda F.; Zhang, Yi; Shin, Tahiro; Curiel, Tyler J.; Zhang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2371-2382</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">CD73 is overexpressed in many types of human and mouse cancers and is implicated in the control of tumor progression.  However, the specific contribution from tumor or host CD73 expression to tumor growth remains unknown to date.  Here, we show that host CD73 promotes tumor growth in a T cell-dependent manner and that the optimal antitumor effect of CD73 blockade requires inhibiting both tumor and host CD73.  Notably, enzymic activity of CD73 on nonhematopoietic cells limited tumor-infiltrating T cells by controlling antitumor T cell homing to tumors in multiple mouse tumor models.  In contrast, CD73 on hematopoietic cells (including CD4+CD25+ Tregs) inhibited systemic antitumor T cell expansion and effector functions.  Thus, CD73 on hematopoietic and nonhematopoietic cells has distinct adenosinergic effects in regulating systemic and local antitumor T cell responses.  Importantly, pharmacol. blockade of CD73 using its selective inhibitor or an anti-CD73 mAb inhibited tumor growth and completely restored efficacy of adoptive T cell therapy in mice.  These findings suggest that both tumor and host CD73 cooperatively protect tumors from incoming antitumor T cells and show the potential of targeting CD73 as a cancer immunotherapy strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwVgJW9GQSfbVg90H21EOLACvtfcHk0ljeSFTlpopKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVaitro%253D&md5=175d9a4ca0c43f1a12bf4e8ce2462da7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1172%2FJCI45559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45559%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShin%26aufirst%3DT.%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%26atitle%3DCD73%2520has%2520distinct%2520roles%2520in%2520nonhematopoietic%2520and%2520hematopoietic%2520cells%2520to%2520promote%2520tumor%2520growth%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2371%26epage%3D2382%26doi%3D10.1172%2FJCI45559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Csóka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selmeczy, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koscsó, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Németh, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepka-Lenhart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gause, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibovich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">Adenosine promotes alternative macrophage activation via A2A and A2B receptors</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1096/fj.11-190934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1096%2Ffj.11-190934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21926236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlCnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=376-386&author=B.+Cs%C3%B3kaauthor=Z.+Selmeczyauthor=B.+Koscs%C3%B3author=Z.+H.+N%C3%A9methauthor=P.+Pacherauthor=P.+J.+Murrayauthor=D.+Kepka-Lenhartauthor=S.+M.+Morrisauthor=W.+C.+Gauseauthor=S.+J.+Leibovichauthor=G.+Hask%C3%B3&title=Adenosine+promotes+alternative+macrophage+activation+via+A2A+and+A2B+receptors&doi=10.1096%2Ffj.11-190934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine promotes alternative macrophage activation via A2A and A2B receptors</span></div><div class="casAuthors">Csoka, Balazs; Selmeczy, Zsolt; Koscso, Balazs; Nemeth, Zoltan H.; Pacher, Pal; Murray, Peter J.; Kepka-Lenhart, Diane; Morris, Sidney M., Jr.; Gause, William C.; Leibovich, S. Joseph; Hasko, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">376-386, 10.1096/fj.11-190934</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Adenosine has been implicated in suppressing the proinflammatory responses of classically activated macrophages induced by Th1 cytokines.  Alternative macrophage activation is induced by the Th2 cytokines interleukin (IL)-4 and IL-13; however, the role of adenosine in governing alternative macrophage activation is unknown.  We show here that adenosine treatment of IL-4- or IL-13-activated macrophages augments the expression of alternative macrophage markers arginase-1, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and macrophage galactose-type C-type lectin-1.  The stimulatory effect of adenosine required primarily A2B receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) increased both arginase activity (EC50 = 261.8 nM) and TIMP-1 prodn. (EC50 = 80.67 nM), and both pharmacol. and genetic blockade of A2B receptors prevented the effect of NECA.  A2A receptors also contributed to the adenosine augmentation of IL-4-induced TIMP-1 release, as both adenosine and NECA were less efficacious in augmenting TIMP-1 release by A2A receptor-deficient than control macrophages.  Of the transcription factors known to drive alternative macrophage activation, CCAAT-enhancer-binding protein β was required, while cAMP response element-binding protein and signal transducer and activator of transcription 6 were dispensable in mediating the effect of adenosine.  We propose that adenosine receptor activation suppresses inflammation and promotes tissue restitution, in part, by promoting alternative macrophage activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon6drkoEh9trVg90H21EOLACvtfcHk0ljeSFTlpopKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlCnsg%253D%253D&md5=437030997ac372ce9c927d8c18e19c45</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1096%2Ffj.11-190934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.11-190934%26sid%3Dliteratum%253Aachs%26aulast%3DCs%25C3%25B3ka%26aufirst%3DB.%26aulast%3DSelmeczy%26aufirst%3DZ.%26aulast%3DKoscs%25C3%25B3%26aufirst%3DB.%26aulast%3DN%25C3%25A9meth%26aufirst%3DZ.%2BH.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DMurray%26aufirst%3DP.%2BJ.%26aulast%3DKepka-Lenhart%26aufirst%3DD.%26aulast%3DMorris%26aufirst%3DS.%2BM.%26aulast%3DGause%26aufirst%3DW.%2BC.%26aulast%3DLeibovich%26aufirst%3DS.%2BJ.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DAdenosine%2520promotes%2520alternative%2520macrophage%2520activation%2520via%2520A2A%2520and%2520A2B%2520receptors%26jtitle%3DFASEB%2520J.%26date%3D2012%26volume%3D26%26spage%3D376%26epage%3D386%26doi%3D10.1096%2Ffj.11-190934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novitskiy, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryzhov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaynagetdinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhomirov, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biaggioni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feoktistov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikov, M. M.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors in regulation of dendritic cell differentiation and function</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1831</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-02-136325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1182%2Fblood-2008-02-136325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=18559975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVylu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=1822-1831&author=S.+V.+Novitskiyauthor=S.+Ryzhovauthor=R.+Zaynagetdinovauthor=A.+E.+Goldsteinauthor=Y.+Huangauthor=O.+Y.+Tikhomirovauthor=M.+R.+Blackburnauthor=I.+Biaggioniauthor=D.+P.+Carboneauthor=I.+Feoktistovauthor=M.+M.+Dikov&title=Adenosine+receptors+in+regulation+of+dendritic+cell+differentiation+and+function&doi=10.1182%2Fblood-2008-02-136325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors in regulation of dendritic cell differentiation and function</span></div><div class="casAuthors">Novitskiy, Sergey V.; Ryzhov, Sergey; Zaynagetdinov, Rinat; Goldstein, Anna E.; Huang, Yuhui; Tikhomirov, Oleg Y.; Blackburn, Michael R.; Biaggioni, Italo; Carbone, David P.; Feoktistov, Igor; Dikov, Mikhail M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1822-1831</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Differentiation of functional dendritic cells (DCs) critically depends on the microenvironment.  DCs differentiate in hypoxic tumor sites and inflamed or damaged tissue.  Because local concns. of adenosine reach high physiol. relevant levels in these conditions, we assessed the expression of adenosine receptors and the effect of their activation on differentiation of human monocytes and mouse peritoneal macrophages and hematopoietic progenitor cells (HPCs) into myeloid DCs.  Stimulation of adenosine receptors skews DC differentiation toward a distinct cell population characterized by expression of both DC and monocyte/macrophage cell surface markers.  Pharmacol. anal. and expts. with cells from A2B adenosine receptor knockout mice identified A2B receptor as the mediator of adenosine effects on DCs.  Unlike normal myeloid DCs, adenosine-differentiated DCs have impaired allostimulatory activity and express high levels of angiogenic, proinflammatory, immune suppressor, and tolerogenic factors, including VEGF, IL-8, IL-6, IL-10, COX-2, TGF-β, and IDO.  They promoted tumor growth if injected into tumors implanted in mice.  Using adenosine desaminase knockout animals, we showed that DCs with proangiogenic phenotype are highly abundant under conditions assocd. with elevated levels of extracellular adenosine in vivo.  Adenosine signaling through A2B receptor is an important factor of aberrant DC differentiation and generation of tolerogenic, angiogenic, and proinflammatory cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgQtMbXlnZUbVg90H21EOLACvtfcHk0ljeSFTlpopKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVylu7rF&md5=c5d285718ba75670e5f392736999a8f7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-02-136325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-02-136325%26sid%3Dliteratum%253Aachs%26aulast%3DNovitskiy%26aufirst%3DS.%2BV.%26aulast%3DRyzhov%26aufirst%3DS.%26aulast%3DZaynagetdinov%26aufirst%3DR.%26aulast%3DGoldstein%26aufirst%3DA.%2BE.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DTikhomirov%26aufirst%3DO.%2BY.%26aulast%3DBlackburn%26aufirst%3DM.%2BR.%26aulast%3DBiaggioni%26aufirst%3DI.%26aulast%3DCarbone%26aufirst%3DD.%2BP.%26aulast%3DFeoktistov%26aufirst%3DI.%26aulast%3DDikov%26aufirst%3DM.%2BM.%26atitle%3DAdenosine%2520receptors%2520in%2520regulation%2520of%2520dendritic%2520cell%2520differentiation%2520and%2520function%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D1822%26epage%3D1831%26doi%3D10.1182%2Fblood-2008-02-136325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrentraut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westrich, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltzschig, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clambey, E. T.</span></span> <span> </span><span class="NLM_article-title">Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e32416</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0032416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1371%2Fjournal.pone.0032416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22389701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ehsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e32416&author=H.+Ehrentrautauthor=J.+A.+Westrichauthor=H.+K.+Eltzschigauthor=E.+T.+Clambey&title=Adora2b+adenosine+receptor+engagement+enhances+regulatory+T+cell+abundance+during+endotoxin-induced+pulmonary+inflammation&doi=10.1371%2Fjournal.pone.0032416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation</span></div><div class="casAuthors">Ehrentraut, Heidi; Westrich, Joseph A.; Eltzschig, Holger K.; Clambey, Eric T.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e32416</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Anti-inflammatory signals play an essential role in constraining the magnitude of an inflammatory response.  Extracellular adenosine is a crit. tissue-protective factor, limiting the extent of inflammation.  Given the potent anti-inflammatory effects of extracellular adenosine, we sought to investigate how extracellular adenosine regulates T cell activation and differentiation.  Adenosine receptor activation by a pan adenosine-receptor agonist enhanced the abundance of murine regulatory T cells (Tregs), a cell type crit. in constraining inflammation.  Gene expression studies in both naive CD4 T cells and Tregs revealed that these cells expressed multiple adenosine receptors.  Based on recent studies implicating the Adora2b in endogenous anti-inflammatory responses during acute inflammation, we used a pharmacol. approach to specifically activate Adora2b.  Indeed, these studies revealed robust enhancement of Treg differentiation in wild-type mice, but not in Adora2b-/- T cells.  Finally, when we subjected Adora2b-deficient mice to endotoxin-induced pulmonary inflammation, we found that these mice experienced more severe inflammation, characterized by increased cell recruitment and increased fluid leakage into the airways.  Notably, Adora2b-deficient mice failed to induce Tregs after endotoxin-induced inflammation and instead had an enhanced recruitment of pro-inflammatory effector T cells.  In total, these data indicate that the Adora2b adenosine receptor serves a potent anti-inflammatory role, functioning at least in part through the enhancement of Tregs, to limit inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIRCjGWLan7Vg90H21EOLACvtfcHk0ljmyY0tBe_JmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ehsb0%253D&md5=619fe098459b52fc5b89b6366ecb218e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0032416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0032416%26sid%3Dliteratum%253Aachs%26aulast%3DEhrentraut%26aufirst%3DH.%26aulast%3DWestrich%26aufirst%3DJ.%2BA.%26aulast%3DEltzschig%26aufirst%3DH.%2BK.%26aulast%3DClambey%26aufirst%3DE.%2BT.%26atitle%3DAdora2b%2520adenosine%2520receptor%2520engagement%2520enhances%2520regulatory%2520T%2520cell%2520abundance%2520during%2520endotoxin-induced%2520pulmonary%2520inflammation%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De32416%26doi%3D10.1371%2Fjournal.pone.0032416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronchese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukashev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apasov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">A2A adenosine receptor protects tumors from antitumor T cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">13132</span>– <span class="NLM_lpage">13137</span>, <span class="refDoi"> DOI: 10.1073/pnas.0605251103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1073%2Fpnas.0605251103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16916931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD28Xptlelsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=13132-13137&author=A.+Ohtaauthor=E.+Gorelikauthor=S.+J.+Prasadauthor=F.+Roncheseauthor=D.+Lukashevauthor=M.+K.+Wongauthor=X.+Huangauthor=S.+Caldwellauthor=K.+Liuauthor=P.+Smithauthor=J.+F.+Chenauthor=E.+K.+Jacksonauthor=S.+Apasovauthor=S.+Abramsauthor=M.+Sitkovsky&title=A2A+adenosine+receptor+protects+tumors+from+antitumor+T+cells&doi=10.1073%2Fpnas.0605251103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A2A adenosine receptor protects tumors from antitumor T cells</span></div><div class="casAuthors">Ohta, Akio; Gorelik, Elieser; Prasad, Simon J.; Ronchese, Franca; Lukashev, Dmitriy; Wong, Michael K. K.; Huang, Xiaojun; Caldwell, Sheila; Liu, Kebin; Smith, Patrick; Chen, Jiang-Fan; Jackson, Edwin; Apasov, Sergey; Abrams, Scott; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13132-13137</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The A2A adenosine receptor (A2AR) has been shown to be a crit. and nonredundant neg. regulator of immune cells in protecting normal tissues from inflammatory damage.  We hypothesized that A2AR also protects cancerous tissues by inhibiting incoming antitumor T lymphocytes.  Here we confirm this hypothesis by showing that genetic deletion of A2AR in the host resulted in rejection of established immunogenic tumors in ≈60% of A2AR-deficient mice with no rejection obsd. in control WT mice.  The use of antagonists, including caffeine, or targeting the A2 receptors by siRNA pretreatment of T cells improved the inhibition of tumor growth, destruction of metastases, and prevention of neovascularization by antitumor T cells.  The data suggest that effects of A2AR are T cell autonomous.  The inhibition of antitumor T cells via their A2AR in the adenosine-rich tumor microenvironment may explain the paradoxical coexistence of tumors and antitumor immune cells in some cancer patients (the "Hellstrom paradox").  We propose to target the hypoxia→adenosine→A2AR pathway as a cancer immunotherapy strategy to prevent the inhibition of antitumor T cells in the tumor microenvironment.  The same strategy may prevent the premature termination of immune response and improve the vaccine-induced development of antitumor and antiviral T cells.  The observations of autoimmunity during melanoma rejection in A2AR-deficient mice suggest that A2AR in T cells is also important in preventing autoimmunity.  Thus, although using the hypoxia→adenosine→A2AR pathway inhibitors may improve antitumor immunity, the recruitment of this pathway by selective drugs is expected to attenuate the autoimmune tissue damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor_lg2Eaf727Vg90H21EOLACvtfcHk0ljmyY0tBe_JmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xptlelsrw%253D&md5=01291e44600fd286b82ea84f0d38aa7c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0605251103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0605251103%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DGorelik%26aufirst%3DE.%26aulast%3DPrasad%26aufirst%3DS.%2BJ.%26aulast%3DRonchese%26aufirst%3DF.%26aulast%3DLukashev%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCaldwell%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DJackson%26aufirst%3DE.%2BK.%26aulast%3DApasov%26aufirst%3DS.%26aulast%3DAbrams%26aufirst%3DS.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DA2A%2520adenosine%2520receptor%2520protects%2520tumors%2520from%2520antitumor%2520T%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D13132%26epage%3D13137%26doi%3D10.1073%2Fpnas.0605251103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paget, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span> <span> </span><span class="NLM_article-title">Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">14711</span>– <span class="NLM_lpage">14716</span>, <span class="refDoi"> DOI: 10.1073/pnas.1308209110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1073%2Fpnas.1308209110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23964122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVKksLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=14711-14716&author=P.+A.+Beavisauthor=U.+Divisekeraauthor=C.+Pagetauthor=M.+T.+Chowauthor=L.+B.+Johnauthor=C.+Devaudauthor=K.+Dwyerauthor=J.+Staggauthor=M.+J.+Smythauthor=P.+K.+Darcy&title=Blockade+of+A2A+receptors+potently+suppresses+the+metastasis+of+CD73%2B+tumors&doi=10.1073%2Fpnas.1308209110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors</span></div><div class="casAuthors">Beavis, Paul A.; Divisekera, Upulie; Paget, Christophe; Chow, Melvyn T.; John, Liza B.; Devaud, Christel; Dwyer, Karen; Stagg, John; Smyth, Mark J.; Darcy, Phillip K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">14711-14716,S14711/1-S14711/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">CD73 inhibits antitumor immunity through the activation of adenosine receptors expressed on multiple immune subsets.  CD73 also enhances tumor metastasis, although the nature of the immune subsets and adenosine receptor subtypes involved in this process are largely unknown.  In this study, the authors revealed that A2A/A2B receptor antagonists were effective in reducing the metastasis of tumors expressing CD73 endogenously (4T1.2 breast tumors) and when CD73 was ectopically expressed (B16F10 melanoma).  A2A-/- mice were strongly protected against tumor metastasis, indicating that host A2A receptors enhanced tumor metastasis.  A2A blockade enhanced natural killer (NK) cell maturation and cytotoxic function in vitro, reduced metastasis in a perforin-dependent manner, and enhanced NK cell expression of granzyme B in vivo, strongly suggesting that the antimetastatic effect of A2A blockade was due to enhanced NK cell function.  Interestingly, A2B blockade had no effect on NK cell cytotoxicity, indicating that an NK cell-independent mechanism also contributed to the increased metastasis of CD73+ tumors.  The authors' results thus revealed that CD73 promotes tumor metastasis through multiple mechanisms, including suppression of NK cell function.  Furthermore, the authors' data strongly suggest that A2A or A2B antagonists may be useful for the treatment of metastatic disease.  Overall, the authors' study has potential therapeutic implications given that A2A/A2B receptor antagonists have already entered clin. trials in other therapeutic settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYO0Dnl_qmy7Vg90H21EOLACvtfcHk0liXsukhqqiGHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVKksLzL&md5=7b55e554c472a46e7f08c2fcb691f1f4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1308209110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1308209110%26sid%3Dliteratum%253Aachs%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DPaget%26aufirst%3DC.%26aulast%3DChow%26aufirst%3DM.%2BT.%26aulast%3DJohn%26aufirst%3DL.%2BB.%26aulast%3DDevaud%26aufirst%3DC.%26aulast%3DDwyer%26aufirst%3DK.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26atitle%3DBlockade%2520of%2520A2A%2520receptors%2520potently%2520suppresses%2520the%2520metastasis%2520of%2520CD73%252B%2520tumors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D14711%26epage%3D14716%26doi%3D10.1073%2Fpnas.1308209110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waickman, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alme, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senaldi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarek, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1007/s00262-011-1155-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs00262-011-1155-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22116345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFKqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=917-926&author=A.+T.+Waickmanauthor=A.+Almeauthor=L.+Senaldiauthor=P.+E.+Zarekauthor=M.+Hortonauthor=J.+D.+Powell&title=Enhancement+of+tumor+immunotherapy+by+deletion+of+the+A2A+adenosine+receptor&doi=10.1007%2Fs00262-011-1155-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor</span></div><div class="casAuthors">Waickman, Adam T.; Alme, Angela; Senaldi, Liana; Zarek, Paul E.; Horton, Maureen; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The A2A adenosine receptor plays a crit. and non-redundant role in suppressing inflammation at sites of hypoxia and tissue damage.  The tumor microenvironment has high levels of adenosine as a result of hypoxia and ectopic expression of enzymes responsible for the generation of extracellular adenosine.  Thus, we sought to det. the ability of A2A receptor null mice to immunol. reject tumors.  We obsd. that mice lacking the A2A adenosine receptor showed significantly delayed growth of lymphoma cells when compared to WT mice.  Furthermore, when immunized with a low dose of tumor or with an irradiated GM-CSF-secreting tumor vaccine, A2A receptor null mice showed significantly enhanced protection from a subsequent high-dose challenge from both immunogenic and poorly immunogenic tumor lines.  This increase in protection was accompanied by an increase in the no. of tumor-antigen-specific CD8 T cells at the vaccine-site draining lymph node.  Finally, we found that A2A receptor null mice displayed more robust anti-tumor responses than WT mice when they were treated with a sol. B7-DC/Fc fusion protein designed to antagonize B7-H1-mediated co-inhibition.  This combinatorial immunotherapy strategy could also be recapitulated with pharmacol. A2A receptor blockade paired with B7-DC/Fc administration.  In light of these data, we believe that blockade of the A2A adenosine receptor is an attractive target for tumor immunotherapy that synergizes with other immunomodulatory approaches currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLwuC7utbv-7Vg90H21EOLACvtfcHk0liXsukhqqiGHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFKqu7s%253D&md5=6f3ac5af343eb37f6bac7109912f370d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00262-011-1155-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-011-1155-7%26sid%3Dliteratum%253Aachs%26aulast%3DWaickman%26aufirst%3DA.%2BT.%26aulast%3DAlme%26aufirst%3DA.%26aulast%3DSenaldi%26aufirst%3DL.%26aulast%3DZarek%26aufirst%3DP.%2BE.%26aulast%3DHorton%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DEnhancement%2520of%2520tumor%2520immunotherapy%2520by%2520deletion%2520of%2520the%2520A2A%2520adenosine%2520receptor%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2012%26volume%3D61%26spage%3D917%26epage%3D926%26doi%3D10.1007%2Fs00262-011-1155-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, S.</span></span> <span> </span><span class="NLM_article-title">Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24660106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVOksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=172-181&author=R.+Iannoneauthor=L.+Mieleauthor=P.+Maiolinoauthor=A.+Pintoauthor=S.+Morello&title=Adenosine+limits+the+therapeutic+effectiveness+of+anti-CTLA4+mAb+in+a+mouse+melanoma+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma mode</span></div><div class="casAuthors">Iannone, Raffaella; Miele, Lucio; Maiolino, Piera; Pinto, Aldo; Morello, Silvana</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-181, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Combination therapies for melanoma that target immune-regulatory networks are entering clin. practice and more are under investigation in preclin. or clin. studies.  Adenosine plays a key role in regulating melanoma progression.  We investigated the effectiveness of cytotoxic T lymphocyte-assocd. antigen 4 (CTLA-4) antibody (mAb) in combination with either modulators of adenosine receptors (AR) activation or an inhibitor of adenosine prodn. in a murine model of melanoma.  We found that treatment with APCP, selective inhibitor of the adenosine-generating nucleotidase CD73, enhanced the activity of anti-CTLA4 mAb, by improving tumor immune response.  Blockade of the adenosine A2a receptor (A2aR), which plays a crit. role in the regulation of T-cell functions, significantly reduced melanoma growth.  Most importantly, combination therapy including an A2aR antagonist with anti-CTLA4 mAb markedly inhibited tumor growth and enhanced anti-tumor immune responses.  Targeting A3R and CTLA4 was not as effective in limiting melanoma growth as targeting A2aR.  These data suggest that the efficacy of anti-CTLA4 melanoma therapy may be improved by targeting multiple mechanisms of immune suppression within tumor tissue, including CD73 or A2a receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzj-TJvGLs97Vg90H21EOLACvtfcHk0liz-iOmrOWEnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVOksrs%253D&md5=9df35166be411b35c4694eb1a4608581</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DMaiolino%26aufirst%3DP.%26aulast%3DPinto%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DS.%26atitle%3DAdenosine%2520limits%2520the%2520therapeutic%2520effectiveness%2520of%2520anti-CTLA4%2520mAb%2520in%2520a%2520mouse%2520melanoma%2520model%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2014%26volume%3D4%26spage%3D172%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuffrida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardiana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaney, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kats, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyorki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kershaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1172/JCI89455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1172%2FJCI89455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28165340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jsFahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=929-941&author=P.+A.+Beavisauthor=M.+A.+Hendersonauthor=L.+Giuffridaauthor=J.+K.+Millsauthor=K.+Sekauthor=R.+S.+Crossauthor=A.+J.+Davenportauthor=L.+B.+Johnauthor=S.+Mardianaauthor=C.+Y.+Slaneyauthor=R.+W.+Johnstoneauthor=J.+A.+Trapaniauthor=J.+Staggauthor=S.+Loiauthor=L.+Katsauthor=D.+Gyorkiauthor=M.+H.+Kershawauthor=P.+K.+Darcy&title=Targeting+the+adenosine+2A+receptor+enhances+chimeric+antigen+receptor+T+cell+efficacy&doi=10.1172%2FJCI89455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy</span></div><div class="casAuthors">Beavis Paul A; Henderson Melissa A; Giuffrida Lauren; Mills Jane K; Sek Kevin; Cross Ryan S; Davenport Alexander J; John Liza B; Mardiana Sherly; Slaney Clare Y; Johnstone Ricky W; Trapani Joseph A; Stagg John; Loi Sherene; Kats Lev; Gyorki David; Kershaw Michael H; Darcy Phillip K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">929-941</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chimeric antigen receptor (CAR) T cells have been highly successful in treating hematological malignancies, including acute and chronic lymphoblastic leukemia.  However, treatment of solid tumors using CAR T cells has been largely unsuccessful to date, partly because of tumor-induced immunosuppressive mechanisms, including adenosine production.  Previous studies have shown that adenosine generated by tumor cells potently inhibits endogenous antitumor T cell responses through activation of adenosine 2A receptors (A2ARs).  Herein, we have observed that CAR activation resulted in increased A2AR expression and suppression of both murine and human CAR T cells.  This was reversible using either A2AR antagonists or genetic targeting of A2AR using shRNA.  In 2 syngeneic HER2+ self-antigen tumor models, we found that either genetic or pharmacological targeting of the A2AR profoundly increased CAR T cell efficacy, particularly when combined with PD-1 blockade.  Mechanistically, this was associated with increased cytokine production of CD8+ CAR T cells and increased activation of both CD8+ and CD4+ CAR T cells.  Given the known clinical relevance of the CD73/adenosine pathway in several solid tumor types, and the initiation of phase I trials for A2AR antagonists in oncology, this approach has high translational potential to enhance CAR T cell efficacy in several cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRg-r0B0lykDP69nzq6467DfW6udTcc2eaT995lEJrcK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jsFahtA%253D%253D&md5=c46df40ff3c7d438497ccb57ca149e5f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1172%2FJCI89455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI89455%26sid%3Dliteratum%253Aachs%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DHenderson%26aufirst%3DM.%2BA.%26aulast%3DGiuffrida%26aufirst%3DL.%26aulast%3DMills%26aufirst%3DJ.%2BK.%26aulast%3DSek%26aufirst%3DK.%26aulast%3DCross%26aufirst%3DR.%2BS.%26aulast%3DDavenport%26aufirst%3DA.%2BJ.%26aulast%3DJohn%26aufirst%3DL.%2BB.%26aulast%3DMardiana%26aufirst%3DS.%26aulast%3DSlaney%26aufirst%3DC.%2BY.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DTrapani%26aufirst%3DJ.%2BA.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DKats%26aufirst%3DL.%26aulast%3DGyorki%26aufirst%3DD.%26aulast%3DKershaw%26aufirst%3DM.%2BH.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26atitle%3DTargeting%2520the%2520adenosine%25202A%2520receptor%2520enhances%2520chimeric%2520antigen%2520receptor%2520T%2520cell%2520efficacy%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D929%26epage%3D941%26doi%3D10.1172%2FJCI89455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haibe-Kains, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">11091</span>– <span class="NLM_lpage">11096</span>, <span class="refDoi"> DOI: 10.1073/pnas.1222251110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1073%2Fpnas.1222251110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=23776241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=11091-11096&author=S.+Loiauthor=S.+Pommeyauthor=B.+Haibe-Kainsauthor=P.+A.+Beavisauthor=P.+K.+Darcyauthor=M.+J.+Smythauthor=J.+Stagg&title=CD73+promotes+anthracycline+resistance+and+poor+prognosis+in+triple+negative+breast+cancer&doi=10.1073%2Fpnas.1222251110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</span></div><div class="casAuthors">Loi, Sherene; Pommey, Sandra; Haibe-Kains, Benjamin; Beavis, Paul A.; Darcy, Phillip K.; Smyth, Mark J.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11091-11096,S11091/1-S11091/21</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using gene-expression data from over 6,000 breast cancer patients, we report herein that high CD73 expression is assocd. with a poor prognosis in triple-neg. breast cancers (TNBC).  Because anthracycline-based chemotherapy regimens are std. treatment for TNBC, we investigated the relationship between CD73 and anthracycline efficacy.  In TNBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was significantly assocd. with a lower rate of pathol. complete response or the disappearance of invasive tumor at surgery.  Using mouse models of breast cancer, we demonstrated that CD73 overexpression in tumor cells conferred chemoresistance to doxorubicin, a commonly used anthracycline, by suppressing adaptive antitumor immune responses via activation of A2A adenosine receptors.  Targeted blockade of CD73 enhanced doxorubicin-mediated antitumor immune responses and significantly prolonged the survival of mice with established metastatic breast cancer.  Taken together, our data suggest that CD73 constitutes a therapeutic target in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6KtLUgWgbYbVg90H21EOLACvtfcHk0liz-iOmrOWEnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLrO&md5=97b58f664273accfcab7096dcbc76db6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1222251110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1222251110%26sid%3Dliteratum%253Aachs%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DHaibe-Kains%26aufirst%3DB.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520promotes%2520anthracycline%2520resistance%2520and%2520poor%2520prognosis%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D11091%26epage%3D11096%26doi%3D10.1073%2Fpnas.1222251110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vecchio, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L.</span></span> <span> </span><span class="NLM_article-title">Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.230003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1124%2Fjpet.115.230003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26791603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVeksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2016&pages=36-44&author=E.+A.+Vecchioauthor=C.+Y.+R.+Tanauthor=K.+J.+Gregoryauthor=A.+Christopoulosauthor=P.+J.+Whiteauthor=L.+May&title=Ligand-independent+adenosine+A2B+receptor+constitutive+activity+as+a+promoter+of+prostate+cancer+cell+proliferation&doi=10.1124%2Fjpet.115.230003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation</span></div><div class="casAuthors">Vecchio, Elizabeth A.; Tan, Christina Y. R.; Gregory, Karen J.; Christopoulos, Arthur; White, Paul J.; May, Lauren T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aberrant ligand-independent G protein-coupled receptor constitutive activity has been implicated in the pathophysiol. of a no. of cancers.  The adenosine A2B receptor (A2BAR) is dynamically upregulated under pathol. conditions assocd. with a hypoxic microenvironment, including solid tumors.  This, in turn, may amplify ligand-independent A2BAR signal transduction.  The contribution of A2BAR constitutive activity to disease progression is currently unknown yet of fundamental importance, as the preferred therapeutic modality for drugs designed to reduce A2BAR constitutive activity would be inverse agonism as opposed to neutral antagonism.  The current study investigated A2BAR constitutive activity in a heterologous expression system and a native 22Rv1 human prostate cancer cell line exposed to hypoxic conditions (2% O2).  The A2BAR inverse agonists, ZM241385 [4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol] or PSB-603 (8-(4-(4-(4-chlorophenyl)piperazide-1-sulfonyl)phenyl)-1-propylxanthine), mediated a concn.-dependent decrease in baseline cAMP levels in both cellular systems.  Proliferation of multiple prostate cancer cell lines was also attenuated in the presence of PSB-603.  Importantly, both the decrease in baseline cAMP accumulation and the redn. of proliferation were not influenced by the addn. of adenosine deaminase, demonstrating that these effects are not dependent on stimulation of A2BARs by the endogenous agonist adenosine.  Our study is the first to reveal that wild-type human A2BARs have high constitutive activity in both model and native cells.  Furthermore, our findings demonstrate that this ligand-independent A2BAR constitutive activity is sufficient to promote prostate cancer cell proliferation in vitro.  More broadly, A2BAR constitutive activity may have wider, currently unappreciated implications in pathol. conditions assocd. with a hypoxic microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgR2SqHb3o7Vg90H21EOLACvtfcHk0ljz-tnDqwlKGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVeksbw%253D&md5=47cef2c343e8efedf7b9497f704e6a33</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.230003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.230003%26sid%3Dliteratum%253Aachs%26aulast%3DVecchio%26aufirst%3DE.%2BA.%26aulast%3DTan%26aufirst%3DC.%2BY.%2BR.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DMay%26aufirst%3DL.%26atitle%3DLigand-independent%2520adenosine%2520A2B%2520receptor%2520constitutive%2520activity%2520as%2520a%2520promoter%2520of%2520prostate%2520cancer%2520cell%2520proliferation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D357%26spage%3D36%26epage%3D44%26doi%3D10.1124%2Fjpet.115.230003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodorescu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strieter, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2B receptor blockade slows growth of bladder and breast tumors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1101845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.4049%2Fjimmunol.1101845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22116822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Gltr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2012&pages=198-205&author=C.+Cekicauthor=D.+Sagauthor=Y.+Liauthor=D.+Theodorescuauthor=R.+M.+Strieterauthor=J.+Linden&title=Adenosine+A2B+receptor+blockade+slows+growth+of+bladder+and+breast+tumors&doi=10.4049%2Fjimmunol.1101845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors</span></div><div class="casAuthors">Cekic, Caglar; Sag, Duygu; Li, Yuesheng; Theodorescu, Dan; Strieter, Robert M.; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">198-205</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The accumulation of high levels of adenosine in tumors activates A2A and A2B receptors on immune cells and inhibits their ability to suppress tumor growth.  Deletion of adenosine A2A receptors (A2AARs) has been reported to activate antitumor T cells, stimulate dendritic cell (DC) function, and inhibit angiogenesis.  In this study, we evaluated the effects of intermittent intratumor injection of a nonselective adenosine receptor antagonist, aminophylline (AMO; theophylline ethylenediamine) and, for the first time to our knowledge, a selective A2BAR antagonist, ATL801.  AMO and ATL801 slowed the growth of MB49 bladder and 4T1 breast tumors in syngeneic mice and reduced by 85% metastasizes of breast cancer cells from mammary fat to lung.  Based on expts. with A2AAR-/- or adenosine A2B receptor-/- mice, the effect of AMO injection was unexpectedly attributed to A2BAR and not to A2AAR blockade.  AMO and ATL801 significantly increased tumor levels of IFN-γ and the IFN-inducible chemokine CXCL10, which is a ligand for CXCR3.  This was assocd. with an increase in activated tumor-infiltrating CXCR3+ T cells and a decrease in endothelial cell precursors within tumors.  Tumor growth inhibition by AMO or ATL801 was eliminated in CXCR3-/- mice and RAG1-/- mice that lack mature T cells.  In RAG1-/- mice, A2BAR deletion enhanced CD86 expression on CD11b- DCs.  Bone marrow chimera expts. demonstrated that CXCR3 and A2BAR expression on bone marrow cells is required for the antitumor effects of AMO.  The data suggest that blockade of A2BARs enhances DC activation and CXCR3-dependent antitumor responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJWI-EUe7h3rVg90H21EOLACvtfcHk0ljz-tnDqwlKGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Gltr7E&md5=dce403f7ab9a9ae0e90df07cf4b9392c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1101845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1101845%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DSag%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTheodorescu%26aufirst%3DD.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2B%2520receptor%2520blockade%2520slows%2520growth%2520of%2520bladder%2520and%2520breast%2520tumors%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D188%26spage%3D198%26epage%3D205%26doi%3D10.4049%2Fjimmunol.1101845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, S.</span></span> <span> </span><span class="NLM_article-title">Blockade of A2B adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1400</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1593/neo.131748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1593%2Fneo.131748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24403862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWls73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1400-1409&author=R.+Iannoneauthor=L.+Mieleauthor=P.+Maiolinoauthor=A.+Pintoauthor=S.+Morello&title=Blockade+of+A2B+adenosine+receptor+reduces+tumor+growth+and+immune+suppression+mediated+by+myeloid-derived+suppressor+cells+in+a+mouse+model+of+melanoma&doi=10.1593%2Fneo.131748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma</span></div><div class="casAuthors">Iannone, Raffaella; Miele, Lucio; Maiolino, Piera; Pinto, Aldo; Morello, Silvana</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1400-1409, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">The A2b receptor (A2bR) belongs to the adenosine receptor family.  Emerging evidence suggest that A2bR is implicated in tumor progression in some murine tumor models, but the therapeutic potential of targeting A2bR in melanoma has not been examd.  This study first shows that melanoma-bearing mice treated with Bay 60-6583, a selective A2bR agonist, had increased melanoma growth.  This effect was assocd. with higher levels of immune regulatory mediators interleukin-10 (IL-10) and monocyte chemoattractant protein 1 (MCP-1) and accumulation of tumor-assocd. CD11b pos. Gr1 pos. cells (CD11b+Gr1+) myeloid-derived suppressor cells (MDSCs).  Depletion of CD11b+Gr1+ cells completely reversed the protumor activity of Bay 60-6583.  Conversely, pharmacol. blockade of A2bR with PSB1115 reversed immune suppression in the tumor microenvironment, leading to a significant melanoma growth delay.  PSB1115 treatment reduced both levels of IL-10 and MCP-1 and CD11b+Gr1+ cell no. in melanoma lesions.  These effects were assocd. with higher frequency of tumor-infiltrating CD8 pos. (CD8+) T cells and natural killer T (NKT) cells and increased levels of T helper 1 (Th1)-like cytokines.  Adoptive transfer of CD11b+Gr1+ cells abrogated the antitumor activity of PSB1115.  These data suggest that the antitumor activity of PSB1115 relies on its ability to lower accumulation of tumor-infiltrating MDSCs and restore an efficient antitumor T cell response.  The antitumor effect of PSB1115 was not obsd. in melanoma-bearing nude mice.  Furthermore, PSB1115 enhanced the antitumor efficacy of dacarbazine.These data indicate that A2bR antagonists such as PSB1115 should be investigated as adjuvants in the treatment of melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCc_1YKSaS8rVg90H21EOLACvtfcHk0lgKc7LWQIhujg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWls73K&md5=0b4cb56ad530f6cca9027d845a7577cc</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1593%2Fneo.131748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.131748%26sid%3Dliteratum%253Aachs%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DMaiolino%26aufirst%3DP.%26aulast%3DPinto%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DS.%26atitle%3DBlockade%2520of%2520A2B%2520adenosine%2520receptor%2520reduces%2520tumor%2520growth%2520and%2520immune%2520suppression%2520mediated%2520by%2520myeloid-derived%2520suppressor%2520cells%2520in%2520a%2520mouse%2520model%2520of%2520melanoma%26jtitle%3DNeoplasia%26date%3D2013%26volume%3D15%26spage%3D1400%26epage%3D1409%26doi%3D10.1593%2Fneo.131748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, S.</span></span> <span> </span><span class="NLM_article-title">Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">27478</span>– <span class="NLM_lpage">27489</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.18632%2Foncotarget.4393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26317647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC287ntVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=27478-27489&author=C.+Sorrentinoauthor=L.+Mieleauthor=A.+Portaauthor=A.+Pintoauthor=S.+Morello&title=Myeloid-derived+suppressor+cells+contribute+to+A2B+adenosine+receptor-induced+VEGF+production+and+angiogenesis+in+a+mouse+melanoma+model&doi=10.18632%2Foncotarget.4393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model</span></div><div class="casAuthors">Sorrentino Claudia; Porta Amalia; Pinto Aldo; Morello Silvana; Miele Lucio</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">27478-89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) is an angiogenic factor critically involved in tumor progression.  Adenosine A2B receptor plays a pivotal role in promoting tumor growth.  The aim of this study was to investigate the role of myeloid-derived suppressor cells (MDSCs) in the pro-angiogenic effects of A2B and to determine whether A2B blockade could enhance the effectiveness of anti-VEGF treatment.  Mice treated with Bay60-6583, a selective A2B receptor agonist, showed enhanced tumor VEGF-A expression and vessel density.  This effect was associated with accelerated tumor growth, which could be reversed with anti-VEGF treatment.  Bay60-6583 increased the accumulation of tumor CD11b+Gr1+ cells.  Depletion of MDSCs in mice significantly reduced A2B-induced VEGF production.  However, A2B receptor stimulation did not directly regulate VEGF expression in isolated tumor myeloid cells.  Mechanistically, Bay60-6583-treated melanoma tissues showed increased STAT3 activation.  Inhibition of STAT3 significantly decreased the pro-tumor activity of Bay60-6583 and reduced tumor VEGF expression.  Pharmacological blockade of A2B receptor with PSB1115 significantly reduced tumor growth by inhibiting tumor angiogenesis and increasing T cells numbers within the tumor microenvironment.  These effects are, at least in part, dependent on impaired tumor accumulation of Gr1+ cells upon A2B receptor blockade.  PSB1115 increased the effectiveness of anti-VEGF treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpoOT32a8a7wvupmecNw_lfW6udTcc2eYzAbmIhLgQiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287ntVKrtA%253D%253D&md5=676b86b21bf78edea849235599f682b8</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4393%26sid%3Dliteratum%253Aachs%26aulast%3DSorrentino%26aufirst%3DC.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DPorta%26aufirst%3DA.%26aulast%3DPinto%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DS.%26atitle%3DMyeloid-derived%2520suppressor%2520cells%2520contribute%2520to%2520A2B%2520adenosine%2520receptor-induced%2520VEGF%2520production%2520and%2520angiogenesis%2520in%2520a%2520mouse%2520melanoma%2520model%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D27478%26epage%3D27489%26doi%3D10.18632%2Foncotarget.4393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Extracellular adenosine regulates naive T cell development and peripheral maintenance</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">2693</span>– <span class="NLM_lpage">2706</span>, <span class="refDoi"> DOI: 10.1084/jem.20130249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1084%2Fjem.20130249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24145516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=2693-2706&author=C.+Cekicauthor=D.+Sagauthor=Y.+J.+Dayauthor=J.+Linden&title=Extracellular+adenosine+regulates+naive+T+cell+development+and+peripheral+maintenance&doi=10.1084%2Fjem.20130249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular adenosine regulates naive T cell development and peripheral maintenance</span></div><div class="casAuthors">Cekic, Caglar; Sag, Duygu; Day, Yuan-Ji; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2693-2706</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Adenosine produced as a byproduct of metabolic activity is present in all tissues and produces dose-dependent suppression of TCR signaling.  Naive T cell maintenance depends on inhibition of TCR signals by environmental sensors, which are yet to be fully defined.  We produced mice with a floxed adenosine A2A receptor (A2AR) gene, Adora2a, and show that either global A2AR deletion or cre-mediated T cell deletion elicits a decline in the no. of naive but not memory T cells.  A2AR signaling maintains naive T cells in a quiescent state by inhibiting TCR-induced activation of the phosphatidylinositide 3-kinase (PI3K)-AKT pathway, thereby reducing IL-7Rα down-regulation and naive T cell apoptosis.  Patterns of IL-7Rα expression on T cells in chimeric mice reconstituted with Adora2a+/+ and Adora2a-/- bone marrow cells suggest that decreased IL-7Rα in naive T cells is a cell-intrinsic consequence of Adora2a deletion.  In addn., A2AR expression increases in early thymic T cell development and contributes to progression of double-neg. thymic precursors to single-pos. thymocytes with increased IL-7Rα expression.  Therefore, A2AR signaling regulates T cell development and maintenance to sustain normal nos. of naive T cells in the periphery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo74zbT0m4BIbVg90H21EOLACvtfcHk0lgKc7LWQIhujg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsbfF&md5=2c4a497e4cfd0ec94d47eeec7ab07e29</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1084%2Fjem.20130249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20130249%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DSag%26aufirst%3DD.%26aulast%3DDay%26aufirst%3DY.%2BJ.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DExtracellular%2520adenosine%2520regulates%2520naive%2520T%2520cell%2520development%2520and%2520peripheral%2520maintenance%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D2693%26epage%3D2706%26doi%3D10.1084%2Fjem.20130249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cekic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">7239</span>– <span class="NLM_lpage">7249</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-3581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-13-3581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25341542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOhtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=7239-7249&author=C.+Cekicauthor=J.+Linden&title=Adenosine+A2A+receptors+intrinsically+regulate+CD8%2B+T+cells+in+the+tumor+microenvironment&doi=10.1158%2F0008-5472.CAN-13-3581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment</span></div><div class="casAuthors">Cekic, Caglar; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7239-7249</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted deletion of the adenosine A2A receptor, an important inhibitory receptor on T cells, paradoxically enhances the growth rate of solid tumors by impairing tumor-assocd. T-cell maintenance and effector/memory differentiation, with implications for clin. testing of A2A receptor antagonists to enhance cancer immunotherapy.  Adenosine A2A receptor (A2AR) blockade enhances innate and adaptive immune responses.  However, mouse genetic studies have shown that A2AR deletion does not inhibit the growth of all tumor types.  In the current study, we showed that growth rates for ectopic melanoma and bladder tumors are increased in Adora2a-/- mice within 2 wk of tumor inoculation.  A2AR deletion in the host reduced nos. of CD8+ T cells and effector-memory differentiation of all T cells.  To examine intrinsic functions in T cells, we generated mice harboring a T-cell-specific deletion of A2AR.  In this host strain, tumor-bearing mice displayed increased growth of ectopic melanomas, decreased nos. of tumor-assocd. T cells, reduced effector-memory differentiation, and reduced antiapoptotic IL7Rα (CD127) expression on antigen-experienced cells.  Intratumoral pharmacol. blockade similarly reduced CD8+ T-cell d. within tumors in wild-type hosts.  We found that A2AR-proficient CD8+ T cells specific for melanoma cells displayed a relative survival advantage in tumors.  Thus, abrogating A2AR signaling appeared to reduce IL7R expression, survival, and differentiation of T cells in the tumor microenvironment.  One implication of these results is that the antitumor effects of A2AR blockade that can be mediated by activation of cytotoxic T cells may be overcome in some tumor microenvironments as a result of impaired T-cell maintenance and effector-memory differentiation.  Thus, our findings imply that the efficacious application of A2AR inhibitors for cancer immunotherapy may require careful dose optimization to prevent activation-induced T-cell death in tumors.  Cancer Res; 74(24); 7239-49. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq94b5Vd4f577Vg90H21EOLACvtfcHk0liP7DUVPqBYSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOhtrnJ&md5=7bb588350820bf2f5392143546f1cc0a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-3581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-3581%26sid%3Dliteratum%253Aachs%26aulast%3DCekic%26aufirst%3DC.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520receptors%2520intrinsically%2520regulate%2520CD8%252B%2520T%2520cells%2520in%2520the%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D7239%26epage%3D7249%26doi%3D10.1158%2F0008-5472.CAN-13-3581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Borstel, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evoniuk, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtman, R. J.</span></span> <span> </span><span class="NLM_article-title">Adenosine potentiates sympathomimetic effects of nicotinic agonists in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>236</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=3003340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaL28Xht1eks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=1986&pages=344-349&author=R.+W.+von%0ABorstelauthor=G.+E.+Evoniukauthor=R.+J.+Wurtman&title=Adenosine+potentiates+sympathomimetic+effects+of+nicotinic+agonists+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine potentiates sympathomimetic effects of nicotinic agonists in vivo</span></div><div class="casAuthors">Von Borstel, Reid W.; Evoniuk, Gary E.; Wurtman, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">344-9</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The effects of adenosine  [58-61-7] (or synthetic adenosine receptor agonists) on a variety of sympathomimetic responses to nicotine  [54-11-5] (or other nicotinic cholinergic agonists) were examd.  Indexes of sympathetic activity examd. were: blood pressure; heart rate; eyelid tension; and vas deferens perfusion pressure.  Elevation of arterial plasma adenosine from its basal level (∼1.5 μM) to 2-3 μM (by i.v. adenosine infusion) had no effect on the basal value of any of these indexes, but increased by 2.5-4-fold their peak responses to nicotine (40 μg/kg i.v.).  Adenosine also strongly enhanced sympathomimetic responses to inhaled cigarette smoke.  The adenosine receptor antagonist caffeine (10 mg/kg) suppressed the ability of adenosine to potentiate these responses to nicotine.  Pressor responses to the nicotinic cholinergic receptor agonists dimethylphenylpiperazinium iodide  [54-77-3], tetramethylammonium  [51-92-3], lobeline  [90-69-7], and cytisin  [485-35-8] were also potentiated by adenosine.  Low doses (0.25-5 μ/kg) of synthetic adenosine receptor agonists potentiated all 4 of the tested sympathomimetic responses to nicotine, exhibiting the rank order of potency: N-cyclopropylcarboxamidoadenosine  [50908-62-8] > 2-chloroadenosine  [146-77-0] > N6-R-phenylisopropyl adenosine  [38594-96-6] > N6-S-phenylisopropyladenosine  [38594-97-7].  The nonpurinergic vasodilator, Na nitroprusside, failed to potentiate responses to nicotine, suggesting that the influence of adenosine on responses to nicotine is not secondary to its direct circulatory effects.  Decentralization of the sympathetic ganglia that control eyelid tension and vas deferens perfusion pressure did not affect responses to nicotine or their potentiation by adenosine, confirming that the loci wherein both adenosine and nicotine act are within or distal to sympathetic ganglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXSNn8zKYGJLVg90H21EOLACvtfcHk0liP7DUVPqBYSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xht1eks74%253D&md5=f754595f152ebec01f1dffa03bb96c35</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BBorstel%26aufirst%3DR.%2BW.%26aulast%3DEvoniuk%26aufirst%3DG.%2BE.%26aulast%3DWurtman%26aufirst%3DR.%2BJ.%26atitle%3DAdenosine%2520potentiates%2520sympathomimetic%2520effects%2520of%2520nicotinic%2520agonists%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1986%26volume%3D236%26spage%3D344%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maenhaut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Sande, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderhaegen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S.</span></span> <span> </span><span class="NLM_article-title">RDC8 codes for an adenosine A2 receptor with physiological constitutive activity</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(05)80909-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2FS0006-291X%2805%2980909-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=2125216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK3MXps1Wrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=1990&pages=1169-1178&author=C.+Maenhautauthor=J.+Van+Sandeauthor=F.+Libertauthor=M.+Abramowiczauthor=M.+Parmentierauthor=J.+J.+Vanderhaegenauthor=J.+E.+Dumontauthor=G.+Vassartauthor=S.+Schiffmann&title=RDC8+codes+for+an+adenosine+A2+receptor+with+physiological+constitutive+activity&doi=10.1016%2FS0006-291X%2805%2980909-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">RDC8 codes for an adenosine A2 receptor with physiological constitutive activity</span></div><div class="casAuthors">Maenhaut, Carine; Van Sande, Jacqueline; Libert, Frederick; Abramowicz, Marc; Parmentier, Marc; Vanderhaegen, Jean Jacques; Dumont, Jacques E.; Vassart, Gilbert; Schiffmann, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1169-78</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">The cDNA of an unidentified recently cloned G protein-coupled receptor, RDC8, has been expressed in Y1 adrenal cells, in dog thyrocytes in primary culture, and in Xenopus oocytes.  In all these systems this resulted in the activation of adenylyl cyclase and of the cAMP cascade in the absence of any added external signal.  However, this physiol. constitutive activator was inhibited by adenosine deaminase and by inhibitors of the adenosine A2 receptor.  Cos 7 cells transfected with RDC8 cDNA constructs acquired binding characteristics of an adenosine A2 receptor.  Moreover, RDC8 mRNA and adenosine A2 receptors display a very similar distribution in the brain.  RDC8 therefore codes for an A2 adenosine receptor.  Whether the physiol. constitutive activation of this receptor is entirely explained by endogeneously produced adenosine is as yet unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKrLE25ynVkrVg90H21EOLACvtfcHk0liP7DUVPqBYSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXps1Wrtw%253D%253D&md5=e925e1af7ccff03114e94ae252121896</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2805%2980909-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252805%252980909-X%26sid%3Dliteratum%253Aachs%26aulast%3DMaenhaut%26aufirst%3DC.%26aulast%3DVan%2BSande%26aufirst%3DJ.%26aulast%3DLibert%26aufirst%3DF.%26aulast%3DAbramowicz%26aufirst%3DM.%26aulast%3DParmentier%26aufirst%3DM.%26aulast%3DVanderhaegen%26aufirst%3DJ.%2BJ.%26aulast%3DDumont%26aufirst%3DJ.%2BE.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DSchiffmann%26aufirst%3DS.%26atitle%3DRDC8%2520codes%2520for%2520an%2520adenosine%2520A2%2520receptor%2520with%2520physiological%2520constitutive%2520activity%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1990%26volume%3D173%26spage%3D1169%26epage%3D1178%26doi%3D10.1016%2FS0006-291X%2805%2980909-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furlong, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selbie, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shine, J.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of a human brain adenosine A2 receptor</span>. <i>Mol. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/0169-328X(92)90152-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2F0169-328X%2892%2990152-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1331670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK3sXit1Kiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1992&pages=62-66&author=T.+J.+Furlongauthor=K.+D.+Pierceauthor=L.+A.+Selbieauthor=J.+Shine&title=Molecular+characterization+of+a+human+brain+adenosine+A2+receptor&doi=10.1016%2F0169-328X%2892%2990152-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of a human brain adenosine A2 receptor</span></div><div class="casAuthors">Furlong, Timothy J.; Pierce, Kerrie D.; Selbie, Lisa A.; Shine, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">62-6</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    </div><div class="casAbstract">A cDNA encoding a G protein-coupled receptor of unknown ligand specificity was isolated from a human hippocampal cDNA library by virtue of the high degree of structural homol. between members of this receptor family.  The cloned receptor DNA was transfected into human embryonic kidney 293 cells.  Stably transfected cell lines bound a variety of adenosine agonists and antagonists with affinities characteristic of a brain adenosine A2a receptor.  The A2a specific agonist CGS21680 stimulated cAMP prodn. but did not alter intracellular calcium concns. in transfected 293 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLrHo7yhb7dLVg90H21EOLACvtfcHk0lh6Q3DZXT19iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXit1Kiu7s%253D&md5=7074217779407edb8a93652462529fd6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0169-328X%2892%2990152-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0169-328X%252892%252990152-2%26sid%3Dliteratum%253Aachs%26aulast%3DFurlong%26aufirst%3DT.%2BJ.%26aulast%3DPierce%26aufirst%3DK.%2BD.%26aulast%3DSelbie%26aufirst%3DL.%2BA.%26aulast%3DShine%26aufirst%3DJ.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520human%2520brain%2520adenosine%2520A2%2520receptor%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D1992%26volume%3D15%26spage%3D62%26epage%3D66%26doi%3D10.1016%2F0169-328X%2892%2990152-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaugeois, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrazzini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Yacoubi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderhaeghen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costentin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, M.</span></span> <span> </span><span class="NLM_article-title">Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1038/41771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2F41771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9262401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2sXlsFSjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=1997&pages=674-678&author=C.+Ledentauthor=J.+M.+Vaugeoisauthor=S.+N.+Schiffmannauthor=T.+Pedrazziniauthor=M.+El+Yacoubiauthor=J.+J.+Vanderhaeghenauthor=J.+Costentinauthor=J.+K.+Heathauthor=G.+Vassartauthor=M.+Parmentier&title=Aggressiveness%2C+hypoalgesia+and+high+blood+pressure+in+mice+lacking+the+adenosine+A2a+receptor&doi=10.1038%2F41771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor</span></div><div class="casAuthors">Ledent, Catherine; Vaugeois, Jean-Marie; Schiffmann, Serge N.; Pedrazzini, Thierry; El Yacoubi, Malika; Vanderhaeghen, Jean-Jacques; Costentin, Jean; Heath, John K.; Vassart, Gilbert; Parmentier, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">6643</span>),
    <span class="NLM_cas:pages">674-678</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Adenosine is released from metabolically active cells by facilitated diffusion, and is generated extracellularly by degrdn. of released ATP.  It is a potent biol. mediator that modulates the activity of numerous cell types, including various neuronal populations, platelets, neutrophils and mast cells, and smooth muscle cells in bronchi and vasculature.  Most of these effects help to protect cells and tissues during stress conditions such as ischemia.  Adenosine mediates its effects through four receptor subtypes: the A1, A2a, A2b and A3 receptors.  The A2a receptor (A2aR) is abundant in basal ganglia, vasculature and platelets, and stimulates adenylyl cyclase.  It is a major target of caffeine, the most widely used psychoactive drug.  Here the authors investigate the role of the A2a receptor by disrupting the gene in mice.  The authors found that A2aR-knockout (A2aR-/-) mice were viable and bred normally.  Their exploratory activity was reduced, whereas caffeine, which normally stimulates exploratory behavior, became a depressant of exploratory activity.  Knockout animals scored higher in anxiety tests, and male mice were much more aggressive towards intruders.  The response of A2aR-/- mice to acute pain stimuli was slower.  Blood pressure and heart rate were increased, as well as platelet aggregation.  The specific A2a agonist CGS 21680 lost its biol. activity in all systems tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0iq2QuhMaEbVg90H21EOLACvtfcHk0lh6Q3DZXT19iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsFSjsLY%253D&md5=c383aa8b1552fe119691ac9f9877a8e9</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2F41771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F41771%26sid%3Dliteratum%253Aachs%26aulast%3DLedent%26aufirst%3DC.%26aulast%3DVaugeois%26aufirst%3DJ.%2BM.%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26aulast%3DPedrazzini%26aufirst%3DT.%26aulast%3DEl%2BYacoubi%26aufirst%3DM.%26aulast%3DVanderhaeghen%26aufirst%3DJ.%2BJ.%26aulast%3DCostentin%26aufirst%3DJ.%26aulast%3DHeath%26aufirst%3DJ.%2BK.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DParmentier%26aufirst%3DM.%26atitle%3DAggressiveness%252C%2520hypoalgesia%2520and%2520high%2520blood%2520pressure%2520in%2520mice%2520lacking%2520the%2520adenosine%2520A2a%2520receptor%26jtitle%3DNature%26date%3D1997%26volume%3D388%26spage%3D674%26epage%3D678%26doi%3D10.1038%2F41771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domenici, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popoli, P.</span></span> <span> </span><span class="NLM_article-title">The role of adenosine tone and adenosine receptors in huntington’s disease</span>. <i>J. Caffeine Adenosine Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1089/caff.2018.0006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1089%2Fcaff.2018.0006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30023989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWltr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=43-58&author=D.+Blumauthor=Y.+Chernauthor=M.+R.+Domeniciauthor=L.+Bueeauthor=C.+Y.+Linauthor=W.+Reaauthor=S.+Ferreauthor=P.+Popoli&title=The+role+of+adenosine+tone+and+adenosine+receptors+in+huntington%E2%80%99s+disease&doi=10.1089%2Fcaff.2018.0006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease</span></div><div class="casAuthors">Blum, David; Chern, Yijuang; Domenici, Maria Rosaria; Buee, Luc; Lin, Chien-Yu; Rea, William; Ferre, Sergi; Popoli, Patrizia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Caffeine and Adenosine Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">43-58</span>CODEN:
                <span class="NLM_cas:coden">JCARCW</span>;
        ISSN:<span class="NLM_cas:issn">2573-3400</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by a mutation in the IT15 gene that encodes for the huntingtin protein.  Mutated hungtingtin, although widely expressed in the brain, predominantly affects striato-pallidal neurons, particularly enriched with adenosine A2A receptors (A2AR), suggesting a possible involvement of adenosine and A2AR is the pathogenesis of HD.  In fact, polymorphic variation in the ADORA2A gene influences the age at onset in HD, and A2AR dynamics is altered by mutated huntingtin.  Basal levels of adenosine and adenosine receptors are involved in many processes crit. for neuronal function and homeostasis, including modulation of synaptic activity and excitotoxicity, the control of neurotrophin levels and functions, and the regulation of protein degrdn. mechanisms.  In the present review, we critically analyze the current literature involving the effect of altered adenosine tone and adenosine receptors in HD and discuss why therapeutics that modulate the adenosine system may represent a novel approach for the treatment of HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhCca2neQiG7Vg90H21EOLACvtfcHk0lhk1qFmplYJSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWltr%252FL&md5=b94dfab0b86db5f4269a2a82999b965f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1089%2Fcaff.2018.0006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcaff.2018.0006%26sid%3Dliteratum%253Aachs%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DChern%26aufirst%3DY.%26aulast%3DDomenici%26aufirst%3DM.%2BR.%26aulast%3DBuee%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DRea%26aufirst%3DW.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DPopoli%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520adenosine%2520tone%2520and%2520adenosine%2520receptors%2520in%2520huntington%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Caffeine%2520Adenosine%2520Res.%26date%3D2018%26volume%3D8%26spage%3D43%26epage%3D58%26doi%3D10.1089%2Fcaff.2018.0006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arosio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gussago, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assolari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scortichini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mari, D.</span></span> <span> </span><span class="NLM_article-title">Down-regulation of adenosine A1 and A2A receptors in peripheral cells from idiopathic normal-pressure hydrocephalus patients</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2015.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.jns.2015.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=26810542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2016&pages=196-199&author=M.+Casatiauthor=B.+Arosioauthor=C.+Gussagoauthor=E.+Ferriauthor=L.+Magniauthor=L.+Assolariauthor=V.+Scortichiniauthor=C.+Naniauthor=P.+D.+Rossiauthor=D.+Mari&title=Down-regulation+of+adenosine+A1+and+A2A+receptors+in+peripheral+cells+from+idiopathic+normal-pressure+hydrocephalus+patients&doi=10.1016%2Fj.jns.2015.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of adenosine A1 and A2A receptors in peripheral cells from idiopathic normal-pressure hydrocephalus patients</span></div><div class="casAuthors">Casati, Martina; Arosio, Beatrice; Gussago, Cristina; Ferri, Evelyn; Magni, Lorenzo; Assolari, Lara; Scortichini, Valeria; Nani, Carolina; Rossi, Paolo Dionigi; Mari, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196-199</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic normal-pressure hydrocephalus (iNPH) is a neurol. disease that usually develops in the elderly.  Natural history of iNPH is still unknown.  It has been hypothesized that cerebrovascular diseases could have a role in etiol. of chronic hydrocephalus and studies show an increased prevalence of cardiovascular diseases in iNPH patients.  Moreover, evidences show a possible alteration of immune system in iNPH patients.  Adenosine (Ado) is a metabolite produced in response to metabolic stress and injury.  Adenosine and its receptors play an important role in vascular protection and in the modulation of inflammatory reactions and neuroinflammation.  Our aim is to evaluate gene and protein expression of A1R and A2AR in the peripheral blood mononuclear cells (PBMCs) from iNPH patients compared to control subjects.  We investigate if Ado system, that plays an important role in central nervous system, in vascular system, and also in inflammation, is involved in pathophysiol. of iNPH disease.  Our anal. showed that A1R mRNA levels and A1R d. in PBMCs from iNPH patients were significantly lower than CT subjects (0.84 ± 0.12 and 2.42 ± 0.42, p < 0.001 and 0.31 ± 0.02 and 0.42 ± 0.04, p = 0.043; resp.).  About A2AR, the gene expression in PBMCs was significantly lower in iNPH than CT (0.65 ± 0.09 and 1.5 ± 0.14, p < 0.001) as well as there was a trend in protein expression: iNPH and CT (0.51 ± 0.05 and 0.62 ± 0.03; p = 0.172).  This preliminary study underlines the involvement of Ado system in iNPH disease whose pathophysiol. is still unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRAhRMcKQsXrVg90H21EOLACvtfcHk0lhk1qFmplYJSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKnsLc%253D&md5=034f6169b287cb51e3794d0975dd205a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2015.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2015.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DCasati%26aufirst%3DM.%26aulast%3DArosio%26aufirst%3DB.%26aulast%3DGussago%26aufirst%3DC.%26aulast%3DFerri%26aufirst%3DE.%26aulast%3DMagni%26aufirst%3DL.%26aulast%3DAssolari%26aufirst%3DL.%26aulast%3DScortichini%26aufirst%3DV.%26aulast%3DNani%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DP.%2BD.%26aulast%3DMari%26aufirst%3DD.%26atitle%3DDown-regulation%2520of%2520adenosine%2520A1%2520and%2520A2A%2520receptors%2520in%2520peripheral%2520cells%2520from%2520idiopathic%2520normal-pressure%2520hydrocephalus%2520patients%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2016%26volume%3D361%26spage%3D196%26epage%3D199%26doi%3D10.1016%2Fj.jns.2015.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cieslak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wujak, M.</span></span> <span> </span><span class="NLM_article-title">Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1007/s11302-018-9633-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs11302-018-9633-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30430356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1SnsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1-15&author=M.+Cieslakauthor=K.+Roszekauthor=M.+Wujak&title=Purinergic+implication+in+amyotrophic+lateral+sclerosis-from+pathological+mechanisms+to+therapeutic+perspectives&doi=10.1007%2Fs11302-018-9633-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives</span></div><div class="casAuthors">Cieslak, M.; Roszek, K.; Wujak, M.</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a clin. heterogeneous disorder characterized by degeneration of upper motor neurons in the brainstem and lower motor neurons in the spinal cord.  Multiple mechanisms of motor neuron injury have been implicated, including more than 20 different genetic factors.  The pathogenesis of ALS consists of two stages: an early neuroprotective stage and a later neurotoxic.  During early phases of disease progression, the immune system through glial and T cell activities provides anti-inflammatory factors that sustain motor neuron viability.  As the disease progresses and motor neuron injury accelerates, a rapidly succeeding neurotoxic phase develops.  A well-orchestrated purine-mediated dialog among motor neurons, surrounding glia and immune cells control the beneficial and detrimental activities occurring in the nervous system.  In general, low ATP (ATP) concns. protect cells against excitotoxic stimuli through purinergic P2X4 receptor, whereas high concns. of ATP trigger toxic P2X7 receptor activation.  Finally, adenosine is also involved in ALS progression since A2A receptor antagonists prevent motor neuron death.  Given the complex cellular cross-talk occurring in ALS and the recognized function of extracellular nucleotides and adenosine in neuroglia communication, the comprehensive understanding of purinome dynamics might provide new research perspectives to decipher ALS and help to design more efficient and targeted drugs.  This review will focus on the purinergic players involved in ALS etiol. and disease progression and current therapeutic strategies to enhance neuroprotection and suppress neurotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFmoWpxuuNM7Vg90H21EOLACvtfcHk0lg0a_n3Ul0zjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1SnsLrL&md5=a9ea6ebacfd9846942208736c3fcfd25</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs11302-018-9633-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-018-9633-4%26sid%3Dliteratum%253Aachs%26aulast%3DCieslak%26aufirst%3DM.%26aulast%3DRoszek%26aufirst%3DK.%26aulast%3DWujak%26aufirst%3DM.%26atitle%3DPurinergic%2520implication%2520in%2520amyotrophic%2520lateral%2520sclerosis-from%2520pathological%2520mechanisms%2520to%2520therapeutic%2520perspectives%26jtitle%3DPurinergic%2520Signalling%26date%3D2019%26volume%3D15%26spage%3D1%26epage%3D15%26doi%3D10.1007%2Fs11302-018-9633-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paganelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resseguier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlinge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malergue, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armangau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerbaul, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenouillet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guieu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruf, J.</span></span> <span> </span><span class="NLM_article-title">Specific pharmacological profile of A2A adenosine receptor predicts reduced fractional flow reserve in patients with suspected coronary artery disease</span>. <i>J. Am. Heart Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e008290</span>, <span class="refDoi"> DOI: 10.1161/JAHA.117.008290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1161%2FJAHA.117.008290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29654194" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=e008290&author=F.+Paganelliauthor=N.+Resseguierauthor=M.+Marlingeauthor=M.+Laineauthor=F.+Malergueauthor=N.+Kipsonauthor=P.+Armangauauthor=N.+Pezzoliauthor=F.+Kerbaulauthor=L.+Bonelloauthor=G.+Mottolaauthor=E.+Fenouilletauthor=R.+Guieuauthor=J.+Ruf&title=Specific+pharmacological+profile+of+A2A+adenosine+receptor+predicts+reduced+fractional+flow+reserve+in+patients+with+suspected+coronary+artery+disease&doi=10.1161%2FJAHA.117.008290"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1161%2FJAHA.117.008290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FJAHA.117.008290%26sid%3Dliteratum%253Aachs%26aulast%3DPaganelli%26aufirst%3DF.%26aulast%3DResseguier%26aufirst%3DN.%26aulast%3DMarlinge%26aufirst%3DM.%26aulast%3DLaine%26aufirst%3DM.%26aulast%3DMalergue%26aufirst%3DF.%26aulast%3DKipson%26aufirst%3DN.%26aulast%3DArmangau%26aufirst%3DP.%26aulast%3DPezzoli%26aufirst%3DN.%26aulast%3DKerbaul%26aufirst%3DF.%26aulast%3DBonello%26aufirst%3DL.%26aulast%3DMottola%26aufirst%3DG.%26aulast%3DFenouillet%26aufirst%3DE.%26aulast%3DGuieu%26aufirst%3DR.%26aulast%3DRuf%26aufirst%3DJ.%26atitle%3DSpecific%2520pharmacological%2520profile%2520of%2520A2A%2520adenosine%2520receptor%2520predicts%2520reduced%2520fractional%2520flow%2520reserve%2520in%2520patients%2520with%2520suspected%2520coronary%2520artery%2520disease%26jtitle%3DJ.%2520Am.%2520Heart%2520Assoc.%26date%3D2018%26volume%3D7%26spage%3De008290%26doi%3D10.1161%2FJAHA.117.008290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arosio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viazzoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastronardi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamaschini, L.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.3233/JAD-2010-090814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.3233%2FJAD-2010-090814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=20413899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFKgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=991-996&author=B.+Arosioauthor=C.+Viazzoliauthor=L.+Mastronardiauthor=C.+Bilottaauthor=C.+Verganiauthor=L.+Bergamaschini&title=Adenosine+A2A+receptor+expression+in+peripheral+blood+mononuclear+cells+of+patients+with+mild+cognitive+impairment&doi=10.3233%2FJAD-2010-090814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Expression in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment</span></div><div class="casAuthors">Arosio, Beatrice; Viazzoli, Chiara; Mastronardi, Luigina; Bilotta, Claudio; Vergani, Carlo; Bergamaschini, Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">991-996</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Adenosine suppresses immune responses through the adenosine A2A receptors (A2AR).  We evaluated the expression of A2AR in blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer's disease (AD), and controls in order to verify if it may help distinguish different forms of cognitive decline.  There was a significant linear increase in both mRNA levels and receptor d. from multiple cognitive domain MCI (mcd-MCI) to amnestic MCI (a-MCI), spanning through AD and controls, without any significant difference between the latter two groups of subjects.  These data, which need to be confirmed in a larger no. of patients, suggest that expression of A2AR in PBMCs may be a valuable means of differentiating a-MCI and mcd-MCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_TImartT_ybVg90H21EOLACvtfcHk0lg0a_n3Ul0zjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFKgsbw%253D&md5=c62a92d7ab78f80930c219a7136e559f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-090814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-090814%26sid%3Dliteratum%253Aachs%26aulast%3DArosio%26aufirst%3DB.%26aulast%3DViazzoli%26aufirst%3DC.%26aulast%3DMastronardi%26aufirst%3DL.%26aulast%3DBilotta%26aufirst%3DC.%26aulast%3DVergani%26aufirst%3DC.%26aulast%3DBergamaschini%26aufirst%3DL.%26atitle%3DAdenosine%2520A2A%2520receptor%2520expression%2520in%2520peripheral%2520blood%2520mononuclear%2520cells%2520of%2520patients%2520with%2520mild%2520cognitive%2520impairment%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2010%26volume%3D20%26spage%3D991%26epage%3D996%26doi%3D10.3233%2FJAD-2010-090814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasko, G.</span></span> <span> </span><span class="NLM_article-title">The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1124/pr.117.014878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1124%2Fpr.117.014878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31235653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFersr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=345-382&author=L.+Antonioliauthor=C.+Blandizziauthor=P.+Pacherauthor=G.+Hasko&title=The+purinergic+system+as+a+pharmacological+target+for+the+treatment+of+immune-mediated+inflammatory+diseases&doi=10.1124%2Fpr.117.014878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases</span></div><div class="casAuthors">Antonioli, Luca; Blandizzi, Corrado; Pacher, Pal; Hasko, Gyoergy</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-382</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such asmultiple sclerosis, rheumatoidarthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus.  Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well.  The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, resp., as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body.  The purinergic signaling complex can regulate the development and course of IMIDs.  Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs.  In addn., we discuss the possible therapeutic applications of drugs acting on purinergic pathways,which have been entering clin. development, to manage patients suffering from IMIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEgKKRAYo4crVg90H21EOLACvtfcHk0lhfurlmqfkM3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFersr%252FI&md5=7c0a822c268a67872d70748e0698e4da</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fpr.117.014878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.117.014878%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DBlandizzi%26aufirst%3DC.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DHasko%26aufirst%3DG.%26atitle%3DThe%2520purinergic%2520system%2520as%2520a%2520pharmacological%2520target%2520for%2520the%2520treatment%2520of%2520immune-mediated%2520inflammatory%2520diseases%26jtitle%3DPharmacol.%2520Rev.%26date%3D2019%26volume%3D71%26spage%3D345%26epage%3D382%26doi%3D10.1124%2Fpr.117.014878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albasanz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptors are up-regulated in Pick’s disease frontal cortex</span>. <i>Brain Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1111/j.1750-3639.2006.00026.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1111%2Fj.1750-3639.2006.00026.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=17107593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=249-255&author=J.+L.+Albasanzauthor=A.+Rodriguezauthor=I.+Ferrerauthor=M.+Martin&title=Adenosine+A2A+receptors+are+up-regulated+in+Pick%E2%80%99s+disease+frontal+cortex&doi=10.1111%2Fj.1750-3639.2006.00026.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptors are up-regulated in pick's disease frontal cortex</span></div><div class="casAuthors">Albasanz, Jose Luis; Rodriguez, Agustin; Ferrer, Isidro; Martin, Mairena</div><div class="citationInfo"><span class="NLM_cas:title">Brain Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">249-255</span>CODEN:
                <span class="NLM_cas:coden">BRPAE7</span>;
        ISSN:<span class="NLM_cas:issn">1015-6305</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Adenosine A2A receptors (A2AR) are highly expressed in striatum.  However, they are also present in extrastriatal structures.  A2AR were studied in post-mortem human frontal cortex from Pick's disease (PiD) and age-matched non-demented controls by radioligand binding assays, Western-blotting, real-time PCR and adenylyl cyclase activity detn.  Satn. binding assay using [3H]ZM 241385, a selective A2A antagonist, as radioligand revealed a significant increase in total adenosine A2AR nos. (Bmax) in frontal cortex from PiD samples (191% of control Bmax), suggesting up-regulation of this receptor.  A significant increase in the level of A2AR was also detected by Western-blotting.  Furthermore, expression of mRNA coding A2AR detd. by quant. real-time PCR was enhanced.  In agreement, stimulation of adenylyl cyclase by CGS 21680, a selective A2A receptor agonist, was significantly strengthened.  Up-regulation of A2B receptors and their corresponding mRNA was also obsd.  These results show that A2A adenosine receptor/adenylyl cyclase transduction pathway is up-regulated and sensitized in frontal cortex brain from PiD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOI4C5n7fB8LVg90H21EOLACvtfcHk0lhfurlmqfkM3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslKlsA%253D%253D&md5=8324c80877cfe6382a4a8217fbca0d98</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fj.1750-3639.2006.00026.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1750-3639.2006.00026.x%26sid%3Dliteratum%253Aachs%26aulast%3DAlbasanz%26aufirst%3DJ.%2BL.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DI.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DAdenosine%2520A2A%2520receptors%2520are%2520up-regulated%2520in%2520Pick%25E2%2580%2599s%2520disease%2520frontal%2520cortex%26jtitle%3DBrain%2520Pathol.%26date%3D2006%26volume%3D16%26spage%3D249%26epage%3D255%26doi%3D10.1111%2Fj.1750-3639.2006.00026.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuscano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trincavelli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerrai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciapparelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucacchini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dell’Osso, L.</span></span> <span> </span><span class="NLM_article-title">Upregulation of A2A adenosine receptors in platelets from patients affected by bipolar disorders under treatment with typical antipsychotics</span>. <i>J. Psychiatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.jpsychires.2004.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.jpsychires.2004.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16431220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FktlGitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2006&pages=81-88&author=C.+Martiniauthor=D.+Tuscanoauthor=M.+L.+Trincavelliauthor=E.+Cerraiauthor=M.+Bianchiauthor=A.+Ciapparelliauthor=L.+Alessioauthor=L.+Novelliauthor=M.+Catenaauthor=A.+Lucacchiniauthor=G.+B.+Cassanoauthor=L.+Dell%E2%80%99Osso&title=Upregulation+of+A2A+adenosine+receptors+in+platelets+from+patients+affected+by+bipolar+disorders+under+treatment+with+typical+antipsychotics&doi=10.1016%2Fj.jpsychires.2004.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of A2A adenosine receptors in platelets from patients affected by bipolar disorders under treatment with typical antipsychotics</span></div><div class="casAuthors">Martini Claudia; Tuscano Daniela; Trincavelli Maria Letizia; Cerrai Elisa; Bianchi Maria; Ciapparelli Antonio; Alessio Lucioni; Novelli Letizia; Catena Mario; Lucacchini Antonio; Cassano Giovanni Battista; Dell'Osso Liliana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-8</span>
        ISSN:<span class="NLM_cas:issn">0022-3956</span>.
    </div><div class="casAbstract">Antipsychotic drugs, potent dopamine receptor antagonists, are commonly used in the treatment of psychotic and affective illness.  The discovery of antagonistic interactions between A2A adenosine receptors (ARs) and D2 dopamine receptors (DRs) in the central nervous system suggests that the adenosine system may be involved in the pathogenesis of psychiatric and neurological disorders.  In the present study, we demonstrated for the first time that human platelets co-express A2A ARs and D2 DRs assembled into an heteromeric complexes.  We also investigated the effects of chronic treatment with either typical or atypical antipsychotics on A2A AR binding parameters and receptors responsiveness in human platelets from patients affected by bipolar disorder.  Chronic administration of typical antipsychotics induced a significant upregulation of A2A AR binding sites.  Since no effects on A2A AR were obtained following "in vitro" platelet treatment with a typical antipsychotic (haloperidol), we could exclude a direct effect of the drug on A2A AR at the peripheral level.  Moreover, typical antipsychotics induced a significant increase in the agonist potency to mediate A2A AR-G protein coupling.  On the contrary, chronic treatment with atypical antipsychotics did not induce any significant alterations in A2A AR equilibrium binding parameters and receptor responsiveness suggesting that typical but not atypical antipsychotic drugs induced a selective modification of A2A AR binding parameters in human platelets.  These results are in accordance with the literature data describing the selective A2A AR upregulation induced by typical antipsychotics in human striatum suggesting platelets as a peripheral model of the interactions between adenosine and dopamine system occurring in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBgNcglAeYobZpSb_XWfMrfW6udTcc2eb9YGrYe3np0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FktlGitg%253D%253D&md5=339c714bf80780d222f57a1a46676112</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2004.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2004.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DTuscano%26aufirst%3DD.%26aulast%3DTrincavelli%26aufirst%3DM.%2BL.%26aulast%3DCerrai%26aufirst%3DE.%26aulast%3DBianchi%26aufirst%3DM.%26aulast%3DCiapparelli%26aufirst%3DA.%26aulast%3DAlessio%26aufirst%3DL.%26aulast%3DNovelli%26aufirst%3DL.%26aulast%3DCatena%26aufirst%3DM.%26aulast%3DLucacchini%26aufirst%3DA.%26aulast%3DCassano%26aufirst%3DG.%2BB.%26aulast%3DDell%25E2%2580%2599Osso%26aufirst%3DL.%26atitle%3DUpregulation%2520of%2520A2A%2520adenosine%2520receptors%2520in%2520platelets%2520from%2520patients%2520affected%2520by%2520bipolar%2520disorders%2520under%2520treatment%2520with%2520typical%2520antipsychotics%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2006%26volume%3D40%26spage%3D81%26epage%3D88%26doi%3D10.1016%2Fj.jpsychires.2004.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wielockx, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Eijk, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerretsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groeneveld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneses, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langereis, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zomer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riksen, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Hoeven, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltzschig, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickkers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kox, M.</span></span> <span> </span><span class="NLM_article-title">Short-term hypoxia dampens inflammation in vivo via enhanced adenosine release and adenosine 2b receptor stimulation</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2018.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.ebiom.2018.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29983349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FlvVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=144-156&author=D.+Kiersauthor=B.+Wielockxauthor=E.+Petersauthor=L.+T.+van+Eijkauthor=J.+Gerretsenauthor=A.+Johnauthor=E.+Janssenauthor=R.+Groeneveldauthor=M.+Petersauthor=L.+Damenauthor=A.+M.+Menesesauthor=A.+Krugerauthor=J.+D.+Langereisauthor=A.+L.+Zomerauthor=M.+R.+Blackburnauthor=L.+A.+Joostenauthor=M.+G.+Neteaauthor=N.+P.+Riksenauthor=J.+G.+van+der%0AHoevenauthor=G.+J.+Schefferauthor=H.+K.+Eltzschigauthor=P.+Pickkersauthor=M.+Kox&title=Short-term+hypoxia+dampens+inflammation+in+vivo+via+enhanced+adenosine+release+and+adenosine+2b+receptor+stimulation&doi=10.1016%2Fj.ebiom.2018.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Short-Term Hypoxia Dampens Inflammation in vivo via Enhanced Adenosine Release and Adenosine 2B Receptor Stimulation</span></div><div class="casAuthors">Kiers Dorien; Wielockx Ben; Meneses Ana M; Kruger Anja; Peters Esther; van Eijk Lucas T; Gerretsen Jelle; John Aaron; Janssen Emmy; Groeneveld Rianne; Peters Mara; Damen Lars; van der Hoeven Johannes G; Pickkers Peter; Langereis Jeroen D; Zomer Aldert L; Blackburn Michael R; Joosten Leo A; Netea Mihai G; Riksen Niels P; Scheffer Gert-Jan; Eltzschig Holger K; Kox Matthijs</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144-156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hypoxia and inflammation are closely intertwined phenomena.  Critically ill patients often suffer from systemic inflammatory conditions and concurrently experience short-lived hypoxia.  We evaluated the effects of short-term hypoxia on systemic inflammation, and show that it potently attenuates pro-inflammatory cytokine responses during murine endotoxemia.  These effects are independent of hypoxia-inducible factors (HIFs), but involve augmented adenosine levels, in turn resulting in an adenosine 2B receptor-mediated post-transcriptional increase of interleukin (IL)-10 production.  We translated our findings to humans using the experimental endotoxemia model, where short-term hypoxia resulted in enhanced plasma concentrations of adenosine, augmentation of endotoxin-induced circulating IL-10 levels, and concurrent attenuation of the pro-inflammatory cytokine response.  Again, HIFs were shown not to be involved.  Taken together, we demonstrate that short-term hypoxia dampens the systemic pro-inflammatory cytokine response through enhanced purinergic signaling in mice and men.  These effects may contribute to outcome and provide leads for immunomodulatory treatment strategies for critically ill patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRV7_vQIOrf5tLIORRPd5lbfW6udTcc2eb9YGrYe3np0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FlvVKgtQ%253D%253D&md5=2710559b0830e4367ee47f08bd2000da</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2018.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2018.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DKiers%26aufirst%3DD.%26aulast%3DWielockx%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DE.%26aulast%3Dvan%2BEijk%26aufirst%3DL.%2BT.%26aulast%3DGerretsen%26aufirst%3DJ.%26aulast%3DJohn%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DE.%26aulast%3DGroeneveld%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DDamen%26aufirst%3DL.%26aulast%3DMeneses%26aufirst%3DA.%2BM.%26aulast%3DKruger%26aufirst%3DA.%26aulast%3DLangereis%26aufirst%3DJ.%2BD.%26aulast%3DZomer%26aufirst%3DA.%2BL.%26aulast%3DBlackburn%26aufirst%3DM.%2BR.%26aulast%3DJoosten%26aufirst%3DL.%2BA.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26aulast%3DRiksen%26aufirst%3DN.%2BP.%26aulast%3Dvan%2Bder%2BHoeven%26aufirst%3DJ.%2BG.%26aulast%3DScheffer%26aufirst%3DG.%2BJ.%26aulast%3DEltzschig%26aufirst%3DH.%2BK.%26aulast%3DPickkers%26aufirst%3DP.%26aulast%3DKox%26aufirst%3DM.%26atitle%3DShort-term%2520hypoxia%2520dampens%2520inflammation%2520in%2520vivo%2520via%2520enhanced%2520adenosine%2520release%2520and%2520adenosine%25202b%2520receptor%2520stimulation%26jtitle%3DEBioMedicine%26date%3D2018%26volume%3D33%26spage%3D144%26epage%3D156%26doi%3D10.1016%2Fj.ebiom.2018.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falconi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonito-Oliva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bartolomeo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massimini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattapposta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locuratolo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Addario, C.</span></span> <span> </span><span class="NLM_article-title">On the role of adenosine A2A receptor gene transcriptional regulation in Parkinson’s disease</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.3389/fnins.2019.00683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.3389%2Ffnins.2019.00683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31354407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BB3MvitFymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=683-683&author=A.+Falconiauthor=A.+Bonito-Olivaauthor=M.+Di+Bartolomeoauthor=M.+Massiminiauthor=F.+Fattappostaauthor=N.+Locuratoloauthor=E.+Daineseauthor=E.+Pascaleauthor=G.+Fisoneauthor=C.+D%E2%80%99Addario&title=On+the+role+of+adenosine+A2A+receptor+gene+transcriptional+regulation+in+Parkinson%E2%80%99s+disease&doi=10.3389%2Ffnins.2019.00683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinson's Disease</span></div><div class="casAuthors">Falconi Anastasia; Di Bartolomeo Martina; Massimini Marcella; Dainese Enrico; D'Addario Claudio; Bonito-Oliva Alessandra; Fisone Gilberto; Fattapposta Francesco; Locuratolo Nicoletta; Pascale Esterina; D'Addario Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">683</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Adenosine A2A receptors (A2ARs) have attracted considerable attention as an important molecular target for the design of Parkinson's disease (PD) therapeutic compounds.  Here, we studied the transcriptional regulation of the A2AR gene in human peripheral blood mononuclear cells (PBMCs) obtained from PD patients and in the striatum of the well-validated, 6-hydroxydopamine (6-OHDA)-induced PD mouse model.  We report an increase in A2AR mRNA expression and protein levels in both human cells and mice striata, and in the latter we could also observe a consistent reduction in DNA methylation at gene promoter and an increase in histone H3 acetylation at lysine 9.  Of particular relevance in clinical samples, we also observed higher levels in the receptor gene expression in younger subjects, as well as in those with less years from disease onset, and less severe disease according to clinical scores.  In conclusion, the present findings provide further evidence of the relevant role of A2AR in PD and, based on the clinical data, highlight its potential role as disease biomarker for PD especially at the initial stages of disease development.  Furthermore, our preclinical results also suggest selective epigenetic mechanisms targeting gene promoter as tool for the development of new treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAeEQq77nyFQ5nADWVYHg1fW6udTcc2eaMvzNKTJmxxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvitFymtw%253D%253D&md5=2aa3f193e9addc8267a7c0ce681af4f2</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2019.00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2019.00683%26sid%3Dliteratum%253Aachs%26aulast%3DFalconi%26aufirst%3DA.%26aulast%3DBonito-Oliva%26aufirst%3DA.%26aulast%3DDi%2BBartolomeo%26aufirst%3DM.%26aulast%3DMassimini%26aufirst%3DM.%26aulast%3DFattapposta%26aufirst%3DF.%26aulast%3DLocuratolo%26aufirst%3DN.%26aulast%3DDainese%26aufirst%3DE.%26aulast%3DPascale%26aufirst%3DE.%26aulast%3DFisone%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Addario%26aufirst%3DC.%26atitle%3DOn%2520the%2520role%2520of%2520adenosine%2520A2A%2520receptor%2520gene%2520transcriptional%2520regulation%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DFront.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D683%26epage%3D683%26doi%3D10.3389%2Ffnins.2019.00683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Attraqchi, O. H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attimarad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopala, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Attraqchi, N. H. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor as a potential drug target - current status and future perspectives</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2716</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.2174/1381612825666190716113444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.2174%2F1381612825666190716113444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31333093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFOrsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=2716-2740&author=O.+H.+A.+Al-Attraqchiauthor=M.+Attimaradauthor=K.+N.+Venugopalaauthor=A.+Nairauthor=N.+H.+A.+Al-Attraqchi&title=Adenosine+A2A+receptor+as+a+potential+drug+target+-+current+status+and+future+perspectives&doi=10.2174%2F1381612825666190716113444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives</span></div><div class="casAuthors">Al-Attraqchi, Omar H. A.; Attimarad, Mahesh; Venugopala, Katharigatta N.; Nair, Anroop; Al-Attraqchi, Noor H. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2716-2740</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine receptors (ARs) are a class of G-protein coupled receptors (GPCRs) that are activated by the endogenous substance adenosine.  ARs are classified into 4 subtype receptors, namely, the A1, A2A, A2B and A3 receptors.  The wide distribution and expression of the ARs in various body tissues as well as the roles they have in controlling different functions in the body make them potential drug targets for the treatment of various pathol. conditions, such as cardiac diseases, cancer, Parkinson's disease, inflammation and glaucoma.  Therefore, in the past decades, there have been extensive investigations of ARs with a high no. of agonists and antagonists identified that can interact with these receptors.  This review shall discuss the A2A receptor (A2AAR) subtype of the ARs.  The structure, properties and the recent advances in the therapeutic potential of the receptor are discussed with an overview of the recent advances in the methods of studying the receptor.  Also, mol. modeling approaches utilized in the design of A2AAR ligands are highlighted with various recent examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVXNrbnwe1QbVg90H21EOLACvtfcHk0liW5LVnhZTdcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFOrsrnF&md5=9599e1c0fa09b706ed37cf23166d6915</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.2174%2F1381612825666190716113444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612825666190716113444%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Attraqchi%26aufirst%3DO.%2BH.%2BA.%26aulast%3DAttimarad%26aufirst%3DM.%26aulast%3DVenugopala%26aufirst%3DK.%2BN.%26aulast%3DNair%26aufirst%3DA.%26aulast%3DAl-Attraqchi%26aufirst%3DN.%2BH.%2BA.%26atitle%3DAdenosine%2520A2A%2520receptor%2520as%2520a%2520potential%2520drug%2520target%2520-%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2019%26volume%3D25%26spage%3D2716%26epage%3D2740%26doi%3D10.2174%2F1381612825666190716113444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayeem, M. A.</span></span> <span> </span><span class="NLM_article-title">Exploring adenosine receptor ligands: potential role in the treatment of cardiovascular diseases</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">917</span>, <span class="refDoi"> DOI: 10.3390/molecules22060917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.3390%2Fmolecules22060917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1arur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=917&author=W.+J.+Geldenhuysauthor=A.+Hanifauthor=J.+Yunauthor=M.+A.+Nayeem&title=Exploring+adenosine+receptor+ligands%3A+potential+role+in+the+treatment+of+cardiovascular+diseases&doi=10.3390%2Fmolecules22060917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring adenosine receptor ligands: potential role in the treatment of cardiovascular diseases</span></div><div class="casAuthors">Geldenhuys, Werner J.; Hanif, Ahmad; Yun, June; Nayeem, Mohammed A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">917/1-917/11</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cardiovascular diseases remain the no. one diseases affecting patients' morbidity and mortality.  The adenosine receptors are G-protein coupled receptors which have been of interest for drugs target for the treatment of multiple diseases ranging from cardiovascular to neurol.  Adenosine receptors have been connected to several biol. pathways affecting the physiol. and pathol. of the cardiovascular system.  In this review, we will cover the different adenosine receptor ligands that have been identified to interact with adenosine receptors and affect the vascular system.  These ligands will be evaluated from clin. as well as medicinal chem. perspectives with more emphasis on how structural changes in structure translate into ligand potency and efficacy.  Adenosine receptors represent a novel therapeutic target for development of treatment options treating a wide variety of diseases, including vascular disease and obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkryKf_Lr83rVg90H21EOLACvtfcHk0liW5LVnhZTdcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1arur3O&md5=048d90bdf6c8957dae91bd550aaf9a8b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22060917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22060917%26sid%3Dliteratum%253Aachs%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DHanif%26aufirst%3DA.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DNayeem%26aufirst%3DM.%2BA.%26atitle%3DExploring%2520adenosine%2520receptor%2520ligands%253A%2520potential%2520role%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D917%26doi%3D10.3390%2Fmolecules22060917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor antagonists and parkinson’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1021/cn2000537</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn2000537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=555-567&author=B.+C.+Shookauthor=P.+F.+Jackson&title=Adenosine+A2A+receptor+antagonists+and+parkinson%E2%80%99s+disease&doi=10.1021%2Fcn2000537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists and Parkinson's Disease</span></div><div class="casAuthors">Shook, Brian C.; Jackson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">555-567</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This Review summarizes and updates the work on adenosine A2A receptor antagonists for Parkinson's disease from 2006 to the present.  There have been numerous publications, patent applications, and press releases within this time frame that highlight new medicinal chem. approaches to this attractive and promising target to treat Parkinson's disease.  The Review is broken down by scaffold type and will discuss the efforts to optimize particular scaffolds for activity, pharmacokinetics, and other drug discovery parameters.  The majority of approaches focus on prepg. selective A2A antagonists, but a few approaches to dual A2A/A1 antagonists will also be highlighted.  The in vivo profiles of compds. will be highlighted and discussed to compare activities across different chem. series.  A clin. report and update will be given on compds. that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9jbqVC-a6P7Vg90H21EOLACvtfcHk0lhaBqKnJhuYCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D&md5=81746259f96dd1a270f12c3cb2dbe1d3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fcn2000537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn2000537%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520and%2520parkinson%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D555%26epage%3D567%26doi%3D10.1021%2Fcn2000537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armentero, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanciego, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span> <span> </span><span class="NLM_article-title">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson’s disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.pharmthera.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21810444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=280-299&author=M.+T.+Armenteroauthor=A.+Pinnaauthor=S.+Ferreauthor=J.+L.+Lanciegoauthor=C.+E.+Mullerauthor=R.+Franco&title=Past%2C+present+and+future+of+A2A+adenosine+receptor+antagonists+in+the+therapy+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pharmthera.2011.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease</span></div><div class="casAuthors">Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Lanciego, Jose Luis; Mueller, Christa E.; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-299</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clin. trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market.  The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia.  At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients.  However, a considerable body of data indicates that in addn. to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration.  Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community.  Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors.  Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2pOYdmdfQMLVg90H21EOLACvtfcHk0lhaBqKnJhuYCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP&md5=39fa871338516f7574deb7845029e624</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPast%252C%2520present%2520and%2520future%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520in%2520the%2520therapy%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D280%26epage%3D299%26doi%3D10.1016%2Fj.pharmthera.2011.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span> <span> </span><span class="NLM_article-title">Recent progress in the discovery of adenosine A2A receptor antagonists for the treatment of Parkinson’s disease</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=20597030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSju7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=466-480&author=U.+Shahauthor=R.+Hodgson&title=Recent+progress+in+the+discovery+of+adenosine+A2A+receptor+antagonists+for+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in the discovery of adenosine A2A receptor antagonists for the treatment of Parkinson's disease</span></div><div class="casAuthors">Shah, Unmesh; Hodgson, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466-480</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Antagonism of the A2A receptor has emerged as a promising non-dopaminergic approach for the potential treatment of Parkinson's disease (PD).  Several pharmaceutical and academic institutions have ongoing research programs in this area, and orally efficacious A2A receptor antagonists were advanced into clin. development.  Traditionally, antagonists of the A2A receptor are classified as xanthine and non-xanthine derivs.  This review provides a detailed summary of the recent SAR development that has led to the discovery of promising non-xanthine-based A2A receptor antagonists.  The current clin. status and the potential utility of A2A receptor antagonists in indications other than PD are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouWpTRXO9ll7Vg90H21EOLACvtfcHk0lg30w6G88cw-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSju7zK&md5=1e9fb4644949ab0efeb9a208bdb1d3d7</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DU.%26aulast%3DHodgson%26aufirst%3DR.%26atitle%3DRecent%2520progress%2520in%2520the%2520discovery%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D466%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cristalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpini, R.</span></span> <span> </span><span class="NLM_article-title">Recent developments in adenosine A2A receptor ligands</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/978-3-540-89615-9_3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2F978-3-540-89615-9_3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=19639279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sktr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2009&pages=59-98&author=G.+Cristalliauthor=C.+E.+Mullerauthor=R.+Volpini&title=Recent+developments+in+adenosine+A2A+receptor+ligands&doi=10.1007%2F978-3-540-89615-9_3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in adenosine A2A receptor ligands</span></div><div class="casAuthors">Cristalli, Gloria; Muller, Christa E.; Volpini, Rosaria</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">Adenosine Receptors in Health and Disease</span>),
    <span class="NLM_cas:pages">59-98</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The development of potent and selective agonists and antagonists of adenosine receptors (ARs) has been a target of medicinal chem. research for several decades, and recently the US Food and Drug Administration has approved Lexiscan, an adenosine deriv. substituted at the 2 position, for use as a pharmacol. stress agent in radionuclide myocardial perfusion imaging.  Currently, some other adenosine A2A receptor (A2AAR) agonists and antagonists are undergoing preclin. testing and clin. trials.  While agonists are potent antiinflammatory agents also showing hypotensive effects, antagonists are being developed for the treatment of Parkinson's disease.  However, since there are still major problems in this field, including side effects, low brain penetration (for the targeting of CNS diseases), short half-life, or lack of in vivo effects, the design and development of new AR ligands is a hot research topic.  This review presents an update on the medicinal chem. of A2AAR agonists and antagonists, and stresses the strong need for more selective ligands at the human A2AAR subtype, in particular in the case of agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZlneM0HaH4rVg90H21EOLACvtfcHk0lg30w6G88cw-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sktr7E&md5=95c3e8fde30c9094d81cea882987ae64</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-89615-9_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-89615-9_3%26sid%3Dliteratum%253Aachs%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DVolpini%26aufirst%3DR.%26atitle%3DRecent%2520developments%2520in%2520adenosine%2520A2A%2520receptor%2520ligands%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2009%26volume%3D193%26spage%3D59%26epage%3D98%26doi%3D10.1007%2F978-3-540-89615-9_3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span> <span> </span><span class="NLM_article-title">Adenosine, adenosine A2A antagonists, and Parkinson’s disease</span>. <i>Parkinsonism Relat. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">406</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/j.parkreldis.2008.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.parkreldis.2008.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=19446490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BD1MvksVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=406-413&author=P.+Jennerauthor=A.+Moriauthor=R.+Hauserauthor=M.+Morelliauthor=B.+B.+Fredholmauthor=J.+F.+Chen&title=Adenosine%2C+adenosine+A2A+antagonists%2C+and+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.parkreldis.2008.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine, adenosine A 2A antagonists, and Parkinson's disease</span></div><div class="casAuthors">Jenner P; Mori A; Hauser R; Morelli M; Fredholm B B; Chen J F</div><div class="citationInfo"><span class="NLM_cas:title">Parkinsonism & related disorders</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">406-13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adenosine derived from the degradation of ATP/AMP functions as a signalling molecule in the nervous system through the occupation of A1, A2, and A3 adenosine receptors.  Adenosine A(2A) receptors have a selective localization to the basal ganglia and specifically to the indirect output pathway, and as a consequence offer a unique opportunity to modulate the output from the striatum that is believed critical to the occurrence of motor components of PD.  Indeed, the ability of A(2A) antagonists to modulate basal ganglia neurotransmission has been shown to be associated with improved motor function in experimental models of PD.  This suggests that A(2A) antagonists would be effective as a symptomatic treatment in humans without provoking marked dyskinesia.  Indeed, the A(2A) antagonist istradefylline reduces OFF time in moderate- to late-stage patients with PD already receiving dopaminergic therapy, with an increase in non-troublesome dyskinesia.  Adenosine and adenosine receptors also exert actions relevant to pathogenesis in PD, raising the possibility of their use as neuroprotective agents.  Both epidemiologic evidence and the current preclinical data strongly support a role for A(2A) antagonists in protecting dopaminergic neurons and influencing the onset and progression of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsdd-F41SVOmBAiYWy6n3SfW6udTcc2eaRzaSNUSUbc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvksVWnsg%253D%253D&md5=3c823d672ed66ea92ef6876eedf544a5</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.parkreldis.2008.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.parkreldis.2008.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DJenner%26aufirst%3DP.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DHauser%26aufirst%3DR.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26atitle%3DAdenosine%252C%2520adenosine%2520A2A%2520antagonists%252C%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DParkinsonism%2520Relat.%2520Disord.%26date%3D2009%26volume%3D15%26spage%3D406%26epage%3D413%26doi%3D10.1016%2Fj.parkreldis.2008.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vu, C.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the design and optimization of adenosine A2A receptor antagonists</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=16022182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFCgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=458-468&author=C.+Vu&title=Recent+advances+in+the+design+and+optimization+of+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the design and optimization of adenosine A2A receptor antagonists</span></div><div class="casAuthors">Vu, Chi B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">458-468</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  In recent years, the adenosine A2A receptor has gained interest as a potential therapeutic target for alleviating the symptoms of Parkinson's disease.  Adenosine A2A receptor antagonists are orally effective in a variety of rodent models of Parkinson's disease.  Traditionally, adenosine A2A receptor antagonists are divided into 2 general classes, xanthine or non-xanthine derivs.  Extensive optimization among the xanthine derivs. has already led to the clin. candidate KW-6002 (Kyowa Hakko Kogyo Co Ltd).  However, there is increasing interest among researchers in this field to explore other classes of compds. as potential antagonists for this particular receptor.  This review highlights the more recent developments in the design and optimization of non-xanthine derivs. as adenosine A2A receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFVWEy9JKDtbVg90H21EOLACvtfcHk0li1-lFE_0t2_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFCgt7c%253D&md5=3d081bf399a0984379c193565a58d337</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DC.%26atitle%3DRecent%2520advances%2520in%2520the%2520design%2520and%2520optimization%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2005%26volume%3D8%26spage%3D458%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1007/s40263-014-0161-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1007%2Fs40263-014-0161-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=24687255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWhtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=455-474&author=A.+Pinna&title=Adenosine+A2A+receptor+antagonists+in+Parkinson%E2%80%99s+disease%3A+progress+in+clinical+trials+from+the+newly+approved+istradefylline+to+drugs+in+early+development+and+those+already+discontinued&doi=10.1007%2Fs40263-014-0161-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued</span></div><div class="casAuthors">Pinna, Annalisa</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-474</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine, glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and contribute to its symptomatol.  Thus, the progress of non-dopaminergic therapies for PD has attracted much interest in recent years.  Among new classes of drugs, adenosine A2A antagonists have emerged as promising candidates.  The development of new highly selective adenosine A2A receptor antagonists, and their encouraging anti-parkinsonian responses in animal models of PD, has provided a rationale for clin. trials to evaluate the therapeutic potential and the safety of these agents in patients with PD.  To date, the clin. research regarding A2A antagonists and their potential utilization in PD therapy continues to evolve between drugs just or previously discontinued (preladenant and vipadenant), new derivs. in development (tozadenant, PBF-509, ST1535, ST4206 and V81444) and the relatively old drug istradefylline, which has finally been licensed as an anti-parkinsonian drug in Japan.  All these compds. have been shown to have a good safety profile and be well tolerated.  Moreover, results from phase II and III trials also demonstrate that A2A antagonists are effective in reducing off-time, without worsening troublesome dyskinesia, and in increasing on-time with a mild increase of non-troublesome dyskinesia, in patients at an advanced stage of PD treated with L-DOPA.  In addn., early findings suggest that A2A antagonists might also be efficacious as monotherapy in patients at an early stage of PD.  This review summarizes pharmacol. and clin. data available on istradefylline, tozadenant, PBF-509, ST1535, ST4206, V81444, preladenant and vipadenant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9RSy9sahNnbVg90H21EOLACvtfcHk0li1-lFE_0t2_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWhtLc%253D&md5=1c12ad215ddb2384ec190027d23a3216</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2Fs40263-014-0161-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-014-0161-7%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520progress%2520in%2520clinical%2520trials%2520from%2520the%2520newly%2520approved%2520istradefylline%2520to%2520drugs%2520in%2520early%2520development%2520and%2520those%2520already%2520discontinued%26jtitle%3DCNS%2520Drugs%26date%3D2014%26volume%3D28%26spage%3D455%26epage%3D474%26doi%3D10.1007%2Fs40263-014-0161-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burbiel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">Multigram-scale synthesis, stability and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson’s disease</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">3308</span>– <span class="NLM_lpage">3318</span>, <span class="refDoi"> DOI: 10.1021/jo0358574</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0358574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFarsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3308-3318&author=J.+Hockemeyerauthor=J.+Burbielauthor=C.+E.+M%C3%BCller&title=Multigram-scale+synthesis%2C+stability+and+photoreactions+of+A2A+adenosine+receptor+antagonists+with+8-styrylxanthine+structure%3A+potential+drugs+for+Parkinson%E2%80%99s+disease&doi=10.1021%2Fjo0358574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Multigram-Scale Syntheses, Stability, and Photoreactions of A2A Adenosine Receptor Antagonists with 8-Styrylxanthine Structure: Potential Drugs for Parkinson's Disease</span></div><div class="casAuthors">Hockemeyer, Joerg; Burbiel, Joachim C.; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3308-3318</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The improved multigram-scale syntheses of the important 8-styrylxanthine A2A adenosine receptor antagonist MSX-2 [I, R = CH2C≡CH, R1 = (CH2)3OH, R2 = H], its water-sol. prodrug MXS-3 [I, R = CH2C≡CH, R1 = (CH2)3OP(O)(OH)2, R2 = H], and KW-6002 [I, R = R1 = Et, R2 = OMe] are described.  N-Alkylation reactions at different positions of the uracil ring were optimized.  Two different methods for xanthine formation from 6-amino-5-cinnamoylaminouracil precursors were investigated: (a) the elimination of water by alk. catalysis and (b) hexamethyldisilazane as a condensing agent; the latter was found to be superior.  The photosensitivity of the 8-styrylxanthines was studied.  The (E)-configurated stryrylxanthine MSX-2 isomerized in dild. soln., and the resulting (Z)-isomer was isolated and characterized.  Furthermore, solid 8-styrylxanthines can dimerize upon exposure to daylight or irradn. with UV light.  The resulting cyclobutane derivs. with head-to-tail (syn) configuration exhibited a considerably lower A2A adenosine receptor affinity than their parent compds.  The dimerization product of MSX-2 was a moderately potent nonselective A1 and A2A antagonist (Ki(A1) = 273 nM, Ki (A2A) = 175 nM) while the dimer of KW-6002 was inactive at A1 and only weakly active at A2A adenosine receptors (Ki = 1.57 μM).  The light sensitivity of 8-styrylxanthine derivs., not only in soln., but also in the solid state, has to be considered when using those compds. as pharmacol. tools or drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH59mwpE6WRLVg90H21EOLACvtfcHk0li1-lFE_0t2_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFarsro%253D&md5=b76c488fd1df3d5c31b3911bf1b27d6b</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjo0358574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0358574%26sid%3Dliteratum%253Aachs%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DBurbiel%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DMultigram-scale%2520synthesis%252C%2520stability%2520and%2520photoreactions%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520with%25208-styrylxanthine%2520structure%253A%2520potential%2520drugs%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3308%26epage%3D3318%26doi%3D10.1021%2Fjo0358574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kjaergaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">A2A adenosine receptor gene deletion or synthetic A2A antagonist liberate tumor-reactive CD8(+) T cells from tumor-induced immunosuppression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1700850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.4049%2Fjimmunol.1700850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29802128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Oqu7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2018&pages=782-791&author=J.+Kjaergaardauthor=S.+Hatfieldauthor=G.+Jonesauthor=A.+Ohtaauthor=M.+Sitkovsky&title=A2A+adenosine+receptor+gene+deletion+or+synthetic+A2A+antagonist+liberate+tumor-reactive+CD8%28%2B%29+T+cells+from+tumor-induced+immunosuppression&doi=10.4049%2Fjimmunol.1700850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression</span></div><div class="casAuthors">Kjaergaard, Jorgen; Hatfield, Stephen; Jones, Graham; Ohta, Akio; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">782-791</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Tumor hypoxia-driven accumulation of extracellular adenosine was shown to facilitate tumor evasion by engaging the immunosuppressive, intracellular cAMP-elevating A2 adenosine receptors (A2R) on tumor-reactive effector T cells, but there remains a need for careful evaluation of the limiting factors and properties of A2R blockade-enabled antitumor immunity.  In studies of A2AR and/or A2BR gene-deficient mice, we found that A2AR deletion-but not A2BR deletion-liberates endogenous CD8+ T cell antitumor immunity against weakly immunogenic MCA205 sarcomas.  Studies of adoptively transferred A2AR-/-, A2BR-/-, or A2AR-/-/A2BR-/- tumor-reactive T cells confirmed that immunosuppression in the tumor microenvironment was mediated by A2AR on CD8+ T cells.  Treatment with A2AR antagonist mimicked A2AR gene deletion in adoptive T cell immunotherapy.  This therapeutic benefit of targeting A2AR was independent of the anatomical location of tumor growth.  The enhanced antitumor reactivity also led to the eradication of established intracranial tumors, which was assocd. with mouse survival and the maintenance of long-lasting, tumor-specific immunol. memory.  The blockade of the A2AR on adoptively transferred T cells by synthetic A2AR antagonist led to higher levels of IFN-γ secretion by tumor-infiltrating CD8+ T cells.  These data clarify the mechanism of hypoxia-driven immunosuppression in the tumor microenvironment by A2AR on tumor-reactive CD8+ T cells and show that selective A2AR antagonists can be effective in improving the outcomes of T cell-based immunotherapies.  Demonstration of the T cell dose dependency of tumor rejection points to a major limitation of current cancer immunotherapies, in which the presence of sufficient nos. of tumor-reactive T cells in a patient is not known.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPGcoGQnU2n7Vg90H21EOLACvtfcHk0lib57Sibn2r1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Oqu7jF&md5=ff4a23b4ef75b4e8df36e42a3945389e</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1700850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1700850%26sid%3Dliteratum%253Aachs%26aulast%3DKjaergaard%26aufirst%3DJ.%26aulast%3DHatfield%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DA2A%2520adenosine%2520receptor%2520gene%2520deletion%2520or%2520synthetic%2520A2A%2520antagonist%2520liberate%2520tumor-reactive%2520CD8%2528%252B%2529%2520T%2520cells%2520from%2520tumor-induced%2520immunosuppression%26jtitle%3DJ.%2520Immunol.%26date%3D2018%26volume%3D201%26spage%3D782%26epage%3D791%26doi%3D10.4049%2Fjimmunol.1700850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A. D.</span>; <span class="NLM_string-name">Robert, F.</span>; <span class="NLM_string-name">Baum, P. R.</span>; <span class="NLM_string-name">Odegard, V.</span></span> <span> </span><span class="NLM_article-title">Application of Istradefylline in Preparation of Medicine for Treating Tumor</span>. PCT Int. Appl. <span class="NLM_patent">WO2019084060 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+A.+D.+Thompson&author=F.+Robert&author=P.+R.+Baum&author=V.+Odegard&title=Application+of+Istradefylline+in+Preparation+of+Medicine+for+Treating+Tumor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DP.%2BA.%2BD.%26atitle%3DApplication%2520of%2520Istradefylline%2520in%2520Preparation%2520of%2520Medicine%2520for%2520Treating%2520Tumor%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunwalder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Psychoyos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cash, W. D.</span></span> <span> </span><span class="NLM_article-title">Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>241</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">420</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=2883298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaL2sXksFWrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=1987&pages=415-420&author=M.+Williamsauthor=J.+Francisauthor=G.+Ghaiauthor=A.+Braunwalderauthor=S.+Psychoyosauthor=G.+A.+Stoneauthor=W.+D.+Cash&title=Biochemical+characterization+of+the+triazoloquinazoline%2C+CGS+15943%2C+a+novel%2C+non-xanthine+adenosine+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical characterization of the triazoloquinazoline CGS 15943A, a novel, nonxanthine adenosine antagonist</span></div><div class="casAuthors">Williams, Michael; Francis, John; Ghai, Geetha; Braunwalder, Albert; Psychoyos, Stacy; Stone, George A.; Cash, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">415-20</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">CGS 15943A (I), a triazoloquinazoline, is a potent and selective adenosine receptor antagonist as assessed by its effects on radioligand binding and adenosine-stimulated adenylate cyclase activity in guinea pig synaptoneurosomes.  At the adenosine A-1 receptor labeled with [3H]cyclohexyladenosine, I had an IC50 value of 20 nM.  At the striatal A-2 receptor labeled with [3H]5'-N-ethylcarboxamidoadenosine (in the presence of a low concn. of cyclopentyladenosine to block A-1 receptors labeled by this nonselective adenosine agonist), I had an IC50 value of 3 nM, indicating that the compd. had some degree of selectivity for the A-2 receptor.  Anal. of the effect of the compd. on the satn. isotherms for each of the receptors indicated that it was a competitive antagonist at the brain A-1 receptor but that it was noncompetitive at the striatal A-2 receptor.  I was a potent adenosine antagonist in the adenosine-stimulated adenylate cyclase system in guinea pig synaptoneurosomes, where the compd. was found to have an IC50 value of 30 to 70 nM against the increase in cAMP evoked by 5 μM adenosine.  I had no effect on the binding of [3H]nitrobenzylthioinosine, a ligand thought to bind to adenosine uptake sites, and, at a concn. of 10 μM, had no effect on beef heart type III phosphodiesterase activity.  In assessing its activity in binding assays for 21 other putative neurotransmitters, I showed no appreciable activity at concns. up to 10 μM, although it was able to inhibit the binding of [3H]flunitrazepam to the central benzodiazepine receptor with an IC50 value of 1020 nM.  I is a potent adenosine antagonist.  Since it is not a xanthine with the underlying assocn. of phosphodiesterase-inhibitory properties, it may be useful in evaluating the role of adenosine in mammalian tissue function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7D611Hdrm6rVg90H21EOLACvtfcHk0lib57Sibn2r1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXksFWrtLc%253D&md5=15287d69f1c5ae5a413f665c137353a7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DGhai%26aufirst%3DG.%26aulast%3DBraunwalder%26aufirst%3DA.%26aulast%3DPsychoyos%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DG.%2BA.%26aulast%3DCash%26aufirst%3DW.%2BD.%26atitle%3DBiochemical%2520characterization%2520of%2520the%2520triazoloquinazoline%252C%2520CGS%252015943%252C%2520a%2520novel%252C%2520non-xanthine%2520adenosine%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1987%26volume%3D241%26spage%3D415%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gatta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Giudice, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borioni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionisotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2 receptor antagonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/0223-5234(93)90087-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2F0223-5234%2893%2990087-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2cXjt1entrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1993&pages=569-576&author=F.+Gattaauthor=M.+R.+Del+Giudiceauthor=A.+Borioniauthor=P.+A.+Boreaauthor=S.+Dionisottiauthor=E.+Ongini&title=Synthesis+of+imidazo%5B1%2C2-c%5Dpyrazolo%5B4%2C3-e%5Dpyrimidines%2C+pyrazolo%5B4%2C3-e%5D1%2C2%2C4-triazolo%5B1%2C5-c%5Dpyrimidines+and+1%2C2%2C4-triazolo%5B5%2C1-i%5Dpurines%3A+new+potent+adenosine+A2+receptor+antagonists&doi=10.1016%2F0223-5234%2893%2990087-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2 receptor antagonists</span></div><div class="casAuthors">Gatta, F.; Del Giudice, M. R.; Borioni, A.; Borea, P. A.; Dionisotti, S.; Ongini, E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">569-76</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">A no. of 2- or 4-fluorobenzyl derivs. of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine and 1,2,4-triazolo[5,1-i]purine have been synthesized.  The interaction with the adenosine A2 and A1 receptors was evaluated using selected biol. assays.  The highest degree of activity was displayed by the 5-amino-2-(2-furyl)-7-(or 8-)-fluorobenzylpyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine I and II (R = 2- and 4-F) and -3-fluorobenzyl-1,2,4-triazolo[5,1-i]purines III (R = 2- and 4-F).  The compd. II (R = 4-F) was the most potent A2 antagonist in the authors' series with a selectivity similar to that of the ref. compd. CGS 15943, but with 75-fold more activity in the platelet aggregation model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVxyuCXbfN5bVg90H21EOLACvtfcHk0liX4Vx643igdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjt1entrg%253D&md5=4efd3e9be2319b631598a20b43b80e91</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2F0223-5234%2893%2990087-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0223-5234%252893%252990087-U%26sid%3Dliteratum%253Aachs%26aulast%3DGatta%26aufirst%3DF.%26aulast%3DDel%2BGiudice%26aufirst%3DM.%2BR.%26aulast%3DBorioni%26aufirst%3DA.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DDionisotti%26aufirst%3DS.%26aulast%3DOngini%26aufirst%3DE.%26atitle%3DSynthesis%2520of%2520imidazo%255B1%252C2-c%255Dpyrazolo%255B4%252C3-e%255Dpyrimidines%252C%2520pyrazolo%255B4%252C3-e%255D1%252C2%252C4-triazolo%255B1%252C5-c%255Dpyrimidines%2520and%25201%252C2%252C4-triazolo%255B5%252C1-i%255Dpurines%253A%2520new%2520potent%2520adenosine%2520A2%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1993%26volume%3D28%26spage%3D569%26epage%3D576%26doi%3D10.1016%2F0223-5234%2893%2990087-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappaterra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionisotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2539</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)80279-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2FS0960-894X%2801%2980279-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2MXit1Orsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=2539-2544&author=P.+G.+Baraldiauthor=S.+Manfrediniauthor=D.+Simoniauthor=L.+Zappaterraauthor=C.+Zocchiauthor=S.+Dionisottiauthor=E.+Ongini&title=Synthesis+of+new+pyrazolo%5B4%2C3-e%5D1%2C2%2C4-triazolo%5B1%2C5-c%5D+pyrimidine+and+1%2C2%2C3-triazolo%5B4%2C5-e%5D1%2C2%2C4-triazolo%5B1%2C5-c%5D+pyrimidine+displaying+potent+and+selective+activity+as+A2a+adenosine+receptor+antagonists&doi=10.1016%2FS0960-894X%2801%2980279-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c]pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Manfredini, Stefano; Simoni, Daniele; Zappaterra, Laura; Zocchi, Cristina; Dionisotti, Silvio; Ongini, Ennio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2539-44</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c]pyrimidines were prepd. and evaluated for their activity as adenosine A2a receptor antagonists.  In the present study, 5-amino-7-(phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261) was identified as potent and selective adenosine A2a antagonist in binding assays (Ki = 2.3 nM, Ki ratio: A2/A2a = 52.6).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXHpSXE_jS2rVg90H21EOLACvtfcHk0liX4Vx643igdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1Orsr4%253D&md5=14674c4312f72b1e58e859f70b7d5d4c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980279-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980279-1%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DManfredini%26aufirst%3DS.%26aulast%3DSimoni%26aufirst%3DD.%26aulast%3DZappaterra%26aufirst%3DL.%26aulast%3DZocchi%26aufirst%3DC.%26aulast%3DDionisotti%26aufirst%3DS.%26aulast%3DOngini%26aufirst%3DE.%26atitle%3DSynthesis%2520of%2520new%2520pyrazolo%255B4%252C3-e%255D1%252C2%252C4-triazolo%255B1%252C5-c%255D%2520pyrimidine%2520and%25201%252C2%252C3-triazolo%255B4%252C5-e%255D1%252C2%252C4-triazolo%255B1%252C5-c%255D%2520pyrimidine%2520displaying%2520potent%2520and%2520selective%2520activity%2520as%2520A2a%2520adenosine%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1994%26volume%3D4%26spage%3D2539%26epage%3D2544%26doi%3D10.1016%2FS0960-894X%2801%2980279-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2255</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F0008-5472.CAN-09-3109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=20179192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFygt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2245-2255&author=D.+Jinauthor=J.+Fanauthor=L.+Wangauthor=L.+F.+Thompsonauthor=A.+Liuauthor=B.+J.+Danielauthor=T.+Shinauthor=T.+J.+Curielauthor=B.+Zhang&title=CD73+on+tumor+cells+impairs+antitumor+T-cell+responses%3A+a+novel+mechanism+of+tumor-induced+immune+suppression&doi=10.1158%2F0008-5472.CAN-09-3109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression</span></div><div class="casAuthors">Jin, Dachuan; Fan, Jie; Wang, Long; Thompson, Linda F.; Liu, Aijie; Daniel, Benjamin J.; Shin, Tahiro; Curiel, Tyler J.; Zhang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2245-2255</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CD73, originally defined as a lymphocyte differentiation antigen, is thought to function as a cosignaling mol. on T lymphocytes and an adhesion mol. that is required for lymphocyte binding to endothelium.  We show here that CD73 is widely expressed on many tumor cell lines and is upregulated in cancerous tissues.  Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP breakdown to immunosuppressive adenosine, we hypothesized that CD73-generated adenosine prevents tumor destruction by inhibiting antitumor immunity.  We confirmed this hypothesis by showing that combining tumor CD73 knockdown and tumor-specific T-cell transfer cured all tumor-bearing mice.  In striking contrast, there was no therapeutic benefit of adoptive T-cell immunotherapy in mice bearing tumors without CD73 knockdown.  Moreover, blockade of the A2A adenosine receptor with a selective antagonist also augmented the efficacy of adoptive T-cell therapy.  These findings identify a potential mechanism for CD73-mediated tumor immune evasion and point to a novel cancer immunotherapy strategy by targeting the enzymic activity of tumor CD73.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKSNnpdNVOrbVg90H21EOLACvtfcHk0liX4Vx643igdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFygt7w%253D&md5=222edb4bbc4908588cafc8a9789dce0d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3109%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DThompson%26aufirst%3DL.%2BF.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DDaniel%26aufirst%3DB.%2BJ.%26aulast%3DShin%26aufirst%3DT.%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%26atitle%3DCD73%2520on%2520tumor%2520cells%2520impairs%2520antitumor%2520T-cell%2520responses%253A%2520a%2520novel%2520mechanism%2520of%2520tumor-induced%2520immune%2520suppression%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2245%26epage%3D2255%26doi%3D10.1158%2F0008-5472.CAN-09-3109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shryock, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowdy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacciari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spalluto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monopoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belardinelli, L.</span></span> <span> </span><span class="NLM_article-title">A<sub>2A</sub>-adenosine receptor reserve for coronary vasodilation</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.98.7.711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1161%2F01.CIR.98.7.711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=9715864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK1cXlslWltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1998&pages=711-718&author=J.+C.+Shryockauthor=S.+Snowdyauthor=P.+G.+Baraldiauthor=B.+Cacciariauthor=G.+Spallutoauthor=A.+Monopoliauthor=E.+Onginiauthor=S.+P.+Bakerauthor=L.+Belardinelli&title=A2A-adenosine+receptor+reserve+for+coronary+vasodilation&doi=10.1161%2F01.CIR.98.7.711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A2A-adenosine receptor reserve for coronary vasodilation</span></div><div class="casAuthors">Shryock, John C.; Snowdy, Stephen; Baraldi, Pier Giovanni; Cacciari, Barbara; Spalluto, Giampiero; Monopoli, Angela; Ongini, Ennio; Baker, Stephen P.; Belardinelli, Luiz</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">711-718</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Adenosine is a potent coronary vasodilator and causes an increase of coronary blood flow by activation of A2A-adenosine receptors (A2A-AdoRs).  The purpose of this study was to test the hypothesis that the high potency of adenosine and adenosine analogs to cause coronary vasodilation is explained by the presence of a large A2A-AdoR reserve ("spare receptors").  A novel, irreversible antagonist of A2A-AdoRs was used to inactivate receptors and reduce the response to agonist.  Agonist-induced increases of coronary conductance before and after exposure of hearts to the irreversible antagonist were compared.  Three agonists were studied: CGS 21680, adenosine, and 2-chloro-N6-cyclopentyladenosine (CCPA).  Data were analyzed to det. agonist KA (equil. dissocn. const.) and EC50 values.  Values of KA for activation of A2A-AdoRs by CGS 21680, adenosine, and CCPA were 105, 1800, and 2630 nmol/L, resp.  In contrast, values of EC50 for CGS 21680, adenosine, and CCPA to increase coronary conductance were 1.5, 85, and 243 nmol/L, resp.  By use of the law of mass action, it was calcd. that half-maximal responses to CGS 21680, adenosine, and CCPA occurred when only 1.3%, 5%, and 9%, resp., of A2A-AdoRs were occupied by agonist.  Thus, the receptor reserves for the 3 A2A-AdoR agonists were large.  The receptor reserve for A2A-AdoRs inducing an increase of coronary conductance can explain both the high potency of adenosine to cause coronary vasodilation and the observation that an A2A-AdoR agonist can cause coronary vasodilation without systemic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQyNzlsplKLVg90H21EOLACvtfcHk0lhM_AtJMPpzQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlslWltb0%253D&md5=1871328e347731d240b749553c1a63a6</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.98.7.711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.98.7.711%26sid%3Dliteratum%253Aachs%26aulast%3DShryock%26aufirst%3DJ.%2BC.%26aulast%3DSnowdy%26aufirst%3DS.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DCacciari%26aufirst%3DB.%26aulast%3DSpalluto%26aufirst%3DG.%26aulast%3DMonopoli%26aufirst%3DA.%26aulast%3DOngini%26aufirst%3DE.%26aulast%3DBaker%26aufirst%3DS.%2BP.%26aulast%3DBelardinelli%26aufirst%3DL.%26atitle%3DA2A-adenosine%2520receptor%2520reserve%2520for%2520coronary%2520vasodilation%26jtitle%3DCirculation%26date%3D1998%26volume%3D98%26spage%3D711%26epage%3D718%26doi%3D10.1161%2F01.CIR.98.7.711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caulkett, P. W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPartlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, B.</span></span> <span> </span><span class="NLM_article-title">Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]triazolo[1,5-a][1,3,5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1039/p19950000801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1039%2Fp19950000801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADyaK2MXltFOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&pages=801-808&author=P.+W.+R.+Caulkettauthor=G.+Jonesauthor=M.+McPartlinauthor=N.+D.+Renshawauthor=S.+K.+Stewartauthor=B.+Wright&title=Adenine+isosteres+with+bridgehead+nitrogen.+Part+1.+Two+independent+syntheses+of+the+%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazine+ring+system+leading+to+a+range+of+substituents+in+the+2%2C+5+and+7+positions&doi=10.1039%2Fp19950000801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]traizolo[1,5-a][1,3,5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions</span></div><div class="casAuthors">Caulkett, Peter W. R.; Jones, Geraint; McPartlin, Mary; Renshaw, Nigel D.; Stewart, Sarah K.; Wright, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">801-8</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Condensation of a 3-substituted 5-amino-1,2,4-triazole with an N-cyanocarbonimidate gave the title compds., in most cases as a mixt. of isomers; sepn. and elaboration then gave [1,2,4]triazolo[1,5-a][1,3,5]triazines bearing a range of substituents in the 5 and 7 positions.  Under milder reaction conditions, less stable isomeric products (e.g., the [1,2,4]triazolo[4,3-a][1,3,5]triazine ring system or an uncyclized N-cyano intermediate) was isolated and shown to rearrange to the [1,5-a] isomer.  A second synthesis was described in which a 2-hydrazido-1,3,5-triazine was cyclodehydrated to give a single isomer with identical substituents in the 5 and 7 positions; the large difference in reactivity between these allows selective replacement at the 7-position with nucleophile.  Addnl., the second synthesis was more readily adaptable to the introduction of substituents at the 2 position of the bicyclic nucleus.  7-Amino-2-(2-furyl)-5-phenoxy[1,2,4]triazolo[1,5-a][1,3,5]triazine was prepd. independently by both synthetic sequences and its structure verified by X-ray crystallog. anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr04m7BOaXYCLVg90H21EOLACvtfcHk0lhM_AtJMPpzQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltFOrsbc%253D&md5=7ff740514304fb8d3398102b62fc25b5</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1039%2Fp19950000801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp19950000801%26sid%3Dliteratum%253Aachs%26aulast%3DCaulkett%26aufirst%3DP.%2BW.%2BR.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DMcPartlin%26aufirst%3DM.%26aulast%3DRenshaw%26aufirst%3DN.%2BD.%26aulast%3DStewart%26aufirst%3DS.%2BK.%26aulast%3DWright%26aufirst%3DB.%26atitle%3DAdenine%2520isosteres%2520with%2520bridgehead%2520nitrogen.%2520Part%25201.%2520Two%2520independent%2520syntheses%2520of%2520the%2520%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazine%2520ring%2520system%2520leading%2520to%2520a%2520range%2520of%2520substituents%2520in%2520the%25202%252C%25205%2520and%25207%2520positions%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1995%26spage%3D801%26epage%3D808%26doi%3D10.1039%2Fp19950000801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, A.</span>; <span class="NLM_string-name">Moreau, J. L.</span>; <span class="NLM_string-name">Poli, S. M.</span>; <span class="NLM_string-name">Riemer, C.</span>; <span class="NLM_string-name">Steward, L.</span></span> <span> </span><span class="NLM_article-title">4-Hydroxy-4-methyl-piperidine-1-carboxylic Acid (4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide</span>. U.S. Pat. Appl. Publ. <span class="NLM_patent">US20050261289 A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=A.+Flohr&author=J.+L.+Moreau&author=S.+M.+Poli&author=C.+Riemer&author=L.+Steward&title=4-Hydroxy-4-methyl-piperidine-1-carboxylic+Acid+%284-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl%29-amide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlohr%26aufirst%3DA.%26atitle%3D4-Hydroxy-4-methyl-piperidine-1-carboxylic%2520Acid%2520%25284-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl%2529-amide%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span>ClinicalTrials.gov
home page. <a href="https://clinicaltrials.gov/ct2/results?cond=&amp;term=SYN115&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://clinicaltrials.gov/ct2/results?cond=&term=SYN115&cntry=&state=&city=&dist=</a> (accessed Jun 17, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov%0Ahome+page.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DSYN115%26cntry%3D%26state%3D%26city%3D%26dist%3D+%28accessed+Jun+17%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaakola, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1217</span>, <span class="refDoi"> DOI: 10.1126/science.1164772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1126%2Fscience.1164772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=18832607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlyqtbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1211-1217&author=V.+P.+Jaakolaauthor=M.+T.+Griffithauthor=M.+A.+Hansonauthor=V.+Cherezovauthor=E.+Y.+T.+Chienauthor=J.+R.+Laneauthor=A.+P.+Ijzermanauthor=R.+C.+Stevens&title=The+2.6+angstrom+crystal+structure+of+a+human+A2A+adenosine+receptor+bound+to+an+antagonist&doi=10.1126%2Fscience.1164772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist</span></div><div class="casAuthors">Jaakola, Veli-Pekka; Griffith, Mark T.; Hanson, Michael A.; Cherezov, Vadim; Chien, Ellen Y. T.; Lane, J. Robert; IJzerman, Adriaan P.; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5905</span>),
    <span class="NLM_cas:pages">1211-1217</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The adenosine class of heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) mediates the important role of extracellular adenosine in many physiol. processes and is antagonized by caffeine.  The authors have detd. the crystal structure of the human A2A adenosine receptor, in complex with a high-affinity subtype-selective antagonist, ZM241385, to 2.6 angstrom resoln.  Four disulfide bridges in the extracellular domain, combined with a subtle repacking of the transmembrane helixes relative to the adrenergic and rhodopsin receptor structures, define a pocket distinct from that of other structurally detd. GPCRs.  The arrangement allows for the binding of the antagonist in an extended conformation, perpendicular to the membrane plane.  The binding site highlights an integral role for the extracellular loops, together with the helical core, in ligand recognition by this class of GPCRs and suggests a role for ZM241385 in restricting the movement of a tryptophan residue important in the activation mechanism of the class A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7QL4wN4TdhrVg90H21EOLACvtfcHk0ljAey5l1BUCwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlyqtbfN&md5=5bdb862b41f345c244f3c162e058206b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164772%26sid%3Dliteratum%253Aachs%26aulast%3DJaakola%26aufirst%3DV.%2BP.%26aulast%3DGriffith%26aufirst%3DM.%2BT.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DThe%25202.6%2520angstrom%2520crystal%2520structure%2520of%2520a%2520human%2520A2A%2520adenosine%2520receptor%2520bound%2520to%2520an%2520antagonist%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1211%26epage%3D1217%26doi%3D10.1126%2Fscience.1164772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhukov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1898</span>– <span class="NLM_lpage">1903</span>, <span class="refDoi"> DOI: 10.1021/jm201376w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201376w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVGqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1898-1903&author=M.+Congreveauthor=S.+P.+Andrewsauthor=A.+S.+Dor%C3%A9author=K.+Hollensteinauthor=E.+Hurrellauthor=C.+J.+Langmeadauthor=J.+S.+Masonauthor=I.+W.+Ngauthor=B.+Tehanauthor=A.+Zhukovauthor=M.+Weirauthor=F.+H.+Marshall&title=Discovery+of+1%2C2%2C4-triazine+derivatives+as+adenosine+A2A+antagonists+using+structure+based+drug+design&doi=10.1021%2Fjm201376w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design</span></div><div class="casAuthors">Congreve, Miles; Andrews, Stephen P.; Dore, Andrew S.; Hollenstein, Kaspar; Hurrell, Edward; Langmead, Christopher J.; Mason, Jonathan S.; Ng, Irene W.; Tehan, Benjamin; Zhukov, Andrei; Weir, Malcolm; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1898-1903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent, ligand efficient, selective, and orally efficacious 1,2,4-triazine derivs. have been identified using structure based drug design approaches as antagonists of the adenosine A2A receptor.  The X-ray crystal structures of compds. 4e and 4g (I) bound to the GPCR illustrate that the mols. bind deeply inside the orthosteric binding cavity.  In vivo pharmacokinetic and efficacy data for compd. 4k are presented, demonstrating the potential of this series of compds. for the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpddydZvtRPv7Vg90H21EOLACvtfcHk0ljAey5l1BUCwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVGqsw%253D%253D&md5=71d76db8a22bf82f11d3632d2917e155</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm201376w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201376w%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DHurrell%26aufirst%3DE.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DNg%26aufirst%3DI.%2BW.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DZhukov%26aufirst%3DA.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DDiscovery%2520of%25201%252C2%252C4-triazine%2520derivatives%2520as%2520adenosine%2520A2A%2520antagonists%2520using%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1898%26epage%3D1903%26doi%3D10.1021%2Fjm201376w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span> <span> </span><span class="NLM_article-title">Controlling the dissociation of ligands from the adenosine A2A receptor through modulation of salt bridge strength</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6470</span>– <span class="NLM_lpage">6479</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00653</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00653" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6470-6479&author=E.+Segalaauthor=D.+Guoauthor=R.+K.+Y.+Chengauthor=A.+Bortolatoauthor=F.+Deflorianauthor=A.+S.+Dor%C3%A9author=J.+C.+Erreyauthor=L.+H.+Heitmanauthor=A.+P.+Ijzermanauthor=F.+H.+Marshallauthor=R.+M.+Cooke&title=Controlling+the+dissociation+of+ligands+from+the+adenosine+A2A+receptor+through+modulation+of+salt+bridge+strength&doi=10.1021%2Facs.jmedchem.6b00653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength</span></div><div class="casAuthors">Segala, Elena; Guo, Dong; Cheng, Robert K. Y.; Bortolato, Andrea; Deflorian, Francesca; Dore, Andrew S.; Errey, James C.; Heitman, Laura H.; IJzerman, Adriaan P.; Marshall, Fiona H.; Cooke, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6470-6479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The assocn. and dissocn. kinetics of ligands binding to proteins vary considerably, but the mechanisms behind this variability are poorly understood, limiting their utilization for drug discovery.  This is particularly so for G protein-coupled receptors (GPCRs) where high resoln. structural information is only beginning to emerge.  Engineering the human A2A adenosine receptor has allowed structures to be solved in complex with the ref. compd. ZM241385 and four related ligands at high resoln.  Differences between the structures are limited, with the most pronounced being the interaction of each ligand with a salt bridge on the extracellular side of the receptor.  Mutagenesis expts. confirm the role of this salt bridge in controlling the dissocn. kinetics of the ligands from the receptor, while mol. dynamics simulations demonstrate the ability of ligands to modulate salt bridge stability.  These results shed light on a structural determinant of ligand dissocn. kinetics and identify a means by which this property may be optimized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_RuyZEvv2gLVg90H21EOLACvtfcHk0lgjytpWrMopgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFygu7w%253D&md5=c3b2db16aef190ae6c213a3a7ba133ba</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00653%26sid%3Dliteratum%253Aachs%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DR.%2BK.%2BY.%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26atitle%3DControlling%2520the%2520dissociation%2520of%2520ligands%2520from%2520the%2520adenosine%2520A2A%2520receptor%2520through%2520modulation%2520of%2520salt%2520bridge%2520strength%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6470%26epage%3D6479%26doi%3D10.1021%2Facs.jmedchem.6b00653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lebon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span> <span> </span><span class="NLM_article-title">Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>474</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">525</span>, <span class="refDoi"> DOI: 10.1038/nature10136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnature10136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21593763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFyqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=474&publication_year=2011&pages=521-525&author=G.+Lebonauthor=T.+Warneauthor=P.+C.+Edwardsauthor=K.+Bennettauthor=C.+J.+Langmeadauthor=A.+G.+W.+Leslieauthor=C.+G.+Tate&title=Agonist-bound+adenosine+A2A+receptor+structures+reveal+common+features+of+GPCR+activation&doi=10.1038%2Fnature10136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation</span></div><div class="casAuthors">Lebon, Guillaume; Warne, Tony; Edwards, Patricia C.; Bennett, Kirstie; Langmead, Christopher J.; Leslie, Andrew G. W.; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">474</span>
        (<span class="NLM_cas:issue">7352</span>),
    <span class="NLM_cas:pages">521-525</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Adenosine receptors and β-adrenoceptors are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins on binding the agonists adenosine or noradrenaline, resp.  GPCRs have similar structures consisting of seven transmembrane helixes that contain well-conserved sequence motifs, indicating that they are probably activated by a common mechanism.  Recent structures of β-adrenoceptors highlight residues in transmembrane region 5 that initially bind specifically to agonists rather than to antagonists, indicating that these residues have an important role in agonist-induced activation of receptors.  Here we present two crystal structures of the thermostabilized human adenosine A2A receptor (A2AR-GL31) bound to its endogenous agonist adenosine and the synthetic agonist NECA.  The structures represent an intermediate conformation between the inactive and active states, because they share all the features of GPCRs that are thought to be in a fully activated state, except that the cytoplasmic end of transmembrane helix 6 partially occludes the G-protein-binding site.  The adenine substituent of the agonists binds in a similar fashion to the chem. related region of the inverse agonist ZM241385 (ref. 8).  Both agonists contain a ribose group, not found in ZM241385, which extends deep into the ligand-binding pocket where it makes polar interactions with conserved residues in H7 (Ser 2777.42 and His 2787.43; superscripts refer to Ballesteros-Weinstein numbering) and non-polar interactions with residues in H3.  In contrast, the inverse agonist ZM241385 does not interact with any of these residues and comparison with the agonist-bound structures indicates that ZM241385 sterically prevents the conformational change in H5 and therefore it acts as an inverse agonist.  Comparison of the agonist-bound structures of A2AR with the agonist-bound structures of β-adrenoceptors indicates that the contraction of the ligand-binding pocket caused by the inward motion of helixes 3, 5 and 7 may be a common feature in the activation of all GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1rCKkCsE9CrVg90H21EOLACvtfcHk0lgjytpWrMopgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFyqsrg%253D&md5=1b8161216b878db48ad33d7e8e007dc7</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnature10136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10136%26sid%3Dliteratum%253Aachs%26aulast%3DLebon%26aufirst%3DG.%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DTate%26aufirst%3DC.%2BG.%26atitle%3DAgonist-bound%2520adenosine%2520A2A%2520receptor%2520structures%2520reveal%2520common%2520features%2520of%2520GPCR%2520activation%26jtitle%3DNature%26date%3D2011%26volume%3D474%26spage%3D521%26epage%3D525%26doi%3D10.1038%2Fnature10136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lebon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of CGS21680 binding to the human adenosine A2A receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1124/mol.114.097360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1124%2Fmol.114.097360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=25762024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=907-915&author=G.+Lebonauthor=P.+C.+Edwardsauthor=A.+G.+W.+Leslieauthor=C.+G.+Tate&title=Molecular+determinants+of+CGS21680+binding+to+the+human+adenosine+A2A+receptor&doi=10.1124%2Fmol.114.097360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of CGS21680 binding to the human adenosine A2A receptor</span></div><div class="casAuthors">Lebon, Guillaume; Edwards, Patricia C.; Leslie, Andrew G. W.; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">907-915</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adenosine A2A receptor (A2AR) plays a key role in transmembrane signaling mediated by the endogenous agonist adenosine.  Here, we describe the crystal structure of human A2AR thermostabilized in an active-like conformation bound to the selective agonist 2-[p-(2-carboxyethyl)phenylethyl-amino]-5'-N-ethylcarboxamido adenosine (CGS21680) at a resoln. of 2.6 Å.  Comparison of A2AR structures bound to either CGS21680, 5'-N-ethylcarboxamido adenosine (NECA), UK432097 [6-(2,2-diphenylethylamino)-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-tetrahydrofuran-2-yl]-N-[2-[[1-(2-pyridyl)-4-piperidyl] carbamoylamino]ethyl]purine-2-carboxamide], or adenosine shows that the adenosine moiety of the ligands binds to the receptor in an identical fashion.  However, an extension in CGS21680 compared with adenosine, the (2-carboxyethyl)phenylethylamino group, binds in an extended vestibule formed from transmembrane regions 2 and 7 (TM2 and TM7) and extracellular loops 2 and 3 (EL2 and EL3).  The (2-carboxyethyl)phenylethylamino group makes van der Waals contacts with side chains of amino acid residues Glu169EL2, His264EL3, Leu2677.32, and Ile2747.39, and the amine group forms a hydrogen bond with the side chain of Ser672.65.  Of these residues, only Ile2747.39 is absolutely conserved across the human adenosine receptor subfamily.  The major difference between the structures of A2AR bound to either adenosine or CGS21680 is that the binding pocket narrows at the extracellular surface when CGS21680 is bound, due to an inward tilt of TM2 in that region.  This conformation is stabilized by hydrogen bonds formed by the side chain of Ser672.65 to CGS21680, either directly or via an ordered water mol.  Mutation of amino acid residues Ser672.65, Glu169EL2, and His264EL3, and anal. of receptor activation either in the presence or absence of ligands implicates this region in modulating the level of basal activity of A2AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbUSE2hiL30bVg90H21EOLACvtfcHk0lj3yUoVYrHHIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wlu7c%253D&md5=156b7c2ef575df49e4a354029f435b7d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.097360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.097360%26sid%3Dliteratum%253Aachs%26aulast%3DLebon%26aufirst%3DG.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DTate%26aufirst%3DC.%2BG.%26atitle%3DMolecular%2520determinants%2520of%2520CGS21680%2520binding%2520to%2520the%2520human%2520adenosine%2520A2A%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D907%26epage%3D915%26doi%3D10.1124%2Fmol.114.097360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nehmé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span> <span> </span><span class="NLM_article-title">Structure of the adenosine A2A receptor bound to an engineered G protein</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>536</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1038/nature18966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fnature18966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=27462812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GrurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=536&publication_year=2016&pages=104-107&author=B.+Carpenterauthor=R.+Nehm%C3%A9author=T.+Warneauthor=A.+G.+W.+Leslieauthor=C.+G.+Tate&title=Structure+of+the+adenosine+A2A+receptor+bound+to+an+engineered+G+protein&doi=10.1038%2Fnature18966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the adenosine A2A receptor bound to an engineered G protein</span></div><div class="casAuthors">Carpenter, Byron; Nehme, Rony; Warne, Tony; Leslie, Andrew G. W.; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">536</span>
        (<span class="NLM_cas:issue">7614</span>),
    <span class="NLM_cas:pages">104-107</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are essential components of the signalling network throughout the body.  To understand the mol. mechanism of G-protein-mediated signalling, solved structures of receptors in inactive conformations and in the active conformation coupled to a G protein are necessary.  Here we present the structure of the adenosine A2A receptor (A2AR) bound to an engineered G protein, mini-Gs, at 3.4 Å resoln.  Mini-Gs binds to A2AR through an extensive interface (1,048 Å2) that is similar, but not identical, to the interface between Gs and the β2-adrenergic receptor.  The transition of the receptor from an agonist-bound active-intermediate state to an active G-protein-bound state is characterized by a 14 Å shift of the cytoplasmic end of transmembrane helix 6 (H6) away from the receptor core, slight changes in the positions of the cytoplasmic ends of H5 and H7 and rotamer changes of the amino acid side chains Arg3.50, Tyr5.58 and Tyr7.53.  There are no substantial differences in the extracellular half of the receptor around the ligand binding pocket.  The A2AR-mini-Gs structure highlights both the diversity and similarity in G-protein coupling to GPCRs and hints at the potential complexity of the mol. basis for G-protein specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr75HihlyPssrVg90H21EOLACvtfcHk0lj3yUoVYrHHIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GrurbP&md5=f5a720baaefe45f5bf4491dfe1fb8a15</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnature18966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18966%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DB.%26aulast%3DNehm%25C3%25A9%26aufirst%3DR.%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DTate%26aufirst%3DC.%2BG.%26atitle%3DStructure%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520bound%2520to%2520an%2520engineered%2520G%2520protein%26jtitle%3DNature%26date%3D2016%26volume%3D536%26spage%3D104%26epage%3D107%26doi%3D10.1038%2Fnature18966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines xac and caffeine</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1016/j.str.2011.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.str.2011.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=21885291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaru7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1283-1293&author=A.+S.+Dor%C3%A9author=N.+Robertsonauthor=J.+C.+Erreyauthor=I.+Ngauthor=K.+Hollensteinauthor=B.+Tehanauthor=E.+Hurrellauthor=K.+Bennettauthor=M.+Congreveauthor=F.+Magnaniauthor=C.+G.+Tateauthor=M.+Weirauthor=F.+H.+Marshall&title=Structure+of+the+adenosine+A2A+receptor+in+complex+with+ZM241385+and+the+xanthines+xac+and+caffeine&doi=10.1016%2Fj.str.2011.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine</span></div><div class="casAuthors">Dore, Andrew S.; Robertson, Nathan; Errey, James C.; Ng, Irene; Hollenstein, Kaspar; Tehan, Ben; Hurrell, Edward; Bennett, Kirstie; Congreve, Miles; Magnani, Francesca; Tate, Christopher G.; Weir, Malcolm; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1283-1293</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Methylxanthines, including caffeine and theophylline, are among the most widely consumed stimulant drugs in the world.  These effects are mediated primarily via blockade of adenosine receptors.  Xanthine analogs with improved properties have been developed as potential treatments for diseases such as Parkinson's disease.  Here we report the structures of a thermostabilized adenosine A2A receptor in complex with the xanthines xanthine amine congener and caffeine, as well as the A2A selective inverse agonist ZM241385.  The receptor is crystd. in the inactive state conformation as defined by the presence of a salt bridge known as the ionic lock.  The complete third intracellular loop, responsible for G protein coupling, is visible consisting of extended helixes 5 and 6.  The structures provide new insight into the features that define the ligand binding pocket of the adenosine receptor for ligands of diverse chemotypes as well as the cytoplasmic regions that interact with signal transduction proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWsexwFu6LD7Vg90H21EOLACvtfcHk0lgjrIFnA4DBEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaru7fE&md5=a25db14aa70c2b42b9c3eb98c3c16bae</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2011.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2011.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DNg%26aufirst%3DI.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DHurrell%26aufirst%3DE.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMagnani%26aufirst%3DF.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520in%2520complex%2520with%2520ZM241385%2520and%2520the%2520xanthines%2520xac%2520and%2520caffeine%26jtitle%3DStructure%26date%3D2011%26volume%3D19%26spage%3D1283%26epage%3D1293%26doi%3D10.1016%2Fj.str.2011.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olieric, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brünle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gashi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworkowski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panepucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skopintsev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panneels, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schertler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Standfuss, J.</span></span> <span> </span><span class="NLM_article-title">Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">542</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00630-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fs41467-017-00630-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28912485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1cboslKltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=542&author=T.+Weinertauthor=N.+Oliericauthor=R.+Chengauthor=S.+Br%C3%BCnleauthor=D.+Jamesauthor=D.+Ozerovauthor=D.+Gashiauthor=L.+Veraauthor=M.+Marshauthor=K.+Jaegerauthor=F.+Dworkowskiauthor=E.+Panepucciauthor=S.+Basuauthor=P.+Skopintsevauthor=A.+S.+Dor%C3%A9author=T.+Gengauthor=R.+M.+Cookeauthor=M.+Liangauthor=A.+E.+Protaauthor=V.+Panneelsauthor=P.+Noglyauthor=U.+Ermlerauthor=G.+Schertlerauthor=M.+Hennigauthor=M.+O.+Steinmetzauthor=M.+Wangauthor=J.+Standfuss&title=Serial+millisecond+crystallography+for+routine+room-temperature+structure+determination+at+synchrotrons&doi=10.1038%2Fs41467-017-00630-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons</span></div><div class="casAuthors">Weinert Tobias; Olieric Natacha; James Daniel; Gashi Dardan; Jaeger Kathrin; Skopintsev Petr; Prota Andrea E; Panneels Valerie; Nogly Przemyslaw; Schertler Gebhard; Steinmetz Michel O; Standfuss Jorg; Cheng Robert; Hennig Michael; Brunle Steffen; Ermler Ulrich; Ozerov Dmitry; Gashi Dardan; Vera Laura; Marsh May; Dworkowski Florian; Panepucci Ezequiel; Basu Shibom; Wang Meitian; Dore Andrew S; Geng Tian; Cooke Robert M; Liang Mengning; Schertler Gebhard; Steinmetz Michel O</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">542</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Historically, room-temperature structure determination was succeeded by cryo-crystallography to mitigate radiation damage.  Here, we demonstrate that serial millisecond crystallography at a synchrotron beamline equipped with high-viscosity injector and high frame-rate detector allows typical crystallographic experiments to be performed at room-temperature.  Using a crystal scanning approach, we determine the high-resolution structure of the radiation sensitive molybdenum storage protein, demonstrate soaking of the drug colchicine into tubulin and native sulfur phasing of the human G protein-coupled adenosine receptor.  Serial crystallographic data for molecular replacement already converges in 1,000-10,000 diffraction patterns, which we collected in 3 to maximally 82 minutes.  Compared with serial data we collected at a free-electron laser, the synchrotron data are of slightly lower resolution, however fewer diffraction patterns are needed for de novo phasing.  Overall, the data we collected by room-temperature serial crystallography are of comparable quality to cryo-crystallographic data and can be routinely collected at synchrotrons.Serial crystallography was developed for protein crystal data collection with X-ray free-electron lasers.  Here the authors present several examples which show that serial crystallography using high-viscosity injectors can also be routinely employed for room-temperature data collection at synchrotrons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2XuDrQ2dPti6Ufuk_1xoTfW6udTcc2eZVsoXoG581lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cboslKltg%253D%253D&md5=2fc0843781c5237cc59b3b64fffc4106</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00630-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00630-4%26sid%3Dliteratum%253Aachs%26aulast%3DWeinert%26aufirst%3DT.%26aulast%3DOlieric%26aufirst%3DN.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DBr%25C3%25BCnle%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DOzerov%26aufirst%3DD.%26aulast%3DGashi%26aufirst%3DD.%26aulast%3DVera%26aufirst%3DL.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DJaeger%26aufirst%3DK.%26aulast%3DDworkowski%26aufirst%3DF.%26aulast%3DPanepucci%26aufirst%3DE.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DSkopintsev%26aufirst%3DP.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DGeng%26aufirst%3DT.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DLiang%26aufirst%3DM.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DPanneels%26aufirst%3DV.%26aulast%3DNogly%26aufirst%3DP.%26aulast%3DErmler%26aufirst%3DU.%26aulast%3DSchertler%26aufirst%3DG.%26aulast%3DHennig%26aufirst%3DM.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DStandfuss%26aufirst%3DJ.%26atitle%3DSerial%2520millisecond%2520crystallography%2520for%2520routine%2520room-temperature%2520structure%2520determination%2520at%2520synchrotrons%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D542%26doi%3D10.1038%2Fs41467-017-00630-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimazu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terakado
Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doak, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nango, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabashi, M.</span></span> <span> </span><span class="NLM_article-title">High-viscosity sample-injection device for serial femtosecond crystallography at atmospheric pressure</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1107/S1600576719012846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1107%2FS1600576719012846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31798359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1GqtrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2019&pages=1280-1288&author=Y.+Shimazuauthor=K.+Tonoauthor=T.+Tanakaauthor=Y.+Yamanakaauthor=T.+Nakaneauthor=C.+Moriauthor=K.+Terakado%0AKimuraauthor=T.+Fujiwaraauthor=M.+Sugaharaauthor=R.+Tanakaauthor=R.+B.+Doakauthor=T.+Shimamuraauthor=S.+Iwataauthor=E.+Nangoauthor=M.+Yabashi&title=High-viscosity+sample-injection+device+for+serial+femtosecond+crystallography+at+atmospheric+pressure&doi=10.1107%2FS1600576719012846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">High-viscosity sample-injection device for serial femtosecond crystallography at atmospheric pressure</span></div><div class="casAuthors">Shimazu, Yoshiaki; Tono, Kensuke; Tanaka, Tomoyuki; Yamanaka, Yasuaki; Nakane, Takanori; Mori, Chihiro; Terakado Kimura, Kanako; Fujiwara, Takaaki; Sugahara, Michihiro; Tanaka, Rie; Doak, R. Bruce; Shimamura, Tatsuro; Iwata, So; Nango, Eriko; Yabashi, Makina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1280-1288</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">1600-5767</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A sample-injection device has been developed at SPring-8 Angstrom Compact Free-Electron Laser (SACLA) for serial femtosecond crystallog. (SFX) at atm. pressure.  Microcrystals embedded in a highly viscous carrier are stably delivered from a capillary nozzle with the aid of a coaxial gas flow and a suction device.  The cartridge-type sample reservoir is easily replaceable and facilitates sample reloading or exchange.  The reservoir is positioned in a cooling jacket with a temp.-regulated water flow, which is useful to prevent drastic changes in the sample temp. during data collection.  This work demonstrates that the injector successfully worked in SFX of the human A2A adenosine receptor complexed with an antagonist, ZM241385, in lipidic cubic phase and for hen egg-white lysozyme microcrystals in a grease carrier.  The injection device has also been applied to many kinds of proteins, not only for static structural analyses but also for dynamics studies using pump-probe techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzrUpnaK2sn7Vg90H21EOLACvtfcHk0lgF8DMtw0MWHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1GqtrnP&md5=2341d4739df5d5e733c6d8962c4033ec</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1107%2FS1600576719012846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1600576719012846%26sid%3Dliteratum%253Aachs%26aulast%3DShimazu%26aufirst%3DY.%26aulast%3DTono%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DYamanaka%26aufirst%3DY.%26aulast%3DNakane%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DC.%26aulast%3DTerakado%2BKimura%26aufirst%3DK.%26aulast%3DFujiwara%26aufirst%3DT.%26aulast%3DSugahara%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DDoak%26aufirst%3DR.%2BB.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DIwata%26aufirst%3DS.%26aulast%3DNango%26aufirst%3DE.%26aulast%3DYabashi%26aufirst%3DM.%26atitle%3DHigh-viscosity%2520sample-injection%2520device%2520for%2520serial%2520femtosecond%2520crystallography%2520at%2520atmospheric%2520pressure%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2019%26volume%3D52%26spage%3D1280%26epage%3D1288%26doi%3D10.1107%2FS1600576719012846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiez-Vandal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span> <span> </span><span class="NLM_article-title">Structures of human A1 and A2A adenosine receptors with xanthines reveal determinants of selectivity</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1275</span>– <span class="NLM_lpage">1285</span>, <span class="refDoi"> DOI: 10.1016/j.str.2017.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.str.2017.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28712806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOlsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1275-1285&author=R.+K.+Y.+Chengauthor=E.+Segalaauthor=N.+Robertsonauthor=F.+Deflorianauthor=A.+S.+Dor%C3%A9author=J.+C.+Erreyauthor=C.+Fiez-Vandalauthor=F.+H.+Marshallauthor=R.+M.+Cooke&title=Structures+of+human+A1+and+A2A+adenosine+receptors+with+xanthines+reveal+determinants+of+selectivity&doi=10.1016%2Fj.str.2017.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of Human A1 and A2a Adenosine Receptors with Xanthines Reveal Determinants of Selectivity</span></div><div class="casAuthors">Cheng, Robert K. Y.; Segala, Elena; Robertson, Nathan; Deflorian, Francesca; Dore, Andrew S.; Errey, James C.; Fiez-Vandal, Cedric; Marshall, Fiona H.; Cooke, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1275-1285.e4</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The adenosine A1 and A2a receptors belong to the purinergic family of G protein-coupled receptors, and regulate diverse functions of the cardiovascular, respiratory, renal, inflammation, and CNS.  Xanthines such as caffeine and theophylline are weak, non-selective antagonists of adenosine receptors.  Here we report the structure of a thermostabilized human A1 receptor at 3.3 Å resoln. with PSB36, an A1-selective xanthine-based antagonist.  This is compared with structures of the A2a receptor with PSB36 (2.8 Å resoln.), caffeine (2.1 Å), and theophylline (2.0 Å) to highlight features of ligand recognition which are common across xanthines.  The structures of A1R and A2aR were analyzed to identify the differences that are important selectivity determinants for xanthine ligands, and the role of T2707.35 in A1R (M2707.35 in A2aR) in conferring selectivity was confirmed by mutagenesis.  The structural differences confirmed to lead to selectivity can be utilized in the design of new subtype-selective A1R or A2aR antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDdYCktAYdKLVg90H21EOLACvtfcHk0ljq5YjgABbOYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOlsbfJ&md5=e759fd60b25beac2d9429809f3b51b02</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2017.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2017.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DR.%2BK.%2BY.%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DFiez-Vandal%26aufirst%3DC.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26atitle%3DStructures%2520of%2520human%2520A1%2520and%2520A2A%2520adenosine%2520receptors%2520with%2520xanthines%2520reveal%2520determinants%2520of%2520selectivity%26jtitle%3DStructure%26date%3D2017%26volume%3D25%26spage%3D1275%26epage%3D1285%26doi%3D10.1016%2Fj.str.2017.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattedi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasio, F. L.</span></span> <span> </span><span class="NLM_article-title">Understanding ligand binding selectivity in a prototypical GPCR family</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2830</span>– <span class="NLM_lpage">2836</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.9b00298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.9b00298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVehurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=2830-2836&author=G.+Mattediauthor=F.+Deflorianauthor=J.+S.+Masonauthor=C.+de+Graafauthor=F.+L.+Gervasio&title=Understanding+ligand+binding+selectivity+in+a+prototypical+GPCR+family&doi=10.1021%2Facs.jcim.9b00298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Ligand Binding Selectivity in a Prototypical GPCR Family</span></div><div class="casAuthors">Mattedi, Giulio; Deflorian, Francesca; Mason, Jonathan S.; de Graaf, Chris; Gervasio, Francesco L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2830-2836</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adenosine receptors are involved in many pathol. conditions and are thus promising drug targets.  However, developing drugs that target this GPCR subfamily is a challenging task.  A no. of drug candidates fail due to lack of selectivity which results in unwanted side effects.  The extensive structural similarity of adenosine receptors complicates the design of selective ligands.  The problem of selective targeting is a general concern in GPCRs, and in this respect adenosine receptors are a prototypical example.  Here we use enhanced sampling simulations to decipher the determinants of selectivity of ligands in A2a and A1 adenosine receptors.  Our model shows how small differences in the binding pocket and in the water network around the ligand can be leveraged to achieve selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbIs4oEcJQ3rVg90H21EOLACvtfcHk0ljq5YjgABbOYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVehurzE&md5=18d573fcaf6a87e58d7b954db1aefacb</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.9b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.9b00298%26sid%3Dliteratum%253Aachs%26aulast%3DMattedi%26aufirst%3DG.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DGervasio%26aufirst%3DF.%2BL.%26atitle%3DUnderstanding%2520ligand%2520binding%2520selectivity%2520in%2520a%2520prototypical%2520GPCR%2520family%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2019%26volume%3D59%26spage%3D2830%26epage%3D2836%26doi%3D10.1021%2Facs.jcim.9b00298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachhawat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M. L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2066</span>– <span class="NLM_lpage">2071</span>, <span class="refDoi"> DOI: 10.1073/pnas.1621423114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1073%2Fpnas.1621423114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28167788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=2066-2071&author=B.+Sunauthor=P.+Bachhawatauthor=M.+L.-H.+Chuauthor=M.+Woodauthor=T.+Ceskaauthor=Z.+A.+Sandsauthor=J.+Mercierauthor=F.+Lebonauthor=T.+S.+Kobilkaauthor=B.+K.+Kobilka&title=Crystal+structure+of+the+adenosine+A2A+receptor+bound+to+an+antagonist+reveals+a+potential+allosteric+pocket&doi=10.1073%2Fpnas.1621423114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket</span></div><div class="casAuthors">Sun, Bingfa; Bachhawat, Priti; Chu, Matthew Ling-Hon; Wood, Martyn; Ceska, Tom; Sands, Zara A.; Mercier, Joel; Lebon, Florence; Kobilka, Tong Sun; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2066-2071</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The adenosine A2A receptor (A2AR) has long been implicated in cardiovascular disorders.  As more selective A2AR ligands are being identified, its roles in other disorders, such as Parkinson's disease, are starting to emerge, and A2AR antagonists are important drug candidates for non-dopaminergic anti-Parkinson treatment.  Here, the authors report the crystal structure of A2A receptor bound to compd. 1, a novel A2AR/N-methyl-D-aspartate (NMDA) receptor subtype 2B (NR2B; NMDA receptor 2B) dual antagonist and potential anti-Parkinson candidate compd., at 3.5 Å resoln.  The A2A receptor with a cytochrome b562-RIL (BRIL) fusion (A2AR-BRIL) in intracellular loop 3 (ICL3) was crystd. in detergent micelles using vapor-phase diffusion.  Whereas A2AR-BRIL bound to antagonist ZM241385 was previously been crystd. in the lipidic cubic phase (LCP), structural differences in the compd. 1-bound A2AR-BRIL prevented formation of the lattice obsd. with the ZM241385-bound receptor.  The crystals grew with a type II crystal lattice in contrast to the typical type I packing seen from membrane protein structures crystd. in LCP.  Compd. 1 bound in a position that overlapped with the native ligand, adenosine, but its methoxyphenyl group extended to an exosite not previously obsd. in other A2AR structures.  Structural anal. revealed that compd. 1 binding resulted in the unique conformations of 2 Tyr residues (Tyr91.35 and Tyr2717.36) which are crit. for the formation of the exosite.  The structure revealed insights into antagonist binding that were not obsd. in other A2AR structures, highlighting flexibility in the binding pocket that may facilitate the development of A2AR-selective compds. for the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5SraoNhZQ0bVg90H21EOLACvtfcHk0ljq5YjgABbOYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCksb8%253D&md5=58ac85e930066ef7a6788c4d7f3a72b3</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1621423114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1621423114%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DBachhawat%26aufirst%3DP.%26aulast%3DChu%26aufirst%3DM.%2BL.-H.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DCeska%26aufirst%3DT.%26aulast%3DSands%26aufirst%3DZ.%2BA.%26aulast%3DMercier%26aufirst%3DJ.%26aulast%3DLebon%26aufirst%3DF.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520bound%2520to%2520an%2520antagonist%2520reveals%2520a%2520potential%2520allosteric%2520pocket%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D2066%26epage%3D2071%26doi%3D10.1073%2Fpnas.1621423114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span>; <span class="NLM_string-name">Macleod, C.</span>; <span class="NLM_string-name">Moulton, B.</span>; <span class="NLM_string-name">Lenagh-Snow, G.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine Derivatives and Their Use Use for the Treatment of Cancer</span>. PCT Int. Appl. <span class="NLM_patent">WO2019122932 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+McCarthy&author=C.+Macleod&author=B.+Moulton&author=G.+Lenagh-Snow&title=Pyrimidine+Derivatives+and+Their+Use+Use+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DC.%26atitle%3DPyrimidine%2520Derivatives%2520and%2520Their%2520Use%2520Use%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beatty, J.</span>; <span class="NLM_string-name">Debien, L.</span>; <span class="NLM_string-name">Jeffrey, J.</span>; <span class="NLM_string-name">Leleti, M. R.</span>; <span class="NLM_string-name">Mandal, D.</span>; <span class="NLM_string-name">Miles, D.</span>; <span class="NLM_string-name">Powers, J.</span>; <span class="NLM_string-name">Rosen, B.</span>; <span class="NLM_string-name">Thomas-Tran, R.</span>; <span class="NLM_string-name">Sharif, E.</span></span> <span> </span><span class="NLM_article-title">Preparation of Azolopyrimidine for the Treatment of Cancer and Immune Related Disorders</span>. PCT Int. Appl. <span class="NLM_patent">WO2018136700 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Beatty&author=L.+Debien&author=J.+Jeffrey&author=M.+R.+Leleti&author=D.+Mandal&author=D.+Miles&author=J.+Powers&author=B.+Rosen&author=R.+Thomas-Tran&author=E.+Sharif&title=Preparation+of+Azolopyrimidine+for+the+Treatment+of+Cancer+and+Immune+Related+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeatty%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520Azolopyrimidine%2520for%2520the%2520Treatment%2520of%2520Cancer%2520and%2520Immune%2520Related%2520Disorders%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido-Shaqfeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the potent and selective A2R antagonist AB928 for the treatment of cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4572</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-4572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2017-4572" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4572&author=M.+J.+Waltersauthor=J.+B.+Tanauthor=A.+Beckerauthor=F.+Yiauthor=T.+Parkauthor=M.+R.+Leletiauthor=B.+Rosenauthor=E.+Sharifauthor=L.+Debienauthor=S.+Youngauthor=W.+H.+Limauthor=S.+Garrido-Shaqfehauthor=J.+C.+Jaenauthor=J.+P.+Powers&title=Characterization+of+the+potent+and+selective+A2R+antagonist+AB928+for+the+treatment+of+cancer&doi=10.1158%2F1538-7445.AM2017-4572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-4572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-4572%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26aulast%3DTan%26aufirst%3DJ.%2BB.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DYi%26aufirst%3DF.%26aulast%3DPark%26aufirst%3DT.%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26aulast%3DRosen%26aufirst%3DB.%26aulast%3DSharif%26aufirst%3DE.%26aulast%3DDebien%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DW.%2BH.%26aulast%3DGarrido-Shaqfeh%26aufirst%3DS.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520potent%2520and%2520selective%2520A2R%2520antagonist%2520AB928%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4572%26doi%3D10.1158%2F1538-7445.AM2017-4572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Direnzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piovesan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handlos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, E. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. J.</span></span> <span> </span><span class="NLM_article-title">AB928, a dual antagonist of the A2AR and A2BR adenosine receptors, relieves adenosine-mediated immune suppression</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">A162</span>, <span class="refDoi"> DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F2326-6074.CRICIMTEATIAACR18-A162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30602507" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=A162&author=D.+Direnzoauthor=D.+Piovesanauthor=J.+Tanauthor=D.+H.+Milesauthor=M.+R.+Leletiauthor=T.+Parkauthor=F.+Sorianoauthor=B.+Handlosauthor=J.+L.+Jeffreyauthor=E.+U.+Sharifauthor=B.+R.+Rosenauthor=U.+Schindlerauthor=J.+P.+Powersauthor=M.+J.+Walters&title=AB928%2C+a+dual+antagonist+of+the+A2AR+and+A2BR+adenosine+receptors%2C+relieves+adenosine-mediated+immune+suppression&doi=10.1158%2F2326-6074.CRICIMTEATIAACR18-A162"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F2326-6074.CRICIMTEATIAACR18-A162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6074.CRICIMTEATIAACR18-A162%26sid%3Dliteratum%253Aachs%26aulast%3DDirenzo%26aufirst%3DD.%26aulast%3DPiovesan%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DMiles%26aufirst%3DD.%2BH.%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26aulast%3DPark%26aufirst%3DT.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DHandlos%26aufirst%3DB.%26aulast%3DJeffrey%26aufirst%3DJ.%2BL.%26aulast%3DSharif%26aufirst%3DE.%2BU.%26aulast%3DRosen%26aufirst%3DB.%2BR.%26aulast%3DSchindler%26aufirst%3DU.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26atitle%3DAB928%252C%2520a%2520dual%2520antagonist%2520of%2520the%2520A2AR%2520and%2520A2BR%2520adenosine%2520receptors%252C%2520relieves%2520adenosine-mediated%2520immune%2520suppression%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26spage%3DA162%26doi%3D10.1158%2F2326-6074.CRICIMTEATIAACR18-A162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piovesan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Direnzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span> <span> </span><span class="NLM_article-title">Combining adenosine receptor inhibition, with AB928, and chemotherapy results in greater immune activation and tumor control</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5556</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-5556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2018-5556" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5556&author=M.+J.+Waltersauthor=D.+Piovesanauthor=J.+Tanauthor=D.+Direnzoauthor=F.+Yinauthor=D.+Milesauthor=M.+R.+Leletiauthor=T.+Parkauthor=F.+Sorianoauthor=E.+Sharifauthor=U.+Schindlerauthor=J.+P.+Powers&title=Combining+adenosine+receptor+inhibition%2C+with+AB928%2C+and+chemotherapy+results+in+greater+immune+activation+and+tumor+control&doi=10.1158%2F1538-7445.AM2018-5556"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-5556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-5556%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26aulast%3DPiovesan%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DDirenzo%26aufirst%3DD.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26aulast%3DPark%26aufirst%3DT.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DSharif%26aufirst%3DE.%26aulast%3DSchindler%26aufirst%3DU.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DCombining%2520adenosine%2520receptor%2520inhibition%252C%2520with%2520AB928%252C%2520and%2520chemotherapy%2520results%2520in%2520greater%2520immune%2520activation%2520and%2520tumor%2520control%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5556%26doi%3D10.1158%2F1538-7445.AM2018-5556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakunnel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M.</span></span> <span> </span><span class="NLM_article-title">Final results of the phase 1 study in healthy volunteers of AB928, a dual antagonist of the A2AR and A2BR adenosine receptors being studied as an activator of anti-tumor immune response</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">viii665</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy303.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1093%2Fannonc%2Fmdy303.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=viii665&author=L.+C.+Seitzauthor=D.+Ashokauthor=M.+Leletiauthor=J.+Powersauthor=B.+Rosenauthor=D.+Milesauthor=E.+Sharifauthor=L.+Jinauthor=A.+Parkauthor=S.+Youngauthor=A.+Riegerauthor=U.+Schindlerauthor=J.+Karakunnelauthor=M.+Walters&title=Final+results+of+the+phase+1+study+in+healthy+volunteers+of+AB928%2C+a+dual+antagonist+of+the+A2AR+and+A2BR+adenosine+receptors+being+studied+as+an+activator+of+anti-tumor+immune+response&doi=10.1093%2Fannonc%2Fmdy303.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy303.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy303.050%26sid%3Dliteratum%253Aachs%26aulast%3DSeitz%26aufirst%3DL.%2BC.%26aulast%3DAshok%26aufirst%3DD.%26aulast%3DLeleti%26aufirst%3DM.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DB.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DSharif%26aufirst%3DE.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DRieger%26aufirst%3DA.%26aulast%3DSchindler%26aufirst%3DU.%26aulast%3DKarakunnel%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DM.%26atitle%3DFinal%2520results%2520of%2520the%2520phase%25201%2520study%2520in%2520healthy%2520volunteers%2520of%2520AB928%252C%2520a%2520dual%2520antagonist%2520of%2520the%2520A2AR%2520and%2520A2BR%2520adenosine%2520receptors%2520being%2520studied%2520as%2520an%2520activator%2520of%2520anti-tumor%2520immune%2520response%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3Dviii665%26doi%3D10.1093%2Fannonc%2Fmdy303.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakunnel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, A.</span></span> <span> </span><span class="NLM_article-title">AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2604</span>, <span class="refDoi"> DOI: 10.1200/JCO.2019.37.15_suppl.2604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1200%2FJCO.2019.37.15_suppl.2604" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=2604&author=J.+D.+Powderlyauthor=P.+L.+de+Souzaauthor=R.+Gutierrezauthor=L.+Horvathauthor=L.+Seitzauthor=D.+Ashokauthor=A.+Parkauthor=M.+J.+Waltersauthor=J.+J.+Karakunnelauthor=W.+Berryauthor=A.+Riegerauthor=A.+Garofaloauthor=D.+W.+Laiauthor=A.+Chaudhry&title=AB928%2C+a+novel+dual+adenosine+receptor+antagonist%2C+combined+with+chemotherapy+or+AB122+%28anti-PD-1%29+in+patients+%28pts%29+with+advanced+tumors%3A+Preliminary+results+from+ongoing+phase+I+studies&doi=10.1200%2FJCO.2019.37.15_suppl.2604"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.2604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.2604%26sid%3Dliteratum%253Aachs%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BSouza%26aufirst%3DP.%2BL.%26aulast%3DGutierrez%26aufirst%3DR.%26aulast%3DHorvath%26aufirst%3DL.%26aulast%3DSeitz%26aufirst%3DL.%26aulast%3DAshok%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26aulast%3DKarakunnel%26aufirst%3DJ.%2BJ.%26aulast%3DBerry%26aufirst%3DW.%26aulast%3DRieger%26aufirst%3DA.%26aulast%3DGarofalo%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DD.%2BW.%26aulast%3DChaudhry%26aufirst%3DA.%26atitle%3DAB928%252C%2520a%2520novel%2520dual%2520adenosine%2520receptor%2520antagonist%252C%2520combined%2520with%2520chemotherapy%2520or%2520AB122%2520%2528anti-PD-1%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520tumors%253A%2520Preliminary%2520results%2520from%2520ongoing%2520phase%2520I%2520studies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D2604%26doi%3D10.1200%2FJCO.2019.37.15_suppl.2604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span>; <span class="NLM_string-name">Miles, D. H.</span>; <span class="NLM_string-name">Powers, J. P.</span>; <span class="NLM_string-name">Rosen, B. R.</span>; <span class="NLM_string-name">Sharif, E. U.</span>; <span class="NLM_string-name">Thomas-Tran, R.</span></span> <span> </span><span class="NLM_article-title">Quinazoline-pyridine Derivatives for the Treatment of Cancer-Related Disorders and Their Preparation</span>. PCT Int. Appl. <span class="NLM_patent">WO2018204661 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+R.+Leleti&author=D.+H.+Miles&author=J.+P.+Powers&author=B.+R.+Rosen&author=E.+U.+Sharif&author=R.+Thomas-Tran&title=Quinazoline-pyridine+Derivatives+for+the+Treatment+of+Cancer-Related+Disorders+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26atitle%3DQuinazoline-pyridine%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Cancer-Related%2520Disorders%2520and%2520Their%2520Preparation%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leleti, M. R.</span>; <span class="NLM_string-name">Miles, D. H.</span>; <span class="NLM_string-name">Powers, J. P.</span>; <span class="NLM_string-name">Rosen, B. R.</span>; <span class="NLM_string-name">Sharif, E. U.</span>; <span class="NLM_string-name">Thomas-Tran, R.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline-pyrazole Derivatives for the Treatment of Cancer-related Disorders</span>. PCT Int. Appl. <span class="NLM_patent">WO2018213377 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+R.+Leleti&author=D.+H.+Miles&author=J.+P.+Powers&author=B.+R.+Rosen&author=E.+U.+Sharif&author=R.+Thomas-Tran&title=Preparation+of+Quinazoline-pyrazole+Derivatives+for+the+Treatment+of+Cancer-related+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLeleti%26aufirst%3DM.%2BR.%26atitle%3DPreparation%2520of%2520Quinazoline-pyrazole%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Cancer-related%2520Disorders%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botting, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerpiniere, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightowler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAteer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padfield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reece, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selwood, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. M.</span></span> <span> </span><span class="NLM_article-title">Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1021/jm800961g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800961g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFSjtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=33-47&author=R.+J.+Gillespieauthor=S.+J.+Bamfordauthor=R.+Bottingauthor=M.+Comerauthor=S.+Dennyauthor=S.+Gaurauthor=M.+Griffinauthor=A.+M.+Jordanauthor=A.+R.+Knightauthor=J.+Lerpiniereauthor=S.+Leonardiauthor=S.+Lightowlerauthor=S.+McAteerauthor=A.+Merrettauthor=A.+Misraauthor=A.+Padfieldauthor=M.+Reeceauthor=M.+Saadiauthor=D.+L.+Selwoodauthor=G.+C.+Strattonauthor=D.+Surryauthor=R.+Toddauthor=X.+Tongauthor=V.+Rustonauthor=R.+Uptonauthor=S.+M.+Weiss&title=Antagonists+of+the+human+A2A+adenosine+receptor.+4.+Design%2C+synthesis%2C+and+preclinical+evaluation+of+7-aryltriazolo%5B4%2C5-d%5Dpyrimidines&doi=10.1021%2Fjm800961g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines</span></div><div class="casAuthors">Gillespie, Roger J.; Bamford, Samantha J.; Botting, Ruth; Comer, Mike; Denny, Sarah; Gaur, Suneel; Griffin, Michael; Jordan, Allan M.; Knight, Anthony R.; Lerpiniere, Joanne; Leonardi, Stefania; Lightowler, Sean; McAteer, Steven; Merrett, Angela; Misra, Anil; Padfield, Antony; Reece, Mark; Saadi, Mona; Selwood, Daniel L.; Stratton, Gemma C.; Surry, Dominic; Todd, Richard; Tong, Xin; Ruston, Vicki; Upton, Rebecca; Weiss, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-47</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonism of the human A2A receptor has been implicated as a point of therapeutic intervention in the alleviation of the symptoms assocd. with Parkinson's disease.  This is thought to occur, at least in part, by increasing the sensitivity of the dopaminergic neurons to the residual, depleted levels of striatal dopamine.  We herein describe a novel series of functionalized triazolo[4,5-d]pyrimidine derivs. that display functional antagonism of the A2A receptor.  Optimization of these compds. has resulted in improvements in potency, selectivity, and the pharmacokinetic properties of key derivs.  These efforts have led to the discovery of I (V2006/BIIB014), which demonstrates strong oral activity in commonly used models of Parkinson's disease.  Furthermore, this deriv. has shown excellent preclin. pharmacokinetics and has successfully completed phase I clin. studies.  This compd. is presently undergoing further clin. evaluation in collaboration with Biogen Idec.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6pAUuqxmjkLVg90H21EOLACvtfcHk0ljsMynBJWXKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFSjtbrP&md5=74142663769a86d6cacc6dce252757eb</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm800961g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800961g%26sid%3Dliteratum%253Aachs%26aulast%3DGillespie%26aufirst%3DR.%2BJ.%26aulast%3DBamford%26aufirst%3DS.%2BJ.%26aulast%3DBotting%26aufirst%3DR.%26aulast%3DComer%26aufirst%3DM.%26aulast%3DDenny%26aufirst%3DS.%26aulast%3DGaur%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DM.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DKnight%26aufirst%3DA.%2BR.%26aulast%3DLerpiniere%26aufirst%3DJ.%26aulast%3DLeonardi%26aufirst%3DS.%26aulast%3DLightowler%26aufirst%3DS.%26aulast%3DMcAteer%26aufirst%3DS.%26aulast%3DMerrett%26aufirst%3DA.%26aulast%3DMisra%26aufirst%3DA.%26aulast%3DPadfield%26aufirst%3DA.%26aulast%3DReece%26aufirst%3DM.%26aulast%3DSaadi%26aufirst%3DM.%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26aulast%3DStratton%26aufirst%3DG.%2BC.%26aulast%3DSurry%26aufirst%3DD.%26aulast%3DTodd%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DRuston%26aufirst%3DV.%26aulast%3DUpton%26aufirst%3DR.%26aulast%3DWeiss%26aufirst%3DS.%2BM.%26atitle%3DAntagonists%2520of%2520the%2520human%2520A2A%2520adenosine%2520receptor.%25204.%2520Design%252C%2520synthesis%252C%2520and%2520preclinical%2520evaluation%2520of%25207-aryltriazolo%255B4%252C5-d%255Dpyrimidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D33%26epage%3D47%26doi%3D10.1021%2Fjm800961g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rucktooa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doré, A. S.</span></span> <span> </span><span class="NLM_article-title">Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-18570-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1038%2Fs41598-017-18570-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=29311713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A280%3ADC%252BC1MzosFaktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=41&author=P.+Rucktooaauthor=R.+K.+Y.+Chengauthor=E.+Segalaauthor=T.+Gengauthor=J.+C.+Erreyauthor=G.+A.+Brownauthor=R.+M.+Cookeauthor=F.+H.+Marshallauthor=A.+S.+Dor%C3%A9&title=Towards+high+throughput+GPCR+crystallography%3A+In+Meso+soaking+of+Adenosine+A2A+Receptor+crystals&doi=10.1038%2Fs41598-017-18570-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals</span></div><div class="casAuthors">Rucktooa Prakash; Cheng Robert K Y; Segala Elena; Geng Tian; Errey James C; Brown Giles A; Cooke Robert M; Marshall Fiona H; Dore Andrew S; Cheng Robert K Y</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Here we report an efficient method to generate multiple co-structures of the A2A G protein-coupled receptor (GPCR) with small-molecules from a single preparation of a thermostabilised receptor crystallised in Lipidic Cubic Phase (LCP).  Receptor crystallisation is achieved following purification using a low affinity "carrier" ligand (theophylline) and crystals are then soaked in solutions containing the desired (higher affinity) compounds.  Complete datasets to high resolution can then be collected from single crystals and seven structures are reported here of which three are novel.  The method significantly improves structural throughput for ligand screening using stabilised GPCRs, thereby actively driving Structure-Based Drug Discovery (SBDD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT__KWoaDFa1cScOqQTSkOffW6udTcc2ebtMR7uQStgzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzosFaktQ%253D%253D&md5=835858f9d8557f79e9325b41fe7e9a89</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-18570-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-18570-w%26sid%3Dliteratum%253Aachs%26aulast%3DRucktooa%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DR.%2BK.%2BY.%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DGeng%26aufirst%3DT.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DG.%2BA.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26atitle%3DTowards%2520high%2520throughput%2520GPCR%2520crystallography%253A%2520In%2520Meso%2520soaking%2520of%2520Adenosine%2520A2A%2520Receptor%2520crystals%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D41%26doi%3D10.1038%2Fs41598-017-18570-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, S. J.</span>; <span class="NLM_string-name">Gillespie, R. J.</span>; <span class="NLM_string-name">Todd, R. S.</span></span> <span> </span><span class="NLM_article-title">Triazolo[4,5-d]pyramidine Derivatives, their Preparation, and Use as Purine Receptor Antagonists for Treating Movement Disorders and Other Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO2009156737 A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+J.+Bamford&author=R.+J.+Gillespie&author=R.+S.+Todd&title=Triazolo%5B4%2C5-d%5Dpyramidine+Derivatives%2C+their+Preparation%2C+and+Use+as+Purine+Receptor+Antagonists+for+Treating+Movement+Disorders+and+Other+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBamford%26aufirst%3DS.%2BJ.%26atitle%3DTriazolo%255B4%252C5-d%255Dpyramidine%2520Derivatives%252C%2520their%2520Preparation%252C%2520and%2520Use%2520as%2520Purine%2520Receptor%2520Antagonists%2520for%2520Treating%2520Movement%2520Disorders%2520and%2520Other%2520Diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willingham, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccione, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaffery, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span> <span> </span><span class="NLM_article-title">A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(l)1 and anti-CTLA-4 in preclinical models</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-18-0056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F2326-6066.CIR-18-0056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=30131376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1emt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=1136-1149&author=S.+B.+Willinghamauthor=P.+Y.+Hoauthor=A.+Hotsonauthor=C.+Hillauthor=E.+C.+Piccioneauthor=J.+Hsiehauthor=L.+Liuauthor=J.+J.+Buggyauthor=I.+McCafferyauthor=R.+A.+Miller&title=A2AR+antagonism+with+CPI-444+induces+antitumor+responses+and+augments+efficacy+to+anti-PD-%28l%291+and+anti-CTLA-4+in+preclinical+models&doi=10.1158%2F2326-6066.CIR-18-0056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models</span></div><div class="casAuthors">Willingham, Stephen B.; Ho, Po Y.; Hotson, Andrew; Hill, Craig; Piccione, Emily C.; Hsieh, Jessica; Liu, Liang; Buggy, Joseph J.; McCaffery, Ian; Miller, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1136-1149</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Adenosine signaling through A2A receptors (A2AR) expressed on immune cells suppresses antitumor immunity.  CPI-444 is a potent, selective, oral A2AR antagonist.  Blockade of A2AR with CPI-444 restored T-cell signaling, IL2, and IFNγ prodn. that were suppressed by adenosine analogs in vitro.  CPI-444 treatment led to dose-dependent inhibition of tumor growth in multiple syngeneic mouse tumor models.  Concns. of extracellular adenosine in the tumor microenvironment, measured using microdialysis, were approx. 100-150 nmol/L and were higher than corresponding s.c. tissue.  Combining CPI-444 with anti-PD-L1 or anti-CTLA-4 treatment eliminated tumors in up to 90% of treated mice, including restoration of immune responses in models that incompletely responded to anti-PD-L1 or anti-CTLA-4 monotherapy.  Tumor growth was fully inhibited when mice with cleared tumors were later rechallenged, indicating that CPI-444 induced systemic antitumor immune memory.  CD8[suplus] T-cell depletion abrogated the efficacy of CPI-444 with and without anti-PD-L1 treatment, demonstrating a role for CD8[suplus] T cells in mediating primary and secondary immune responses.  The antitumor efficacy of CPI-444 with and without anti-PD-L1 was assocd. with increased T-cell activation, a compensatory increase in CD73 expression, and induction of a Th1 gene expression signature consistent with immune activation.  These results suggest a broad role for adenosine-mediated immunosuppression in tumors and justify the further evaluation of CPI-444 as a therapeutic agent in patients with solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5x2Tft7FzvrVg90H21EOLACvtfcHk0lgkTenZL0fvkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1emt7k%253D&md5=effa3cf830866317986507d2e061aa5d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0056%26sid%3Dliteratum%253Aachs%26aulast%3DWillingham%26aufirst%3DS.%2BB.%26aulast%3DHo%26aufirst%3DP.%2BY.%26aulast%3DHotson%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DC.%26aulast%3DPiccione%26aufirst%3DE.%2BC.%26aulast%3DHsieh%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DMcCaffery%26aufirst%3DI.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26atitle%3DA2AR%2520antagonism%2520with%2520CPI-444%2520induces%2520antitumor%2520responses%2520and%2520augments%2520efficacy%2520to%2520anti-PD-%2528l%25291%2520and%2520anti-CTLA-4%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2018%26volume%3D6%26spage%3D1136%26epage%3D1149%26doi%3D10.1158%2F2326-6066.CIR-18-0056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquerre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versluys, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poussereau-Pomie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paillasse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swindells, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisztwan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel non-brain penetrant A2AR inhibitor and proof-of-concept of CD73 and A2AR/CD73 small-molecule inhibitors for cancer immunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">3768</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-3768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2018-3768" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=3768&author=P.+Fonsauthor=A.+Bellauthor=M.+Esquerreauthor=S.+Versluysauthor=F.+Bertrandauthor=C.+Poussereau-Pomieauthor=A.+Schreyerauthor=R.+Coxauthor=J.+Besnardauthor=M.+Paillasseauthor=M.+Swindellsauthor=J.+Lisztwanauthor=C.+Johnstoneauthor=M.+Whittakerauthor=A.+Hopkins&title=Identification+of+a+novel+non-brain+penetrant+A2AR+inhibitor+and+proof-of-concept+of+CD73+and+A2AR%2FCD73+small-molecule+inhibitors+for+cancer+immunotherapy&doi=10.1158%2F1538-7445.AM2018-3768"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-3768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-3768%26sid%3Dliteratum%253Aachs%26aulast%3DFons%26aufirst%3DP.%26aulast%3DBell%26aufirst%3DA.%26aulast%3DEsquerre%26aufirst%3DM.%26aulast%3DVersluys%26aufirst%3DS.%26aulast%3DBertrand%26aufirst%3DF.%26aulast%3DPoussereau-Pomie%26aufirst%3DC.%26aulast%3DSchreyer%26aufirst%3DA.%26aulast%3DCox%26aufirst%3DR.%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DPaillasse%26aufirst%3DM.%26aulast%3DSwindells%26aufirst%3DM.%26aulast%3DLisztwan%26aufirst%3DJ.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DM.%26aulast%3DHopkins%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520novel%2520non-brain%2520penetrant%2520A2AR%2520inhibitor%2520and%2520proof-of-concept%2520of%2520CD73%2520and%2520A2AR%252FCD73%2520small-molecule%2520inhibitors%2520for%2520cancer%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D3768%26doi%3D10.1158%2F1538-7445.AM2018-3768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubukov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for allosteric regulation of GPCRs by sodium ions</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1126/science.1219218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1126%2Fscience.1219218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=22798613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2012&pages=232-236&author=W.+Liuauthor=E.+Chunauthor=A.+A.+Thompsonauthor=P.+Chubukovauthor=F.+Xuauthor=V.+Katritchauthor=G.+W.+Hanauthor=C.+B.+Rothauthor=L.+H.+Heitmanauthor=A.+P.+Ijzermanauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structural+basis+for+allosteric+regulation+of+GPCRs+by+sodium+ions&doi=10.1126%2Fscience.1219218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions</span></div><div class="casAuthors">Liu, Wei; Chun, Eugene; Thompson, Aaron A.; Chubukov, Pavel; Xu, Fei; Katritch, Vsevolod; Han, Gye Won; Roth, Christopher B.; Heitman, Laura H.; IJzerman, Adriaan P.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">6091</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Pharmacol. responses of G protein-coupled receptors (GPCRs) can be fine-tuned by allosteric modulators.  Structural studies of such effects have been limited due to the medium resoln. of GPCR structures.  We reengineered the human A2A adenosine receptor by replacing its third intracellular loop with apocytochrome b562RIL and solved the structure at 1.8 angstrom resoln.  The high-resoln. structure allowed us to identify 57 ordered water mols. inside the receptor comprising three major clusters.  The central cluster harbors a putative sodium ion bound to the highly conserved aspartate residue Asp2.50.  Addnl., two cholesterols stabilize the conformation of helix VI, and one of 23 ordered lipids intercalates inside the ligand-binding pocket.  These high-resoln. details shed light on the potential role of structured water mols., sodium ions, and lipids/cholesterol in GPCR stabilization and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvcjQimGnIMLVg90H21EOLACvtfcHk0lgkTenZL0fvkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKqtbs%253D&md5=782b2235b76ef77b11b6456f8e4485e1</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1126%2Fscience.1219218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1219218%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChun%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DA.%2BA.%26aulast%3DChubukov%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DRoth%26aufirst%3DC.%2BB.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructural%2520basis%2520for%2520allosteric%2520regulation%2520of%2520GPCRs%2520by%2520sodium%2520ions%26jtitle%3DScience%26date%3D2012%26volume%3D337%26spage%3D232%26epage%3D236%26doi%3D10.1126%2Fscience.1219218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of novel highly potent A2A adenosine receptor antagonists for cancerimmunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">4110</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-4140" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4110&author=K.+Leeauthor=S.+Junauthor=E.+Byunauthor=H.+Leeauthor=Y.+Leeauthor=M.+Moonauthor=Y.-Y.+Kimauthor=H.+J.+Kangauthor=Y.+Ahnauthor=Y.+Kimauthor=K.+H.+Suh&title=Discovery+and+characterization+of+novel+highly+potent+A2A+adenosine+receptor+antagonists+for+cancerimmunotherapy&doi=10.1158%2F1538-7445.AM2019-4140"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4140%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%26aulast%3DJun%26aufirst%3DS.%26aulast%3DByun%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DMoon%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DY.-Y.%26aulast%3DKang%26aufirst%3DH.%2BJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520novel%2520highly%2520potent%2520A2A%2520adenosine%2520receptor%2520antagonists%2520for%2520cancerimmunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D4110%26doi%3D10.1158%2F1538-7445.AM2019-4140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houthuys, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyawouame, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deregnaucourt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiercz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detheux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quéva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span> <span> </span><span class="NLM_article-title">A novel adenosine A2A receptor antagonist optimized for high potency in adenosine-rich tumor microenvironment boosts anti-tumor immunity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1683</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-1683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2017-1683" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1683&author=E.+Houthuysauthor=M.+Brouwerauthor=F.+Nyawouameauthor=R.+Pirsonauthor=R.+Marillierauthor=T.+Deregnaucourtauthor=J.+Marchanteauthor=J.+Swierczauthor=C.+Moulinauthor=V.+Bolauthor=G.+Driessensauthor=M.+Detheuxauthor=C.+Qu%C3%A9vaauthor=S.+Crosignaniauthor=B.+Gomes&title=A+novel+adenosine+A2A+receptor+antagonist+optimized+for+high+potency+in+adenosine-rich+tumor+microenvironment+boosts+anti-tumor+immunity&doi=10.1158%2F1538-7445.AM2017-1683"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-1683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-1683%26sid%3Dliteratum%253Aachs%26aulast%3DHouthuys%26aufirst%3DE.%26aulast%3DBrouwer%26aufirst%3DM.%26aulast%3DNyawouame%26aufirst%3DF.%26aulast%3DPirson%26aufirst%3DR.%26aulast%3DMarillier%26aufirst%3DR.%26aulast%3DDeregnaucourt%26aufirst%3DT.%26aulast%3DMarchante%26aufirst%3DJ.%26aulast%3DSwiercz%26aufirst%3DJ.%26aulast%3DMoulin%26aufirst%3DC.%26aulast%3DBol%26aufirst%3DV.%26aulast%3DDriessens%26aufirst%3DG.%26aulast%3DDetheux%26aufirst%3DM.%26aulast%3DQu%25C3%25A9va%26aufirst%3DC.%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DGomes%26aufirst%3DB.%26atitle%3DA%2520novel%2520adenosine%2520A2A%2520receptor%2520antagonist%2520optimized%2520for%2520high%2520potency%2520in%2520adenosine-rich%2520tumor%2520microenvironment%2520boosts%2520anti-tumor%2520immunity%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D1683%26doi%3D10.1158%2F1538-7445.AM2017-1683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houthuys, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basilico, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deregnaucourt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detheux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiercz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span> <span> </span><span class="NLM_article-title">EOS100850, a non-brain penetrant highly selective A2A receptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">3261</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-3261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-3261" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=3261&author=E.+Houthuysauthor=P.+Basilicoauthor=M.+Brouwerauthor=T.+Deregnaucourtauthor=M.+Detheuxauthor=G.+Driessensauthor=B.+Gomesauthor=X.+Leroyauthor=J.+Marchanteauthor=R.+Marillierauthor=J.+Swierczauthor=S.+Crosignani&title=EOS100850%2C+a+non-brain+penetrant+highly+selective+A2A+receptor+antagonist%2C+uniquely+maintains+high+potency+within+the+adenosine+rich+tumor+microenvironment&doi=10.1158%2F1538-7445.AM2019-3261"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-3261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-3261%26sid%3Dliteratum%253Aachs%26aulast%3DHouthuys%26aufirst%3DE.%26aulast%3DBasilico%26aufirst%3DP.%26aulast%3DBrouwer%26aufirst%3DM.%26aulast%3DDeregnaucourt%26aufirst%3DT.%26aulast%3DDetheux%26aufirst%3DM.%26aulast%3DDriessens%26aufirst%3DG.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DLeroy%26aufirst%3DX.%26aulast%3DMarchante%26aufirst%3DJ.%26aulast%3DMarillier%26aufirst%3DR.%26aulast%3DSwiercz%26aufirst%3DJ.%26aulast%3DCrosignani%26aufirst%3DS.%26atitle%3DEOS100850%252C%2520a%2520non-brain%2520penetrant%2520highly%2520selective%2520A2A%2520receptor%2520antagonist%252C%2520uniquely%2520maintains%2520high%2520potency%2520within%2520the%2520adenosine%2520rich%2520tumor%2520microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D3261%26doi%3D10.1158%2F1538-7445.AM2019-3261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preillon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederix, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basilico, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houthuys, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span> <span> </span><span class="NLM_article-title">EOS100850, an A2A receptor antagonist with prolonged pharmacodynamic activity, mediates the generation of specific durable immune responses in a murine breast cancer model</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">4147</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-4147" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4147&author=R.+Pirsonauthor=A.+C.+Michauxauthor=D.+Jamartauthor=J.+Preillonauthor=K.+Frederixauthor=P.+Basilicoauthor=C.+Martinoliauthor=X.+Leroyauthor=G.+Driessensauthor=E.+Houthuysauthor=S.+Chappelauthor=S.+Crosignaniauthor=R.+Marillier&title=EOS100850%2C+an+A2A+receptor+antagonist+with+prolonged+pharmacodynamic+activity%2C+mediates+the+generation+of+specific+durable+immune+responses+in+a+murine+breast+cancer+model&doi=10.1158%2F1538-7445.AM2019-4147"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4147%26sid%3Dliteratum%253Aachs%26aulast%3DPirson%26aufirst%3DR.%26aulast%3DMichaux%26aufirst%3DA.%2BC.%26aulast%3DJamart%26aufirst%3DD.%26aulast%3DPreillon%26aufirst%3DJ.%26aulast%3DFrederix%26aufirst%3DK.%26aulast%3DBasilico%26aufirst%3DP.%26aulast%3DMartinoli%26aufirst%3DC.%26aulast%3DLeroy%26aufirst%3DX.%26aulast%3DDriessens%26aufirst%3DG.%26aulast%3DHouthuys%26aufirst%3DE.%26aulast%3DChappel%26aufirst%3DS.%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DMarillier%26aufirst%3DR.%26atitle%3DEOS100850%252C%2520an%2520A2A%2520receptor%2520antagonist%2520with%2520prolonged%2520pharmacodynamic%2520activity%252C%2520mediates%2520the%2520generation%2520of%2520specific%2520durable%2520immune%2520responses%2520in%2520a%2520murine%2520breast%2520cancer%2520model%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D4147%26doi%3D10.1158%2F1538-7445.AM2019-4147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span>; <span class="NLM_string-name">Gomes, B.</span>; <span class="NLM_string-name">Houthuys, E.</span></span> <span> </span><span class="NLM_article-title">2-Oxothiazole Derivatives as A2A Inhibitors for the Use in the Treatment of Cancers</span>. PCT Int. Appl. <span class="NLM_patent">WO2018178338 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Crosignani&author=B.+Gomes&author=E.+Houthuys&title=2-Oxothiazole+Derivatives+as+A2A+Inhibitors+for+the+Use+in+the+Treatment+of+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26atitle%3D2-Oxothiazole%2520Derivatives%2520as%2520A2A%2520Inhibitors%2520for%2520the%2520Use%2520in%2520the%2520Treatment%2520of%2520Cancers%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertorelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varty, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachowicz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forlani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredduzzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impagnatiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolussi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neustadt, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggiani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.149617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1124%2Fjpet.108.149617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=19332567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=294-303&author=R.+A.+Hodgsonauthor=R.+Bertorelliauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=A.+Forlaniauthor=S.+Fredduzziauthor=M.+E.+Cohen-Williamsauthor=G.+A.+Higginsauthor=F.+Impagnatielloauthor=E.+Nicolussiauthor=L.+E.+Parraauthor=C.+Fosterauthor=Y.+Zhaiauthor=B.+R.+Neustadtauthor=A.+W.+Stamfordauthor=E.+M.+Parkerauthor=A.+Reggianiauthor=J.+C.+Hunter&title=Characterization+of+the+potent+and+highly+selective+A2A+receptor+antagonists+preladenant+and+SCH+412348+%5B7-%5B2-%5B4-2%2C4-Difluorophenyl%5D-1-piperazinyl%5Dethyl%5D-2-%282-furanyl%29-7H-pyrazolo%5B4%2C3-e%5D%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-c%5Dpyrimidin-5-amine%5D+in+rodent+models+of+movement+disorders+and+depression&doi=10.1124%2Fjpet.108.149617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span></div><div class="casAuthors">Hodgson, Robert A.; Bertorelli, Rosalia; Varty, Geoffrey B.; Lachowicz, Jean E.; Forlani, Angelo; Fredduzzi, Silva; Cohen-Williams, Mary E.; Higgins, Guy A.; Impagnatiello, Francesco; Nicolussi, Elisa; Parra, Leonard E.; Foster, Carolyn; Zhai, Ying; Neustadt, Bernie R.; Stamford, Andrew W.; Parker, Eric M.; Reggiani, Angelo; Hunter, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adenosine A2A receptor has been implicated in the underlying biol. of various neurol. and psychiatric disorders, including Parkinson's disease (PD) and depression.  Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] are potent competitive antagonists of the human A2A receptor (Ki = 1.1 and 0.6 nM, resp.) and have > 1000-fold selectivity over all other adenosine receptors, making these compds. the most selective A2A receptor antagonists reported to date.  Both compds. attenuate hypolocomotion induced by the A2A receptor agonist CGS-21680 [2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine], suggesting that they inhibit A2A receptor activity in vivo.  Their high degree of selectivity and robust in vivo activity make preladenant and SCH 412348 useful tools to investigate the role of the A2A receptor system in animal models of PD and depression.  Oral administration of preladenant and SCH 412348 (0.1-1 mg/kg) to rats potentiated 3,4-dihydroxy-L-phenylalanine (L-Dopa)-induced contralateral rotations after 6-hydroxydopamine lesions in the medial forebrain bundle and potently attenuated the cataleptic effects of haloperidol.  Preladenant (1 mg/kg) inhibited L-Dopa-induced behavioral sensitization after repeated daily administration, which suggests a reduced risk of the development of dyskinesias.  Finally, preladenant and SCH 412348 exhibited antidepressant-like profiles in models of behavioral despair, namely the mouse tail suspension test and the mouse and rat forced swim test.  These studies demonstrate that preladenant and SCH 412348 are potent and selective A2A receptor antagonists and provide further evidence of the potential therapeutic benefits of A2A receptor inhibition in PD (with reduced risk of dyskinesias) and depression (one of the primary nonmotor symptoms of PD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNkJMOfNlLc7Vg90H21EOLACvtfcHk0litApd9HgzbJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D&md5=b8ce809c2d57a994d201ecca4daa39a3</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.149617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.149617%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DForlani%26aufirst%3DA.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DCohen-Williams%26aufirst%3DM.%2BE.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DNicolussi%26aufirst%3DE.%26aulast%3DParra%26aufirst%3DL.%2BE.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DReggiani%26aufirst%3DA.%26aulast%3DHunter%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520the%2520potent%2520and%2520highly%2520selective%2520A2A%2520receptor%2520antagonists%2520preladenant%2520and%2520SCH%2520412348%2520%255B7-%255B2-%255B4-2%252C4-Difluorophenyl%255D-1-piperazinyl%255Dethyl%255D-2-%25282-furanyl%2529-7H-pyrazolo%255B4%252C3-e%255D%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-c%255Dpyrimidin-5-amine%255D%2520in%2520rodent%2520models%2520of%2520movement%2520disorders%2520and%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D294%26epage%3D303%26doi%3D10.1124%2Fjpet.108.149617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanzer, E. M.</span>; <span class="NLM_string-name">Schiemann, K.</span>; <span class="NLM_string-name">Klein, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Thiazolopyridine Derivatives as Adenosine Receptor Antagonists for the Treatment of Hyperproliferative or Infectious Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO2019025099 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+M.+Tanzer&author=K.+Schiemann&author=M.+Klein&title=Preparation+of+Thiazolopyridine+Derivatives+as+Adenosine+Receptor+Antagonists+for+the+Treatment+of+Hyperproliferative+or+Infectious+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTanzer%26aufirst%3DE.%2BM.%26atitle%3DPreparation%2520of%2520Thiazolopyridine%2520Derivatives%2520as%2520Adenosine%2520Receptor%2520Antagonists%2520for%2520the%2520Treatment%2520of%2520Hyperproliferative%2520or%2520Infectious%2520Diseases%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanzer, E. M.</span>; <span class="NLM_string-name">Schiemann, K.</span>; <span class="NLM_string-name">Klein, M.</span></span> <span> </span><span class="NLM_article-title">Benzimidazole Derivatives as Adenosine Receptor Antagonists and Their Preparation</span>. PCT Int. Appl. <span class="NLM_patent">WO2019038215 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+M.+Tanzer&author=K.+Schiemann&author=M.+Klein&title=Benzimidazole+Derivatives+as+Adenosine+Receptor+Antagonists+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTanzer%26aufirst%3DE.%2BM.%26atitle%3DBenzimidazole%2520Derivatives%2520as%2520Adenosine%2520Receptor%2520Antagonists%2520and%2520Their%2520Preparation%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanzer, E. M.</span>; <span class="NLM_string-name">Schiemann, K.</span>; <span class="NLM_string-name">Klein, M.</span></span> <span> </span><span class="NLM_article-title">Quinoxaline Derivatives as Adenosine Receptor Antagonists and Their Preparation</span>. PCT Int. Appl. <span class="NLM_patent">WO2019038214 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+M.+Tanzer&author=K.+Schiemann&author=M.+Klein&title=Quinoxaline+Derivatives+as+Adenosine+Receptor+Antagonists+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTanzer%26aufirst%3DE.%2BM.%26atitle%3DQuinoxaline%2520Derivatives%2520as%2520Adenosine%2520Receptor%2520Antagonists%2520and%2520Their%2520Preparation%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crespo
Crespo, M. I.</span>; <span class="NLM_string-name">Prat, Q. M.</span>; <span class="NLM_string-name">Gual Roig, S.</span>; <span class="NLM_string-name">Castro Palomino
Laria, J. C.</span>; <span class="NLM_string-name">Slee, D. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2,6-Bis(heteroaryl)-4-aminopyrimidines as Adenosine Receptor Antagonists</span>. PCT Int. Appl. <span class="NLM_patent">WO2005058883 A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+I.+Crespo%0ACrespo&author=Q.+M.+Prat&author=S.+Gual+Roig&author=J.+C.+Castro+Palomino%0ALaria&author=D.+H.+Slee&title=Preparation+of+2%2C6-Bis%28heteroaryl%29-4-aminopyrimidines+as+Adenosine+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrespo%2BCrespo%26aufirst%3DM.%2BI.%26atitle%3DPreparation%2520of%25202%252C6-Bis%2528heteroaryl%2529-4-aminopyrimidines%2520as%2520Adenosine%2520Receptor%2520Antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho Gomez, J. A.</span>; <span class="NLM_string-name">Castro Palomino
Laria, J. C.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-Aminopyrimidine Derivatives and Their Use as Therapeutic Adenosine A2A Receptor Antagonists</span>. PCT Int. Appl. <span class="NLM_patent">WO2011121418 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+A.+Camacho+Gomez&author=J.+C.+Castro+Palomino%0ALaria&title=Preparation+of+4-Aminopyrimidine+Derivatives+and+Their+Use+as+Therapeutic+Adenosine+A2A+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%2BGomez%26aufirst%3DJ.%2BA.%26atitle%3DPreparation%2520of%25204-Aminopyrimidine%2520Derivatives%2520and%2520Their%2520Use%2520as%2520Therapeutic%2520Adenosine%2520A2A%2520Receptor%2520Antagonists%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mediavilla-Varela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noyes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span> <span> </span><span class="NLM_article-title">A novel antagonist of the immune checkpoint protein adenosine a2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/j.neo.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1016%2Fj.neo.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=28582704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=530-536&author=M.+Mediavilla-Varelaauthor=J.+Castroauthor=A.+Chiapporiauthor=D.+Noyesauthor=D.+C.+Hernandezauthor=B.+Allardauthor=J.+Staggauthor=S.+J.+Antonia&title=A+novel+antagonist+of+the+immune+checkpoint+protein+adenosine+a2a+receptor+restores+tumor-infiltrating+lymphocyte+activity+in+the+context+of+the+tumor+microenvironment&doi=10.1016%2Fj.neo.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment</span></div><div class="casAuthors">Mediavilla-Varela, Melanie; Castro, Julio; Chiappori, Alberto; Noyes, David; Hernandez, Dalia C.; Stagg, John; Antonia, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">530-536</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BACKGROUND: Therapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with various tumor types.  The success of these studies has led to the development of various antibodies/inhibitors for the different checkpoint proteins involved in immune evasion of the tumor.  Adenosine present in high concns. in the tumor microenvironment activates the immune checkpoint adenosine A2a receptor (A2aR), leading to the suppression of antitumor responses.  Inhibition of this checkpoint has the potential to enhance antitumor T-cell responsiveness.  METHODS: We developed a novel A2aR antagonist (PBF-509) and tested its antitumor response in vitro, in a mouse model, and in non-small cell lung cancer patient samples.  RESULTS: Our studies showed that PBF-509 is highly specific to the A2aR as well as inhibitory of A2aR function in an in vitro model.  In a mouse model, we found that lung metastasis was decreased after treatment with PBF-509 compared with its control.  Furthermore, freshly resected tumor-infiltrating lymphocytes from lung cancer patients showed increased A2aR expression in CD4+ cells and variable expression in CD8+ cells.  Ex vivo studies showed an increased responsiveness of human tumor-infiltrating lymphocytes when PBF-509 was combined with anti-PD-1 or anti-PD-L1.  CONCLUSIONS: Our studies demonstrate that inhibition of the A2aR using the novel inhibitor PBF-509 could lead to novel immunotherapeutic strategies in non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmcbcq1F7t-rVg90H21EOLACvtfcHk0ljQfeiKG6PH3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsr0%253D&md5=71f91937d08afe3424abb5556e1993ac</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DMediavilla-Varela%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DNoyes%26aufirst%3DD.%26aulast%3DHernandez%26aufirst%3DD.%2BC.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26atitle%3DA%2520novel%2520antagonist%2520of%2520the%2520immune%2520checkpoint%2520protein%2520adenosine%2520a2a%2520receptor%2520restores%2520tumor-infiltrating%2520lymphocyte%2520activity%2520in%2520the%2520context%2520of%2520the%2520tumor%2520microenvironment%26jtitle%3DNeoplasia%26date%3D2017%26volume%3D19%26spage%3D530%26epage%3D536%26doi%3D10.1016%2Fj.neo.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bilic, S.</span>; <span class="NLM_string-name">Camacho Gomez, J. A.</span>; <span class="NLM_string-name">Cameron, J. S.</span>; <span class="NLM_string-name">Castro-Palomino Laria, J. C.</span>; <span class="NLM_string-name">Howard, D. R.</span></span> <span> </span><span class="NLM_article-title">1-(4-Amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol for Use in Treating Cancer</span>. PCT Int. Appl. <span class="NLM_patent">WO2018146612 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Bilic&author=J.+A.+Camacho+Gomez&author=J.+S.+Cameron&author=J.+C.+Castro-Palomino+Laria&author=D.+R.+Howard&title=1-%284-Amino-5-bromo-6-%281H-pyrazol-1-yl%29pyrimidin-2-yl%29-1H-pyrazol-4-ol+for+Use+in+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBilic%26aufirst%3DS.%26atitle%3D1-%25284-Amino-5-bromo-6-%25281H-pyrazol-1-yl%2529pyrimidin-2-yl%2529-1H-pyrazol-4-ol%2520for%2520Use%2520in%2520Treating%2520Cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galezowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegrzyn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commandeur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedzic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowogrodzki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeremeta-Spisak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzielak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Łozińska-Raj, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wronowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swirski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radzimierski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziembik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierzwicka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojcik-Jaszczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gocek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grycuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierzchala, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of novel dual A2A /A2B adenosine receptor antagonists for cancer immunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">3770</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-3770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2018-3770" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=3770&author=M.+Galezowskiauthor=P.+Wegrzynauthor=A.+Bobowskaauthor=C.+Commandeurauthor=K.+Dziedzicauthor=M.+Nowogrodzkiauthor=A.+Obaraauthor=J.+Szeremeta-Spisakauthor=A.+Dzielakauthor=I.+%C5%81ozi%C5%84ska-Rajauthor=M.+Dudekauthor=A.+Janigaauthor=J.+Reusauthor=M.+Wronowskiauthor=M.+Swirskiauthor=A.+Radzimierskiauthor=M.+Ziembikauthor=J.+Mierzwickaauthor=K.+Wojcik-Jaszczynskaauthor=E.+Gocekauthor=K.+Grycukauthor=A.+Golasauthor=O.+Pierzchalaauthor=J.+Zachmannauthor=M.+Nowak&title=Characterization+of+novel+dual+A2A+%2FA2B+adenosine+receptor+antagonists+for+cancer+immunotherapy&doi=10.1158%2F1538-7445.AM2018-3770"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-3770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-3770%26sid%3Dliteratum%253Aachs%26aulast%3DGalezowski%26aufirst%3DM.%26aulast%3DWegrzyn%26aufirst%3DP.%26aulast%3DBobowska%26aufirst%3DA.%26aulast%3DCommandeur%26aufirst%3DC.%26aulast%3DDziedzic%26aufirst%3DK.%26aulast%3DNowogrodzki%26aufirst%3DM.%26aulast%3DObara%26aufirst%3DA.%26aulast%3DSzeremeta-Spisak%26aufirst%3DJ.%26aulast%3DDzielak%26aufirst%3DA.%26aulast%3D%25C5%2581ozi%25C5%2584ska-Raj%26aufirst%3DI.%26aulast%3DDudek%26aufirst%3DM.%26aulast%3DJaniga%26aufirst%3DA.%26aulast%3DReus%26aufirst%3DJ.%26aulast%3DWronowski%26aufirst%3DM.%26aulast%3DSwirski%26aufirst%3DM.%26aulast%3DRadzimierski%26aufirst%3DA.%26aulast%3DZiembik%26aufirst%3DM.%26aulast%3DMierzwicka%26aufirst%3DJ.%26aulast%3DWojcik-Jaszczynska%26aufirst%3DK.%26aulast%3DGocek%26aufirst%3DE.%26aulast%3DGrycuk%26aufirst%3DK.%26aulast%3DGolas%26aufirst%3DA.%26aulast%3DPierzchala%26aufirst%3DO.%26aulast%3DZachmann%26aufirst%3DJ.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520novel%2520dual%2520A2A%2520%252FA2B%2520adenosine%2520receptor%2520antagonists%2520for%2520cancer%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D3770%26doi%3D10.1158%2F1538-7445.AM2018-3770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galezowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegrzyn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedzic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeremeta-Spisak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowogrodzki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozinska-Raj, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wronowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zastawna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkiewicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogacki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziembik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grycuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiatrowska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewandowska, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkiewicz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzozka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">Novel dual A2A A2B adenosine receptor antagonists for cancer immunotherapy: in vitro and in vivo characterization</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">4135</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-4135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=31209060" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4135&author=M.+Galezowskiauthor=P.+Wegrzynauthor=A.+Bobowskaauthor=K.+Dziedzicauthor=J.+Szeremeta-Spisakauthor=M.+Nowogrodzkiauthor=G.+Satalaauthor=A.+Obaraauthor=I.+Lozinska-Rajauthor=M.+Dudekauthor=A.+Janigaauthor=J.+Reusauthor=M.+Wronowskiauthor=M.+Zastawnaauthor=G.+Statkiewiczauthor=M.+Rogackiauthor=M.+Ziembikauthor=K.+Grycukauthor=F.+Soukouauthor=K.+Michalikauthor=A.+Adamusauthor=K.+Wiatrowskaauthor=N.+Lewandowskaauthor=A.+Golasauthor=O.+Haberkiewiczauthor=R.+Porterauthor=K.+Brzozkaauthor=M.+Nowak&title=Novel+dual+A2A+A2B+adenosine+receptor+antagonists+for+cancer+immunotherapy%3A+in+vitro+and+in+vivo+characterization&doi=10.1158%2F1538-7445.AM2019-4135"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4135%26sid%3Dliteratum%253Aachs%26aulast%3DGalezowski%26aufirst%3DM.%26aulast%3DWegrzyn%26aufirst%3DP.%26aulast%3DBobowska%26aufirst%3DA.%26aulast%3DDziedzic%26aufirst%3DK.%26aulast%3DSzeremeta-Spisak%26aufirst%3DJ.%26aulast%3DNowogrodzki%26aufirst%3DM.%26aulast%3DSatala%26aufirst%3DG.%26aulast%3DObara%26aufirst%3DA.%26aulast%3DLozinska-Raj%26aufirst%3DI.%26aulast%3DDudek%26aufirst%3DM.%26aulast%3DJaniga%26aufirst%3DA.%26aulast%3DReus%26aufirst%3DJ.%26aulast%3DWronowski%26aufirst%3DM.%26aulast%3DZastawna%26aufirst%3DM.%26aulast%3DStatkiewicz%26aufirst%3DG.%26aulast%3DRogacki%26aufirst%3DM.%26aulast%3DZiembik%26aufirst%3DM.%26aulast%3DGrycuk%26aufirst%3DK.%26aulast%3DSoukou%26aufirst%3DF.%26aulast%3DMichalik%26aufirst%3DK.%26aulast%3DAdamus%26aufirst%3DA.%26aulast%3DWiatrowska%26aufirst%3DK.%26aulast%3DLewandowska%26aufirst%3DN.%26aulast%3DGolas%26aufirst%3DA.%26aulast%3DHaberkiewicz%26aufirst%3DO.%26aulast%3DPorter%26aufirst%3DR.%26aulast%3DBrzozka%26aufirst%3DK.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DNovel%2520dual%2520A2A%2520A2B%2520adenosine%2520receptor%2520antagonists%2520for%2520cancer%2520immunotherapy%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D4135%26doi%3D10.1158%2F1538-7445.AM2019-4135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bobowska, A.</span>; <span class="NLM_string-name">Galezowski, M.</span>; <span class="NLM_string-name">Nowak, M.</span>; <span class="NLM_string-name">Commandeur, C.</span>; <span class="NLM_string-name">Szeremeta-Spisak, J.</span>; <span class="NLM_string-name">Nowogrodzki, M.</span>; <span class="NLM_string-name">Obara, A.</span>; <span class="NLM_string-name">Dzielak, A.</span>; <span class="NLM_string-name">Lozinska, I.</span>; <span class="NLM_string-name">Dudek, M.</span>; <span class="NLM_string-name">Janiga, A.</span>; <span class="NLM_string-name">Reus, J.</span>; <span class="NLM_string-name">Wronowski, M.</span>; <span class="NLM_string-name">Zastawna, M.</span>; <span class="NLM_string-name">Radzimierski, A.</span>; <span class="NLM_string-name">Swirski, M.</span>; <span class="NLM_string-name">Zachmann, J.</span>; <span class="NLM_string-name">Fabritius, C.-H.</span>; <span class="NLM_string-name">Porter, R.</span>; <span class="NLM_string-name">Fogt, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazo[1,2-a]pyrazines as Adenosine A2A Receptor Modulators for the Treatment of Various Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO2019002606 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+Bobowska&author=M.+Galezowski&author=M.+Nowak&author=C.+Commandeur&author=J.+Szeremeta-Spisak&author=M.+Nowogrodzki&author=A.+Obara&author=A.+Dzielak&author=I.+Lozinska&author=M.+Dudek&author=A.+Janiga&author=J.+Reus&author=M.+Wronowski&author=M.+Zastawna&author=A.+Radzimierski&author=M.+Swirski&author=J.+Zachmann&author=C.-H.+Fabritius&author=R.+Porter&author=J.+Fogt&title=Preparation+of+Imidazo%5B1%2C2-a%5Dpyrazines+as+Adenosine+A2A+Receptor+Modulators+for+the+Treatment+of+Various+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBobowska%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Imidazo%255B1%252C2-a%255Dpyrazines%2520as%2520Adenosine%2520A2A%2520Receptor%2520Modulators%2520for%2520the%2520Treatment%2520of%2520Various%2520Diseases%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhukov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span> <span> </span><span class="NLM_article-title">Identification of novel adenosine A2A receptor antagonists by virtual screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1904</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1021/jm201455y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201455y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1904-1909&author=C.+J.+Langmeadauthor=S.+P.+Andrewsauthor=M.+Congreveauthor=J.+C.+Erreyauthor=E.+Hurrellauthor=F.+H.+Marshallauthor=J.+S.+Masonauthor=C.+M.+Richardsonauthor=N.+Robertsonauthor=A.+Zhukovauthor=M.+Weir&title=Identification+of+novel+adenosine+A2A+receptor+antagonists+by+virtual+screening&doi=10.1021%2Fjm201455y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screening</span></div><div class="casAuthors">Langmead, Christopher J.; Andrews, Stephen P.; Congreve, Miles; Errey, James C.; Hurrell, Edward; Marshall, Fiona H.; Mason, Jonathan S.; Richardson, Christine M.; Robertson, Nathan; Zhukov, Andrei; Weir, Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1904-1909</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Virtual screening was performed against exptl. enabled homol. models of the adenosine A2A receptor, identifying a diverse range of ligand efficient antagonists (hit rate 9%).  By use of ligand docking and Biophys. Mapping (BPM), hits 1 and 5 were optimized to potent and selective lead mols. (11-13 from 5, pKI = 7.5-8.5, 13- to >100-fold selective vs. adenosine A1; 14-16 from 1, pKI = 7.9-9.0, 19- to 59-fold selective).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroN2ZrmhhzurVg90H21EOLACvtfcHk0ljIcqP2Wuiy3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOqug%253D%253D&md5=89f18c8a19339aeb6d082bbb8bb0c830</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm201455y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201455y%26sid%3Dliteratum%253Aachs%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DHurrell%26aufirst%3DE.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DC.%2BM.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DZhukov%26aufirst%3DA.%26aulast%3DWeir%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520novel%2520adenosine%2520A2A%2520receptor%2520antagonists%2520by%2520virtual%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1904%26epage%3D1909%26doi%3D10.1021%2Fjm201455y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M. S.</span>; <span class="NLM_string-name">Andrews, S. P.</span>; <span class="NLM_string-name">Mason, J. S.</span>; <span class="NLM_string-name">Richardson, C. M.</span>; <span class="NLM_string-name">Brown, G. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1,2,4-Triazin-3-amine Derivatives as A1 and A2a Receptor Inhibitors Useful in the Treatment of Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO2011095625 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+S.+Congreve&author=S.+P.+Andrews&author=J.+S.+Mason&author=C.+M.+Richardson&author=G.+A.+Brown&title=Preparation+of+1%2C2%2C4-Triazin-3-amine+Derivatives+as+A1+and+A2a+Receptor+Inhibitors+Useful+in+the+Treatment+of+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%2BS.%26atitle%3DPreparation%2520of%25201%252C2%252C4-Triazin-3-amine%2520Derivatives%2520as%2520A1%2520and%2520A2a%2520Receptor%2520Inhibitors%2520Useful%2520in%2520the%2520Treatment%2520of%2520Diseases%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span>Protein
Data Bank home page. <a href="http://www.rcsb.org/structure/6GT3" class="extLink">http://www.rcsb.org/structure/6GT3</a> (accessed Jun 17, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Protein%0AData+Bank+home+page.+http%3A%2F%2Fwww.rcsb.org%2Fstructure%2F6GT3+%28accessed+Jun+17%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, D. A.</span></span> <span> </span><span class="NLM_article-title">The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">Lb</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-LB-192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-LB-192" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=Lb-192&author=C.+Barbonauthor=A.+Borodovskyauthor=Y.+Wangauthor=L.+Prickettauthor=K.+Sachsenmeierauthor=A.+Schullerauthor=W.+Shaoauthor=C.+Barrettauthor=S.+Fawellauthor=D.+A.+Mele&title=The+A2AR+antagonist+AZD4635+prevents+adenosine-mediated+immunosuppression+of+CD103%2B+dendritic+cells&doi=10.1158%2F1538-7445.AM2019-LB-192"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-LB-192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-LB-192%26sid%3Dliteratum%253Aachs%26aulast%3DBarbon%26aufirst%3DC.%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPrickett%26aufirst%3DL.%26aulast%3DSachsenmeier%26aufirst%3DK.%26aulast%3DSchuller%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DBarrett%26aufirst%3DC.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DMele%26aufirst%3DD.%2BA.%26atitle%3DThe%2520A2AR%2520antagonist%2520AZD4635%2520prevents%2520adenosine-mediated%2520immunosuppression%2520of%2520CD103%252B%2520dendritic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DLb%26epage%3D192%26doi%3D10.1158%2F1538-7445.AM2019-LB-192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DelSignore, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strittmatter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sah, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5580</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-5580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2017-5580" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=5580&author=A.+Borodovskyauthor=Y.+Wangauthor=M.+Yeauthor=J.+C.+Shawauthor=K.+F.+Sachsenmeierauthor=N.+Dengauthor=K.+J.+DelSignoreauthor=A.+J.+Fretlandauthor=J.+D.+Clarkeauthor=R.+J.+Goodwinauthor=N.+Strittmatterauthor=C.+Hayauthor=V.+R.+Sahauthor=D.+Lawsonauthor=C.+Reimerauthor=M.+Congreveauthor=J.+S.+Masonauthor=F.+H.+Marshallauthor=P.+Lyneauthor=R.+Woessner&title=Preclinical+pharmacodynamics+and+antitumor+activity+of+AZD4635%2C+a+novel+adenosine+2A+receptor+inhibitor+that+reverses+adenosine+mediated+T+cell+suppression&doi=10.1158%2F1538-7445.AM2017-5580"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-5580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-5580%26sid%3Dliteratum%253Aachs%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DShaw%26aufirst%3DJ.%2BC.%26aulast%3DSachsenmeier%26aufirst%3DK.%2BF.%26aulast%3DDeng%26aufirst%3DN.%26aulast%3DDelSignore%26aufirst%3DK.%2BJ.%26aulast%3DFretland%26aufirst%3DA.%2BJ.%26aulast%3DClarke%26aufirst%3DJ.%2BD.%26aulast%3DGoodwin%26aufirst%3DR.%2BJ.%26aulast%3DStrittmatter%26aufirst%3DN.%26aulast%3DHay%26aufirst%3DC.%26aulast%3DSah%26aufirst%3DV.%2BR.%26aulast%3DLawson%26aufirst%3DD.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DPreclinical%2520pharmacodynamics%2520and%2520antitumor%2520activity%2520of%2520AZD4635%252C%2520a%2520novel%2520adenosine%25202A%2520receptor%2520inhibitor%2520that%2520reverses%2520adenosine%2520mediated%2520T%2520cell%2520suppression%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D5580%26doi%3D10.1158%2F1538-7445.AM2017-5580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlix, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugundu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linghu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrop, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M. S.</span></span> <span> </span><span class="NLM_article-title">Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">Ct026</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-CT026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;key=10.1158%2F1538-7445.AM2019-CT026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=Ct026&author=J.+Bendellauthor=T.+Bauerauthor=M.+Patelauthor=G.+Falchookauthor=J.+L.+Karlixauthor=E.+Limauthor=G.+Mugunduauthor=P.+D.+Mitchellauthor=G.+P.+Pouliotauthor=G.+Moorthyauthor=B.+Linghuauthor=L.+McGrathauthor=B.+Harropauthor=W.+Shaoauthor=C.+G.+Drakeauthor=K.+Sachsenmeierauthor=M.+S.+Merchant&title=Evidence+of+immune+activation+in+the+first-in-human+Phase+Ia+dose+escalation+study+of+the+adenosine+2a+receptor+antagonist%2C+AZD4635%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1538-7445.AM2019-CT026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-CT026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-CT026%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DKarlix%26aufirst%3DJ.%2BL.%26aulast%3DLim%26aufirst%3DE.%26aulast%3DMugundu%26aufirst%3DG.%26aulast%3DMitchell%26aufirst%3DP.%2BD.%26aulast%3DPouliot%26aufirst%3DG.%2BP.%26aulast%3DMoorthy%26aufirst%3DG.%26aulast%3DLinghu%26aufirst%3DB.%26aulast%3DMcGrath%26aufirst%3DL.%26aulast%3DHarrop%26aufirst%3DB.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DSachsenmeier%26aufirst%3DK.%26aulast%3DMerchant%26aufirst%3DM.%2BS.%26atitle%3DEvidence%2520of%2520immune%2520activation%2520in%2520the%2520first-in-human%2520Phase%2520Ia%2520dose%2520escalation%2520study%2520of%2520the%2520adenosine%25202a%2520receptor%2520antagonist%252C%2520AZD4635%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DCt026%26doi%3D10.1158%2F1538-7445.AM2019-CT026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span>Sosei
Heptares home page. <a href="https://www.soseiheptares.com/uploads/publications/BioCentury%20March%20%2026%202018%20-%20Optimism%20for%20A2A.pdf" class="extLink">https://www.soseiheptares.com/uploads/publications/BioCentury%20March%20%2026%202018%20-%20Optimism%20for%20A2A.pdf</a> (accessed Jun 17, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sosei%0AHeptares+home+page.+https%3A%2F%2Fwww.soseiheptares.com%2Fuploads%2Fpublications%2FBioCentury%2520March%2520%252026%25202018%2520-%2520Optimism%2520for%2520A2A.pdf+%28accessed+Jun+17%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EIY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EIY','PDB','4EIY'); return false;">PDB: 4EIY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UZA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UZA','PDB','3UZA'); return false;">PDB: 3UZA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GT3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GT3','PDB','6GT3'); return false;">PDB: 6GT3</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00237&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-21%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00237" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00237" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b30f44c8a2495","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
